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SUMMARY 
BACKGROUND 
Arrhythmia is a cardiovascular disorder which can lead to several complications. Over 
the past decade the introduction of many new drugs has raised concerns about their 
questionable benefits and cost-effectiveness. Classification of antiarrhythmic drugs has 
not been fully resolved. Although numerous clinical trials have been conducted, the 
value of antiarrhythmic drugs in many indications remains controversial. Two meta-
analyses of clinical trials addressing the indication of quinidine (Class I) for 
maintenance of sinus rhythm after cardioversion have suggested high efficacy rates but 
increased mortality relative to placebo. Several overviews which were conducted to 
evaluate the impact of antiarrhythmic therapy on improving survival post acute 
myocardial infarction, have defined a turning point in the management strategy from 
Class I to Class III drugs, particularly amiodarone and sotalol, due to the unfavourable 
mortality outcome with the former Class. 
MAJOR AIMS 
This thesis was conducted with three major aims: 
1) To assess both qualitatively and quantitatively the benefits and risks associated 
with flecainide (Class Ie), amiodarone (Class III), and sotalol (Class III & II) in 
treatment of chronic atrial fibrillation, acute medical or surgical supraventricular 
arrhythmias, and life-threatening ventricular arrhythmias developing post acute 
myocardial infarction; 
2) To produce an overall summary estimate of effectiveness and probabilities of 
incidence of adverse effects, which can be useful for subsequent incorporation 
in cost-effectiveness analysis; 
3) To validate the usefulness of various therapeutic outcomes implemented by 
general treatment guidelines. 
OVERVIEW OF THESIS 
A meta-analysis was carried out to compare the efficacy and safety of three 
antiarrhythmic agents (flecainide, sotalol, and amiodarone) in maintaining sinus rhythm 
after cardioversion of chronic atrial fibrillation. 42 of 119 clinical trials retrieved 
satisfied the predefined inclusion criteria. Data from 17 amiodarone trials (5 
randomised, and 12 uncontrolled), 8 sotalol trials (6 randomised, and 2 
nonrandomised), and 19 flecainide trials (8 randomised, 4 nonrandomised controlled, 
and 6 uncontrolled) were pooled separately after testing for homogeneity of treatment 
effect across the trials. Although the pooled rate difference in proportion of patients 
remaining in sinus rhythm between amiodarone and placebo (2 trials) was statistically 
nonsignificant (RD3mon = 16.1 %,95% CI = -29.7 to 61.7, P>0.05), the pooled effect 
compared to Class IA drugs (3 trials) demonstrated significant differences at all time 
intervals (RDs were 20.5%, 31 %, and 28.8% at 3, 6, and 12 months respectively). 
Aggregating sotalol efficacy data in randomised or nonrandomised controlled trials has 
yielded highly significant effect in favour of sotalol as compared to placebo and equal 
effect as compared to Class IA and Class IC at all time points. Furthermore, 
comparison of flecainide to placebo or Class IA has revealed a highly superior effect in 
favour of flecainide. The calculated summary statistics (ORpeto, ORMH, RD, and RR) 
for the incidence of mortality and pro arrhythmia in the full-exposure group in 
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amiodarone and sotalol trials were not significant, affirming the safety of those two 
drugs. In flecainide placebo-controlled trials, the ORMH for mortality and 
proarrhythmia were 1.8 (95% CI, 1.2-2.7, P=0.002), and (95% CI, 4.23-10.6, 
P<O.OOl) respectively, thus indicating low benefit-risk ratio for flecainide as compared 
to amiodarone. The validity of this meta-analysis was examined by assessment of 
publication bias using funnel-plots. A funnel-plot of the amiodarone clinical trials 
displayed the shape of an 'inverted funnel', thus suggesting an evidence of low 
retrieval bias. However, due to the small sample size identified (18 trials only), a firm 
conclusion with regard to absence of publication bias could not be drawn. 
Evolving strategies for management of newly occurring supraventricular arrhythmias 
were reviewed. A meta-analysis was undertaken to determine the most effective agent 
for prompt cardioversion to sinus rhythm. Flecainide efficacy relative to placebo was 
confirmed by pooling data from 5 placebo-controlled trials (OR3hrs, 7.2; 95% CI, 4.7 
to 11.1; Z=8.9; and ORShrs, 5.5; 95% CI, 3.6 to 8.4; Z=7.85). However, pooling the 
data from three amiodarone, placebo-controlled trials at 3 and 8 hour-intervals 
demonstrated a nonsignificant effect (OR3hrs, 1.3; 95% CI, 0.7-2.4; Z=0.85; and 
ORShrs, 1.03; 95% CI, 0.6-1.8, Z=0.12). All individual odds ratios for intravenous 
sotalol compared to placebo were highly significant with pooled OR at 1 hour of 8.8 
(95% CI, 4.7-16.5; Z=6.8). The effect sizes of the three agents on mean ventricular 
response rate was estimated for both converted and unconverted patients. Whilst the 
effect size of flecainide versus placebo was not statistically significant at any time point, 
those of sotalol and amiodarone were statistically and clinically meaningful for both 
converted and unconverted patients. It is suggested that for acute cardioversion, 
intravenous flecainide or sotalol should be initially implemented. Intravenous 
amiodarone can be subsequently introduced for controlling the ventricular rate in 
persistent unconverted patients. 
Recent meta-analyses of randomised controlled trials of secondary prevention of 
myocardial infarction by antiarrhythmic agents have questioned the validity of using 
arrhythmia suppression as a substitutive end point for mortality. A meta-analysis 
examining the effect of sotalol and amiodarone for prevention of death post acute 
myocardial infarction was undertaken. In addition to single point estimates of pooled 
odds ratios of total mortality and sudden death, a meta-analysis of survival data which 
included censored end points was employed. An attempt was made to reconstruct the 
life tables in individual trials of amiodarone. The Kaplan-Meier percentages were 
recalculated and pooled at specific time points to reproduce the final meta-analytic 
survival curves of total mortality and sudden death. The meta-analysis confirmed the 
clinical efficacy of amiodarone for prolonging the survival in patients with congestive 
heart failure or myocardial infarction. The nonparametric log-rank odds ratio method 
was applied to raw actuarial data deduced from published Kaplan-Meier graphs as well 
as data generated by curve fitting. Pooling each set of data separately has yielded 
highly significant log-rank ORs for total mortality in the first set of four trials with 
censoring (log-rank OR at 102 months, 0.598; 95% CI, 0.43 to 0.83; Z = -3). 
However, log-rank ORs from data generated by curve fitting of data from a further 
three trials, were nonsignificant up to 48 months (log-rank OR, 0.87; 95% CI, 0.72 to 
1.06, Z = -1.4). Merging of the two data sets has suggested strong evidence of 
efficacy for improving survival in terms of both total mortality and sudden death. 
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CHAPTER ONE 
CARDIAC ARRHYTHMIAS 
~ 
1.1 INTRODUCTION 
Disturbances in cardiac rhythm are a common problem in clinical practice and a number 
of drugs are available to treat these disorders. To understand how these drugs work it 
is essential to understand the electrical properties of cardiac cells, and the genesis of the 
arrhythmia. This chapter presents a brief description of the electrophysiological 
characteristics of cardiac cells. Some universal definitions and classifications of 
arrhythmias are introduced. The main mechanisms by which arrhythmia develops are 
delineated and the various techniques for the assessment of arrhythmia are described as 
follows: 
1.2 Electrophysiological Properties of Cardiac Cells 
1.2.1 Action Potential 
There is a voltage difference referred to as the resting membrane potential across the cell 
membrane of all types of cardiac cells. This membrane potential is caused by an 
uneven distribution of ions (principally sodium, potassium, and calcium) across the cell 
membrane (Neal, 1992; Scott, 1994). The membrane potential of specific cells in the 
myocardium gradually and spontaneously decreases (depolarises, or becomes less 
negative) over time. The exact mechanism for this alteration remains unclear, but it 
possibly involves small changes in the flux of sodium and potassium ions. Principally, 
the cell membrane is permeable to potassium ions, but is relatively impermeable to 
sodium and calcium. The potassium ions continue to diffuse out of the cell until the 
resting concentration gradient of the normal cardiac cells is reached (usually 
sodium/potassium = 0.0 1 to 0.07 mMIlitre). The outward movement of potassium ions 
is impaired by fixed negative charges inside the cell presumably proteins and 
polypeptides which are two large to diffuse out of the cell, thus tend to attract 
potassium ions. The intracellular potential at which the net passive flux of potassium 
ions equals zero is called the equilibrium potential for potassium or intracellular 
potassium. The movement of other ions is subsequently modulated by this 
phenomenon. Eventually, if the cell is allowed to depolarize to a certain critical voltage 
(the threshold potential), a full blown action potential results. The action potential is 
composed of five phases (Bigger, 1994). The dominant ion movement in each phase is 
illustrated in Table 1.1 and Figure 1.1. 
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Table 1.1 Phases of Cardiac Action Potential 
Phase Dominant ion movement 
o Fast sodium inward I rapid depolarisation 
1 Transient potassium outward I partial repolarisation 
2 Slow calcium inward I slow repolarisation 
3 Fast potassium outward I rapid repolarisation 
4 Sodium inward and potassium outward I resting potential 
The period between phase 0 and midway through phase 3 is called the effective 
refractory period during which the cell cannot be depolarised or conduct an impulse. 
The long refractory period of cardiac fibres normally protects them from re-excitation 
during a heart beat. Afterwards, the cell is repolarised to its baseline level due to fast 
outward flow of potassium at the end of phase 3. 
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Figure 1.1 Schamtic representation of cardiac action potential 
Automaticity and Sinus Rhythm 
The process of spontaneous depolarization is referred to as automaticity (or pacemaker 
activity). This phenomenon normally occurs in tissues comprising the Sinoatrial node 
(SAN), Atrioventricular (A V) node, bundle of His, and the Purkinje fibres. Under 
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certain pathologic conditions, nonpacemaker tissues can assume the property of 
spontaneous depolarization leading to dysrhythmias. Different pacemaker cells possess 
different intrinsic rates of depolarization, and thus different levels of automaticities. 
The SA node is the normal pacemaker of the heart and possesses the fastest, intrinsic 
rate followed by the AV node and the ventricular Purkinje fibres (Singer et ai., 1967). 
In a normal heart, the SA node depolarises rapidly and steadily until it reaches a 
threshould potential at which it generates an impulse. The impulses are conducted from 
the SA node across the atria to the A V node and then down the bundle of His to 
Purkinje fibres and ventricles (Bigger, 1994). This is referred to as sinus rhythm. 
However, under pathologic conditions, certain nonpacemaker cells are allowed to reach 
their thresholds earlier and initiate a wave of depolarization (Noble, 1979; DiFrancesco, 
1981). 
1.3 Relationship of the Electrocardiogram to the 
Anatomy of Cardiac Conduction System 
The electrical activities induced by the conduction of impulse to myocardial tissue and 
its subsequent depolarisation and repolarisation can be recorded by the surface 
electrocardiogram (ECG) (Myerburg et ai., 1994). The ECG is practical in providing 
indications to the nature and cause of an arrhythmia (Figure 1.2) (Scott, 1994). 
R 
P 
a s 
~_--,I LJ 
T 
PR intervau SoT segment 
a=lS 
complex 
Figure 1.2 Electrocardiogram (ECG) 
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The P wave depicts atrial depolarization and the QRS complex represents ventricular 
depolarization. The interval between the two (PR interval ) is the time required to 
conduct the beat through the A V node which is prolonged in A V block. The QRS 
complex is usually narrow when the impulses to the ventricles are initiated from above 
(SAN), and wide when they are originating from an ectopic site. The T wave 
designates ventricular repolarization, thus a QT interval is a measurement of the 
duration of depolarisation and repolarisation of the ventricular myocardium. QT 
interval may be modified by some drugs such as class III antiarrhythmics (Scott, 
1994). A prolonged QT interval referred to as QTc (usually more than 0.38 seconds) 
predisposes to a pathological condition characterised by polymorphic QRS complex due 
to fast ventricular rhythm. This condition is termed torsades de pointes. 
1.4 Definition of Arrhythmia 
Arrhythmia is an abnormal cardiac rhythm which consists of cardiac depolarizations 
that deviate from normal sinus rhythm in one or more aspects: there is an abnormality in 
the site of origin of impulse, its rate or regularity, or its conduction (WHOIISC Task 
Force, 1978). 
1.5 Mechanisms of Arrhythmias 
Many factors can precipitate or exacerbate arrhythmias: ischemia, hypoxia, acidosis or 
alkalosis, electrolyte abnormalities, excessive catecholamine exposure, autonomic 
influences, drug toxicity (e.g. digitalis intoxication) and the presence of scarred or 
otherwise diseased tissue (Hoffman et a/., 1964). However, all arrhythmias result 
from disturbances in impulse formation, impulse conduction, or both (Waldo and Wit, 
1994). 
Disturbances in Impulse Formatioll 
Abnormal impulse formation can originate from a normal pacemaker site (sinus node) 
or at an abnormal pacemaker site (ectopic site). Examples of arrhythmia caused by 
abnormal impulse formation at the normal pacemaker site include sinus tachycardia and 
sinus bradycardia. Arrhythmias originating from a site other than the sinus node 
(ectopic site) occur under several conditions. If the rate of the sinus node discharge is 
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especially slowed, other cells possessing automaticity (cells of the electrical conducting 
system) and atrial or ventricular muscle cells, which do not possess the ability to 
depolarize simultaneously, may be allowed to reach a threshold and initiate a beat. In 
addition, automaticity of such tissues may be enhanced by reduced level of membrane 
potential which may lead to partial or complete inactivation of the fast inward sodium 
current, and thus, the upstroke of action potential will be primarily due to inward 
calcium current (Grant, 1992). 
Disturbances in impulse conduction 
Severely depressed conduction may result in several, easily recognised arrhythmias (for 
example, atrioventricular nodal block, bundle branch block. A more subtle, common 
abnormality of conduction is re-entry, in which one impulse re-enters and excites areas 
of the heart more than once. Three main conditions must coexist for initiation of re-
entry (Myerburg et al., 1994). Firstly, there must be an obstacle (anatomic or 
physiologic) to homogenous conduction, thus establishing a circuit around which the 
re-entrant wavefront can propagate. Secondly, there must be unidirectional block at 
some point in the circuit. Thirdly, conduction time around the circuit must be long 
enough so that the impulse does not enter refractory tissue as it travels around the 
obstacle. Thus, the conduction time must exceed the effective refractory period. 
1.6 Classification of Arrhythmia 
A simple and useful way to classify rhythm disorders is by anatomic location of the 
disorder. Arrhythmias, originating in the SA node, atrial muscle, A V node or His 
bundle, occur above the ventricles and may be classified as Supraventricular 
arrhythmias. This includes sinus bradycardia, paroxysmal atrial tachycardia, atrial 
flutter, and atrial fibrillation. Arrhythmias originating from ventricular tissue may be 
classified as ventricular arrhythmias. 
1.6.1 Supraventricular Arrhythmias 
1.6.1.1 Atrial Fibrillation 
Atrial fibrillation is the most frequently sustained arrhythmia, and it was termed by 
cardiologists as "grandfather of the arrhythmia" due to its old recognition (Selzer, 
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1982). Later on, due to its high prevalence in the elderly population, it was regarded as 
the "arrhythmia of grandfathers" (Meijler and Wittkampf, 1991). 
1.6.1.1.2 Definition 
The definition of atrial fibrillation according to WHO-ISFC task force is "an irregular, 
disorganised, electrical activity of the atria. P waves are absent and the baseline 
consists of irregular wave forms which continuously change in shape, duration, 
amplitude and direction" (WHOIISC Task Force, 1978). 
1.6.1.1.3 Epidemiology and Risk Factors 
A number of conditions were reported to be associated with atrial fibrillation (Kannel et 
ai., 1982; Kannel et ai., 1983). Some of these conditions are listed in Table 1.2. The 
presence of rheumatic heart disease was found to be the most powerful predictor of risk 
of atrial fibrillation followed by the presence of heart failure, hypertensive heart 
disease, and coronary heart disease (Kannel and Wolf, 1992). 
Table 1.2 Cardiovascular and Noncardiovascular Precipitants of Atrial 
Fibrillation 
Etiologic Category Disease State or Drug 
Cardiovascular Mitral valve disease 
Congestive cardiomyopathy 
Coronary artery disease 
Myocardial infarction 
Hypertension 
Pericarditis 
Cardiac surgery 
Pulmonary Pulmonary embolus 
Pneumonia 
Chronic obstructive pulmonary disease (cor pulmonale) 
Endocrine Hyperthyroidism 
Pheochromocytoma 
Drugs Alcohol 
Methy lxanthines 
Sympathomimetics 
Amphetamines 
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1.6.1.2 Atrial Flutter 
Atrial flutter is another form of supraventricular arrhythmia with more rapid, regular 
rhythm than atrial fibrillation (Waldo, 1987). There are two types of atrial flutter: type I 
(classical) and type II (very rapid). Type I atrial flutter is characterised by a range of 
atrial rates from 240 to 340 beats/min, and type II atrial flutter by a range of 340 to 433 
beats/min (Waldo and Maclean, 1980; Wells et al., 1979). Both types are not usually 
persistent, and frequently revert to sinus rhythm or atrial fibrillation either 
spontaneously or as a result of therapy (Bellet, 1963). Its clinical significance is 
primarily due to its association with a rapid ventricular response rate, thus leading to 
severe symptoms. 
1.6.2 Ventricular Arrhythmias 
1.6.2.1 Prevalence 
A number of studies have demonstrated that simple ventricular arrhythmias are common 
in the general population and may be observed in 35%-50% of healthy young adults 
during ambulatory ECG monitoring (Bigger, 1983; Messineo, 1989). However, the 
incidence of ventricular arrhythmia increases with age in subjects both with and without 
clinically evident heart disease (Hinkle et al., 1974). Moreover, several studies have 
suggested significantly greater chance of severe ventricular arrhythmia with ventricular 
scarring due to infarction, hypertrophy, or infection. In addition, it may be triggered or 
aggravated by exercise due to increased sympathetic activity and heart rate (Bigger, 
1983). 
1.6.2.2 Clinical and Diagnostic Subclassification 
Ventricular arrhythmias can be classified into four main clinical categories which are 
defined as follows (Anderson, 1994): 
i. Ventricular fibrillation, characterised on the EGG by irregular undulations of 
various sizes and number. 
ii. Non-sustained ventricular tachycardia (VT) which is defined as three or more 
consecutive ventricular premature beats at a rate of > 120/min and lasting <30 
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seconds. 
111. Sustained VT which is defined as three or more consecutive ventricular 
premature beats at a rate of > 120/min, continuing for> 30 seconds or requiring 
termination before this time because of haemodynamic instability. 
iv. Simple ventricular ectopic activity may be defined as ventricular premature beats 
(VPBs) that exhibit a simple QRS morphology (uniform or unifocal VPBs). 
This may occur in an isolated or nonrepetitive pattern rather than in pairs or 
salvos, and occur beyond the T -wave of the preceding QRS complex. 
1.6.2.3 Prognostic Subclassifications 
Ventricular arrhythmia has recently been divided into risk categories of benign, 
prognostic ally important (potentially malignant), and malignant for purposes of risk 
assessment and clinical management (Bigger, 1983; Anderson, 1990; Morganroth, 
1993). This classification of ventricular arrhythmia was based primarily on the risk of 
sudden cardiac death associated with the ventricular arrhythmia, and depended less on 
the actual form of ventricular arrhythmia (Morganroth et al., 1984). 
Benign Ventricular Arrhythmias 
The arrhythmia would be considered benign if the patient had ventricular tachycardia 
which did not produce hemodynamic consequences, and was associated with a normal 
left ventricle. This type of arrhythmias would be in the form of ventricularly premature 
complexes and episodic nonsustained ventricular tachycardia (NSVT). They are not 
often associated with any presenting symptoms, and there is no evidence of any major 
increase in the risk of mortality. Therefore, there would be no indication for drug 
therapy, since no benefit could be expected from suppressing the arrhythmia. Patients 
who fall in this group are usually without any underlying, structural heart disease. 
Malignant Ventricular Arrhythmias 
At the other end of the spectrum are patients with malignant or lethal ventricular 
arrhythmias, which are associated with the highest risk of sudden cardiac death due to 
severe hemodynamic consequences which include definite presyncope, angina, heart 
failure, syncope or cardiac collapse. This type of ventricular arrhythmia is usually in 
the form of sustained ventricular tachycardia and/or ventricular fibrillation. In contrast 
to benign arrhythmia, aggressive treatment of malignant arrhythmias has been 
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emphasised for immediate relief of hemodynamic symptoms and subsequent prevention 
of sudden cardiac death. The majority of these patients have serious left ventricular 
dysfunction (mean left ventricular ejection fraction (L VEp), approximately 30% or less) 
(Anderson et al., 1990). 
Potentially Malignant Ventricular Arrhythmias 
The most complex part of the spectrum between benign and malignant ventricular 
arrhythmias embraces patients with potentially lethal ventricular arrhythmias, which are 
characterised by a grade increase in risk of mortality due to left ventricular dysfunction 
and the presence of VPCs and/or NSVT. Patients in this spectrum are different from 
those in the benign ventricular arrhythmia group, since they have some mild structural 
heart disease. They also differ from malignant ventricular arrhythmia because they do 
not have any significant hemodynamic symptoms. These patients may occasionally feel 
palpitations or dizziness, but the majority are unaware of even frequently occurring 
PVCs. 
1.7.3 Arrhythmias following Cardiac Surgery 
Cardiac arrhythmias are the most common, significant postoperative complications of 
cardiac surgery which requires cardiac consultations (Table 1.3). Atrial fibrillation is 
probably the most frequent type of significant arrhythmia following both valvular and 
coronary artery bypass grafting (CAB G) (Ormerod et al., 1984). Although ventricular 
arrhythmias are less frequent (Abedin et al., 1977), postsurgically sustained ventricular 
tachycardia and ventricular fibrillation are still regarded life-threatening events which 
will demand long-term treatment. 
Table 1.3 Incidence of Arrhythmias after Cardiac Surgery (Abedin et al., 
1977) 
Type of Arrhythmia Incidence (%) 
Atrial fibrillation 5-40 
Nonsustained ventricular ectopy I 36 
Sustained ventricular ectopy 0.5-1.5 
Bundle branch block I 17-45 
Complete A V block <4 
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1.8 Techniques for Assessment of the Arrhythmia 
1.8.1 Electrocardiogram (ECG) 
ECG is the most commonly employed cardiovascular laboratory technique which is 
non-invasive, simple to record and highly reproducible (Fisch, 1995). However, 
despite its high sensitivity and specificity for diagnosis of arrhythmia, it has 
drawbacks. It only detects the activity voltage of atrial and ventricular myocardium, 
without recording the electrical activity of more specialised tissue on which the 
mechanism of arrhythmia is most commonly dependent. Thus, a single accurate 
arrhythmia mechanism, or diagnosis may not often be obtained. 
1.8.2 Ambulatory (Holter) Electrocardiography 
In contrast to previous standard ECG, continuous examination of the patients over an 
extended period of time under different physical and psychological conditions is 
significant (Kennedy, 1995). Moreover, due to its higher sensitivity, the detection of 
transient, widely variable cardiac arrhythmia is possible. In addition, it has been 
widely employed for assessment of management of arrhythmia in clinical trials. 
1.8.3 Exercise Testing 
Exercise testing is an established tool for assessment of patients with heart diseases 
(Podrid, 1995). Exercise causes several physiologic changes due to sympathetic 
stimulation leading to an increase in heart rate, systolic blood pressure, and myocardial 
contractility. These alterations cause an increase in myocardial oxygen demand, and 
myocardial ischemia in patients with impaired oxygen delivery. This ischemia can 
provoke clinical arrhythmia due to disturbance in impulse conduction. However. 
exercise testing is of significant value for detecting arrhythmia in patients with transient 
symptoms when other techniques fail to detect the cause. It is also useful for exposing 
harmful drugs effects such as proarrhythmia, which will be discussed later in Chapter 
Two. 
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1.8.4 Invasive Cardiac Electrophysiology Studies 
The newer intracardiac electrophysiological studies provide more detailed analysis of 
the mechanism underlying the cardiac arrhythmia. As a result, it enables clinicians to: 
1) produce a more accurate diagnosis, 2) assess the prognosis, 3) and initiate 
antiarrhythmic treatments on a more logical basis (Zaim et al., 1995). 
In these tests, a pacing catheter is placed in the patient's right atrium and ventricle. 
Single or repeated pulses of electrical current are given at various times within the 
cardiac cycle to induce premature ventricular depolarization (Podrid, 1985; Zaim et aI., 
1995). The end point of stimulation may include induction of sustained ventricular 
tachycardia, non-sustained ventricular tachycardia or fibrillation. Once the arrhythmia 
has been reproducibly induced, an antiarrhythmic drug is administered and the 
procedure is repeated. Failure to induce the arrhythmia after drug administration is 
strongly predictive of long-term efficacy of the drug. Enhanced induction or induction 
in a patient who was previously uninducible indicates a proarrhythmic drug effect. 
After a washout period, another drug is evaluated. 
In the next chapter we will examine the various treatment options. 
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CHAPTER TWO 
PERSPECTIVES ON THE CURRENT 
TREATMENTS OF CARDIAC ARRHYTHMIAS 
2.1 INTRODUCTION 
Therapeutic modalities of cardiac arrhythmias have grown far more complex in recent 
years compared to simple approaches of the past (Vaughan Williams, 1984). Our 
understanding of the various factors predisposing to arrhythmia, and of 
electrophysiological mechanisms involved in receptor and channel function in the 
myocardium, has advanced substantially over recent years (Vaughan Williams, 1989; 
Task Force of the Working Group on Arrhythmias of the European Society of 
Cardiology, 1991; Vaughan Williams, 1992; Ahmed and Singh, 1993; Singh, 1996). 
Clinicians can now select from 80 agents licensed for a wide range of antiarrhythmic 
indications. Generally, antiarrhythmic drugs are initiated with two aims (Morganroth, 
1993): 
• reducing the frequency of recurrence of symptomatic arrhythmias, thus 
improving the quality of life of the patient. 
• to prolong life in patients with 'potentially lethal arrhythmias. 
However, these potential benefits are rarely devoid of serious risks (Roden, 1994). 
Thus, a general understanding of the pharmacology of these drugs and factors which 
modify their benefitrisk ratios is important. 
In addition to pharmacological therapy, several nonpharmacological interventions have 
been introduced. These include electrical cardioversion, permanent pacemakers, 
surgery, and implantation of cardioverter-defibrillator (Anderson, 1994). Drug 
therapy, however, remains the most common approach but there has been increased 
concern about its efficacy, safety, and cost-effectiveness. 
The aims of this chapter are firstly to clarify the various Classifications of 
antiarrhythmic drugs, related pharmacological and electrophysiological phenomena and 
secondly, to delineate major reported complications of those drugs. 
2.2 Classifications Of Antiarrhythmic Drugs 
The actions of antiarrhythmic drugs have been classified by several means. Each 
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approach has its strengths and limitations. Most commonly employed approaches were 
devised by Vaughan-Williams classification and Sicilian Gambit (Task Force of the 
Working Group on Arrhythmias of the European Society of Cardiology, 1991; 
Vaughan Williams, 1984; Vaughan Williams, 1989; Vaughan Williams, 1992). 
2.2.1 Vaughan-Williams Classification 
This system categorises antiarrhythmic drugs into five main classes, according to their 
cellular electrophysiologic effects on the action potential of various tissue models as 
shown in Table 2.1 (Vaughan Williams, 1992; Hondeghem, 1995; Siddoway, 1995). 
The primary sites of drug action in this classification are the ion channels (sodium, 
potassium and calcium channels) and the receptors (mainly B receptors). 
Table 2.1 
Class 
IA 
IB 
IC 
IT 
ill 
N 
V 
Digitalis 
Adenosine 
Vaughan-Williams classification of antiarrhythmics 
(Siddoway, 1995) 
Membrane Effect ECG Effect Drugs 
Sodium channel block, i QRS, i QT Quinidine 
intermediate kinetics, (intervals) Procainamide 
potassium channel block Disopyramide 
Sodium channel block, rapid ! QT interval Lidocaine 
kinetics Tocainide 
Mexiletine 
Sodium channel block, slow ii QRS interval Aecainide 
kinetics Propafenone 
Moricizine 
Cibenzoline 
B-Receptor inhibition ! HR, i PR interval Propranolol 
Potassium channel block i QT interval Bretylium 
Amiodarone 
Sotalol 
Calcium channel block ! HR, i PR interval Verapamil 
Diltiazem 
Time-dependent block of !HR Alinidine 
inward current activated by 
hyperpolarisation (lh) 
Sodium, potassium--A TPase i PR, ! QT interval Digoxin 
inhibition Digitoxin 
AI-Receptor agonist ! HR, i PR interval Adenosine 
i, increase; !, decrease; ECG, electrocardiogram; HR, heart rate 
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2.2.1.1 Class I Antiarrhythmic Agents 
The subdivision of Class I drugs, which are all sodium channel blockers, into 
subclasses lA, IB, and IC was mainly based on three pharmacodynamic theories: 
electrical modulation of channel activity, use dependence, and onset / offset kinetics 
(Vaughan Williams, 1992; Hondeghem, 1995). 
Sodium channels are usually modulated into three states according to membrane 
potential in a time-dependent mode. During each action potential, the channels are 
transiently open (activated) during phase 0, inactivated during the phases I and 2, and 
during the repolarisation in phases 3 and 4 they are rested. Class I drugs possess high 
affinity for the sodium channels in the activated and inactivated states, and low affinity 
in the resting stages (Hondeghem and Katzung, 1977). Two mechanisms have been 
proposed to show how drugs reduce the inward sodium current through the channels; 
modification of the voltage dependent behaviour of the channel (Class Ib) and/or 
blocking the channel (Class Ia and Class Ie). 
Acnvlted 
CD Na 
Na 
o C 
Inactivated 
Figure 2.1 Schematic representation of the electrical modulation of cardiac sodium 
channel (adapted from Hondeghem, 1995). 
2.2.1.1.1 Use Dependence and Onset I Offset Kinetics 
Since blocking of the channels occurs only during the activated and/or inactivated states 
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with each action potential, and dissipates by the end of depolarisation when the 
channels are inactivated, the degree of blocking is thought to increase the higher the 
intensity of the channel usage per unit time. This phenomenon which is termed use 
dependence accord the drugs to affect abnormal premature diastole rather than normal 
sinus rhythm. 
However, the level of use-dependent blocking by various Class I subdivisions is based 
on the speed of their attachment to, and detachment from the sodium channels 
(Vaughan-Williams, 1989). Until the onset / offset kinetics (receptor binding kinetics) 
of these agents were examined, a distinct explanation for the reported increase in 
arrhythmic mortality associated with Class Ie drugs in The Cardiac Arrhythmia 
Suppression Trial was not possible (Vaughan-Williams, 1992). Class Ie were found to 
have slow-inlslow-out (SISO) kinetics, thus resulting in excessive levels of block, 
while Class la and Ib drugs produced intermediate blocking with fast onset/offset 
kinetics respectively (Hondeghem, 1995). 
2.2.1.1.2 Selectivity, Efficacy and Potency 
Selectivity of an antiarrhythmic agent may be defined as the ability to interfere with a 
certain arrhythmia in more than 99% of cases, while with normal sinus rhythm in less 
than 1 % of cases (Hondeghem, 1995). Efficacy indicates the maximum effect that the 
drug can produce, while potency refers to the concentration required to achieve 50% of 
the maximum effect. It was reported that Class I agents in general have poor 
selectivity, particularly against tachycardias. Thus, they would be frequently 
pro arrhythmic. Furthermore, although Class Ie (flecainide and encainide) were 
extremely potent (producing significant blocking during normal sinus beat at a very low 
concentrations), they fail to suppress the tachycardia effectively. Consequently, 
effective concentrations of Class Ie would be expected to be highly toxic. 
2.2.1.2 Class II Antiarrhythmic Agents 
Several beta-adrenergic blockers are now approved as Class II antiarrhythmic agents 
(Frishman and Cavusoglu, 1995). Beta-blockers are commonly marketed as racemic 
mixtures, with the beta-blocking activity mainly found in the levorotatory isomer (I). 
The dextrorotatory (d) isomer possess no clinical effect except for d-sotalol, which has 
Class III antiarrhythmic activity, and d-propranolol, which has Class I (quinidine-like) 
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membrane stabilising activity (Frishman, 1981). 
Three major mechanisms have been proposed for the antiarrhythmic effect of beta-
blockers. The first and major effect results from a catecholamine inhibitory effects 
leading to inhibition of pacemaker potential and depression of excitability and 
conduction. The second, an electrophysiologic effect is due to a membrane stabilising 
'local anesthetic' activity. The third effect which is a Class III antiarrhythmic activity is 
specific for sotalol. However, the antiarrhythmic effectiveness of beta-blockers is 
primarily due to beta-blockade, with the membrane stabilising activity being clinically 
nonsignificant. The later effect is only manifested at excessive propranolol doses, and 
many other beta-blockers devoid of this activity are clinically effective (Frishman and 
Cavusoglu, 1995). 
Although beta-blockers have different selectivity for blocking Bland B2 receptors, they 
show no differences in their antiarrhythmic potencies (Frishman, 1981). 
2.2.1.3 Class III Antiarrhythmic Agents 
Class III antiarrhythmic agents block outward flow through potassium channels, 
consequently slowing repolarisation of the cell and prolonging the duration of the action 
potential and the effective refractory period (Siddoway, 1995). In addition, some 
agents (amiodarone and sotalol) have Class II anti adrenergic actions. Two major 
drawbacks characteristic of these agents are reverse use-dependence and torsades de 
pointes. 
2.2.1.3.1 Reverse Use-dependence 
Unlike Class I agents which exhibit use-dependence (more intense blocking at higher 
heart rates), most new Class III agents, including sotalol, displayed a reverse use-
dependence phenomenon (Lazzara, 1996). Reverse use-dependence implies that they 
tend to substantially prolong the action potential at slow heart rates (normal sinus beat), 
and their effect declines at fast heart rates (tachycardias) (Hondeghem, 1995). In 
addition, an excessive effect appeared following a long diastolic interval. This may be 
responsible for their pro arrhythmic actions. The mechanism by which these agent 
prolong the action potential is not entirely resolved. Amiodarone is an exception in that 
it uniformly lengthens the action potential irrespective of heart rate (Naccarelli and 
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Dougherty, 1995). 
2.2.1.3.2 Torsades de pointes 
This type of pro arrhythmia occurs as a result of excessive prolongation of the QT 
interval, which triggers premature ventricular contractions (PVCs) and ventricular 
tachycardia (Lazzara, 1996). 
2.2.1.4 Class IV Antiarrhythmic Agents 
Class IV antiarrhythmics primarily act by blocking the slow calcium channels, thus 
causing a depressant effect on the SA and A V nodes which are depolarised 
predominantly due to the inward calcium currents (Singh, 1995). This depressant 
effect involves an increase in refractoriness. However, not all calcium channel blockers 
are antiarrhythmics. For example, nifedipine and other calcium antagonists with a 
selective action on blood vessels, despite blocking calcium current in nodal cells, can 
cause a reflex sympathetic stimulation due to their negative inotropic effect on other 
myocardial and vascular smooth muscle cells. These lead to an increase in heart rate 
and shortening of duration of the action potential (Vaughan-Williams, 1992). 
2.2.1.5 Other Antiarrhythmic Agents 
Some drugs possessing antiarrhythmic effects are not described in the Vaughan-
Williams Classification scheme. For example, adenosine and digoxin (Vaughan-
Williams, 1992). Adenosine is a cardioselective cholinergic agonist which produces a 
depressant effect on nodal tissues (Siddoway, 1995). Digoxin induces blocking of 
sodium-potassium ATPase, thus causing an increase in intracellular sodium and 
calcium, leading to enhancement of myocardial contractility and reduction of A V 
conduction (Siddoway, 1995). 
2.2.2 How Useful is the Vaughan-Williams 
Classification? 
Although the previous classification is widely used by clinicians, the following 
criticisms have recently been raised (Task Force of the Working Group on Arrhythmias 
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of the European Society of Cardiology, 1991; Ahmed and Singh, 1993): 
1. A drug in one class may produce multiple class effects. For example, it is not 
known which class action determines amiodarone's efficacy in prevention of 
mortality prior to myocardial infarction. 
2. The classification does not take into account the effect of active metabolites 
which may have diverse actions from their 'parent' drugs. For instance, N-
acetylprocainamide which is the major metabolite of procainamide (Class I 
drug) produces a Class III effect. As a result, the clinical effect manifested 
during procainamide therapy may be dependent on relative concentration of the 
two compounds. This is again determined by other factors such as genetically 
determined drug metabolism pathways (Siddoway, 1995). 
3. The classification, with the exception of Class II drugs, is essentially based on 
electrophysiological studies using isolated, normal cardiac tissues. In diseased 
tissues, the channels and receptors are modified, and the actions of drugs on 
these tissues may not be frrmly predicted. 
However, the classification is still worthwhile. Drugs in one class share similar 
toxicity profiles (Siddoway, 1995). For example, drugs delaying conduction (Class I, 
III, or IV) would be contraindicated in diseases characterised by conduction disorder, 
while drugs prolonging the QT interval (Class IA or III) would exacerbate the 
proarrhythmia in patients with pre-existing QT prolongation. 
2.2.3 Sicilian Gambit 
To overcome the problems highlighted in Vaughan-Williams classification, the "Sicilian 
Gambit" framework was developed in an attempt to link the cellular electrophysiologic 
action of antiarrhythmic drugs to their observed clinical efficacy in humans (Task Force 
of the Working Group on Arrhythmias of the European Society of Cardiology, 1991; 
Ahmed and Singh, 1993). This approach uses three alternative levels for classification: 
classification at the molecular level, classification according to effect on different types 
of human arrhythmias, and classification on the basis of effect on measurable clinical 
parameters. 
Although the "Sicilian Gambit" provides a useful theoretical framework to which new 
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knowledge can be added, and from which ideas regarding drug development can be 
gained, Vaughan-Williams (1992) has criticised its limited clinical utility due to the 
following (Vaughan-Williams, 1992): 
1. The molecular basis used is deemed more practical for basic scientists rather 
than clinicians. 
2. Classification based on type of human arrhythmias would lead to a large 
number of diagnostic classes. Secondly, drug efficacy differs for evenly 
morphologically similar arrhythmias. Moreover, only a limited number of 
studies have involved interindividual comparisons of drugs in the same setting, 
and different mechanisms might lead to the same "phenotype" of arrhythmia on 
the surface electrocardiogram. 
3. The third level of classification depends on defining the mechanism of an 
arrhythmia and to predict the "vulnerable clinical parameters" that can be 
targeted by specific ion current. However, in clinical practice, a definite 
mechanism for most arrhythmias is difficult to define, and if known cannot be 
instantly correlated to cellular electrophysiology. In addition, this new 
classification system is very similar to the old Vaughan-Williams classification. 
For the present, rejecting the conventional classification of antiarrhythmics seems 
unreasonable and consideration of the two systems as complementary is worthwhile 
(Singh, 1996). 
2.3 Complications Induced by Antiarrhythmics 
The risks of antiarrhythmic therapy involve not only noncardiac side-effects and the 
potential for organ toxicity, but also cardiac effects, such as aggravation of arrhythmia, 
namely proarrhythmia and sudden death (Podrid, 1985; Morganroth, 1993). 
2.3.1 Proarrhythmia 
The term "proarrhythmia" or "arrhythmogenicity" is defined as "the capacity of cardiac 
or noncardiac drugs to aggravate an existing arrhythmia or provoke a new arrhythmia at 
therapeutic or subtheraputic level" (Kerin et at., 1994). In 1987, it was agreed by a 
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group of European and American physicians at the American College of Cardiology 
meeting to employ the term arrhythmogenesis if aggravation of arrhythmias is due to 
any cause, and the term proarrhythmia for specific drug therapy (Morganroth, 1992). 
Proarrhythmia is described as "early" if it occurs within 30 days of treatment. Later on, 
with the evolution of new concepts on proarrhythmia, more detailed clinical definitions 
were proposed (Velebit et aI., 1982; Morganroth and Horowitz, 1984). Morganroth 
(1992) classified early proarrhythmia into two types: 
1 . Provocation types which include the new onset of: 
Ventricular premature complexes> lOOper day 
Nonsustained ventricular tachycardia 
Sustained ventricular tachycardia 
Polymorphic ventricular tachycardia 
Ventricular fibrillation 
2. Aggravation types which include: 
Increased frequency of ventricular premature contractions or 
couplets 
Increased duration, frequency (rate increase ~1O%), or rate of 
ventricular tachycardia 
A number of predisposing factors to proarrhythmia have been suggested; organic heart 
disease particularly, if patients are treated with Class Ic drugs, rapid high dose titration, 
the presence of atrial arrhythmias, or electrolyte imbalance (Kerin et al., 1994; 
Morganroth, 1993). 
2.3.2 Sudden Cardiac Death 
The potential increase in likelihood of sudden death with antiarrhythmic therapy is a 
serious shortcoming, particularly if the benefit of treatment is considered to be very 
minimal, and especially in asymptomatic ventricular arrhythmias (Roden, 1994). 
Sudden death, which is also referred to as "late" proarrhythmia or arrhythmic death, is 
defined as "death restricted to a narrow time span, such as instantaneous death, death 
within less than 24 hours, or simply prehospitalisation death" (Segal et al., 1985). 
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Thus, the definition should include three essential elements: a natural process, an 
unexpected occurrence, and a rapid development. The risk of arrhythmic mortality is 
markedly increased in the setting of myocardial infarction complicated with premature 
ventricular contractions, which may degenerate into serious sudden lethal arrhythmia 
(The Cardiac Arrhythmia Suppression Trial Investigators, 1989). 
2.4 Aims and Objectives of This Thesis 
This thesis summarises the research based-evidence for the effectiveness of common 
antiarrhythmic drugs in the management of three major types of arrhythmia: 
(A) Acute, recent-onset supraventricular arrhythmia in medical and 
postsurgical patients. 
(B) Chronic atrial fibrillation. 
(C) Ventricular arrhythmias prior to or after acute myocardial infarction. 
The aims of the quantitative work described in this thesis are: 
2.4.1 To define and comment on the various therapeutic end points and treatment 
strategies employed for the various arrhythmias. 
2.4.2 To summarise quantitatively the evidence on the efficacy of drugs used for each 
of the types of arrhythmias described above. 
2.4.3 To undertake a risk and benefit assessment of antiarrhythmic drug therapy. 
21 
CHAPTER THREE 
METHODS OF ANALYSIS AND CROSS 
DESIGN SYNTHESIS 
3.1 INTRODUCTION 
It is now recognised that the relationship between research findings and their 
implementation into practice is complex (Delamothe, 1994; Sacket and Cook, 1994). 
The question of how research findings are used has in itself become an exciting field 
for research and development (Fowkes and Fulton, 1991; McCormack and Levine, 
1993). There is an increasing awareness that critical appraisal of information from 
medical literature would have important implications for the clinical management of 
patients and resources within the health system (Mulrow, 1994). Three barriers have 
been identified by clinicians in obtaining clinically important information. These are the 
lack of adequate time necessary for keeping up to date information, the use of out of 
date text books, and disorganised journals (Oxman, 1995). 
In this chapter, the rationale for meta-analysis, the steps involved and the various 
statistical techniques applied, are discussed. These techniques have been assembled 
into 3 groups; firstly those which could be employed for combining primary studies 
even in the absence of complete sets of outcome data, secondly, those generated to 
combine studies with discrete data as outcomes and thirdly those which are ideal for 
combining outcomes expressed as continuous data. The problems and limitations 
associated with meta-analysis, particularly publication bias and missing data, are 
highlighted. 
3.2 Definition of Medical Effectiveness 
"Medical effectiveness" refers to the extent to which treatments achieve specific 
outcomes (Silberman et aI., 1992; Tones, 1997). 
Silberman et al. (1992) have identified three major dimensions or sources of complexity 
which comprise the "effectiveness domain". These include the following: 
(1) Variety of patients and forms of the disease. A treatment may be 
more effective for certain types of patients than others. 
(2) Varying implementations of the treatment under investigation. A 
treatment may be less effective if it is executed in a less than optimal 
method. 
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(3) Different outcome measures. A treatment may seem to be more or less 
effective depending upon the particular type of outcome measure that is 
employed as an end point. 
Accordingly, they stated that: 
" .. A study that captures only a very limited number of points may not, by itself, 
adequately capture the full story or "truth" about the effectiveness of the treatment in 
question. If a rigorous scientific study includes only certain kinds of patients, only 
selected (perhaps optimal) forms of implementing the treatment, and a single outcome 
measure, that study can tell a small part of the story. Certainly, an equally scientific 
study of the same treatment could yield very different results if it highlighted different 
kinds of patients, implementations, and outcomes." As a result, clinical researchers 
aspired to improve the evaluation strategy and to develop optimal study designs for 
achieving greater coverage of the effectiveness domain, while maximising scientific 
rigor (Silberman et aI., 1992). 
3.3 Efficacy versus Effectiveness 
The term efficacy refers to the extent of benefit derived from a particular treatment 
under ideal circumstances of formal randomised clinical trials. On the other hand, 
effectiveness describes the degree to which a given intervention has achieved its goals 
under the prime conditions of the real word of clinical practice (Sinclair and Bracken, 
1992; Tones, 1997). 
In fact, two types of trial design were defined according to the objective undertaken. 
The first kind of study is termed the 'explanatory' trial, in which the principal question 
to be answered is 'Can this treatment work?'. In the second type of study, the 
'pragmatic trial', the main question addressed is 'Does this treatment work?'. Thus, 
the explanatory trials aim to evaluate the 'efficacy' of a particular intervention when it is 
provided in ideal circumstances, while pragmatic trials tend to appraise the 
'effectiveness' of the same form of intervention as it is manipUlated in conditions that 
are similar to everyday practice (Chalmers, 1992). 
The ultimate applicability of the results of a randomised trial is limited by the degree of 
modification of the patients inclusion criteria and intervention procedures as delineated 
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in the registered trial. Extrapolation of the results to broader limits is not always valid. 
Applicability depends on the type of outcome measures and efficacy end points which 
is targeted in a particular trial (Charlson and Horwitz, 1984). Many interventions can 
be evaluated using different outcomes. A reviewer should concentrate on the major 
outcomes of clinical significance and watch out for 'substitution game' or what has 
been called the 'surrogate markers', when a transitional outcome such as blood 
cholesterol level is substituted for a more relevant clinical outcome of heart attack, 
stroke or death (Sinclair and Bracken, 1992; Li Wan Po, 1996). 
3.4 Study Designs 
Over the past few years, a variety of studies with different designs have been employed 
to evaluate treatment effects. Each design, however, has characteristic strengths and 
weaknesses. 
3.4.1 Early Approaches 
In the past 150 to 200 years, the practice of medicine with regard to treatment 
effectiveness was primarily based on personal observations by individual clinicians, 
which reflects their expertise and sagacity to interpret the observed merits of treating a 
specific patient with a particular therapy (Sechrest and Figueredo, 1991). The 
advantage of this approach is that conclusions obtained are strengthened with clinically 
relevant experiences. However, this approach is associated with a number of 
weaknesses which may include the possibility that the observed outcomes are 
coincidental to the treatment, rather than induced by it (Silberman et al., 1992). 
Consequently, a more objective approach, which was termed the "numerical method", 
was developed (Louis, 1834; 1835). This method highlighted the significance of 
accurate recordings of treatments and numerical presentations of patient outcomes. 
Other controlled designs have been generated since. For example, historical control 
trials compare outcomes for patients currently receiving new treatment with historically 
recorded outcomes for patients who had previously received different treatments (Mike, 
1982). The weakness of these studies derives primarily from the inadequacy to 
confirm that the observed effect is solely attributed to treatment. 
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3.4.2 Randomised Clinical Trials 
In early 1920s, a significant controlled tool for comparing interventions was introduced 
in the form of randomised controlled trial (Fisher, 1935). Randomised clinical trial 
(RCT) depends on a chance process (randomisation) for assigning all individuals to 
two alternative treatments, therefore confirming that the only source of differences 
between the two groups, at baseline, will be chance (Chalmers, 1989; Armitage and 
Berry, 1994). 
The employment of strict randomisation procedures prevents the possibility of 
investigators assigning healthier patients to the new treatment, and insures a statistical 
expectation of equivalence in the two groups (Peto et aI., 1993). Therefore, it would 
be appropriate to interprete any difference in outcome, which is larger than that which 
would be expected on the basis of chance alone, as a statistically significant indicator of 
a treatment effect (Peto et al., 1993). 
However, studies that claim to have assigned individuals to alternative forms of 
treatment may have become subject to selection biases if precautions have not been 
taken to secure true randomisation. Such biases can be introduced by selectively 
entering a candidate, depending on prior knowledge of the group to which they have 
been allocated, or selectively withdrawing him before complete formal registration. As 
a result, to ensure true randomisation, it is important that assignment is carried out by a 
central co-ordinating office and only after registration of all eligible candidates in the 
trial (Chalmers, 1989). Furthermore, the power of randomisation is greatly maximised 
by reducing the investigator bias when interpreting outcomes. A common suggestion 
to alleviate this bias is the use of the double-blind method, in which neither the 
investigator nor the recipient has any knowledge of which particular intervention is to 
be received. This method is essentially recommended when the outcome in question is 
of a subjective "soft" nature such as self-reported symptoms, rather than unambiguous 
"hard" outcomes such as death (Chalmers, 1989). 
In spite of properly designing randomised controlled trials to reduce the potential of 
selection and observer bias, the results may still be misleading due to random errors 
resulting from the play of chance. This can occur as a result of falsely interpreting an 
important clinical difference between two interventions when it does not exist or 
interpreting no clinical difference when it does exists (Peto et al., 1976). Random error 
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can be reduced by increasing the sample size. 
Non-randomised clinical trials using historical or concurrent controls are more prone to 
bias. It has been shown that such designs were much more likely to find a treatment 
benefit than studies utilising randomised controls (Bracken, 1992). This was explained 
by the fact that the control groups in the historical control studies had worse outcomes 
than the controls in the randomised controlled studies, since they are usually constituted 
of patients with poor prognosis, non-compliant patients, or patients who have other 
adverse characteristics that might preclude them from enrolment in prospective 
randomised trials (Sinclair and Bracken, 1992). 
Clinical trials are designed to answer a specific question or questions. Generally, these 
questions can be answered with two different approaches. The first approach has been 
given such names as fastidious, explanatory, and intention-to-treat. The second 
approach has been termed as pragmatic and management (Feinstein, 1983). The 
conflicts in the two approaches involve the choice of patients to be included in the trial, 
the comparative agent to be tested against the principal agent under investigation, the 
dosage regimen, the type of data used to show responses to treatment and the method 
of analysing the data after the trial has been completed. Explanatory trials address 
whether or not an intervention has any effects and how it produces its effects. This is 
usually tested by including a relatively homogeneous group of patients obtained with 
strict inclusion criteria (with similar gender and race, without any other associated 
diseases and concomitant medications). Fastidious (explanatory) investigators 
standardise the comparison by choosing placebo controls, double blind procedures and 
fixed regimens. Moreover, they tend to express the treatment outcomes as "hard" 
clinical endpoints and prefer to reduce the bias due to any personal or clinical decisions 
that are made after randomisation by using intention-to-treat analysis (Sackett and Gent, 
1979). On the other hand, pragmatic trials are conducted not only to test if the 
intervention has any effects, but also to explain the consequences of its employment in 
similar aspects to ordinary clinical practice. As a result, a pragmatic designer will 
include heterogeneous populations of patients and favour to choose active controls with 
flexible regimens. In addition, intervention is evaluated using "soft" outcomes such as 
comfort and quality of life, which are more meaningful to the patients and their 
families. Despite all the conflicts that could arise, it may always be possible to justify 
both approaches when a trial is designed to satisfy questions to be answered. 
The weaknesses of randomised studies are mainly due to their typically high cost. 
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Consequently, randomised studies have been conducted to formally evaluate relatively 
few medical interventions. Moreover, many trials were designed to enroll a limited 
subset of patients, and to answer only a specific question. However, it is uncertain that 
the results of such trials may be generalised to all patients. 
3.4.3 Traditional Reviewing Techniques 
A summary of the findings of a collection of individual research studies is called a 
review. A literature review is a fundamental scientific tool which is not new and 
plausibly employed in many research fields (Glass, 1976; Sackett et at., 1991). Its 
rationale is based on four major concepts. Firstly, individual primary studies may 
contribute incomplete evidence of treatment effectiveness due to poor design and small 
sample size. Secondly, a particular study may include a narrow spectrum of patients 
which will make the generalisability of findings to other type of patients uncertain. 
Thirdly, large quantities of information are published annually in the literature which 
need refinement, evaluation, and synthesis. Mulrow (1994) stated "systematic review 
separates the insignificant, unsound, or redundant deadwood in the medical literature 
from the salient and critical studies that are worthy of reflection". Finally, overviews 
facilitate integration of the serious portions of available medical information to make 
decisions about cost-effectiveness of certain treatment protocols and diagnostic tests 
(Sackett et at., 1991; Haynes, 1992; Mulrow, 1994). 
However, traditional reviewing techniques are qualitative in nature which means that 
formal statistical techniques are usually not applied. A survey of 50 review articles 
published in four major medical journals, conducted in 1987 by Mulrow, has shown 
that at that time the majority of medical reviews did not use scientific methods to 
identify, assess, and synthesise information. As a result, subjective narrative 
conclusions can be drawn. Further, with a traditional review, the process of 
identifying and including relevant studies is often performed selectively and 
unsystematically. Consequently, several reviewers often draw very different 
conclusions from the same set of studies. Chalmers (1982) has stated that 'in some 
instances, there is evidence that the conclusions reached by reviewers are based more 
on factors such as their training and how they make their living than on the available 
evidence'. 
In recent years, many authors have recognised the imperfections associated with 
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traditional and informal reviews (Light and Smith, 1971; Cooper and Arkin, 1981; 
Peto, 1987; Fowkes and Fulton, 1991). Consequently, the technique of overview has 
evolved. This technique systematically retrieves all the primary studies. Sackett et al. 
(1991) elucidated that "when a review strives to comprehensively identify and track 
down all the literature on a topic, we call it an overview." 
The systematic review process attempts to make reviewing practices distinct and it is 
based on objective procedures rather than personal judgment rules. The reviewer 
describes how primary studies were identified, and defines the objectives and criteria 
for inclusion or exclusion of the primary studies to increase the reliability and 
representativeness of the review (Oxman and Guyatt, 1988; Sackett et al., 1991). 
Different reviewers using the same research and analytic strategy should arrive at the 
same conclusion. 
The magnitude of the findings is not conventionally confronted in a review (Light and 
Smith, 1971). A formal quantitative approach for the synthesis of evidence derived 
from a set of similar but independent experiments is called meta-analysis. 
3.4.4 Data-base Analyses 
With the novel advances in computer storage and retrieval, data base-analysis has been 
proposed. Computerised data-bases routinely preserve records for thousands of 
patients. In several data-bases, details regarding diagnosis, treatment, and outcome are 
recorded for each patient (McDonald, 1991). Recently, analysts concerned with 
medical effectiveness have begun to use these data-bases (McDonald, 1991; Ellwood, 
1988; Roper et al., 1988). 
Data-base analyses have a number of advantageous characteristics. A clear advantage is 
that many data-bases cover the full range of patients receiving the treatment in medical 
practice. This is considered important, particularly since randomised studies and even 
meta-analyses of randomised studies, have limited coverage. Furthermore, other 
advantages of data-base analyses include (1) their timeliness (2) their low cost, because 
the data have already been collected and (3) their independence from the ethical 
affections identified with manipulation of interventions in randomised clinical trials 
(Silberman et al., 1992). 
Nevertheless, the outcome of this approach suffers from several potential deficiencies. 
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These include limited patient descriptors, possible recording and transcription errors, 
and missing data. Focusing on treatment effect estimation, the outstanding defect of 
data base analyses is "comparison bias", which means that the patient groups being 
compared were not comparable at baseline (Byar, 1980). 
3.4.5 Meta-Analyses 
3.4.5.1 Definition and Nomenclature 
"Meta-analyses" or "quantitative overviews", as many medical researchers call them 
(Yusuf et al., 1987; Peto, 1987), expand knowledge by statistically combining the 
results of multiple studies, and randomised studies, that all address essentially the same 
research question (Teagarden, 1989). Other definitions are similar: "a quantitative 
methodology for integrating empirical research literature" (Diamond and Forrester, 
1983); "an attempt to improve traditional methods of narrative review by systematically 
aggregating information and quantifying its impact" (Wittes, 1987). 
The word Meta is derived from the Greek word meta which means "after". Other terms 
used to describe this type of research include integrative research review, research 
consolidation, data synthesis, pooled analysis and combining studies (Jenicek, 1989). 
Most of these terms are used interchangeably. In this thesis, the term meta-analysis 
will be used to designate the process of synthesising the results of similar but separate 
randomised clinical trials. 
Meta-analysis includes a collection of techniques which were first employed in social 
sciences, particularly in psychological and educational research. Some examples were 
also to be found in agricultural research (Pearson, 1904; Tippet, 1931; Fisher, 1932; 
Cochran, 1937; Glass, 1976). Clinical and medical researchers adopted the method in 
the 1980s (Sacks et ai., 1987). 
Social scientists who first practised meta-analysis, used a standardised "effect size" to 
combine results from studies with different outcome measures (for example, different 
measures of self-esteem) (Hedges, 1982). Later, many medical researchers combined 
only studies which had the same "endpoint" (for example, 5-year survival), only 
randomised, placebo-controlled clinical trials, or those that met both criteria (Peto, 
1987). 
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3.4.5.2 Potentials of Meta-Analysis 
1. To approximate the results of a single large study at a small fraction of the cost 
of conducting a new large study. 
2. To increase statistical power as a result of 'pooled estimate' . 
3. To resolve uncertainty of complex medical problems when a number of primary 
studies disagree. 
4. To draw conclusions on how to plan new studies or clinical trials. 
5. To answer questions not posed at the start of individual trials. 
6. To identify beneficial or harmful interventions many years before this is 
discovered by SUbjective, narrative and qualitative review. 
7. To provide a greater stability for the estimate of a treatment's effect in a 
particular subgroup. When the numbers of patients in that subgroup are not 
large enough, within individual small studies, drawing a stable conclusion 
about a treatment effect is not feasible. However, using meta-analysis to 
combine the outcomes for that subgroup in multiple studies enables more stable 
evaluation (Light, 1984). 
8. To investigate potential sources of clinical and statistical heterogeneity, in 
particular the clinical differences between the studies included, and to attempt to 
quantify a better overall estimate of the influence of these sources (Thompson, 
1994). 
9. To provide more useful summary measures for incorporation in 
pharmacoeconomic analysis (for example, cost effectiveness, cost benefit or 
cost utility analysis). 
10. To ensure the validity of original research studies, particularly when there are 
difficulties in interpretation which may render research results invalid (Cooper, 
1984). For example, some methods of problem formulation (e.g. post hoc 
hypothesis formulation), data collection (e.g. nonrandom sampling), data 
evaluation (e.g. eliminating subjects whose behaviour contradicts the research 
hypothesis), data analysis (e.g. failure to apply a statistical methods to evaluate 
a certain outcome measure) and reporting (e.g. failure to describe procedures 
conclusively). 
30 
3.4.5.3 Why Meta-analysis of Randomised Clinical 
Trials? 
Randomised clinical trials have increasingly become the principal method by which the 
efficacy of drug therapy is evaluated (Chalmers, 1989; Feinstein, 1983). Statistically 
significant results reported in these trials may significantly affect medical practice and 
the physicians' opinions in prescribing drug treatment. 
The appropriate application of the results of clinical trials to practice of medicine 
requires that both the scientific validity of the experiments and the generalis ability of 
their results to large patient populations are properly documented. 
In cardiovascular fields, many clinical trials have been designed to investigate the 
efficacy of various interventions, preventing clinical events such as myocardial 
infarction, sudden death, and stroke. Some of these controlled trials compare 
treatments and may produce moderate differences in outcome, but these differences can 
be clinically important. Such differences are sometimes hardly detected if the sample 
size of the trial is small and requires the recruitment of several thousands of patients 
(Peto, 1987). For example, if a treatment which produces 10% reduction in the risk of 
death is tested in a trial involving one thousand patients equally randomised, 450 deaths 
would be expected in the treatment group and 500 deaths in the control group. The 
significance of such a result is minimal and nonessential from a statistical point of view 
and it may be dispersed or even ejected as irrelevant. However, Glass (1987), the 
creator of the term 'meta-analysis', has declared, "by what logic would one want to 
overlook small effects that are actually present but are obscured by uncontrolled error? 
One may not be satisfied with small effects, but rejecting them as inadequate is different 
from not seeing them at all. If effects are small, one tries to increase them if one can, or 
one lives with them if one must." (Gottman and Glass, 1978). Due to this reason, Peto 
(1987) has highlighted the value of meta-analysis for capturing a credible conclusion by 
basing evidence primarily on an overview of all patients studied in all related unbiased 
trials. 
In addition to a sufficiently large sample size, randomisation is an important element to 
avoid bias particularly if the treatment does not produce a large effect. Therefore, rneta-
analyses have to be confined to RCTs (Sinclair and Bracken, 1992). 
Chalmers et al. (1987) measured the degree by which meta-analyses of smaller 
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controlled trials agreed with large multicentre studies. They found that the results 
produced by one meta-analysis which included 12 trials of intravenous beta-blocker for 
acute myocardial infarction in a total of 4408 patients, were similar to the results of two 
separate, large trials, one of which included 5778 patients and the other 16,027. 
Another meta-analysis of intravenous streptokinase for acute myocardial infarction 
involving 11 randomised, controlled trials and a total of 5268 patients resulted in an 
estimate of effect of similar magnitude to that of a large cooperative study involving 
11,712 patients. 
3.4.5.4 Meta-analysis Methodology 
Most of the fundamental, methodological issues associated with primary research 
studies are applicable to meta-analysis. This requires an explicit statement of the 
objective and precise description of research design; data definition including 
determination of the sample size and verifying independent and dependent variables; 
data retrieval procedures; considerations of data quality and use of appropriate statistical 
techniques. However, meta-analysis differs from primary research in certain aspects. 
In meta-analysis, a single study forms the unit of analysis and its findings and features 
contribute to the data set for a meta-analysis (McCain, 1986). 
Regardless of the analytical and statistical methods employed, all meta-analyses 
involves a series of steps. Some of which are associated with preparation, 
performance, or presentation stage. The sequence of these stages is the same as for any 
other type of research. Since the method of research of this thesis is mainly meta-
analysis the practical steps are discussed in detail in this chapter. 
3.4.5.4.1 Statement of Objective and Research Question 
This is the initial step of the planning phase and the foundation on which any meta-
analysis is built. During this phase, the research question and protocol should be 
explicitly defined (L' Abbe et al., 1987). For example, does the intervention prevent a 
specific clinical event? Formulation of research question and objectives should take 
place before collecting any data. 
The statement of the objective must capture the essence of the project but does not need 
to include all the details (Teagarden, 1989). Investigators can also suggest additional 
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secondary questions such as what is the subgroup for which the intervention may be 
most effective or how the intervention may affect other efficacy outcomes. 
In considering the research questions and objectives, it is important to be satisfied that 
the trials retrieved are addressing the same questions, enrolling comparable patients, 
inspecting the same interventions, and evaluating the same outcome. 
3.4.5.4.2 Data Definition 
As mentioned above, data definition should be performed before data collection. It is 
vital to provide a clear definitions for the variables of interest which include the 
independent and dependent variables, design and sample of trials to be included, and 
methods used for identifying and analysing studies. Independent variables include the 
patient characteristics, diagnoses and drug dosage. Dependent variables are outcome 
measures such as quality of life, decrease in blood pressure, success rates, pain scores 
or sudden death. 
3.4.5.4.3 Definition of Inclusion Criteria 
A meta-analyst should set a list of inclusion criteria for entry into the analysis. 
Generally, there is no standardised criteria for inclusion into a meta-analysis and they 
are usually adjusted according to the distinctive objectives of the analysis (Sacks et al., 
1987; L' Abbe et al., 1987). A clear explanation for the adoption of such criteria should 
be provided. 
3.4.5.4.3.1 Defining acceptable studies 
Inclusion criteria with respect to study design is the subject of debate. Most studies on 
treatment or prevention utilise designs which can be categorised into one of five 
classes. These classes can be listed in the following ascending order of methodological 
quality (Li Wan Po, 1996): 
1 . Case reports 
2. Surveillance data 
3. Cross sectional study 
4. Case control study 
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5. Cohort study 
6. Non-randomised trials with historical controls (i.e. observational studies 
comparing current patients who receive the intervention of interest with earlier 
patients of similar criteria, either from a similar institution or from the literature, 
but they did not receive the intervention). 
7. Non-randomised trials with concurrent controls (Le. observational studies 
comparing a contemporaneous treatment group with a control group). 
8. Randomised controlled trials (RCTs). 
The majority of meta-analyses in health care have tested the effectiveness of 
interventions using RCTs only, since they are the least prone to bias. 
Some meta-analysts have used data from non-randomised studies (Schneider, 1986), 
while others restrict their analyses to RCTs (Thompson and Pocock, 1991). In 
situations when RCTs are unethical or not appropriate in certain clinical settings, an 
overview of available studies still seems to offer the advantage of systematic search. 
Some authors (Wortman and Yeaton, 1983; L' Abbe et al., 1987) have suggested that 
changing inclusion criteria to include various types of studies can reinforce the analysis 
and lead to more reliable and valid conclusions. For instance, a primary analysis for 
data from RCTs can be undertaken first. Then, a secondary analysis can be repeated in 
the same manner, but this time by adding data from studies which were primarily 
excluded, such as nonrandomised trials. Such a sensitivity analysis can be used to test 
the validity of inclusion and exclusion criteria which constitute basic subjective 
components of meta-analysis. 
In addition to combining study results within the separate design categories, some 
analysts have created a new technique for combining results across categories called 
cross-design synthesis which is a topic of current methodologic interest (Colditz, 1988; 
Eddy etal., 1989; Rubin, 1990). These techniques were developed to account for the 
weaknesses associated with the generalis ability problems in existing randomised 
studies and comparison bias in data-base analyses. These challenges consider the 
elucidation of recognised bias in individual studies and bias due to cross-study 
differences, which include major differences in study designs and in the patient 
population included. A number of methodological options can be followed by the 
investigator to satisfy these demands which can be summarised in the following tasks: 
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1. Adjusting each randomised study's treatment effect. For example, standardise 
results to correct for over or under representation (FIeiss, 1973; Deming, 
1964). 
2. Stratifying studies by type of design (Light and Pillemer, 1984) and by 
coverage of patient subgroups (Himel et aI., 1986). 
3. Matching data base patients to those covered in randomised studies (Hlatky, 
1991) and identifying those remaining data-base patients not covered in 
randomised studies. 
4. Combing estimates of the treatment's effect within each stratum with adjustment 
for differences in quality, in studies' population coverage, and in reliability. 
This is by using models that account for differences (Eddy et aI., 1989) or by 
taking a weighted average with weights defined by the inverse of variances 
(Hedges and Olkin, 1985). 
5. Synthesising estimates across design categories (i.e. across strata). 
6. Providing an estimate for the empty stratum by using results from other strata. 
This process is called "projection" (Rubin, 1990; Colditz et al., 1988). 
However, many refinements need to be generated. Regardless of the employed study 
criteria, their rationale should be explained and a list of included and excluded studies 
should be provided. 
3.4.5.4.3.2 Defining acceptable patients 
Any patient characteristic or factor that could precipitate a systematic variation in results 
needs to be determined. Methods for treating systematic differences, such as blocking 
or blinding must be considered. 
3.4.5.4.3.3 Defining acceptable treatments 
The analyst must define the drug or intervention used and designate equivalent forms 
(for example, tablets, capsules, injectables, suppositories) or products (for example, 
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brands, generics) that would be permissible as equivalents. The dose and route of 
administration should be specified as well as acceptable regimens. Different dose 
regimens can lead to different response rates and stratificati.on may be required at the 
analysis. Exposure to the drug and patient compliance must be confirmed, particularly 
in epidemiologic studies or uncontrolled trials (Einarson et aI., 1988). 
3.4.5.4.3.4 Defining acceptable comparison groups 
Many clinical trials employ a control group which may receive placebo, standard 
therapy, or another comparable drug. Other studies may use historical controls or each 
subject may serve as his own control. A satisfactory meta-analysis requires that the 
comparison groups be either identical or very similar. Otherwise, differences in effect 
could be attributed to the differences in comparison groups and not to the drug under 
investigation. The analyst must determine what comprises acceptable comparisons. If 
different comparison types are used, sub-analyses for subgroups could be performed. 
3.4.5.4.3.5 Defining outcomes 
For each analysis, the acceptable outcomes must be defined. The outcome of interest 
may be measured by a continuous variable, such as a pain relief, or a quality of life 
score. Also it can be measured by categorical variables, such as sudden death, cured, 
not cured, or adverse events, by an ordered categorical variable, such as tumor stage. 
Categorical variables which change with time can be represented using life tables or 
survival curves. 
3.4.5.4.4 Definition of Exclusion Criteria 
Exclusion criteria should describe the reasons for rejecting some studies which met the 
inclusion criteria. The most common reason is inadequacy to provide sufficient 
substantial data. 
Exclusion criteria may explain variables more precisely than the inclusion criteria. For 
example, if the inclusion criteria accepted RCTs of amiodarone in patients with atrial 
fibrillation, the exclusion criteria could exclude patients with atrial fibrillation due to 
surgery (postoperative atrial fibrillation). 
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Exclusion criteria also specify confounding variables and how they must be controlled. 
It may exclude studies that did not match or control for confounding factors, including 
age, diet, smoking, alcohol consumption, or concurrent drug use. 
3.4.5.4.5 Data Collection 
For the results to be satisfactory, as for any literature review in a particular research 
field, one of the prerequisites is that they have been established on thorough inspection 
of the opinions of as big a fraction as possible of all the pertinent investigations. 
Consequently, an exhaustive literature of published and unpublished sources is 
required to retrieve as many ofthe relevant articles as possible (Glass, 1976). 
Data collection in meta-analysis includes all the procedures related to data identification 
including definition of data-base to be used, Key words employed, research strategy, 
and methods of data extraction. 
3.4.5.4.5.1 Identification of literature sources 
A very important aspect of meta-analysis is that it constrains a careful systematic search 
of all available sources of literature for complete verification of pertinent studies. As a 
result, a researcher should approach all accessible computerised and printed sources. 
Manual search of relevant journals, text books, dissertation theses, and reports from 
conferences and meetings is compulsory with regard to the financial and time 
limitations for performing a meta-analysis. Theses are high quality research materials, 
even if they may not have been published because they addressed an unpopular subject. 
Hence, "Dissertation Abstracts" may be a good source for location of such studies. 
Other forms of unpublished literature may be obtained by either formal or informal 
contact with experts in the field. Manual scrutinising of printed abstracting agencies 
and indices such as Index Medicus, Current Contents, and International Pharmaceutical 
Abstracts is recommended. 
A computerised search is performed through electronic data-bases, available in ON-
Line or CD-ROM versions. The On-line versions are universally applied and more 
widespread than CD-ROM versions, since they accommodate a larger bulk of literature 
than do the CD-ROM versions. 
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MEDLINE is the on-line version of 3 print indexes: Index Medicus, Index to Dental 
Literature and the International Nursing Index. It is provided by the U.S. National 
Library of Medicine, Bethesda, MD. It has strong English language and American 
literature preference. It covers more than 3,600 international journals published in over 
70 countries. In MEDLINE, an article is indexed using index terms (called MeSH 
headings) describing the content of the article and characteristics of research. 
The Excerpta Medica Data-bases (EMBASE) and the Institute for Scientific Information 
Inc Databases are available on-line. The Bath Information & Data Services (BIDS) of 
these databases are provided by Bath University. 
The BIDS EMBASE provides access to a major pharmacological and biomedical 
literature data-base covering about 3,500 journals from 110 countries. EMBASE 
comprises mainly journal literature (plus some book reviews and conference 
proceedings) with strong coverage of European journals. It goes back to 1980 and is 
updated weekly. The basic unit of information is an article. 
3.4.5.4.5.2 What are the potential biases in identification of 
relevant studies? 
Despite the efficiency of electronic databases for providing easier and faster access to a 
large body of published literature, identification of all relevant studies is still difficult. 
It has been reported that electronic searches may identify only 20 and 50% of acceptable 
studies (Bernstein, 1988; Chalmers et al., 1992). However, applying various search 
strategies will improve the generation of eligible reports. Gotzsche (1991) has shown 
that a search strategy for recalling double-blind trials in MEDLINE using the Medical 
Subject Heading (MeSH) "Comparative study" gave a yield of 122 reports with recall 
equal to 93.1 % and precision of 19%. When a combined search strategy with 
additional Key words such as "Double-blind method" was applied, the recall increased 
to 97.9% with a reduced precision of 17.3%. 
Ideally, a manual search of the pertinent journals as well as the references of all 
retrieved articles should be performed for further information. However, to depend 
entirely on the reference lists of published reports may lead to citation bias. A recent 
study of double-blind trials of non-steroidal anti-inflammatory drugs showed a high 
frequency of multiple publication and reference bias (Gotzsche, 1987). This was 
ascribed to citation of previously published reports which were biased towards positive 
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trials of the drug. 
In addition to citation bias, there are difficulties arising from indexing biases due to 
studies submitted only to minor or unimportant journals which are not indexed in any 
of the available databases, or indexed under wrong Key words. 
Furthermore, in many areas of research, two types of studies are most unlikely to be 
published. They are those which do not report significant differences between a certain 
treatment and control, and studies which show results not consistent with contemporary 
experiences (Jenicek, 1989). Consequently, such studies may be rejected from 
publication in major journals, submitted to minor journals, or have their publication 
post-poned for several years with an increased chance of being lost forever. When 
these studies are not published, they would remain in "file drawers" which would result 
in publication bias (Rosenthal, 1979). This can affect the conclusion derived from a 
meta-analysis based entirely on published studies (Simes, 1987; Chalmers, 1989). 
An attempt to minimise publication bias by obtaining data unreported in published 
reports, or by seeking information about any completed but unpublished studies from 
authors, was suggested (L' Abbe and Detsky, 1987; Chalmers, 1989). Nevertheless, 
there remains a debate about the significance of obtaining such information and the 
influence of their inclusion on the results of a meta-analysis (Peto, 1987; Yusuf, 1987; 
Sacks etal., 1987; Begg and Berlin, 1988). Chalmers eta!' (1987) have conducted 
comparisons of overviews which included unpublished data and those which utilised 
only published results. Although the conclusions sometimes differed, in most cases 
they were similar. 
In general, publication bias tends to favour positive treatment effects (Christensen and 
Gluud, 1995; Reid et aI., 1996). 
3.4.5.4.6 Evaluating the Quality of Relevant Studies 
The assessment of the quality of research is a subject of continuing debate (Chalmers et 
al., 1981; L' Abbe, 1987; Liberati et al., 1986; Colditz et aI., 1988; Jenicek et al., 1989; 
Miller et al., 1989; Fowkes and Fulton, 1991). The importance of qualitative 
assessment of individual studies before combining them in meta-analysis has been 
stressed by several authors (Sacks et al., 1987; Jenicek, 1989; Vandekerckhove et al., 
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1993). 
Assessment of quality is not an easy task. For a study to be included in a meta-
analysis, it should be of sufficiently high quality of design and execution to confmn the 
scientific validity and generalisability of the results to larger populations. 
For assessing the quality of a study, at least two authors should review and score the 
articles independently (L' Abbe et aI., 1987). In order to minimise bias, the journal in 
which the report appeared, the institution, the authors, the sponsoring agencies and the 
results should be masked. The articles should be judged on the methods used rather 
than on their results. Blinding and photocopying of the articles must be performed by a 
person not involved in data analysis. 
3.4.5.4.6.1 Quality assessment tools 
Several quality assessment tools have been developed for the evaluation of clinical trials 
(Chalmers, 1981; Liberati etal., 1986; Detsky etal., 1992; Simon and Wittes, 1985). 
Feinstein (1985) designed a qualitative tool for assessing case-control studies. He 
proposed the availability of 20 conditions for conforming the autonomy from random 
errors and significant types of biases. Although this tool would produce a quantitative 
quality scores, it was considered of no value if a major bias existed. 
A collection of criteria was introduced by Simon and Wittes (1985) and Grant (1989) to 
be employed by the editorial committee. The set included nine components for 
qualitative assessment of medical reports such as sufficient explanation of patient 
characteristics and reporting of loss to follow-up. Since it was formulated to be used 
by editorials, numerical scores were not given. 
Lichtenstein et al. (1987) generated 34 guidelines to be used for rating distinctions of 
case-control studies. The most essential items were procedures of data collection, 
sources of cases and controls, blinding of investigators, delineation of sampling and 
analytic techniques, and details of exposure. However, a quality score was not 
provided. 
Fowkes and Fulton (1991) highlighted important features which they thought should be 
cosidered when appraising medical research papers. They provided a set of six 
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guidelines each with its individual criteria, which were not essentially applicable to all 
categories of study design. The guidelines were in the form of the following questions: 
Study design appropriate to objectives?, study sample representative?, control group 
acceptable?, quality of measurements and outcomes?, completeness?, distorting 
influences? In judging the quality of measurements and outcomes, it was essential to 
consider the validity of measurements made, as well as its reproducibility, which is the 
evidence of consistency of measurement, by repeating the evaluation at different 
intervals and on different subjects. Thus, criteria of guidelines facilitated the 
conduction of detailed assessment of the methods and results to check its adequacy and 
completeness for achieving the objectives. When examining the criteria for each 
guideline, they recommended accrediting the deficiency of each criteria as 'major' or 
'minor' in terms of their anticipated influence on outcomes, and hence, on drawing 
conclusions. Unfortunately, the detailed assessments would not be converted to an 
overall score on the virtue of a paper. 
The previous quality assessment tools suffer from inherent subjectivity, since the 
criteria within these tools are usually not weighted, and the pros and cons of a particular 
research are not adjusted properly. For instance, depending on the objectives of the 
research, certain features of study design have a greater influences on the results and 
conclusion, such as in clinical trials blind allocation and randomisation of patients to 
different treatment may, apparently, be more serious than the influence of confounding 
factors or reproducibility of measurements. Furthermore, these tools were not 
developed specifically for the evaluation of the quality of RCTs or to distinguish their 
suitablity to be combined in meta-analysis. The major tools manipulated in meta-
analysis are discussed following. 
Chalmers et al. (1981) created a quality scoring system with the objective of producing 
a quantitative score, reflecting the overall quality of each RCT to be used in meta-
analysis. This system was based on their personal experiences in analysing clinical 
trials. The assessment scheme consisted of four divisions: basic descriptive material, 
the study protocol, the analysis of data, and data useful for potential combining of 
several RCT results. The first part was concerned with fundamentally identifying 
information, such as the name of the author(s), journal, sources of financial support, 
and whether or not the journal was peer reviewed. This part was not given any score. 
The second part dealt with the specific elements of good protocol design and was 
considered the most essential. The overall index is divided into three parts: a) the 
design and protocol of the trial with 60% of the weights; b) the statistical analysis of the 
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trial with 30% of the weights; and c) the presentation of the trial results with 10% of the 
weights. Within each division, a score is assigned for each applicable item. The score 
is then divided by the total possible score, giving an overall quality index by adding up 
the three forms' itemised scores and dividing by the total possible score. Although the 
flexibility of the method allows its application for the assessment of trials with different 
objectives and endpoints, it has some defects, due to its subjective interpretations, even 
after the evaluators discussion which may add to subjectivity of the evaluation. 
Further, its meticulous grading for incomplete reporting in published study report, 
which may improperly reduce the quality score for a study, particularly when such 
items were omitted from reports due to restricted publication policy rather than because 
they were not considered in the study design. 
Liberati et al. (1986) modified Chalmers' instrument to satisfy specific requirements of 
long-term trials in oncology, since there are usually high dropout rates, treatment 
groups are commonly small, and predicted outcomes require long-term follow-up. 
Consequently, some new points were introduced, and adjusted weights were assigned 
to others. The overall score was split into two divisions to assess the internal validity 
of a study. These divisions were concerned with the merit of its design and 
adminstration, and the external validity which assess the information that reflects the 
generalis ability of the results. Nevertheless, assigned scores were not based on any 
discerned absolute measures of quality, and a clear justification for its use was not 
provided. 
Koes et al. (1991) introduced a list of criteria which they had modified after it was first 
developed by Ter Riet et al. (1990). Although they claimed that the criteria were based 
on generally accepted principles of intervention research, a detailed explanation was not 
presented. Furthermore, the weight assigned for each criterion was arbitrarily selected 
(for example, five points were added to the study if it was stated that the intervention 
was handled by qualified therapist, and the five points were subtracted from the 17 
points given for the sample size). In addition, marking a study as positive or negative 
was based on the results without taking into account that negative results might be 
produced due to the inadequacy of small study populations for observing the treatment 
differences between the intervention and reference treatments. 
An illustrated bibliography of 25 scales and checklists for assessment of RCT quality 
was introduced by Moher et al. (1995) who have carried a MEDLINE search between 
January 1966 and December 1992. These tools were published between 1961 and 
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1993. Three of the scales were developed to assess the quality of trial reports which 
reflect the extent of "providing information about the design, conduct, and analysis of 
the trial". 8 were developed to assess "methodological quality" which was defined as 
"the confidence that the trial design, conduct, and analysis has minimised or avoided 
biases in its treatment comparisons". The remaining 14 were to judge both 
methodological quality and the quality of the report. Most of the scales were designed 
to be used in the context of assessing the quality of trials combined in meta-analysis. 
Since some of the scales were restricted for use in specific trials, they recommended 
caution in employing for other types of trials, and they suggested the utilisation of more 
than scales to verify whether different scales would produce comparable results. 
Consequently, this would assist the evaluators in choosing the appropriate scale, or 
performing some modification to former scales, in order to develop a fitting scale for 
distinctive new issues that need to be addressed. 
3.4.5.4.6.2 What is the impact of study quality on the results of a 
meta-analysis? 
The extent to which quality index of RCTs influence the estimation of effectiveness is 
unknown and discrepancies of authors' opinions continues. Some researchers have 
affirmed that they have not observed any association between effect size and overall 
quality index (Emerson et al., 1990). On the other hand, others have highlighted the 
impact of variations in the quality of the individual studies on meta-analysis, its threats 
to validity, and its consideration as an identified source of heterogeneity in the results 
(Peto, 1987; Chalmers et al., 1989; Jenicek, 1989; Detsky et aI., 1992). 
Detsky et al. (1992) highlighted the possibility of reducing precision and adding 
variability to estimates of effect, when poor studies are combined with high quality 
studies. They stated that the conclusion of a meta-analysis, combining studies with 
diverse quality, may suffer from Type 1 error (by concluding that treatment has effect 
when in fact it has not), or Type 2 error (by concluding that treatment does not work 
when it does). 
3.4.5.4.6.3 How the quality score can be incorporated into 
meta-analysis? 
Individual quality scores can be used in the process of generating pooled estimates of 
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treatment effects by one of the following five methods (L' Abbe et al., 1987; Einarson, 
1988; Detsky et at., 1992): 
1. Setting a quality score as a cut off point for inclusion or exclusion of studies in 
a meta-analysis. 
2. Incorporating the quality scores as a weight in the statistical pooling of the data. 
3. Sensitivity analysis to identify whether design flaws may affect the overall 
results. 
4. Examination of the relationship between study quality and effect size. A visual 
plot of the effect size against quality score can be performed (Detsky et a/., 
1992). 
5. Sequential combination of trial results based on quality scores. This technique 
can be used to investigate the impact of individual trials on the accumulated 
effect size estimates. 
3.4.5.4.6.4 Inter-rater reliability 
If several evaluators assess the quality of the trials, inter-rater agreement should be 
assessed to resolve the contradictions and to minimise the potential for error and bias 
due to the subjectivity element (Fleiss, 1981; Rosenthal, 1984). 
3.4.5.4.7 Data Extraction 
A number of authors have emphasised the significance of controlling for observer bias 
during the process of data extraction (Sacks et al., 1987; Chalmers et ai., 1981) and 
have suggested separation of Materials and Methods sections from the Results section. 
Data describing details of patients characteristics in included studies, such as age, sex, 
ranges of diagnostic criteria, or other associated diseases, should be collected since 
these details are essential for determining the validity and generalis ability of a meta-
analysis. 
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3.4.5.4.8 Statistical Analysis and Pooling Techniques 
Various statistical methods for pooling results from individual studies have been 
presented (Light & Pillemer, 1984; Hedges & Olkin, 1985; Dersimonian & Laird, 
1986; Cooper, 1989; Berlin et al., 1989; Laird & Mosteller, 1990; Rosenthal,1991). 
The application of two or more methods and comparison of results are recommended 
by some authors (Fleiss, 1993). 
Some of the techniques are only used to test the statistical significance of the overall 
effect and to determine its direction without giving an estimation for the magnitude of 
the treatment effect (Light & Pillemer, 1984; Thompson & Pocock, 1991). 
Combining summary statistics in meta-analysis can be approached using two models. 
The first of these, which is referred to as a fixed-effects model, assumes a common 
underlying true treatment effect in the individual trials and any difference among the 
trials is ascribed only to chance. This model reflects the random variation within each 
trial but not potential heterogeneity between trials. Conversely, a random effects model 
assumes that the true treatment effects in the different trials are randomly positioned 
about some central value and takes into account both random variation within trials and 
heterogeneity between them (Dersimonian & Laird, 1986; Laird & Mosteller, 1991; 
Thompson & Pocock, 1991). 
The two groups of statistical techniques are now discussed in detail. 
3.4.5.4.8.1 
3.4.5.4.8.1.1 
Methods for pooling primary studies which are not 
based on outcome measurements 
"Vote Counting" method 
The simplest quantitative method available for combination of the results of several 
studies is "vote counting". A sign test is carried out to establish whether the pooled, 
statistically significant, studies suggest that "positive" studies occur more frequently 
than "negative" studies as follows: 
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Where, Z is the standard normal deviate; 
Np = the number of significant positive findings; and 
Nt = the total number of significant findings: "positive" or "negative". 
The p-value is obtained by referring the Z-statistic to the Standard Normal distribution. 
A statistically significant Z value would suggest that the treatme~t is effective (Cooper, 
1989). 
3.4.5.4.8.1.2 Combining of studies using significance tests 
One of the best known methods is Fisher's method based on the U statistic (Rosenthal, 
1991; Jones, 1995): 
It 
u= - 2 L logePi 
i=l 
which has a X2 distribution with 2k degrees of freedom. Pi is the one-sided p-value 
from the ith of k studies. Another method proposed by Mosteller and Bush (1954) 
involves adding the Z values corresponding to each of the p levels in the studies 
included. For example, to combine the results of two studies, the two Z values 
obtained can be summed and divided by "2 to get a new Z value: 
Zl+ Z2 
,fi , which is again standard normal. 
However, the advantages of such methods are excessively confined to hypothesis 
testing and are of limited application, particularly where the estimation methods of the 
magnitude of effects and the confidence intervals are favoured. 
3.4.5.4.8.2 Statistical techniques for conversion and pooling of 
outcome data 
A variety of statistical methods are used for pooling reported trial outcomes. An 
important common feature is the conversion of individual study outcomes to a common 
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metrics, such as standardised mean difference (effect size), relative risk (RR), or odds 
ratio (OR). The choice of metric depends on the type of outcome data. Discrete or . 
proportional data are usually combined using odds ratio (OR) or rate difference (RD), 
while continuous data can be expressed by the effect size (ES). 
3.4.5.4.8.2.1 Combining categorical variables (discrete data) 
3.4.5.4.8.2.1.1 Combining raw data 
Combining raw data from the different studies does not account for the random 
variation within each study or across studies and hence it may present deceptive 
consequences. Furthermore, the estimations may be contradictory. 
3.4.5.4.8.2.1.2 Conversion to summary measures 
The most commonly used summary measures for categorical outcomes are: odds ratio 
(OR), relative risk (RR), and rate difference (RD). 
A • The Odds Ratio 
An individual odds ratio is calculated from a single contingency table ("2 x 2" table). 
Mantel and Haenszel method (1959) pools the odds ratios from a series of contingency 
tables ("2 x 2" tables). This method has been subsequently represented by Yusuf and 
Peto (1985) to calculate individual OR and pooled OR in meta-analysis, and since then 
it is commonly referred to as Mantel-Haenszel-Peto method or simply, as Peto method. 
This method allows the calculation of individual OR for each study with the associated 
95% confidence interval and the pooled OR with its 95% confidence interval by 
designating a weight for each study based on their sample sizes. The Mantel-Haenzel 
method weights unlogged DRs inversely to the variance. As a result, these methods 
can be used to test the "null hypothesis" (for the direction of the effect) as well as to 
determine the range of the effect and the significance of any differential effects (Berlin 
et al., 1989). 
Careful interpretation of the results is recommended when Peto's method is used. It 
has been shown that this method may produce biased summary odds ratios (Greenland 
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and Salvan, 1990) when there is a serious imbalance in the number of patients or 
frequencies of events between the treatment groups and the control groups, which is 
very common in observational studies (Thompson and Pocock, 1991; Fleiss, 1993). 
Also there is a potential bias when the overall OR is far from unity (Fleiss, 1993). 
However, this is infrequent in RCTs. 
The fixed-effects model assumes no differences in the underlying true treatment effect, 
and the authors have presented a formal test for the homogeneity of the odds ratios, that 
is, a test that the observed treatment effects vary only randomly around some common 
value. The test statistic has an approximate chi-square distribution with a degrees of 
freedom equal to K-l (where K is usually exactly equal to the number of studies) 
(Yusuf et al., 1985; Berlin et al., 1989). 
The procedures for estimation of pooled OR by Peto's method can be summarised as 
follows: 
In the i th trial, (i= 1 , .... ,K), with Ni the total number of patients in the trial, let nj be the 
number of patients in the treatment group, let the total number of events from both 
treatment and control groups be dj , and let the number of events in the treatment group 
be Oi. Expected number of events in the treatment group can be calculated by Ej = 
(n/Ni)di. Under the null hypothesis of no treatment effect, the quantity 0i-Ei should 
vary randomly around zero, with variance Vi= Ei x [(1- n/Nj) (Ni-dj)/(Nj-l)]. The 
individual odds ratios for each trial can be calculated as follows: 
The approximate standard error of the natural logarithm of ORj is estimated by 
and its 95% confidence interval by 
exp [lnORj ± 1.96 SE (lnORj)] 
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A test statistic for the hypothesis of no effect of treatment which has an approximate X2 
distribution with one degree of freedom is 
An approximate X2 test of homogeneity uses the test statistic 
k [L (OJ- E)]2 k (0 _ E )2 
2 ~[i i]_ 
Xk-l = i.J V ---:-k---
j=l ar j 
i=1 
L Var j 
j=l 
The pooled odds ratio (O~) from k studies is estimated by: 
k 
L (OJ - E j ) 
O~ = exp[ j= 1 k ] 
L Var j 
j=l 
and an estimate of the approximate standard error of the natural logarithm of O~ is 
presented by: 
with 95% confidence interval 
exp[LnOR ± 1.96 SE (LnOR)], with dJ=I. 
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Other fixed-effect methods used for calculating the pooled odds ratio include the 
Woolfs method, which uses a weighted average oflog OR's (Thompson and Pocock, 
1991; Fleiss, 1993). 
B • The Relative Risk 
For calculation of categorical response variables in clinical trials (such as 
improved/unimproved), or in cross-sectional or longitudinal epidemiological studies, 
the following procedures can be followed (Rothman, 1986; Fleiss, 1993): 
Within a study with sample sizes of n 1 and n2, let aj and bj be the observed rates of 
occurrence of an event in the treatment and control groups respectively, and let PI and 
P2 be the expected values of aj and bj. The relative risk in the ith trial is given by: 
Consider the values for the two possible outcomes as presented for the ith study in the 
following 2><2 table: 
Table X: Contingency Table 
Group 
(Number of patients) 
Outcome Treatment Control 
Good aj bj I 
Poor Cj dj 
Total nl n2 
If al -0 or bl -0, RR1IS usually adjusted to 
(a j + 0.5) I [(a j + 0.5) + (c j + 0.5)] RR j = --~----~------~--~ (b j + 0.5) I [(b j + 0.5) + (d j + 0.5)] 
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Total 
Nl 
N2 
Nt 
RRj is approximately normally distributed about a mean of AA. The logarithm of RRj 
(lnRRj) has a sampling variance estimated by 
The standard error of InRRj is 
and the 95% confidence interval ofRRj is produced by 
A significance test for RRj is based on the Z statistic 
InRRj 
Z= SE(lnRR) 
To test the null hypothesis of homogeneity of RRj's, the Q statistic (DerSimonian and 
Laird, 1986) is calculated: 
(lnRRj - InAA)2 
Q= L Var(lnRR) 
where InAA is a weighted average logarithm value of InRRj' s, that is 
InRR= ----
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where Wi, the individual study weight is estimated aSWj= IN ar (lnRRj), with standard 
error of natural logarithm of RR 
SE(lnRR) = (L W)-1/2 
The pooled rut therefore, is obtained by 
LWjlnRRj 
R~= exp ( ) 
LWj 
C. The Rate Difference 
The RR describes the relative, rather than the absolute, magnitude of reduction in the 
event rate. For example, an RR of 0.8 indicates a 20% reduction in the rate of events in 
the treatment group relative to the rate of events in the controls. The rate difference, on 
the other hand, is an absolute difference scale worthwhile for the assessment of the 
potential public health consequences of treatment (Berlin et al., 1989). Hence, an RD 
of -0.4 indicates an absolute 40 percentage point reduction of events in the treated 
group (Hamilton, 1979; Rothman, 1986). The inverse of rate difference (11Rf» allows 
the estimation of the numbers needed to treat (NNT) in order to prevent one patient 
having an event (Sackett et al., 1991). 
The pooled difference between event rates in the treatment and control groups can be 
estimated by using the DerSimonian and Laird-modified Cochran method (D&L 
method). Assuming dti and dci to be the number of events in the treated and control 
groups, respectively, and the corresponding sample size to be nti and nei. the 
proportions of events in the treated and control groups are:P = d. / n . and P = d . / n . 
II II CI CI· 
The rate difference in the ilh study is estimated by: 
e = RD.= p.-p. I II CI 
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with a binomial variance estimated by 
with Wi= lISi. The standard error of InRDi is SE(lnRDj) = ...JS j, giving an approximate 
for RDi of 
exp[lnRDi± 1.96 SE (lnRDi)] 
A test of homogeneity (Cochran, 1954) is given by 
It 
Q = L w j (9 j -e w )2 
j=l 
where Wi = SrI. e ,the pooled RD is approximated by 
w 
e = ---
w 
3.4.5.4.8.2.2 Combining continuous variables 
The most commonly applied methods for combining continuous data are the 
standardised mean difference (SMD) and the weighted mean difference (MDw). 
A • Standardised mean difference 
The SMD, which is also called effect size, is useful for combining results of studies' 
expressed as continuous outcomes (Laird and Mosteller, 1990). The main objective is 
to convert the effect to a unitless measure to allow the combination of different 
outcomes (Glass, 1976; Rosenthal & Rubin, 1978; Hedges & Oikin, 1985). However, 
it is essential to differentiate between "effect size" and the more general expression "size 
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of the effect", since the latter can be used interchangeably with any logical measure, 
while the former has specific technical assumption in meta-analysis (Laird and 
Mosteller, 1990). 
Many effect sizes have been employed in meta-analysis including Cohen's d, Glass's 
fl, and Hedges's g. Glass (1976) suggested that the difference between two means of 
the treatment and control group, X Ii and Xci , in the ith trial, (i = 1, 2, ...... , k) be 
di vided by the standard deviation of the control group, S cit and hence Glass's delta or 
~ can be represent as: 
Hedges (1982) showed that the Glass's estimator is biased and the replacement of Sci 
by Si, the pooled within-groups standard deviation produced less bias 
However, when the S is based on two different conditions which vary greatly from 
each other, or if the comparison is undertaken among different treatment levels, it is 
suggested that the standard deviation of control is more appropriate, since pooling two 
variances could result in two different standardized values of the identical mean 
difference within a trial, where several treatments are compared to a control. In this 
case, the assumption of equal population standard deviations is not valid and the use of 
Glass's delta is recommended (Hedges & Olkin, 1985). 
In addition, Hedges (1982) has also reported on the following simple estimator that is 
more accurate: 
X .-X. 
ESi =C (m) hS C1, i= 1, .... , k 
c 
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where m = nti + nci - 2. C(m) is given approximately by: 
3 
C (m) = 1 - 4m _ 1 
Hedges showed that if the assumption for the t test between means are met in each 
study, then the sampling variance of ESj is approximately 
Consequently, the standard error ofESj is 
If the components for effect sizes are not reported precisely in articles, estimation of 
effect size can be obtained from sample sizes, t tests and correlation coefficients 
reported as shown by Laird and Mosteller (1990): 
Furthermore, Hedges pointed out the possibility of computing pooled Scp from the 
standard error data by applying the following equation: 
where SEc is the standard error of the control group. Then, effect size is estimated by 
Before pooling the individual effect sizes it is essential to test for the homogeneity 
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across them by the calculation of Q statistics as: 
Q = L wj(SMDj-SM DW)2 
j 
where SM Dw is the weighted average value of ESj given by the formula: 
LwjSMD j 
j 
---- , with weight calculated as Wi = 11 Vi' 
B. Weighted mean difference 
The weighted mean difference is the opposite of SMD and it is calculated as 
k 
LWiMDi 
MDw = _i=_l"""'k __ 
where MDj represents the absolute difference in mean values between the treatment and 
control groups, X Ii - X ci without standardisation and Wi = 
1 
S ~ 2' where Sti 
II Sci (-+-) 
n· n II ci 
and Sci represent the standard deviations for the treatment and control groups, and nti 
and nci. the sample sizes. 
The 95% CI for MDj is MD j±1.96SE (MDj), where SE(MDj) = 1 s/ + S;j . The 
n ,j nci 
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95% CI of MDw calculated as MDw±I.96SE (MDw) and its standard error as SE 
(MDw) = t. (Sinclair and Bracken, 1992), 
LW i 
i=l 
The overall effect is expressed in the same units as the individual mean values in the 
primary studies and thus it can be easily interpreted. If the interval of the 95% CI does 
not include 0, the difference can be considered as significant at least for the nominal p 
value of 0.05 (Bracken, 1992). 
3.4.5.4.9 Evaluation of Bias and Confounding 
An important concern in meta-analysis is to achieve a greater objectivity, 
generalisability, and precision by including all the available evidence from relevant 
studies. However, the aims of meta-analysis are usually broader than those of smaller 
individual studies which differ substantially in their patient selection, baseline disease 
severity, treatment regimens, and various other forms of confounding, interactions, and 
bias which account for differences in results among studies other than that due to 
chance (Thompson, 1994). Hence, a failure to investigate potential sources of 
heterogeneity may lead to misleading conclusions (L' Abbe et al., 1987; Thompson & 
Pocock, 1991). 
Although a test for heterogeneity of treatment effects between trials can be performed, 
such a test is of limited value in clinical practice, not only because it has low power to 
detect any real difference that may exist, but mainly because some heterogeneity will 
definitely exist even if the test was statistically non-significant (Thompson & Pocock, 
1991; Morris et al., 1992; Gansevoort et al.; 1995). A meta-analysis that merely 
displays the pooled result of a group of studies using the random-effects method 
without appraising the impact of differences in study design, is a misuse of this method 
(Morris, 1994). 
Several statistical approaches and formal tools can be employed in meta-analysis for 
detecting and quantifying the influence of certain biases and confounders that contribute 
to heterogeneity in study results (Morri~ et ai., 1992). These tools are comparable to 
conventional statistical techniques used for evaluation of bias in a single experimental 
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study and they include stratification, meta-regression, sensitivity analysis, and quality 
scoring (Licciardone et al., 1990; Teo et al., 1991; Morris, 1994; Berkey et al., 1995; 
Tweedie & Mengersen, 1995). Stratified analysis is the most commonly utilised tool, 
particularly for grouping studies according to differences in study design to inspect the 
impact of such differences on final outcome. 
In addition, meta-regression was proposed for estimating the effect of treatment versus 
control as a function of continuous or categorical clinical variables that influence 
efficacy (for example, age, weight, gender) and other design factors (for example, 
sample size, randomisation, blindness) (Greenland, 1987). A random-effects 
regression model was developed in that context to augment the random-effects model of 
DerSimonian and Laird for the synthesis of 2 x 2 tables (Berkey et al., 1995). This 
model is based on the general relationship operated in weighted least squares regression 
techniques: 
In (R) = Bo+BlMl+e 
where R is the relative risk, Bo is the baseline risk, Ml is the effect modifier with 
coefficient B 1, and e is an error term. The effect and effect modifier are weighted by 
the reciprocal of the variance for each study. The random-effect regression model can 
be represented by: 
y.= X.a + B.+ e· I I I I 
where Xj is a row vector representing the values of covariates for study i, a is a column 
vector of regression coefficients. The Bi symbolise the ith trial's true deviation from the 
true mean of all trials having the same covariate values (specified in Xj). The Bj and ej 
are independent, therefore var (Yj) = D + Uj2, where Uj2 is the within-study variance 
estimated from individual studies and D is across-study variance. When studies are 
homogenous, the D approaches 0 and the random-effects regression model reduces to a 
fixed effect analysis. 
Although the meta-regression is a more powerful tool than simple stratification, its 
implementation is not always obtainable if most fitting data is missing from published 
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reports of clinical trials and a meta-analyst must employ stratification. 
Sensitivity analysis is another tool which can be applied in meta-analysis to study the 
quantal dose-response relationships (Berlin, 1993; Tweedie & Mengersen, 1995). The 
merit of such an approach derives from its importance for investigating causal 
relationships. 
Furthermore, quality scoring techniques represent a constructive tool for evaluating the 
sources of bias which are difficult to quantify, precisely those related to study design 
and methodology. Therefore, developed quality scores may provide possible, credible 
explanation for heterogeneity in results among studies of various designs (Yusuf et al., 
1985; Morris et al., 1992). 
3.4.5.4.10 Assessing the Risk of Publication Bias 
Publication bias originates in several ways (Chann, 1982; Parmley, 1994). Dickersin 
et al. (1987) contacted 318 authors of published trials asking whether they had taken 
part in any unpublished randomised clinical trials. 156 responded that they had 
participated in 271 unpublished and 1,041 published trials. They claimed that the 
dominant rationality for nonpublication was negative results and a lack of interest. As a 
result, they advised the registration of all studies before data collection, so that they 
could be traced regardless of their publication status. Morris (1994) stated that "in the 
absence of a registry of epidemiologic studies, it is difficult, if not impossible, to 
quantify publication bias. 
Glass et al. (1981) reported that published sources tended to contain studies that agreed 
with existing scientific consensus, and that any study not substantiating validated 
practice might not be submitted by the investigator for publication or accepted for 
publication. 
Due to former information, publication bias is considered to has a serious implications 
for the validity and reliability of meta-analyses conclusions (Begg and Berlin, 1989). 
Cooper (1987) confirmed that all published and unpublished conducted studies should 
be identified and included in meta-analysis to minimise the publication bias in a meta-
analysis. Several methods aiming to detect the existence of pUblication bias and 
estimating its impact on certain meta-analysis have been presented. These methods are 
either graphical or numerical. 
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A technique for detecting the presence of publication bias was first introduced by Light 
and Pillemer (1984). Termed a funnel-graph, the technique involves plotting the 
sample sizes of the component published studies versus the summary outcome 
measures, or effect sizes. The individual study measures should be distributed 
symetrically around the unidentified true effect to yield a funnel-shaped graph in the 
absence of publication bias. Truncation of the lower half of the funnel will indicate that 
small negative studies have probably not been published. 
In addition to the informal examination of publication bias by visual inspection of the 
funnel-plot, formal test for publication bias was proposed by Begg and Mazumdar 
(1994) using an adjusted rank correlation as a statistical analog of the funnel plot. The 
concept of this test is to examine the correlation between effect estimates and their 
variances after standardising for the effect sizes to stabilise the variances (Begg, 1994) 
as follows: 
where tj and \)j are the estimated effect sizes and sampling variances from the k studies 
in the meta-analysis, i = 1, ........ , k. The t is estimated by: 
h • (~-1 )-1 . th . f-were \) i = \) i - i..J \) j IS e varIance 0 ti - t . 
The variances are usually inversely proportional to the sample sizes. Thus the test is 
similar to correlating effect size with sample size. Nevertheless, the two approaches 
may yield different results if an odds ratio or relative risk is employed, and if a 
significant imbalance in sample sizes exists (Begg and Mazumdar, 1994). 
Rosenthal (1979) termed publication bias as a "file drawer problem" due to the 
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accumulation of a number of unpublished studies in researchers' file drawers. He 
introduced a formula for estimating the number of studies that would have to 
accumulate in the file drawers before the overall probability of a Type I error is brought 
to any level of significance (p = 0.05). This number is termed by Cooper (1979) as the 
fail safe N (Nfs): 
LZ 
N fs.OS = ( 1.645 )2_N 
where N is the number of included studies in a meta-analysis. Z scores corresponding 
to the P values for individual effect sizes can be obtained from tables of normal 
distribution. 
Rosenthal's "Fail-Safe N" does not assess the impact of publication bias on the actual 
effect size. It is only appropriate when the number of studies themselves are the 
variable of concern (Einarson et al., 1988). An alternative approach which considers 
the influence of the file drawer problem on the effect size was proposed by Orwin 
(1983). The statistic is calculated as follows: 
N( ES - ESc) 
N fs = ESc - ES fs 
where N is the number of included studies, ES is the weighted average effect size 
obtained from meta-analysis, Nfs is the number of studies of a given effect size ES fs 
required to be added to N, to produce an overall effect size of ES c' The ES c is the 
criterion effect size selected according to Cohen's (1969) specification for an effect size 
of 0.2 as small, 0.5 as medium, and 0.8 as large. The ES fs of the studies to be added 
is usually considered to be "0" or any Cohen's criterion value required to be tested by 
an investigator (Einarson et al., 1988). Although this method was developed for effect 
size, other estimation of the size of effect, such as OR, RR, or RD, can be tested by 
substituting ES with pooled OR, RR, or RD. 
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CHAPTER FOUR 
ANTIARRHYTHMIC DRUGS FOR 
MAINTENANCE OF SINUS RHYTHM AFTER 
CARDIOVERSION 
A META-ANALYSIS 
4.1 INTRODUCTION 
Chronic atrial fibrillation (AF) is one of the most frequently encountered arrhythmias, 
occurring in 0.4% of the general population and 2% to 5% of patients over 60 years of 
age (Cairns and Connolly, 1991). A number of predisposing factors described earlier 
in Chapter One may result in atrial fibrillation including cardiovascular, pulmonary, or 
endocrine problems. Usually chronic atrial fibrillation is associated with symptoms due 
to haemodynamic insufficiency as a result of inadequate ventricular filling. Such 
symptoms, include palpitations, shortness of breath, headache, or even syncope, may 
occur at rest or during exercise, thus affecting the quality of life of the patients. In 
addition, chronic atrial fibrillation has a deleterious effect on cardiac function and 
consequently increases the risk of premature death (Levy, 1994). The risk of embolic 
complication was estimated to range from 5.6 fold in chronic atrial fibrillation not 
associated with heart disease, to 17-fold when it is secondary to rheumatic heart disease 
(Kannel et al., 1982). The primary end points of therapy were thought to be the rapid 
restoration of sinus rhythm, prevention of embolism, and maintenance of sinus rhythm 
prior to cardioversion. However, although the conversion to sinus rhythm, either by 
electrical or pharmacological means, is reported to be highly successful in this group of 
patients. The probability of recurrence of the attacks is also very high regardless of 
maintenance with further theraputic interventions (Clark and Cotter, 1993). As a result, 
secondary end points are often of interest when conversion to sinus rhythm or complete 
abolishing of atrial arrhythmia is not possible, and they include the following: i) control 
of ventricular rate both at rest and during exercise, ii) shortening the duration of the 
recurrent episodes, iii) and lengthening of the time to first recurrence and the interval 
between attacks (Pritchett and Lee, 1988). These end points are considered important 
for improving the quality of life of the patients. 
Cardioversion to sinus rhythm can be safely repeated by electrical or pharmacological 
methods. Electrical cardioversion successfully restores sinus rhythm in more than 90% 
of patients. However, only 25% remain in sinus rhythm for one year without chronic 
antiarrhythmic therapy (Sodermark etal., 1975; Hillestad et ai., 1971). In addition, 
electrical transthoracic countershock needs general anesthesia and prolonged 
anticoagulation before it can be performed. Therefore, several medical protocols using 
various drugs, administered either intravenously or orally, have been proposed in the 
past 10 years for rapid cardioversion (Middlekauff et al., 1992). Afterwards, 
prophylactic antiarrhythmic therapy can be initiated, sometimes even prior to 
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cardioversion, since the relapse risk is reported to be high in the first few days after 
cardioversion (Sopher and Camm, 1996). Although prophylactic therapy is crucial for 
many patients, it is frequently associated with intolerance and increased risk of more 
malignant ventricular arrhythmia developing. As a result, rigorous investigations are 
deemed to be essential prior to making a decision to institute antiarrhythmic therapy 
(Clark and Cotter, 1993). 
Class IA drugs (Chapter Two), particularly quinidine, have been commonly employed 
for conversion and maintenance of sinus rhythm after cardioversion. Two recent meta-
analyses evaluated the efficacy of quinidine for maintenance of sinus rhythm and the 
associated risk of proarrhythmia and mortality (Coplen et aI., 1990; Reimold et al., 
1992). The first meta-analysis pooled data only from randomised controlled trials, 
while the second meta-analysis pooled data separately from randomised controlled, 
non-randomised controlled, and uncontrolled clinical trials. Both meta-analyses 
reported higher efficacy rates for maintenance of sinus rhythm for quinidine treatment 
compared to placebo. The pooled results of randomised clinical trials showed a 
consistent positive difference in terms of proportion of patients maintaining sinus 
rhythm relative to placebo (rate differences were 23.6%, 23.4%, 24.4% at 3, 6, and 12 
months respectively), although the absolute percentage of patients maintaining sinus 
rhythm decreased with time. However, quinidine treatment was associated with a 
threefold excess in total mortality at one year (the summary odds ratio of Mantel and 
Haenszel was 3.5; 95% CI, 1-12.4; P < 0.05). Furthermore, several studies have 
reported major problems with quinidine, such as pro arrhythmia in the form of torsade 
de pointes, and serious noncardiac and organ toxicity (for example, syncope), during 
its use in the long-term treatment of atrial fibrillation (Selzer and Wray, 1964; 
Anderson, 1990; Feld, 1990). All of these previous studies have raised several 
questions about the safety of this agent and its appropriate indication for treatment of 
atrial fibrillation. Furthermore, in some countries the results from the two quinidine 
meta-analyses have led to major changes in choice of treatment for atrial fibrillation. 
For instance, in Sweden, use of quinidine in patients with atrial fibrillation has been 
abandoned (Edvardsson, 1993). 
Subsequently, other Class IA drugs such as disopyramide and Class IC antiarrhythmic 
agents, including flecainide, encainide, and propafenone, have been evaluated for 
terminating episodes of acute or paroxysmal atrial fibrillation and for maintenance of 
sinus rhythm after successful DC conversion in patients refractory to Class IA agents. 
Several small clinical trials have been conducted with various designs and involving a 
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wide range of patient populations. These trials involved either placebo-control and/or 
direct comparisons with other active antiarrhythmic drugs. Efficacy in those trials 
ranged from 39% to 64% at 6 months. Most have reported that noncardiovascular side-
effects are rare, but cardiovascular toxicity, such as heart failure exacerbation, 
brady arrhythmias, and atrial and ventricular proarrhythmia, occured in 7% to 27% of 
patients receiving those drugs (Bauernfeind and WeIch, 1990; Edvardsson, 1993). In 
addition, although Class IC agents appear to be effective in preventing the recurrence of 
atrial fibrillation, even in patients who have been refractory to quinidine, they tend to 
depress myocardial function and thus increase the risk of serious proarrhythmia, 
particularly late proarrhythmia (Falk, 1989). The Cardiac Arrhythmia Suppression 
Trial (CAST) has highlighted this postulation since 1989 (The Cardiac Arrhythmia 
Suppression Trial Investigators, 1989). Although this study was designed to test 
whether suppression of premature ventricular contraction would improve survival prior 
to myocardial infarction, some physicians have suggested that such agents should also 
not be used for treating atrial fibrillation or for maintaining sinus rhythm (Anderson, 
1990). In the USA and Sweden, these drugs are only approved for treatment of 
supraventricular arrhythmia in patients devoid of any complicated heart disease 
(Edvardsson, 1993). 
Recently, newer Class III agents, mainly amiodarone and sotalol, have been introduced 
to the market as alternatives to quinidine and Class IC agents (Anonymous, 1989; 
Follath et aI., 1993; Levy, 1994). These agents act by prolonging the duration of 
action potential with corresponding prolongation of refractoriness of the myocardial 
tissue (Vaughan Williams, 1992). Amiodarone is being unique by possessing all other 
four Classes' actions (Edvardsson, 1993). Several studies have reported high efficacy 
rates with this agent ranging from 50% to almost 80% (Zarembski et al., 1995). 
Studies have shown that amiodarone may produce lower mortality compared with Class 
I drugs in patients with previous myocardial infarction or advanced heart disease 
(Middlekauff, 1991). However, it was associated with long-term toxicity, particularly 
pulmonary fibrosis, alopecia, hyperthyroidism or hypothyroidism, and visual 
disturbances (Wilson and Podrid, 1991). Nevertheless, most of these adverse effects 
were dose-related, and were not reported in patients receiving less than 300 mg/day 
(Dusman, 1990). Furthermore, amiodarone has a long half-life, with considerable 
interindividual variation (13 to 17 days), and the elimination period can reach 12 
months, particularly in elderly subjects (Puech, 1991). This would limit its use to 
second-line therapy where other agents fail (Bauernfeind and Welch, 1990). On the 
other hand, sotalol, which possesses a non-selective beta-blocker activity in addition to 
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Class III action, has been shown to be highly effective for maintenance of sinus rhythm 
in up to 50% of patients at 6 months with little serious toxicity (Juul-Moller et al., 
1990). The antiarrhythmic efficacy of sotalol in maintenance of sinus rhythm is mainly 
ascribed to its beta-blocking activity, which rendered sufficient rate-control, either 
during chronic atrial fibrillation or during relapse of paroxysmal atrial fibrillation 
(Edvardsson, 1993). However, sotalol is contraindicated in the patient with impaired 
cardiac function, due to its significant negative inotropic effects. 
A recent meta-analysis was conducted to assess the efficacy of flecainide and 
amiodarone for maintenance of sinus rhythm (Zarembski et aI., 1995). The studies 
included in that meta-analysis have no placebo-controlled population. Furthermore, 
direct comparisons of the data obtained from the amiodarone and flecainide population 
were not possible. In this meta-analysis patients with paroxysmal atrial fibrillation and 
those who develop atrial arrhythmias prior to surgery were excluded. 
A systematic search for published meta-analyses of antiarrhythmic drugs clinical trials 
did not identify any meta-analysis designed to estimate the magnitude of effect of 
sotalol for the treatment of atrial fibrillation. 
Due to the previously reported difficulties associated with the treatment of atrial 
fibrillation, and as a result of the growing interest in this broad area of use of 
antiarrhythmic drugs (Singh, 1995), this chapter describes a meta-analysis which was 
conducted with the following objectives: 
• 
• 
• 
To confirm the results of the previously conducted meta-analyses of quinidine for 
maintenance of sinus rhythm (Coplen et aI., 1990; Reimold et al., 1992). 
To estimate the relative efficacy of sotalol, amiodarone, and flecainide for 
maintenance of sinus rhythm in patients with paroxysmal or chronic atrial 
fibrillation in studies with long term follow-up (~3 months). 
To undertake a subgroup analysis to identify patients, who are more likely to 
benefit from a particular treatment. 
• To examine the impact of various study designs on outcome in trials of 
antiarrhythmic agents. 
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• To assess quantitatively the incidence rate of proarrhythmic events, mortality due to 
various causes, new congestive heart failure, and other serious side effects upon 
treatment with any of the agents considered. 
• Assessment of possible publication bias using contemporary approved graphical 
and numerical techniques. 
4.2 METHODS 
4.2.1 Definition of Inclusion Criteria 
4.2.1.1 Design of Primary Studies 
Studies using the following designs were included: randomised controlled trial with 
parallel control group(s), randomised controlled trial with sequential controls (cross-
over study), non-randomised controlled trial with parallel control group(s), non-
randomised controlled trial with sequential controls (non-random cross-over), and 
uncontrolled trials which involved one treatment group without application of 
randomisation for allocation of treatment group. For the randomised controlled and 
non-randomised controlled, the simultaneous control group may either receive placebo, 
no active treatment, or any other active antiarrhythmic agents for the purpose of direct 
comparison. 
In the clinical trials evaluating the effectiveness of treatment for maintenance of sinus 
rhythm, it was crucial for a study to be included to have carried a longitudinal follow-
up of the patients after cardioversion for a period of not less than three months. 
4.2.1.2 Diagnostic Criteria and Types of Patients Included 
Patients of any age, and of either sex, with an established diagnosis of chronic or 
paroxysmal AF undergoing cardioversion to sinus rhythm, were included. Chronic AF 
was defined as continuous AF, in which sinus rhythm had been present briefly after 
prior pharmacological or electrical cardioversion. Paroxysmal AF was defined as 
recurrent self-terminating episodes lasting 48 hours, alternating with periods of sinus 
rhythm (Reimold et al., 1993). Patients with chronic atrial flutter (AFL) or with other 
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forms of atrial tachycardia, such as supraventricular tachycardia (SVT), paroxysmal 
supraventricular tachycardia (PSVT), or paroxysmal atrial tachycardia (PAT), were also 
included. These patterns of arrhythmias usually occur simultaneously and generally 
degenerate into atrial fibrillation, which sometimes makes it difficult to distinguish from 
each other (Roark et al., 1986; Henthorn et al., 1991). 
Trials that enrolled only patients with acute AF «1 months), and/or AF that developed 
prior to cardiac or thoracic surgery, were excluded. 
4.2.1.3 Types of Interventions 
Interventions involved comparisons of orally or intravenously administered doses of 
quinidine, flecainide, amiodarone, or sotalol versus placebo and/or any other 
antiarrhythmic agents given initially for cardioversion to restore sinus rhythm. The 
trials were included if the dose was titrated sequently to the maximum tolerated doses or 
until the sinus rhythm was restored, to avoid misinterpretation of inefficacy at low 
doses. If the atrial fibrillation persisted, direct-current cardioversion could be 
performed. After restoration of sinus rhythm by either electrical or pharmacologic 
cardioversion prior to the dose titration phase, maintenance doses could be adjusted 
downward to avoid or reduce side-effects if necessary. 
4.2.1.4 Study Parameters and Outcomes 
Trials were included if they reported the maintenance of sinus rhythm as the primary 
end point, and if they provided information from which the number of patients 
remaining in sinus rhythm at different follow-up time points could be obtained. 
Maintenance of sinus rhythm was documented by the absence of AF attack as recorded 
in a telemetry ward, and later by 12-lead electrocardiogram, Holter monitoring as 
reported by general practitioners, and/or electrocardiogrphic telephone transmitteror as 
reported by patients (Reimold et al., 1993; Zarembski et al., 1995). 
The secondary end points reported in the clinical trials were the incidence of deaths, 
proarrhythmic events, or other severe adverse effects. Proarrhythmia was defined 
according to the criteria proposed by Morganroth et al. (Chapter Two). 
Trials were excluded if they did not satisfy any of the above inclusion criteria, if they 
68 
provide unclear explanation of study design, or if follow-up data at different time points 
were not reported. 
4.2.2 Data Identification and Selection of Primary 
Trials 
To identify all clinical trials of flecainide, sotalol, and amiodarone in maintaining sinus 
rhythm after cardioversion, the English and non-English language literature was 
scrutinised from 1966 to July 1997, using MEDLINE database and the Bath Institute of 
Scientific Information Data Service (BIDS). Both the BIDS EMBASE and BIDS lSI 
were searched respectively. The subject heading employed were 'atrial fibrillation', 
'clinical trials', 'comparative study', 'random allocation', 'randomised controlled 
trials', 'placebo', 'double-blind method', 'single-blind method'. 
Table 4.1 MEDLINE search strategy 
Steo No. Method of search 
1 ANTIARRHYTHMIC AGENTS explode 
2 ATRIAL FIBRILLATION* 
3 explode ATRIAL FIBRILLATION/aIl subheadiJ!gs in MeSH 
4 A TRIAL ARRHYTHMIA * 
5 exolode ATRIAL ARRHYTHMIAlall subheadings in MeSH 
6 CARDIOVERSION explode 
7 HUMAN 
8 (lor 2 or 3 or 5 or 6) and (HUMAN in MeSH) 
9 Name of the drug explode 
10 8 and 9 
11 CLINICAL 
12 TRIALS 
13 CLINICAL TRIALS 
14 EXPLODE CLINICAL-TRIALS I all subheadings in MeSH 
15 RANDOM * 
16 RANDOM-ALLOCATION (Term aIlows no subheadings) in MeSH 
17 I RANDOMISED-CONTROLLED-TRIALS I all subheadings in MEeSH 
18 DOUBLE-BLIND-METHOD explode 
19 SINGLE-BLIND-METHOD exolode 
20 PLACEBO(Term allows no subheadings) in MeSH 
21 PLACEBO jtext word.l 
22 META-ANALYSIS explode 
23 OVERVIEWexmode 
24 HUMAN 
25 (11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23) and 
26 25 and 8 
27 25 and 9 
28 26 and 9 
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All of these terms were combined with each drug in MEDLINE database by applying a 
strategy which allows the identification of the maximum number of clinical trials reports 
using the combination of text words, "wild cards" and MeSH (Medical Subject 
Headings) terms as shown in Table 4.1. 
A similar strategy was used in BIDS EMBASE and BIDS lSI by combining the 
previous terms with drug names cited in the title, abstract, and/or keywords as shown 
in the Table 4.2. Although the period covered by MEDLINE extended back to 1966, 
BIDS search covered the period from 1981 to July 1997. 
Table 4.2 BIDS search strategy 
Sten No. Mpthotl of ~p!lrch 
I ANTIARRHYTHMIC AGENTS in title keyword and abstract 
2 A TRIAL FIBRILLA nON* in title keyword and abstract 
3 A TRIAL ARRHYTHMIA * in title, keyword and abstract 
4 CARDIOVERSION in title keyword, and abstract 
5 I HUMAN in title keyword and abstract 
6 Name of the drug 
7 1+5+6 
8 I 2+5+6 
9 3+5+6 
10 4+5+6 
II CLINICAL TRIALS in title, keyword, and abstract 
12 11+6 
13 RANDOM in title, keyword and abstract 
14 I 13+6 
15 DOUBLE-BLIND in title, keyword, and abstract 
16 15+6 
17 SINGLE-BLIND in title keyword and abstract 
18 17+6 
19 PLACEBO 
20 19+6 
21 1+12, 1+14 1+16, 1+18, then 1+20 
22 2+12,2+14,2+16,2+18, then 2+20 
23 3+12,3+14 3+16 3+18, then 3+20 
24 4+12,4+14,4+16,4+18, then 4+20 
Trade names of the drugs such as Tarnbocor and R-818 for flecainide; Cordarone and 
Amiodarone Hydrochloride for arniodarone; and Beta-Cardone, Sotacor, Sotazide, and 
Tolerzide for sotalol, were also combined. 
Relevant reports of clinical trials and meta-analyses were identified, recorded and 
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photocopied. The references cited in reports of clinical trials, meta-analyses, and 
reviews were scanned to identify other pertinent studies missed by the computerised 
search. Articles not available in the local university's libraries were requested through 
inter-library loans. Manual search of germane textbooks and INDEX MEDICUS 
(1996-1997) complemented the search. Letters were sent to the information officers of 
the pharmaceutical companies which are known to manufacture or market each drug to 
supply any information on unpublished trials. An attempt was made to identify 
obvious duplications in the studies retrieved. When there was duplication, the most 
recent report was used in the analysis, supplemented with information in earlier reports 
where necessary. Letters to the editors, case reports, foreign language reports without 
English abstracts, trials of the drugs for other potential indications, pharmacokinetic 
trials, and reviews were obtained and cited, but were not included in the analysis. 
Clinical trials of flecainide, amiodarone, and sotalol, were assessed for inclusion using 
the predefined inclusion and exclusion criteria (section 4.2.1). 
4.2.3 Data Extraction 
Data concerned with any of the following subheadings were extracted from the text, 
tables, and figures in the published clinical trials. 
4.2.3.1 Study Design Characteristics 
Clinical trials identified for each drug (flecainide, amiodarone, sotalol) were Classified 
according to the scheme proposed by Bailar et al. (1984): randomised controlled trials 
with parallel or sequential control groups, non-randomised controlled trials with parallel 
or sequential control; uncontrolled studies. For each trial the following information 
with regard to execution and protocol was extracted: 
• N arne of the first author 
• Publication status (full report! abstract! unpublished data) 
• Publication date 
• Design of the study 
• Number of patients enrolled 
• Number of patients in the full-exposure group defined as patients who were 
randomised, and received study medication even if the patient did not achieve sinus 
rhythm after cardioversion, or had no long-term follow-up 
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• Number of patients in the long-term treatment group, which includes patients who 
received one of the maintenance drugs under investigation or placebo, and were 
followed up longitudinally after they were successfully converted to sinus rhythm, 
either pharmacologically or electrically. This group excludes patients who failed to 
achieve sinus rhythm after cardioversion, patients who experienced intolerable side 
effects, patients lost to follow-up due to death, or patients excluded from longitudinal 
follow-up for various reasons 
• Number of patients allocated to each treatment group 
• Control used (active (name of drug) or placebo) 
• Dosage regimen during the initial titration phase and then maintenance dose during 
follow-up (mg/day) 
• Time of randomisation to study medication or control (before or after cardioversion) 
• The use of direct current cardioversion (DCC) 
• Previous agents used 
• Concomitant drugs administered which are most commonly ventricular rate regulating 
agents (digoxin, beta-blockers, and calcium-channel blockers) and anticoagulants 
• Duration of follow-up (months). 
4.2.3.2 Population Characteristics of the Included Studies 
The following details of patient population (in all treatment groups) were extracted from 
each trial when available: 
• Overall reported mean age (range) for all study groups, and for each study group if 
available 
• Number of males/ number of females 
• Left atrial diameter, mm (range), as measured by echocardiographic examination 
• Duration of atrial fibrillation (AF) defined as the number of months since the first 
documented occurrence of AF 
• Pattern of AF (chronic, paroxysmal), and number of patients with each pattern 
• Number of patients with other forms of supraventricular arrhythmias (AFL, PAT, and 
PSVT) 
• Cardiac diagnosis and likely etiologies of AF in patients enrolled. The number of 
patients with a given cardiac diagnosis in both the treatment and control group was 
tabulated separately. 
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4.2.3.3 Outcome Measures 
The following data essential for analysis of efficacy and adverse effects was extracted: 
• The number of patients converted to sinus rhythm by means of drug alone in each of 
the study groups 
• The number of patients converted to sinus rhythm by means of drug and direct current 
cardioversion in each of the study groups 
• The number of patients remaining in sinus rhythm at 3, 6, and 12 months after 
successful cardioversion in each of the study groups, where available. 
• Censored observations in each study according to Kaplan-Meier analysis from the text 
(Coldman and Elwood, 1979; Reimold et ai., 1992). 
• The number of patients remaining at risk was deduced from the Kaplan-Meier survival 
graph. However, if the numbers of patients remaining in sinus rhythm at 3, 6, and 12 
months tabulated in the paper matched the ones on the graph, it was assumed that there 
was no censoring. 
• The cumulative incidence of death, proarrhythmia, or any adverse effect in each study 
arm was collected, on an intention-to-treat basis. 
4.2.4 Statistical Analysis and Data Synthesis 
4.2.4.1 Efficacy Outcome 
The pooled proportion (P) of patients remaining in sinus rhythm at 3, 6, and 12 
months, in either the treatment or control group, was calculated separately for each trial 
design (Coplen et ai., 1990; Reimold et ai., 1992) as follows: 
P= ----
where S is the Kaplan-Meier estimate (proportion) of patients remaining in sinus 
rhythm at certain time point t for each individual study, and W = lI(variance of S). The 
variance of S is calculated according to Greenwood's formula (Hunter and Schmidt, 
1990) as follows: 
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2 d 
(S) . n (n -d) 
where d is the number of patients reverting to sinus rhythm in the interval (t-l) to t, and 
nt is the total number of patients at risk during, or at the beginning of, the same 
interval. 
For comparing treatments the rate difference (RD) in the proportions of patients 
maintaining sinus rhythm with the two drugs being compared, was calculated for each 
individual study. The RD values were pooled using the fixed-effects assumption, 
unless a test of homogeneity was statistically significant. In such a case, the 
DerSimonian and Laird random-effects model was employed (Chapter 3). 
In addition, reference standard values for P with quinidine at 3, 6 and 12 months (that 
were obtained from the meta-analysis by Coplen et al. (1990)), were employed to 
calculate the individual and pooled RDs of each trial design, particularly, uncontrolled 
studies, which lack a formal comparison to placebo or active control. These values 
were equal to 69.4%, 57.7% and 50.2% at 3,6 and 12 months respectively. 
To compare the P of different treatment groups in different trial designs (for example, 
PT of randomised controlled trials versus PT of non-randomised controlled), the Z value 
was calculated as follows: 
Z= 
where PIT and P2T are pooled estimates of the percentage of patients in sinus rhythm at 
time t for groups 1 and 2 respectively, and SIV is the sum of the variances of Ph and 
P2T. The statistical significance of z can be obtained from tables of standard normal 
distribution, where z > 1.96 gives a two-sided significance p value of < 0.05. 
4.2.4.2 Subgroup Stratified Analyses 
Stratified analysis according to the trial design, type of control (placebo or active drug), 
and type of patients (chronic or paroxysmal AF), was undertaken to identify sources of 
clinical and statistical heterogeneity of effect. Details of this analysis are shown in 
Table 6 of Appendix 4.2. 
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4.2.4.3 Mortality and Adverse Effects 
The incidence of mortality, proarrhythmia, and other side effects were estimated by 
employment of various statistical parameters that are well defined for dichotomous data . 
. These parameters included the odds ratio (OR), relative risk (RR), and rate difference 
(RD) and their 95% CI. The employment of these different parameters would verify 
the robustness of the results, since each one has its own value, and none of them was 
judged to be better than the others (Berlin et aI., 1989). However, RD is typically 
preferred due to its absolute clinical representation. 
The individual and pooled OR were calculated by both the Mantel and Haenszel 
technique for combining data from a series of2x2 tables, as well as by Peto's method 
as described in Chapter 2. The 95% confidence interval for the Mantel-Haenszel odds 
ratio were calculated by the method of Woolf (1955). The individual and pooled RR 
and RD were calculated under the assumption of fixed-effects model (Rothman, 1986). 
To avoid bias in OR estimation when small numbers are analysed, or when zero values 
are reported, 0.5 was added to each cell in the 2x2 table before calculation. The test of 
homogeneity was performed in each case to examine the consistency of trend across 
studies. The random-effects model would be utilised if heterogeneity existed. 
The previous parameters were computed separately for each trial design and for each 
drug. 
4.2.4.4 Patients' Cardiac Diagnoses 
The chi-square test was used to estimate the differences in distribution of cardiac 
diagnoses across trials' populations of different drugs (amiodarone, sotalol, and 
flecainide clinical trials), and across various treatment groups. 
4.3 RESULTS 
4.3.1 Description of Trials Identified 
Literature search between 1966 and July 1997 identified a total of 119 published studies 
of amiodarone (45), sotalol (28), and flecainide (47), examining their efficacy for 
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maintenance of sinus rhythm prior to cardioversion of chronic or paroxysmal atrial 
fibrillation. Only 42 (Appendix 4.1) of these studies were trials that satisfied the 
inclusion criteria (17 for amiodarone, 8 for sotalol, and 19 for flecainide). The 
remaining 77 studies (28 for amiodarone, 20 for sotalol, and 29 for flecainide) were 
omitted from analysis due to the following reasons: the trial was designed to test the 
efficacy for acute conversion of recent-onset AF of -5:.72 hours (Appendix 5.1: 12 for 
amiodarone, 5 for sotalol, 15 for flecainide), or AF developed after a cardiac or thoracic 
surgery (Appendix 5.1: 3 for amiodarone, 5 for sotalol, 4 for flecainide) to normal 
sinus rhythm, with short study observation period; the study was designed to evaluate 
other secondary efficacy endpoints such as control of ventricular rate both at rest and 
during exercise (1 for sotalol, Appendix 4.1: 1); published report did not contain 
longitudinal follow-up data for the patients at different time points prior to 
cardioversion (9 for amiodarone, Appendix 4.1: 1,3,4,5,6, 7, 8, 9, 10; 5 for sotalol, 
Appendix 4.1: 3, 4, 7, 8, 9; 3 for flecainide, Appendix 4.1: 3, 4, 9); the design of the 
trial permitted the addition of other concomitant antiarrhythmic drugs to the amiodarone 
sotalol, or flecainide treatment arms at any stage of the trial (1 for amiodarone, 
Appendix 4.1: 3; 1 for sotalol, Appendix 4.1: 2); the trial was a duplicate publication (1 
for sotalol, Appendix 4.1: 6; 5 for flecainide, Appendix 4.1: 1, 2, 5, 6, 7); and data 
were reported in the form of review (2 for the flecainide, Appendix 4.1: 8, 11), or case 
report (1 for sotalol, Appendix 4.1: 5). 
The characteristics of the trials of amiodarone, sotalol, and flecainide included in the 
analysis are summarised in Tables 4.3, 4.4, and 4.5 respectively. As shown for 
amiodarone, 5 studies were RCTs, and 12 trials were uncontrolled. For sotalol, 6 
studies were RCTs, and 2 trials were nonrandomised controlled. For flecainide, 9 
studies were RCTs, 4 trials were nonrandomised controlled, and 6 trials were 
uncontrolled. 11 of the total 20 RCTs employed placebo comparisons (2 for 
amiodarone, 2 for sotalol, and 7 for flecainide). 11 were head to head comparisons of 
various antiarrhythmic drugs. 10 RCTs adopted an open-label, parallel design (5 for 
amiodarone, 3 for sotalol, and 2 for flecainide). 2 RCTs were double-blind, parallel 
design (1 for sotalol, and 1 for flecainide), and 5 RCTs were double-blind, crossover 
design (all for flecainide). All the nonrandomised trials utilised an open-label, 
crossover design. 
The included trials enrolled a total of 3937 patients, however; the full exposure group 
involved 3712 patients. Data regarding the maintenance of sinus rhythm during the 
long-term follow-up were provided for 3534 patients: 876 patients received 
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Table 4.3 Characteristics of randomised controlled, and uncontrolled trials of amiodarone included in analysis 
Ralldomised 
Study name No. of Long-term Treatment Type of conlrol Full Dosage; LD and Tillie DCC Concomitanl Duratioll of 
patients follow-up allocation exposure maintenance dose amiodarolle drugs follow-up 
enrolled group (Amiodaro group (mglday) started months 
nelCon- (range) 
trol) 
Vitolo et al. 1981 54 chronic AF 54 28/26 Quinidine 23 400 mg/day for the first After CV NA Quinidine was 12.6 (6-36) 
15 days; added to 
then for 5 days each amiodarone for 
week (oral) the first 7 days 
Martin et af. 1986 70PAF 65 43/22 Disopyramide 70 600 mg/day for 2 weeks; NA NA Possibly digoxin 16.2 
then 400 mg for a 
further 2 weeks; 
then 200 mg daily (oral) 
Bosi et af. 1990 97 chronic AF 97 48/49 Placebo 97 600 mg/day for 10 days; After CV NA Not used (12-48) 
then I grnlweek for 30 
days; 
then maintenance dose 
(NS) for 12 to 48 
months (oral) 
Zehender et af. 40 chronic AF 23 12111 Quinidine + Verapamil 40 200 mg/3 h (IV); Before CV Nonresponders Heparin 15,000 24 
1992 then 50 mglh for 3 days; to amiodarone I.U.lday 
then 200 mg 4 times/day were treated subcutaneously 
for II days; with electrical 
then maintenance dose cardioversion 
of 200 mg/day 
long et al. 1995 87 chronic AF 83 40143 Placebo 87 200 mg three times a Before CV After 4 weeks Possibly low dose 6(2-15) 
day for 4 weeks; if patient not in propranolol or 
then 200 mg/day for I NSR verapamil to 
month; control the 
then 200 mg every other ventricular rate of 
day for I month (oral) AFbelow 100 
beats per minute 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; LD, loading dose; CV, cardioversion; DCC, direct current cardioversion; NA, not applicable; NS, not stated; IV, intravenous; NSR, normal sinus rhythm 
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Table 4.3 Characteristics of randomised controlled, and uncontrolled trials of amiodarone included in analysis (continued) 
Uncontrolled 
Study name No. of Long-term Treatment Fill/ Dosage Time DCC Previolls Concomitant drllg /Jllratioll (~f 
patiellts fol/ow-up group allocation exposure amiodarolle agellt IIsed fol/ow-IIP 
enrolled (Amiodarolle grollp started mOllths 
IColltro/) (rallge) 
Leak et al. 1979 9PSVT 14 14 14 600-800 mg/day for Before CV Only when Quinidine, NS 16.8 
2 PAF 3 weeks; then 200- required due procainamide, 
3PSVT+WPW 600 mg/day to attacks disopyramide, 
antazoline, 
lidocaine, 
bretylium, 
I propranolol, 
phenytoin 
Blomtrom et al. 13 chronic AF 21 21 21 600 mg/day for I Before CV After 2-4 NS Conceivably digoxin 19 (348) 
1984 8 PAF week; weeks 
then 200 mg daily 
Pod rid et al. 1981 20PAF 29 29 29 600 mg/day for I NA NA Quinidine, NS 13.4 (4-40) 
9PSVT week; procainamide, 
then reduced to 200 aprinidine, 
mg/day; mexiletine, 
then it may be bretylium, 
increased to 400 propranolol, 
mg/day phenytoin, 
disopyramide, 
lorcainide, 
encainide 
Grasboys et al. 1983 121 chronic AF 121 121; 95 AF, 21 121 600-1200 mg/day Before CV After loading Quinidine, Digoxin, verapamil, 8- 27.3 
SVT,5 for 5-7 days; dose if procainamide, blockers 
AF+SVT then 200-600 required aprinidine, 
mg/day mexiletine 
Horowitz et al. 1985 11 chronic AF 38; 10 chronic AF 11 chronic AF 11 chronic AF 1 g/day for 5 day; Before CV After I month Quinidine, Digoxin, 8-blockers, calcium 15 
27 PAF 27 PAF 27PAF 27 PAF then 600 mg/day if patient not procainamide, channel blockers 
for 1 month; inNSR disopyramide 
then 400 mg/day 
for 3 months; 
then 200 mg/day 
Gold et al. 1986 68 chronic AF 68 68 68 800 mg/day for 1 Before CV After 4-6 Quinidine, Digoxin, 8-blockers, calcium 21 (3-56) 
or PAF week; weeks if procainamide, channel blockers 
then 400 mg/day patient not disopyramide 
reverted to 
NSR 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; PSVT, paroxysmal supraventricular tachycardia; WPW, Wolf-Parkinson syndrome; LD, loading dose; CV, cardioversion; DCC, direct current cardioversion; 
NA, not applicable; NS, not stated; NSR, normal sinus rhythm 
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Table 4.3 Characteristics of randomised controlled, and uncontrolled trials of amiodarone included in analysis (continued) 
Uncontrolled (continued) 
Study name No. of patients LOllg·term Treatmellt Ful/ Dosage Time DCC Previous COllcomitallt drug Duratiol/ of 
el/rol/ed fol/ow·up group al/ocatioll exposure amiodarol/e agel/t used fol/ow·up 
(Amiodaro group started mOl/ths 
I/e/Col/trol) (ral/ge) 
Blevins et af. 1987 38; 25 chronic AF 32; 19 chronic AF, 32 38 5 mg/kg IV over Before CV after 4-5 weeks if Quinidine, Digoxin, B-blockers, calcium 16 (3-27) 
13 PAF 13 PAF 30 min; no conversion, or procainamide, channel blockers 
then 600-800 earlier if disopyramide 
mg/day for 5-7 hemodynamically 
days; unstable 
then 200-400 
mg/day 
Brodsky et al. 1987 28 chronic AF 28 28 28 600 mg/day for 30 Before CV After I month of Quinidine, Digoxin, B-blockers, calcium 22 (12-38) 
days; amiodarone procainamide, channel blockers 
then 400 mg/day therapy if patient flecainide 
for 30 days; not in NSR 
then 200-400 
mg/day 
Mostow et al. 1990 19; 9 AF, I AFL, 19 19 19 1600 mg/day for 4 Before CV After 48-96 Quinidine, discontinued before 16.1 
6 PAF, 3 atrial days; hours if the procainamide, amiodarone dosing 
tachycardia then 400-800 patient not in disopyramide 
mg/day NSR 
Levy et al. 1991 112 chronic AF 102 102 112 200 mg/day Before CV After 4 weeks for Class IA NS 12 
(abstract) all patients antiarrhythmic 
drugs 
Gosselink et al. 89 chronic AF 89 89 89 600 mg/day for 4 Before CV After I month if Flecainide, Discontinued before starting 20.7 
1992 weeks; patient not in sotalol, amiodarone dosage 
then 200 mg/day NSR quinidine, 
disopyramide, 
propafenone 
Chun et al. 1995 110; 53 chronic 1I0 110 110 800 mg to 1,600 Before CV After 30 days if NS NS 36 (1-137) 
AF or AFL mg/day for 7 to 14 sinus rhythm was 
57PAF days; not restored 
then 200 to 300 
mg/day (mean 
268±100) 
AF, atrial fibrillation; AFL, atrial fibrillation; PAF, paroxysmal atrial fibrillation; PSVT, paroxysmal supraventricular tachycardia; LD, loading dose; CV, cardioversion; DCC, direct current cardioversion; NA, 
not applicable; NS, not stated; NSR, normal sinus rhythm 
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Table 4.4 Characteristics of sotalol clinical trials included in analysis 
Ralldomised COil trolled 
Stlldy lIame Year of No. of LOllg· Treatmellt Type of colltrol 1'111/ Dosage; LD alld Tillie DeC Previous COllcollli- Duratioll 
publicatioll patiellts term al/ocatioll exposure mailltellallce dose sotalol agellt IIsed tallt drllg of follow-
ellrolled follow-up (Sola[oIlColI- group (mg/day) started up 
group trol) mOllths 
luul-Moller et 1990 183 AF 174 95n9 Quinidine 174 160 mg/day for I After CY Started before NS Digoxin 6 
at. week; randomisation 
then 320 mg/day for all patients 
Singh et al. 1991 34 AF 18 1216 Placebo 34 80-320 mg/day Before CY If sinus rhythm NS Digoxin 6 
could not be 
established 
during 
treatment 
Reimold et al. 1993 53 AF 98 49/49 Propafenone 100 160-320 mg/day; Before CY If sinus rhythm Quinidine, Possibly 6- 12 
47 PAF then a maintenance was not procainamide, blockers, 
dose of 160-960 restored at the disopyramide calcium 
mg/day highest channel 
tolerated dose blockers 
Kalusche et al. 1994 82AF 78 41137 Quinidine!verapamil 82 NS Before CY If sinus rhythm NS NS 12 
combination could not be 
established 
during 
treatment 
Carunchio et al. 1995 66PAF 66 20/26120 26 Placebo 66 NS NA NA NS NS 12 
20 Flecainide 
Hohnloser et al. 1995 50AF 38 17I21 Quinidine 50 160 mg/day at day Before CY On day 8 in NA Digoxin, 6 
I; then 320 mg/day patients with warfarin 
for the next 6 days; persistent AF sodium, 
then 160-320 heparin 
mg/day 
AF, atrial fibrillation; AFL, atrial fibrillation; PAF, paroxysmal atrial fibrillation; PSYT, paroxysmal supraventricular tachycardia; LD, loading dose; CY, cardioversion; DCC, direct current cardioversion; NA, not 
applicable; NS, not stated; NSR, normal sinus rhythm 
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Table 4.4 Characteristics of sotalol clinical trials included in analysis (continued) 
NOIl-ralldomised cOlltrolled (sequelltial or serial treatmellt) 
Study name Year of No. of Long-term Treatment Type of Full Dosage; LD and Time DCC Previous agellt Duratioll 
publication patients follow-up allocation conlrol exposure mail/tel/alice sOlalol used of 
enrolled group (Sotaloi/Coll trol) group dose (mg/day) started follow-up 
Crijns et al. 1991 186 AF 127 53/ 127/34 127 Flecainide 127 320 mg/day After CY Before initiation of treatment NA 5.6 
34 Amiodarone with f1ecainide in stage I and 
electrical recardioversion for 
a recurrence before entering 
stage II (sotalol) and stage III 
(amiodarone) 
Antman et al. 1990 109 109 481109 Propafenone 109 160-960 mg/day Before CV Cardioversion was Conventional. 5.6 
AF53 performed when sinus type IA 
PAF 56 rhythm had not been restored antiarrhythmic 
pharmacologically at the drugs: Quinidine, 
maximum tolerated dose. procainamide or 
One or more additional disopyramide 
cardioversion procedures 
were performed if recurrent 
atrial fibrillation occurred 
after an initial successful 
cardioversion 
- -
AF, atrial fibrillation; AFL, atrial fibrillation; PAF, paroxysmal atrial fibrillation; PSYT, paroxysmal supraventricular tachycardia; LD, loading dose; CY, cardioversion; DCC, direct current cardioversion; NA, not 
applicable; NS, not stated; NSR, normal sinus rhythm 
81 
Table 4.5 Characteristics of randomised controlled, nonFandomised control, and uncontrolled trials of flecainide included in analysis 
Rondomised controlled 
---
Stlldy /lame No. of Long-term Treatment 1)"pe of Full J)osoge; LJ) alld Ti 11/ e J)CC I'rel'ious agellt C(Jllcomitallt drugs Duratioll oj 
patiellts follow-up allocatioll ('olltrol exposure mailltenallce Flecainide used fol/ow-up 
ellrol/ed group (Flecaillid group dose (l1/g/day) started mont".~ 
elCoII- (range) 
trol) 
Rasmussen et al. 1988 60 chronic AF 56 28128 Disopyramide 60 300 mg/day Before CV NA NS NS 6 
(abstract) 
Van-Gelder et al. 1989 180 chronic AF 73 36/37 No treatment 81 180±32 mg/day After CV Before NS Anticoagulants, 12 
initiation of verapamil 
treatment for 
all patients 
and 
recardioversi 
on for no-
treatment 
group if 
arrhythmia 
recurred 
Anderson et al. 1989+ 64 PAF 48 48/48 Placebo 64 200-400 mg/day Before CV NA Digitalis, class I Digitalis glycosides 5 
agents, 
amiodarone, Beta-
blocker, Calcium 
channel antagonist 
Pritchett et al. 199 I + 73; 28 PSVT, 42; 14 PSVT, 42142 Placebo 50 50, 100,200, and Before CV NA NS Digitalis glycosides 4 
45 PAF or 28 PAF or 300 mg/day 
PAFL PAFL (patients entered 
all dosage period) 
Henthorn et al. 1991 + 51 PSVT 34 34/34 Placebo 48 300 mg/day Before CV NA Digoxin, Beta- All agents discontinued 4 
blocker, Calcium before initiation of 
channel antagonist treatment 
Pietersen et al. 1991 + 48 PAF or 43 43/43 Placebo 48 300 mg/day Before CV NA NS Digitalis glycosides 3 
PAFL 
Lau et al. 1992+ 19PAF 19 19/15/1 8 15 Placebo 19 200 mg/day Before CV NA Digoxin, Beta- All agents discontinued 32 
18 Quinidine blocker before initiation of 
treatment 
Chimienti et al. 1994 335; 200 PAF, 265; 159 PAF, 129/136 Propafenone 335 100 or 200 Before CV NA NS NS 12 
\35 PSVT I06PSVT mg/day 
-
AF, atrial fibrillation; AFL, atrial fibrillation; PAF, paroxysmal atrial fibrillation; PAFL, paroxysmal atrial flutter; PSVT, paroxysmal supraventricular tachycardia; LD, loading dose; CV, cardioversion; DeC, 
direct current cardioversion; NA, not applicable; NS, not stated; NSR, normal sinus rhythm; +, randomised placebo-controlled crossover study 
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Table 4.5 Characteristics of randomised controlled, nonrandomised control, and uncontrolled trials of f1ecainide included in analysis (continued) 
NOIl-ralldom;sed cOlltrolled 
Study IIame No. of Long-term Treatment T)'pe of Full Dosage; LD Tillie DCC Previous COl/com ita 1/ t /Juratiol/ of 
patiellts follow-up allocatioll cOl/trol exposure alld Flecail/ide agent used drugs follow-up 
enrolled group ( Flecaillid group mail/tenallce started mOlltlls 
elColl- dose (range) 
trol) (mg/day) 
Crijnselal.1991 186 AF 127 127/34/53 53 Sotalol 127 420±98 mg/day After CY Before initiation of NA Diuretics, 25 
34 Amiodarone treatment with angiotensin-
flecainide in stage converting 
1 and electrical enzyme 
recardioversion inhibitor, 
for a recurrence verapamil 
before entering 
stage II (sotalol) 
and stage III 
(amiodarone) 
Anderson el al. t 1994 49; 21 PSYT, 42 42142 Placebo-baseline 49 200 or 300 Open label NA Aecainide NS 17 
28PAF mg/day follow up after 
CV 
Mary-Rabine el af. 55; 39 PAF, 55 55/13 Amiodarone + 55 100-300 Before CY NA Digoxin, NS 3-32 
1988 16 PSYT flecainide mg/day disopyramide, 
quinidine, 
Beta-blockers, 
amiodarone 
Leclercq el al. 1992 52PAF 52 19/33 Amiodarone + 53 200mg±22 Before CY NA Amiodarone, NS 12-69.6 
flecainide mg/day without quinidine 
a loading dose 
--
AF, atrial fibrillation; AFL, atrial fibrillation; PAF, paroxysmal atrial fibrillation; PAFL, paroxysmal atrial flutter; PSYT, paroxysmal supraventricular tachycardia; LD, loading dose; CY, cardioversion; DCC, 
direct current cardioversion; NA, not applicable; NS, not stated; t, multicentre, open-label, outpatient, placebo-baseline controlled 
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Table 4.5 Characteristics of randomised controlled, nonrandomised control, and uncontrolled trials of flecainide included in analysis (continued) 
Uncolltrolled 
Study name No. of patients Long-term Treatment Full Dosage Time DCC Previous agent used Concomitant drug Duration of 
enrolled follow-up allocation exposure flecainide follow-up 
group (Flecainide group started months 
IControl) (range) 
Berns er al. 1987 39; 5 AF, 25 39 39 39 200 mg/day; then Before CV For patients who did Digoxin, Beta-blockers, Digoxin, Beta- 5.4 
PAF.9 PAT dose adjustments not convert to sinus Calcium channel blockers, Calcium 
(total dose 100-400 rhythm within 10 antagonist, at least one channel antagonist 
mg/day) days of initiation of class IA agent 
therapy 
Zeigler et al. 1988 16SVT 16 16 16 2.8-5.6 mg/Kg/day Before CV NA NS NS 9 (4-16) 
Sonnhag el al. 1988 20PAF 20 20 20 300 mg/day Before CV Had been attempted Verapamil, digoxin, Digoxin 11-38 
in 5 patients, totally, atenolol, disopyramide, 
14 times quinidine, diltiazem, 
Beta-blockers, sotalol 
Zee-Cheng el al. 19 PSVT 15 15 19 200-400 mg/day After CV NA NS Beta-blockers 19 (2-48) 
1988 
Anderson JL 1992 66; 41 PAF,25 66 66 66 300mg/day Open label Only in 3 patients to Verapamil, digoxin, NS 15 
PSVT follow up terminate attacks of atenolo1, disopyramide, 
after CV AF quinidine, diltiazem 
Clementy el al. 1992 944 PAF 944 944 944 200-400 mg/day After CV NS Digoxin, Beta-blockers, Attempted for 9 
(mean; 190±33) Calcium channel conversion to sinus 
antagonist rhythm before 
initiation of treatment 
- ----- -- -----
AF, atrial fibrillation; AFL, atrial fibrillation; PAF, paroxysmal atrial fibrillation; PAFL, paroxysmal atrial flutter; PSVT, paroxysmal supraventricular tachycardia; LD, loading dose; CV, cardioversion; DCC, 
direct current cardioversion; NA, not applicable; NS, not stated 
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amiodarone, 335 received sotalol, 1746 received flecainide, 385 received placebo, and 
636 received other antiarrhythmic drugs as active control (of which 144 patients 
received quinidine, 50 received disopyramide, 48 received quinidine/verapamil 
combination, 294 received propafenone, and 46 received amiodarone plus flecainide). 
The sample size of each study ranged from 14 to 944, with a mean of 94 patients over 
all the studies. 
Initiation of treatment was started before cardioversion in 31 trials, after cardioversion 
in 9 trials, and it was not stated in 3 trials. The direct current cardioversion (Dee) was 
applicable in 24 trials (13 for amiodarone, 7 for sotalol, 5 for flecainide). An attempt 
for electrical recardioversion was made after a mean of 3.42 weeks (range 0.28 to 6) if 
sinus rhythm was not restored at the highest tolerated dose during treatment. However, 
Dee was not applicable in 18 trials (4 for sotalol, 1 for sotalol, 14 for flecainide). 
The average follow-up time for all patients was 16.34±13.2 months (range 3 to 69.6), 
for amiodarone trials 19.23±10.3 months (range 4 to 48), for sotalol trials 9.83±6.5 
months (range 3.9 to 25), and for flecainide trials 16.68±16.9 months (range 3 to 
69.6). 
The amiodarone dosage schedule varied across studies with an average loading dose of 
766±371 mg/day (range 200 to 1600) for an average of 15 days (range 3 to 40), then 
an average maintenance dose of 333.41±184 mg/day (range 200 to 800). The sotalol 
dosage was started with an average loading dose of 296±250.3 mg/day for an average 
of 5 days (range 1 to 7), then a maintenance dose of 330±272 mg/day (range 80 to 
960). Flecainide dose was initially titrated for individual patient from 200 to 400 
mg/day, and the largest dose that was well tolerated was selected. The mean dose of 
flecainide received over all the studies was 232±101.1 mg/day (range 50 to 420). 
4.3.2 Population Characteristics of the Included 
Studies 
The mean age of the patients, across all studies which reported the age (38 studies) was 
57.51±11.33 years (range 13 to 77). In the 36 studies reporting gender, there was a 
total of 1208 women and 1894 men with a mean of 55 men and 36 women in the 
sample. Only 29 studies stated the duration of atrial fibrillation disorders with a mean 
of 61.04±98.8 months (range 0.033 to 444). The left atrial diameter was mentioned in 
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18 studies, with a mean of 46.16±3.8 mm (range 42 to 57). Tables 1, 2, and 3 of 
Appendix 4.2 describe the details for characteristics of populations included in 
amiodarone, sotalol, and flecainide individual trials respectively. 
Most trials enrolled only patients with chronic atrial fibrillation (7 for amiodarone, 5 for 
sotalol, and 3 for flecainide). Eight trials enrolled only patients with paroxysmal atrial 
fibrillation (1 for amiodarone, 1 for sotalol, and 6 for flecainide). Four trials (for 
flecainide) were performed in patients with paroxysmal supraventricular tachycardia or 
paroxysmal atrial tachycardia only. Sixteen trials dealt with a mixed patient population 
(9 for amiodarone, 1 for sotalol, and 6 for flecainide). From the total 4001 patients 
enrolled, 1743 patients had chronic atrial fibrillation (901 in amiodarone clinical trials, 
638 in sotalol clinical trials, and 260 in flecainide clinical trials), 81 had atrial flutter (in 
amiodarone trials), 1942 had paroxysmal atrial fibrillation (271 in amiodarone clinical 
trials, 149 in sotalol clinical trials, and 1522 in flecainide clinical trials), 350 had 
paroxysmal supraventricular tachycardia (63 in amiodarone clinical trials, and 303 in 
flecainide clinical trials), and 12 had paroxysmal atrial tachycardia (3 in amiodarone 
clinical trials, and 9 in flecainide clinical trials). 
The mean heart volume was only stated in two trials of amiodarone (Vitolo et aI., 1981; 
and Blomstrom et a/., 1984), and it was within radiologically normal limits. The 
cardiothoracic ratio was used for manifestation of cardiac severity in only one trial of 
amiodarone (Vitolo et aI., 1981), and it was <0.5. 
Table 4.6 summarises the mean characteristics of patients treated with amiodarone, 
sotalol, flecainide, placebo, and other comparative antiarrhythmic drugs employed 
including quinidine, quinidine/verapamil combination, disopyramide, and propafenone. 
Patients' characteristics for each type of treatment group were tabulated separately. 
Continuous data were compared using unpaired t-test, and one way analysis of the 
variance. Discrete variables were compared using the chi-square test. The comparison 
in age, duration of atrial fibrillation, and left atrial diameter did not show any statistical 
differences among the treatment groups (P>0.05). 
Cardiac diagnoses were reported for a total of 4073 patients. Tables 4, 5, and 6 of 
Appendix 4.2 show the different cardiac diagnoses of patients enrolled in amiodarone, 
sotalol, and flecainide clinical trials respectively. The distribution of the diagnoses was 
tabulated, and examined with respect to various treatment groups (Table 4.6), as well 
as different drugs' trial populations (Table 4.7). Valvular heart disease was the primary 
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Table 4.6 ]\\ean characteristics of all treatnll'nt groups included in the analysis 
Variables All Amiodarolle Solalol Flecaillide Placebo Olher Test of P-value 
treatmellt comparative drugs sigllificallce 
groups (aU) 
Study groups (N) 64 17 8 18 9 12 - -
Patients (n) 3937 888 335 1746 385 645 - -
Age 57.5±11.33 58.53±14.7 60.75±1.67 53.98±12.55 54.9±14.32 60.53±6.84 ANOYA P=0.566 
F=0.7408 
Chronic AF (n) 1743 803 269 198 139 252 X2=1019.24 P<O.OOOI 
AFL (n) 81 81 0 0 0 0 X2=283.8 P<O.OOOI 
PAF (n) 1942 244 42 1386 223 206 X2=501.9 P<O.OOOI 
PSVT (n) 350 47 0 240 96 63 X2=141.9 P<O.OOOI 
PAT (n) 12 3 0 9 0 0 X2=6.82 P=0.25II 
Duration (months) 61.04±98.8 80.71±124 21.47±20.83 42. 1 9±42.56 18.05±19.97 11.26±22.24 ANOYA P=0.25 I 1 
F=1.3969 
Left atrial diameter (mm) 46.16±3.8 47.22±4.46 45.4±2.97 44.33±1.I5 45.5±3.79 46.4±3.2 ANOYA P=0.864 
F=O.3724 
Cardiac diagnosis (n) 4073 887 608 1952 366 260 
- -
Valvular (n) 730 192 131 320 41 46 23.1 0.00012 
Hypertension (n) 595 54 76 363 55 47 69.37 P<O.ooOI 
Ischemic heart disease (n) 453 171 68 147 20 47 97.5 P<O.OOOI 
Thyroid (n) 75 0 6 69 0 0 60.7 P<O.ooOI 
Lone fibrillator (n) 1064 195 \03 578 101 87 40.2 P<O.ooOI 
Congenital heart disease 43 15 9 16 3 0 8.4 P=0.078 (n) 
Pericarditis (n) 0 0 0 0 0 0 - -
Cardiac surgery (n) 117 31 36 38 6 6 28.92 P<O.OOOI 
CHF (n) 554 110 130 217 95 2 109.41 P<O.ooOI 
Cardiomyopathy (n) 172 84 15 46 5 22 96.51 P<O.OOOI 
Miscellaneous (n) 270 35 34 158 40 3 38.9 P<O.OOOI 
AF, atrial fibrillation; AFL, atrial flutter; PAF, paroxysmal atrial fibrillation; PAT, paroxysmal atrial tachycardia; PSVT, paroxysmal supraventricular tachycardia; ANOYA, One-way Analysis of the variance; X2, 
Chi-square test; t, total number of patients for whom cardiac diagnosis was reported; CHF, congestive heart failure 
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I 
diagnosis in 20.7% of the population enrolled in the amiodarone clinical trials, 24.9% 
of the patients in the sotalol trials, and 15.7% of the patients in flecainide trials 
(P<O.OOOI). Hypertension was found in 5.8% of the amiodarone trials' populations, 
18.7% of sotalol trials' populations, and 17.4% of flecainide populations (P<O.OOOI). 
The proportion of patients with ischemic heart diseases and cardiomyopathy was 
significantly higher in amiodarone and sotalol clinical trials than flecainide trials 
(P<O.OOOI). There were more patients with congestive heart failure or cardiac surgery 
in the sotalol clinical trials than in the amiodarone and flecainide trials. However, 
patients with thyroid dysfunction and lone fibrillator were more common in the 
flecainide trials (P<O.OOOl). In addition, examination of distribution of the same 
diagnoses across individual treatment groups as shown in Table 4.6 (patients receiving 
arniodarone, sotalol, flecainide, placebo, and active control separately), has confirmed 
significant statistical differences in all diagnoses categories (P<O.OOOI). 
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Table 4.7 Distribution of cardiac diagnoses in amiodarone, sotalol, and flecainide clinical trials 
Diagnosis Allliodarone clil/ical trials SOlalol clil/ical trials Flecaillide clil/ical trials elii-square test P-value 
11 (%) 11 (%) 11 (%) 
Valvular heart 225 (20.7%) 160 (24.9%) 332 (15.7%) 25.496 P<O.OOOI 
disease 
Hypertellsioll 63 (5.8%) 120 (18.7%) 367 (17.4%) 77.886 P<O.OOOI 
Ischemic heart 193 (17.7%) 97 (15.1%) 157 (7.4%) 73.232 P<O.OOOI 
disease 
Thyroid 0(0%) 6 (0.9%) 69 (3.3%) 43.43 P<O.OOOI 
LOlle fibrillator 258 (23.7%) 170 (26.5%) 605 (28.7%) 6.677 P=0.035 
(110 heart disease) 
COllgellital heart 16 (1.47%) 9 (1.4%) 18 (0.85%) 2.985 P=0.225 
disease 
Pericarditis 0(0%) 0(0%) 0(0%) - -
Alcohol 43 (3.9%) 36 (5.6%) 38 (1.8%) 27.48 P<O.OOOI 
associated 
CHF 110 (10.1%) 132 (20.6%) 296 (14%) 31.544 P<O.OOOI 
Cardiomyopathy 88 (8.1%) 33 (5.1%) 46 (2.2%) 58.635 P<O.OOOI 
Miscellalleous 38 (3.5%) 34 (5.3%) 158 (7.5%) 19.797 P<O.OOOI 
- Total 1089 642 2110 
x2, Chi-square test; CHF. congestive heart failure 
• 
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4.3.3 Efficacy 
4.3.3.1 Conversion to Sinus Rhythm 
The efficacy for conversion to sinus rhythm via drug alone, or via drug and direct 
current cardioversion (DCC) was reported in only 22 papers: 10 for amiodarone 
(Zehender eta!., 1992; Jong etal., 1995; Horowitz eta!., 1985; Gold eta!., 1986; 
Brodsky et al., 1987; Levy et al., 1991; Mostow et al., 1990; Gosselink et al., 1992; 
Blevins et al., 1987; Leak et al., 1979),6 for sotalol (Juul-Moller et al., 1990; Singh et 
aI., 1991; Reimold et ai., 1993; Kalusche et a!., 1994; Hohnloser et aI., 1995; Antman 
et al., 1990) and 6 for flecainide: Gelder et al., 1988; Rasmussen et aI., 1988; 
Anderson et aI., 1989; Pietersen et aI., 1991; Pritchett et ai., 1991; Henthorn et aI., 
1991; Lau et a!., 1992; Sonnhag et a!., 1988; Anderson, 1992; Clementy et al., 1992; 
Anderson et ai., 1994; Leclercq et al., 1992; Crijns et aI., 1991; Mary-Rabine et al., 
1988; Chimienti et al., 1994; Zeigler et ai., 1988; Berns et al., 1987; Chouty et ai., 
1988; Zee-Cheng et aI., 1988) as illustrated in Table 4.8. 
Table 4.8 Conversion to NSR 
Drug RCTs Converted to Converted to NSR 
NSR via drug via drug alld DCC 
alolle (no.o/ (110.0/ patients) 
patients) 
Tx.group Cont.group Tx.group Cont.group 
Amiodarone RCfs 130/430 (30.2%) 1lI63 (17.5%) 260/430 (60.5%) 25/63 (39.7%) 
Sota101 RCfs 32/242 (13.2%) 54/239 (22.6%) 189/242 (78%) 177/239 (74%) 
F1ecainide RCTs 24211 068(22.7%) I 30/86 (34.9%) 21511115 (19.3%~ 37186 (43%) 
NSR, normal sinus rhythm; DCC, direct current cardioversion; Tx, treatment; Cont. control 
The incomplete reporting of cardioversion efficacy data in many individual trials, as 
well as the variation in control groups, prevented the systematic pooling by meta-
analysis techniques. 
4.3.3.2 Maintenance of Sinus Rhythm 
Prior to cardioversion, a total of 3937 patients were followed up for maintenance of 
sinus rhythm (993 in amiodarone clinical trials, 708 in sotalol clinical trials, and 1956 
in flecainide clinical trials), Of the total 4088 patients enrolled initially (1006 in 
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amiodarone clinical trials, 810 in sotalol clinical trials, and 2276 in flecainide clinical 
trials) 284 patients were excluded from analysis for various reasons as shown in Table 
4.9. A further 234 patients were lost to follow up (33 in amiodarone group, 2 in 
sotalol group, 199 in flecainide group, 2 in quinidine group, and 2 in placebo group), 
and a total of 456 patients were withdrawn due to intolerable side effects (77 receiving 
amiodarone, 23 receiving sotalol, 263 receiving flecainide, 38 receiving quinidine, 8 
receiving quinidine plus verapamil, 10 receiving disopyramide, 13 receiving 
propafenone, and 24 receiving placebo). 
The Kaplan-Meier percentages of patients remaining in sinus rhythm in the different 
treatment groups, the rate differences (RDs) obtained from individual trials, as well as 
the weight assigned to each trial, are listed in Tables 4.10, 4.11, and 4.12. Table 4.10 
.a and Table 4.10.b give the results for amiodarone in the randomised controlled and 
uncontrolled trials respectively. Table 4.IO.c and Table 4.IO.d provide the results for 
sotalol from the randomised and nonrandomised controlled trials respectively. 
Similarly Tables 4.10.e, 4.lOJ, and 4.1O.g give the results for flecainide from 
randomised, nonrandomised controlled, and uncontrolled trials respectively. Tables 
4.11, and 4.12 present similar results for the three drugs at 6, and 12 months 
respectively. 
4.3.3.2.1 Amiodarone Clinical Trials 
Figure 4.1 shows a conventional meta-analysis plot (Walker et al., 1988) for the 
individual RDs, fixed-effects weighted mean RDs, and the random-effects corrected 
weighted mean RDs at 3,6, and 12 months intervals. The solid vertical line on the plot 
indicates a zero-effect. The dark points represent the individual study effects. A 
negative RD value indicates lower efficacy for the treatment than control group. The 
horizontal lines around these point estimates represent the 95% confidence intervals for 
each trial's mean effect. A point estimate of the RD to the right of the solid line 
suggests higher efficacy level in the treatment group. However, it is only significantly 
higher (at P<O.05) if the entire confidence interval for that trial is also to the right of the 
solid line. This was only noticed for three trials (Vitolo et at., 1981; Martin et al. , 
1986; long et al., 1995). 
The absolute efficacy of amiodarone was tested in two trials only (Figure 4.1: Analysis 
group 1). One trial provided data at 3 months only (long et al., 1995) and the other at 
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Table 4.9 Details of follow-up 
Treatmellt group Amiodarolle Sotalol Flecaillide Placebo Otllers 
No. of patients excluded from 
I 
47 
I 
24 142 
I 
37 
I 
34 
analysis 
Reasons for exclusion I 
Failure to achieve sinus rhythm 22 20 6 I 28 13 
Death 20 I 0 2 0 0 
Intolerable side effects 5 I 0 24 8 12 
Protocol violation 3 4 20 5 8 
Others 15 0 21 I 14 1 
No. lost to follow-up 33 2 199 2 2 
No. of withdrawals due to 77 (8.7%) 23 (7%) 263 (15.1%) 24 (6.2%) 69 (10.8%) 
intolerable side effects (%) 
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Trials (Comparison group) 
Favours control Favours amiodarone 
Trials (Comparison group) 
Favours control Favours amiodarone 
Bosi et al 1990 (Placebo) ~ J 
Vitolo et al1981 (Quinidine) 
Martin et al1986 (disopyrarnide) . 
-.-
Jong et al 1995 (Placebo) I i I Zehender et al 1992 (Quinidine+veraparnil) 
Pooled RDmean at 3M (Fixed-effects) 
Pooled RDmean at 3 M (Fixed-effects) j 
> 
Vitolo et al1981 (Quinidine) 
Pooled RDmean at 3 M (Random-effects) • Martin et a1 1986 (disopyrarnide) 
Pooled RDmean at 6 M (Fixed-effects) 
Bosi et al1990 (6 M) I 
• 
Vitolo et al1981 (Quinidine) g 
Martin et al1986 (disopyramide) . 
Bosi et a11990 (12 M) ~ i Pooled RDmean at 12 M (Fixed-effects) 
- - _._-
-0.4 -0.2 o 0.2 0.4 0.6 0.8 -0.4 -0.2 o 0.2 0.4 0.6 0.8 
Rate Difference (RD) Rate Difference (RD) 
Figure 4.1 Amiodarone randomised clinical trials for maintenance of sinus rhythm (N=S); Analysis group 1: amiodarone vs placebo (left panel) and 
Analysis group 2: amiodarone vs class I (right panel). The figure illustrates the individual study RDs with their associated 9S%CI (error bars, thin lines). 
The weighted pooled mean RD in fixed or random-effects models are displayed at the bottom for each time interval (at 3,6, and 12 months) in thick lines. 
The trials are in ascending order of the year of publication. The comparison groups are shown in brackets. 
all time intervals (Bosi et ai., 1990). The pooled mean RD at 3 months was 10.2% 
(95% CI -3.34 to 23.7), which is statistically not significant (Z= 1.48, P=0.139). The 
test of homogeneity was significant (Q=IO.61, df=l, P=O.OOI). As a result, the data 
were pooled using a random effect model. The weight assigned for each trial in fixed 
and random-effects model are shown in Table 4.10.a. The corrected mean RD was 
16.1 (95% CI -29.7 to 61.9). Although the point estimates of the pooled fixed and 
random-effects RDs versus placebo at three months intervals are to the right of the solid 
line, their wide confidence interval crosses it, indicating nonstatistical significance. The 
individual RD of the second trial at 6 and 12 months was statistically not significant 
(RD% = -6.7, 95% CI -23.6 to 10.2; Z= -0.77, 1»0.05). However, the result of this 
trial may suffer from type two error reflected by the small sample size. A possible 
explanation for the heterogeneity in treatment effect between the two trials is the 
employment of low dose propranolol or verapamil to control the ventricular rate in the 
second trial (long et ai., 1995). 
The direct comparisons of amiodarone (head to head comparison) to other 
antiarrhythmic drugs in Class I, have shown a significant treatment advantage in favour 
of amiodarone, which was maintained at all time intervals (Figure 4.1). The pooled 
mean RDs were 20.5%, 31.01 %, 28.8% at 3, 6, and 12 months respectively. In 
contrast to analysis group 1, there was no evidence of heterogeneity (1)>0.1). 
Pooling the data from all the amiodarone RCTs, regardless of control group type, have 
shown statistically significant results at 3 and 6 month intervals as the pooled RDs were 
15.3% (SE, 4.8; Z=3.3, P<O.Ol) and 12.24% (SE, 6; Z=2.01, P<O.05) respectively. 
However, the pooled RD did not reach statistical significance at 12 months (RD=ll.l; 
SE, 6.1; Z= 1.8, P=0.0718). To test the homogeneity of effect across the studies, the 
Q statistic was calculated for each time point. This calculation has revealed statistical 
heterogeneity for the effect at all time intervals (at 3 months, Q=16.58, df=4, P=O.OI; 
at 6 months, Q=IO.15, df=2, P=0.006; and at 12 months, Q=8.7, df=2, P=O.013). 
This would primarily be due to variation in control group type (placebo or active), or 
due to differences in population type (chronic or paroxysmal AF). As a result, a 
stratified analysis was carried out. Table 7.a of Appendix 4.2 illustrates the 
recalculated pooled mean RDs, and Q statistic for the analysis subgroups predefined in 
section 4.2.4.2. 
An indirect comparison of amiodarone to quinidine was performed by pooling 
individual RDs which were obtained by substraction of quinidine reference standard 
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(Rei mold et al., 1992) from the rate observed in the amiodarone treatment arms of 
RCTs (Table 7.a of Appendix 4.2). The pooled mean RDs obtained from this 
comparison were highly statistically significant (P<0.01) at 3, 6, and 12 months. 
Figure 4.5 displays the weighted pooled percentages of patients in sinus rhythm in the 
amiodarone-treated group (P t) compared to weighted pooled percentages of patients in 
sinus rhythm in comparator drug group, placebo group, as well as quinidine reference 
standard pooled percentages at 3, 6, and 12 months intervals. This figure has the 
advantage that it shows the effect of treatments under investigation separately. 
The data regarding the maintenance of sinus rhythm in chronic and paroxysmal AF 
patients were also provided in 11 uncontrolled trials of amiodarone at 3 and 6 months, 
and in 8 uncontrolled trials at 12 months. The P t obtained from pooling these trials 
compared to P t of RCTs was not statistically different at 3, and 6 months (P>0.05). 
However, it was statistically significant at 12 months, showing more efficacy of 
amiodarone in RCTs (P<0.05). The pooled RDs between P t in uncontrolled trials and 
quinidine reference standard were also highly statistically different at 3, 6, and 12 
months (P<0.01). However, the homogeneity test demonstrated heterogeneity across 
the individual studies RDs at 3, and 6 month intervals (at 3 months; Q=53.8, df=lO, 
P<O.OI; and at 6 months; Q=63.3, df=lO, P<O.OI). Applying the random-effects 
model has yielded non-significant RDs at all times intervals. This may be due to the 
fact that the uncontrolled trials of amiodarone enrolled populations with different types 
of patients including both chronic (79.8%) and paroxysmal AF (20%), while the RCTs 
of quinidine (from which the standard quinidine meta-analytic P t was calculated), 
included only chronic AF patients. To test for this possibility, stratified analysis was 
performed by calculating the Pt values for chronic and paroxysmal AF patients 
separately in uncontrolled trials, as well as RCTs of amiodarone. 
Recomparison of the new amiodarone uncontrolled trials' Pt values for chronic AF 
patients only to standard quinidine meta-analytic P t values, shows highly significant 
differences at 3, and 6 months (P<O.01), but not at 12 months (P=0.45). In addition, 
evidence of heterogeneity disappeared (P>0.05) when RDs of chronic AF patients for 
uncontrolled trials and RCTs were pooled separately (Table 7.a of Appendix 4.2). The 
pooled RDs between Pt of RCTs and standard quinidine reference were hig~ly 
statistically significant at all time intervals, and the test of homogeneity was not 
significant (Table 7.a of Appendix 4.2: Analysis group 5A). 
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Pooling the efficacy of amiodarone for paroxysmal AF (P AF) patients in uncontrolled 
trials have shown important effect, with absolute percentages of patients remaining free 
of any attacks equal to 86.6% (95% CI 81.3 to 91.9), 67.5% (95% CI 58.8 to 76.1), 
61.9% (95% CI 54.1 to 69.6) at 3,6, and 12 months respectively. The weighted RDs 
comparing these percentages to standard quinidine reference, except at 6 months, were 
statistically significant. The efficacy of amiodarone for (P AF) was evaluated in only 
one RCT (Martin et al., 1986). 
4.3.3.2.2 Sotalol Clinical Trials 
A total of 8 trials of sotalol were identified (Table 4.4). 6 were RCTs involving direct 
comparison to other antiarrhythmic drugs (2 to quinidine; 1 to quinidine plus verapamil; 
1 to propafenone; and 1 to flecainide) or to placebo (2 trials). 2 were nonrandomised 
controlled (NonRCTs); involving sequential or serial treatments with flecainide, sotalol, 
and then amiodarone in one trial, or propafenone, then sotalol in another trial. Actuarial 
survival curves were presented in five trials. Kaplan-Meier percentages of patients in 
sinus rhythm were either extracted from the text or estimated from the survival curves 
(Table 4.10.c and Table 4.10.d at 3 months; Table 4.11.c and 4.11.d at 6 months; 
then, Table 4.12.c and Table 4.12.d at 12 months for RCTs and NonRCTs 
respectively). 
Figure 4.3 gives a confidence interval plot for results from individual RCTs and 
NonRCTs with associated 95% CI intervals. The trials are ordered by year of initiation 
of the trial. In RCT, pooling the effect of sotalol versus Class IA drugs (3 trials), and 
versus Class IC (2 trials) did not show any superiority of sotalol over other treatments 
at any time point. In NonRCTs, the pooled effect versus Class IC (2 trials) has also 
indicated equal efficacy. Another trial which employed sequental design has 
demonstrated a nonsignificant difference in the rate of relapse between sotalol-treated 
patients and amiodarone-treated patients at all time points. Comparing the pooled size 
of effect versus all other drugs in RCTs and NonRCTs has confirmed the conclusions 
of the previous stratified analysis without any evidence of heterogeneity (Table 7.h of 
Appendix 4.2: Analysis group 4 and group 5). 
Comparing the efficacy of sotalol to placebo in two RCTs has demonstrated highly 
significant efficacy at 6 and 12 months, with RDs equal to 36 (95% CI 16.32 to 55.7), 
and 33.1 (95% CI 5.7 to 60.5) respectively (Figures 4.2, and 4.6). 
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Figure 4.2 Efficacy of sotalol versus placebo in RCTs for maintenance of sinus rhythm. 
The figure illustrates the individual study RDs with their associated 95% CI (error bars, 
thin lines). The weighted pooled mean RD using the fixed and random-effects models are 
displayed at the bottom for each time interval (at 3, 6, and 12 months) in thick lines. 
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Figure 4.3 Sotalol randomised (N=5) and nonrandomised (N=3) clinical trials for 
maintenance of sinus rhythm (Analysis group 4 & 5: sotalol vs other antiarrhythmic 
drugs in RCTs and NonRCTs). The figure illustrates the individual study RDs with their 
associated 95% CI (error bars, thin lines). The weighted pooled mean RD versus Class 
IA & IC under fixed-effects model are displayed at the bottom for each time interval (at 
3,6, and 12 months) in thick lines. The comparison groups are shown in brackets. 
When the results of sotalol treatment arms in RCTs were indirectly compared to 
standard quinidine reference, the pooled RD was statistically significant only at three 
months in favour of quinidine (RD, -7.7; z=-2.34, P<0.05). However, when PAF 
patients were excluded from pooling, the RDs were not significant at all times, 
indicating that sotalol and quinidine are equally effective. Furthermore, sotalol 
treatment arms in NonRCTs (Crijns et al., 1991; and Antman et al., 1990), in which 
sotalol was initiated as a second choice prior to failure of the first drug, were compared 
to quinidine standard, and in contrast to RCTs, the pooled RDs were highly significant 
at all time points in favour of quinidine. Comparison of the absolute percentages (Pt) in 
RCTs and NonRCTs was statistically significant at all time points (P<0.05). These 
results have showed that sotalol fared better in RCTs than in NonRCTs. Furthermore, 
this meta-analytic pooling have negated the theory which suggested that sequentially 
changing the type of drug after a recurrence may improve arrhythmia prognosis, as 
each drug exert its beneficial effect in suppressing atrial fibrillation by different 
mechanism of action (Crijns et al., 1991; and Antman et al., 1990). On the contrary, it 
has been concluded that continuation of treatment with the same drug would yield a 
better outcome. 
4.3.3.2.3 Flecainide Clinical Trials 
A total of 18 trials of flecainide were identified. 8 were RCTs with parallel (N=3) or 
crossover design (N=5). In the crossover design trials, flecainide was compared to 
placebo in 4 trials, and to placebo and quinidine in 1 trial. The parallel design trials 
involved comparison to placebo in one trial, and to active treatment with disopyramide 
or propafenone in two trials. In addition, 4 nonrandomised controlled trials, and 6 
uncontrolled studies met the inclusion criteria. All the nonrandomised trials adapted 
open-label crossover design, and the comparison group received amiodarone plus 
flecainide in two trials (Mary-Rabine et al., 1988; Leclercq et aI., 1992), placebo in one 
(Anderson et al., 1994), and sotalol then amiodarone in one trial (Crijns et aI., 1991). 
Figure 4.4 illustrates individual and mean RDs for each trial design separately. As 
shown in the previous figure, pooling data from randomised, placebo-controlled, 
crossover design trials (N=5), and placebo-controlled, parallel design trial (N=I) was 
only possible at 3 months (RDmean, 33.35; Z=9.3, P<O.OI; Q, 24.8; P<O.OOI). 
Excluding the placebo-controlled parallel design trial (Van-Gelder et a/., 1989) from the 
previous group did not affect the significance of the results (Analysis group 6). 
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Figure 4.4 Flecainide randomised, placebo-controlled trials (N=6), randomised comparative 
trials (N=3), and nonrandomised trials (N=4). The figure illustrates the individual study RDs 
with their associated 95% CI (error bars, thin lines). The weighted pooled mean RD in fixed 
and random-effects model are displayed at the bottom, only when pooling is justified (thick 
lines). The comparison groups are shown in brackets. 
The pooled effect from two RCTs compared to Class IA (quinidine and disopyramide) 
was highly statistically significant in favour of flecainide. However, pooling data from 
the two non-randomised trials involving the comparison of flecainide against flecainide 
with amiodarone did not suggest any statistically significant difference (RD mean, 5.5 
Z=O.56, P>O.05), despite the significance of the point estimate in one of the trials as 
shown in Figure 4.4. 
The indirect comparison of flecainide treatment arms in RCTs, NonRCTs, and 
uncontrolled trials against quinidine standard suggest efficacy in favour of quinidine at 
3 months. However, at 6 and 12 months, the pooled estimates were in favour of 
flecainide in RCTs, but no statistically significant difference was seen in the NonRCTs 
and uncontrolled trials (Table 7.c of Appendix 4.2). 
4.3.3.2.4 Indirect comparisons 
The meta-analytic pooled percentages of patients remaining in sinus rhythm in 
flecainide, sotalol, amiodarone treatment arms in RCTs, as well as quinidine standard 
are depicted in Figure 4.7.A for comparison. As shown, amiodarone showed the 
highest efficacy at 3 months only, with statistically significant difference compared to 
all other drugs. However, flecainide showed the highest efficacy at 6 and 12 months 
with statistically significant difference compared to quinidine and sotalol. These results 
suggested equal efficacy of amiodarone and flecainide at 6 and 12 months. 
Figure 4.7.B depicted the pooled percentages in NonRCTs. As shown, flecainide 
displayed higher efficacy compared to quinidine and sotalol (P<O.05). Figure 4.7.C 
depicted the pooled percentages in uncontrolled trials with highly significant difference 
in favour of amiodarone compared to quinidine and flecainide at 3 and 6 months, yet 
flecainide and amiodarone were equally effective for prevention of relapse at 12 
months. 
To confirm the previous conclusions, the drugs were compared with respect to their 
effects on chronic AF only as shown in Figure 4.8 for RCTs and NonRCTs. In this 
comparison, flecainide and amiodarone have demonstrated equal efficacy at the three 
time intervals, and sotalol exhibited the least efficacy. 
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Table 4.10 Kaplan-l\leier estimates for patients remaining in sinus rh)"thm, and indh'idual RDs at 3 months 
a. Amiodarolle ralldomised clinical trial 
Study name Amiodarone Control ST o/,(S£) W,ST Sp c;..(SE) W.Sp RD (%) Statistic % Weight Assigned ill 
(no. of (no. of patients, type (95% CI) for effect 
patients and of control or drug) 
type of 
arrhythmias) 
Fired Effects Random Effects 
Vitolo et al. 1981 28 chronic AF 29 Quinidine 78.6 (7.8) 0.0166 41.4 (9) 0.01196 37.2 3.1 ** 69.553 18.9 
(13.6-60.7) P<O.OOI 
Martin et al. 1986 43PAF 122 Disopyramide 79.1 (6.2) 0.02598 154.5 (10.6) 0.00887 24.5 1.99* 166.144 18.64 (0.4-48.6) (P=0.047) 
Bosi et al. 1990 148 chronic AF 149 Placebo 72.9 (6.4) 0.024 79.6 (5.8) 0.03 -6.7 -0.77 NS 134.61 21.7625 ( -23.6-10.2) (P=1.56) 
Zehender et aI. 1992 12 chronic AF II Quinidine N erapamil 91.7 (7.97) 0.0157 90.9 (8.7) 0.01331 0.75 0.064 NS 72.052 19.0838 
( -22.3-23.9) (P=0.95) 
long et al. 1995 39 chronic AF 25 Placebo 64.1 (7.7) 0.0169 24 (8.5) 0.0137 40.1 3.49** 75.779 19.3357 
07.6-62.6) P<O.OI 
Pooled rates (SE) 170 136 76.9 (3.2) 0.099 63.1 (3.6) 0.078 418.138 97.722 
95%CI (70.7-83.1) (56-70.1) 
AF. atrial fibrillation; PAF. paroxysmal atrial fibrillation; ST% (SE) and Sp% (SE). Kaplan-Meier estimates (% of patients remaining in sinus rhythm) for treatment group and controls. respectively with their standard errors; 
W.ST. weight of ST; W.SP. weight of Sp; RD. risk difference; 95% CI; 95% confidence interval; * statistically significant (P<0.05); ** highly statistically significant (P<O.OI) 
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Tahle 4.10 K~lplan-l\leier estimates for patients remaining in sinus rh~,thl11, and indhidual RDs at 3 months (continued) 
b. Amiodarolle llllcolltrolled clillica/ trials 
Study /lame Amiodartille (110. of COlltrol .'iT (SE) lI',ST ' SP(SE) IV.S" RI) ('il) Statistic '7t I\'ei/.:", 
patiellts, alld type of (110. l~r patiellts, (95'1c Cl) ./ilr (:ffect Assiglled ill 
a rrII y tlImius) type of cOlltrol or 
drug) 
I I I I I I I I 1 Fixed Effects 1 Ralldom Effects 
Leak et al. 1979 14; 9 PSVT, 2 PAF, 3 1- /
50 (13.4) 10.0056 169.4 (2,4) 10.1756 -19.4 -1.4 NS 154.3 1 15.69 PSVT+WPW (-46-7.3 ) (P=0.162) 
Podrid et ul. 1981 26; 18 PAF, 8 PSVT - 80,8 (7.7) 0.01674 69.4 (2,4) 0.1756 11.4 1,4 NS 152.83 19.3 
(-4.5-27.2) (P=0.162) 
Grasboys et al. 1983 121; 95 chronic AF, 21 - 80,99 (3.6) 0.078596 69.4 (2,4) 0.1756 11,6 2.7** 542.99 21.2024 
SVT and 5 SVT +AF (3.2-20) 
Blomstrom et al. 1984 21; 13 chronic AF, 8 PAF - 71,4 (9.9) 0.01029 69.4 (2,4) 0.1756 2.1 0.2 NS 97.205 17.98 
(-17.9-21.9) (P=0.842) 
Horowitz et al. 1985 38; II chronic AF 
- 152,6 (8,1) 0.015242 69.4(2,4) 10.1756 -16.8 -\.99* 140.25 19.0648 
27PAF (-33.3_-0.22) (P=0.047) 
Gold et al. 1986 68; 54 chronic or - 86,8 (4.1) 10.059215 69.4 (2,4) 0.1756 17.4 3.3** 414.26 20.95 
paroxysmal AF, 14 chronic ( -6.3-25.5) 
AF 
Blevins et al. 1987 32; 19 chronic AF - 53.1 (8.8) 0.01285 69.4 (2.4) 0.1756 -16.3 -\.7 NS 119.742 20.3261 
13 PAF (-34.2 1.6) (0.09) 
Brodsky et aI. 1987 28 chronic AF - 75 (8.2) 0,014933 69.4 (2,4) 0.1756 5.6 0.66 NS 137.6 19.0156 
(-11.1 22.3) (P=0.51 ) 
Levy et al. 1991 102 chronic AF - 32,4 (4.6) 0.046606 69.4 (2,4) 0.1756 -37 -7.1** 368.323 22.9561 (-47.3 -26.8) 
Gossenlink el al. 1992 80AFor AFL - 63.8 (5.4) 0.034618 69.4 (2.4) 0.1756 -5.7 -0.96 NS 289.2 20.5 (-17.2-5.9) (P=0.34) 
Chun et al. 1995§ 110; 53 chronic AF or AFL - 92.7 (2.5) 0,163 69.4 (2,4) 0.1756 23.4 6.8** 845.7 21.5 
and 57 PAF ( 16.6-30.1) 
Mostow et al. 1990 19; 9 AF, 1 AFL, 6 PAF, 3 - 52.6 (11,5) 0.0076 169.4 (2.4) 0.1756 -16.8 -1.4 NS /73.042 16.95 
atrial arrhythmia (-39.7-6.2) (P=0.16) 
Pooled rates (SE) 675; 470 AF, 205 PAF - 76.7 (1.5) 0.4685 169.4 (0.69) 2.12 4.5 (1.8) 3290.75 232.129 
95%CI 73.9-79.6 68.1-70.8 -1.03-7.8 
Z (P) 2.6** (P=0.009) 
- ------
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier estimates (% of 
patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.S T, weight of ST; W.Sp, weight of Sp; RD, risk difference; 95% Cl; 95% confidence interval; §, retrospective 
uncontrolled study, which was grouped with uncontrolled studies; *, NSR sustained, but it there may be a relapse during the NSR period and number of patients with AF or PAF was not stated; * statistically significant 
(P<O.05); ** highly statistically significant (P<O.OI) 
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Table .... 10 Kaplan-l\leier estimates for patients remaining in sinus rh),thm, and individual RDs at 3 months (continm'd) 
c. Sotalol randomised clinical trials 
---
Study lIallle Sotalol I COlltrol ST (SE) W,ST 5" (SE) lV.S" RD (%) I Statistic for % Weight 
(110. of patiellts alld (110. of patiellts alld (95% el) effect Assiglled 
type of arrhythmia) type of cOlltrol or drug) ill 
I I I I I Fixed Effects Ralldom Effects I 
Juul-Moller et at. 1990 95 chronic AF 79 Quinidine 60 (5.03) 0.0395B 54.4 (5.6) 0.031B5 5.6 (-9.2-20.3) 0.74 NS 176.491 59.31B3 
(P=0.459) 
Singhelai.1991 12 chronic AF 6 Placebo 41.7 (14.2) 0.00494 0 - 41.7 (13.B-69.6) 2.93** 49.371 31.7997 
Reimold el al. 1993 49; 27 AF, 22 PAF 49 Propafenone; 24 AF, 25 4B.9B (7.14) 0.01961 146.9 (7.13) 0.019674 2.04 (-17-2I.B) 0.2 NS 9B.205 146.784 PAF (P=0.84) 
Kalusche el al. 1994 41 chronic AF 37 Quinidine'Verapamil 63.4 (7.5) 0.01767 175.7 (7.1) 0.0201 1-12.3 (-32.5-7.95) -1.19 NS 94.041 45.B2 
(P=0.234) 
Carunchio el al. 1995 20PAF 26 Placebo BO (B.9) 0.0125 76.9 (B.3) 0.014646 3.1 (-20.8-26.9) 0.253 NS 67.442 3B.4 
(P=0.8) 
Carunchio et al. 1995 20PAF 20 Aecainide 80 (B.9) 0.0125 90 (6.7) 0.022 -10 (-31.9-11.9) -0.89 NS BO 42.21 
(P=0.37) 
Hohnloser et al. 1995 17 chronic AF 21 Quinidine 76.5 (10.3) 0.009448 85.7 (7.64) 0.01715 -9.24 (-34.6-15.9) -0.72 NS 60.92 36.22 
(P=0.47) 
Pooled rates (SE) 234 238 63.5 (2.9) 0.1163 69.B (2.B) 0.1254 626.47 300.6 
95%CI 57.B-69.3 64.3-75.4 I 
Z (P) 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; Sr% (SE) and Sp% (SE), Kaplan-Meier estimates (% of 
patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.Sr , weight of Sr; W.Sp, weight of Sp; RD, risk difference; 95% CI; 
95% confidence interval; * statistically significant (P<O.05); *. highly statistically significant (P<O.O I) 
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Table 4.10 Kaplan-l\feier estimates for patients remaining in sinus rhythm, and individual RDs at 3 months (continued) 
d. Sotalol nonrandomised clinical trials 
Study name Sotalol Control SdSE) W.Sr SI' (SE) W.SI' RD (%) Statistic % Weight 
(no. of patients and (no. of patients, type of (95% Cl) for effect Assigned in 
type of arrhythmias) control or active drug) 
I I I I Fixed Effects Random Effects 
erijns et al. 1991 ** /53 chronic AF 127 F1ecainide 54.72 (6.8) 0.021391 44.1 (4.4) 0.05152 10.6 1.31 NS 151.148 126.788 (-5.3-26.6) (P=0.19) 
erijnsetal. 1991** 53 chronic AF 34 Amiodarone 54.72 (6.8) 0.021391 58.8 (8.4) 0.01404 -4.12 -0.38 NS 84.753 76.51 
(-25.4-17.2) (P=0.7) 
Antman et aI. 1990** 48 chronic AF or PAF 109 Propafenone 29.2 (6.6) 0.023234 34.86 (4.6) 0.04799 -5.7 -0.71 NS 156.557 130.572 
(-21.4-9.97) (P=0.48) 
Pooled rates (SE) 101 270 45.7 (3.9) 0.066 42.01 (2.97) 0.11356 0.9 (5) 392.458 333.87 
95%el 38.1-53.4 36.2-47.83 -8.96-10.8 
Z (P) 0.185 NS (P=0.85) I 
AF. atrial fibrillation; PAF, paroxysmal atrial fibrillation; AR.., atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier estimates (% of 
patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST• weight of ST; W.S P• weight of Sp; RD. risk difference; 95% el, 95% confidence interval; • statistically 
significant (P<O.05); •• highly statistically significant (P<O.OI) 
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Tahle .t.IO Kaplan-l\leier estimates for patients remaining in sinus rh)"thm, and indhidual nDs at 3 months (continued) 
e. Flecaillide ralldol1lised c1illical trials 
Study name Flecainide COlltrol I Sr(SE) W.Sr Sp (SE) I w.s~ ND (o/c) I Statistic % Weight (110. of patients alld (110. of patiellts, type of (95% Cl) for effect Assiglled ill 
type of arrhythmias) cOlltrol) 
I / Fixed Effects Ralldom Effects 
Rasmussen et al. 28 chronic AF 28 Disopyramide 85.7 (6.6) 0.02267 46.43 (9.4) 0.01126 39.3 (16.72-6\.9) 3.4** 75.436 23.1 
(abstract) 1988 
Van-Gelder et al. 1989 36 chronic AF 37 Placebo 64 (8) 0.015625 49 (8.22) 0.01481 15 (-7.5-37.5) 1.3 (P=0.19) 76.022 23.12 
Anderson et af. 1989 48PAF 48 Placebo /31.3 (6.7) 0.022342 8.33 (4) 0.06284 22.9 (7.6-38.2) 2.9** 164.817 27.6 
Pritchett et al. 1991 42; 28 PAF, 14 PSVT 42; 28 PAF, 14 PSVT, / 69.1 (7.1) 0.019652 14.3 (5.4) 0.0343 54.8 (37.23-72.3) 6.12** 124.938 26.3 
Placebo 
Henthorn et al. 1991 34 PSVT 34 Placebo 79 (7) 0.020494 14.7 (6.1) 0.0271 64.3 (46.2-82.4) 6.95** 116.71 25.86 
Pietersen et al. 1991 43PAF 43 Placebo 27.91 (6.8) 0.021373 4.7 (3.2) 0.09696 23.3 (8.44-38.1) 3.1** 175.13 27.92 
Lau et al. 1992 19PAF 15 Placebo 21.1 (9.4) 0.011432 0(0) - 21.1 (2.7-39.4) 2.25* 114.32 25.74 
Lau et al. 1992 19PAF 18 Quinidine 21.1 (9.4) 0.011432 11.11 (7.4) 0.01822 9.94 (-13.4-33.33) 0.83 (P=O.4) 70.3 22.6 
NS 
Chimienti et aI. 1994 129; 77 PAF, 52 PSVT 136; 82 PAF, 54 PSVT, 84.5 (3.2) 0.0983 73.7 (3.8) 0.0701 110.8 (1.1-20.5) 2.184* 
1
409
.
1 30.7 
Propafenone 
Pooled rates (SE) 379; 64 chronic AF, 215 40 I; 65 chronic AF, 234 65.8 (2.03) 0.2435 25.3 (1.7) 0.335571 1326.67 232.86 
PAF, 100 PSVT PAF, 102 PSVT 
95%CI /61.8-69.73 21.87-28.6 
Z (P) 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AA.., atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier estimates (% of 
patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.S p, weight of Sp; RD, risk difference; 95% CI; 95% confidence interval; * statistically 
significant (P<O.05); ** highly statistically significant (P<O.OI) 
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Table 4.10 Kaplan-l\Ieier estimates for patients remaining in sinus rh)'thm, and indhidual RDs at 3 months (continued) 
f. Flecaillide llollralldom;sed clillical trials 
Study name Flecaillide COlltrol Sr (SE) W.Sr Sp (SE) W.Sp RlJ (%) Statistic % Weight 
(no. of patiellts alld (110. of patiellts and (95% Cl) for effect Assiglled ill 
type of arrhythmia) type of cOlltrol) 
I I Fixed Effects Random Effects 
Crijns et al. 1991 127 chronic AF 53 Sotalol 44.1 (4.4) 0.05152 46.8 (6.8) 0.0214 -10.6 (-26.6-5.3) -1.31 (NS) 151.148 8.9 
Crij ns et al. 1991 127 chronic AF 34 Amiodarone 44.1 (4.4) 0.05152 71.24 (8.4) 10.01404 1-14.73 (-33.4-3.9) 1-1.55 (NS) 1110.314 8.7 
Anderson et al. t 1994 42; 25 PAF, 17 PSVT 42 Placebo; 25 PAF, 17 73.8 (6.8) 0.02173 33.1 (5.8) 10.0303 57 (39.7-74.6) 16 .43** 126.43 18.8 PSVT 
Mary-Rabine et al. 1988 55; 39 PAF, 16 PSVT 13 Amiodarone+flecainide; 69.1 (6.2) 0.0258 191.2 (13.8) 0.00523 122.9 (-6.8-52.7) 1.5 (NS) 43.479 7.7597 
12 PAF, I PSVT 
Leclercq et al. 1992 19PAF 33 Amiodarone+flecainide 68.4 0.00879 55.7 (7.5) 0.01797 -7.34 (-32.8-18.2) -0.5 (NS) 59.042 8.1427 (10.7) 
Pooled rates (SE) 243; 83 PAP, 127 chronic 175; 56 PAF, 87 chronic 53.5 (2.5) 0.15938 46.2 (3.4) 0.0889 490.413 42.28 
AF,33 PSVT AF,I8 PSVT 
95%CI 48.6-58.4 39.6-52.7 
Z(P) 1 
- ---
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier estimates (% of 
patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of Sp; RO, risk difference; 95% CI; 95% confidence interval; * statistically 
significant (P<O.05); ** highly statistically significant (P<O.OI) 
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Table 4.10 Kaplan-Meier estimates for patients remaining in sinus rhythm, and individual RDs at 3 months (continued) 
g. Flecaillide uncolltrolled clinical trials 
-
-_._-
Study name I Flecainide Control Sr(SE) W.Sr Sp(SE) W.Sp RD (%) Statistic for % Weight (no. of patients and (no. of patients, (95% CI) effect Assigned in 
type of arrhythmia) type of control) 
Fixed Effect. Random Effects 
Berns et al. 1987 39; 5 chronic AF, 25 PAF, 9 - 56.5 (7.9) 0.015861 69.4 (2.4) 0.17564 -13 (-29.2-3.3) -1.6 (NS) 145.47 295.2 
AT 
Zeigler et al. 1988 16PSVT 
- 150 (12.5) 0.0064 69.4 (2.4) 0.17564 -19.4 (-44.3-5.5) -1.5 (NS) 61.75 78.69 
Sonnhag et af. 1988 120PAF - 160 (11) 0.008333 69.4 (2.4) 0.17564 -9.4 (-31.4-12.6) -0.84 (NS) 79.56 110.1 
Zee-Cheng et al. 1988 15 PSVT - 60 (12.6) 0.00625 69.4 (2.4) 0.17564 -9.4 (-34.6-15.83) -0.73 (NS) 60.35 76.44 
Anderson JL 1992 66; 25 PSVT. 41 PAF - 65.2 (5.9) 0.029069 69.4 (2.4) 0.17564 -4.3 (-16.7-8.2) -0.671 (NS) 249.41 1913.16 
Clementy et at. 1992 944 PAF - 62.7 (1.6) 0.403693 69.4 (2.4) 0.17564 -6.7 (-12.3_-1.1) -2.34* (P=0.02) 1223.91 -374.58 
Pooled rates (SE) 1100; 1030 P AF; 65 PSVT; - 62.4 (1.5) 0.469606 69.4 (0.97) 1.054 -7.5 (2.3) 1820.45 2099.01 
5 chronicAF 
95%CI 59.5-65.3 67.5-71.31 -12.1_-2.9 
Z (P) I -3.2** (P=0.0014) I 
-~ 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier estimates (% 
of patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of Sp; RD, risk difference; 95% CI; 95% confidence interval; * 
statistically significant (P<O.05); ** highly statistically significant (P<O.O I) 
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Table 4.11 Kaplan-Meier estimates for patients remaining in sinus rhythm, and indiyidual RDs at 6 months 
a. Amiodarolle randomised clinical trials 
Study name Amiodarolle (110. of Control Sr(SE) W.ST Sp (SE) W.Sp RIJ (0/,) Statistic % Weight Assigned ill 
patients alld type of (no. of patiellts, type (95% CI) for effect 
arrhythmia) of control) 
Fixed Effects Random Effects 
Vitolo et al. 1981 128 chronic AF 29 Quinidine 78.6 (7.8) 10.01663 14 1.4(9.1) 0.01196 37.2 13.11 ** 69.553 15.99 (13.7-60.7) 
Martin et al. 1986 43PAF 22 Disopyramide 179.1 (6.2) 0.025983 154.5 (10.6) I 0.00887 24.5 11.99** 166.144 15.81 (0.4-48.6) 
Bosi et al. 1990 48 chronic AF 49 Placebo 72.9 (6.4) 0.024306 79.6 (5.8) 0.03017 -6.7 -0.77 NS 134.605 17.9961 
( -23.5-10.2) (P=0.44) 
Zchender et al. 1992 12 chronic AF II Quinidine Nerapamil - - - - - - - -
Jong et al. 1995 39 chronic AF 25 Placebo - - - - - - - -
Pooled rates (SE) 170 136 76.7 (3.9) 0.06692 66.3 (4.4) 0.05 270.3 49.796 
95%CI 69.1-84.3 57.6-74.95 I 
Z(P) I I 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT. paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier estimates (% 
of patients remaining in sinus rhythm) for treatment group and controls. respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of Sp; RD, risk difference; 95% CI; 95% confidence interval; * 
statistically significant (P<O.05); ** highly statistically significant (P<O.O I) 
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Table ~.ll Kaplan-Meier estimates for patients remaining in sinus rh)'thm, and individual RDs at 6 months (('ontinued) 
b. Amiodarone ullcontrolled clinical trials 
-_. -
-
Study lIallle I A ",iodarolle (110. of COlltrol SdSE) I W.ST jSP(SE) W.Sp RlJ ('7c) Statistic for % Weight patiellts alld type of (110. of patients, (95% CI) effect Assigned in 
arrhythmia) type of control) 
I I I I I I I I I Fiud Effect. I Random Effect. 
Leak et al. 1979 14; 9 PSVT, 2 PAF, 3 - 50 (13.4) 0.0056 57.7 (2.6) 0.152824 -7.7 -0.57 NS 54.02 14.13 
PSVT+WPW (-34.4-18.9) (P=0.57) 
Podrid et al. 1981 26; 18 PAF, 8 PSVT - - - - - - - - -
Grasboys et al. 1983 121; 95 chronic AF, 21 - 80.99 (3.6) 0.078596 57.7 (2.6) 0.152824 23.3 5.31** 519.03 18.5 
SVT and 5 SVT+AF (14.7-31.8) 
Blomstrom et al. 1984 21; 13 chronic AF, 8 PAF 1- 61.9 (10.6) 10.008911 57.7 (2.6) 10.152824 4.2 0.39 NS 84.145 15.6 (-17.2-25.6) (P=0.7) 
Horowitz et al. 1985 38; II chronic AF - 52.6 (8.1) 10.01524 57.7 (2.6) 0.152824 -5.1 -0.59 NS 138.6 16.8 
27PAF (-21.7-11.6) (P=0.56) 
Gold et af. 1986 68; 54 chronic or - 73.5 (5.4) 0.034937 57.7 (2.6) 0.152824 15.8 2.7** 284.362 19.9914 
paroxysmal AF, 14 (4.2-27.5) 
chronic AF 
Blevins et at. 1987 38; 25 chronic AF - 53.1 (8.8) 0.01285 57.7 (2.6) 0.152824 -4.6 -0.5 NS 118.54 18.2 
13 PAF (-22.6-13.4) (P=0.62) 
Brodsky et al. 1987 28 chronic AF - 75 (8.2) 0.014933 57.7 (2.6) 0.152824 17.3 2.01* 136.04 16.8 (0.49-34.1) (P=0.04) 
Levy et a/. 1991 112 chronic AF - 32.4 (4.6) 0.046606 57.7 (2.6) 0.152824 -25 -4.8** 357.141 20.3 (-35.7_-15) 
Gossenlink et al. 1992 80 AF or AFL - 63.8 (5.4) 0.034618 157.7 (2.6) 0.152824 6.1 1.02 NS 282.3 17.92 
(-5.6-17.7) (P=0.154) 
Chun et al. 1995§ 110; 53 chronic AF or - 92.7 (2.5) 0.163113 57.7 (2.6) 0.152824 35.11 9.8** 789.005 18.7 
AFL and 57 PAF (28.1-42) 
Mostow et al. 1990 19; 9 AF, 1 AFL, 6 PAF, - 31.6 (10.7) 0.008794 57.7 (2.6) 0.152824 -26.1 -2.4* 83.151 15.6 
3 atrial arrhythmia (-47.6 -4.6) 
Pooled rates (SE) 675; 470 AF, 205 PAF - 74.2 (1.5) 0.451514 57.7 (0.77) 1.68 12.6 (1.9) 3014.775 187.2 
95%CI 71.2-77.24 56.2-59.2 8.9-16.2 
Z(P) 6.7** (P<O.OI) 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier estimates (% 
of patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of Sp; RD, risk difference; 95% Cl; 95% confidence interval; * 
statistically significant (P<O.05); ** highly statistically significant (P<O.OI) 
106 
Table 4.11 Kaplan-~Ieicr estimates for patients remaining in sinus rhythm, and individual RDs at 6 months 
(continued) 
c. Sotalol randomised clinical trials 
--
Study name Sotalol COlltrol SdSE) W,ST Sp(SE) W.Sp RD (%) Statistic % Weight 
(no. of (110. of patiellts, (95o/D Cl) for effect Assiglled ill 
patiellts alld type of COlltrol) 
type of 
arrhythlllia) 
Fixed Effects Random Effects 
luul-Moller et al.195 79 Quinidine 51.6 (5.13) 0.038 48.1 (5.6) 0.032 3.5 0.46 NS 172.7 37.4 
1990· (-11.4-18.4) (P=0.65) 
Singh etal. 
112 
6 Placebo 41.7 (14.2) 10.0049 0 - 41.7 2.93** 49.371 24.3 
1991· 03.8-69.6) 
Reimold et al. 49 49 Propafenone 46.94 (7.1) 0.0197 40.8 (7.02) 0.0202 6.12 0.613 NS 99.872 32.3 
1993* ( -13.5-25.7) 
Kalusche et al. 41 37 QuinidinelVerapamil 63.42 (7.5) 0.0177 75.7 (7.1) 0.0201 -12.3 -1.189 NS 94.041 31.7 
1994· (-32.5-7.95) (P=0.234) 
Carunchio et al. 20 20 Aecainide 65 (10.7) 0.00879 80 (8.9) 0.0125 -15 -1.078 NS 51.613 24.8 
1995· (-42.3-12.3) (P=0.28) 
Carunchio et al. 20 26 Placebo 65 (10.7) 0.00879 34.6 (9.3) 0.01149 30.4 2.144 NS 49.8 24.4 
1995· (2.6-58.2) (P=0.016) 
Hohnloser et al. 17 21 Quinidine 76.5 (10.3) 0.009448 185.7 (7.6) 0.0172 -9.24 -0.72 NS 60.92 26.8 
1995 (-34.4-15.9) (P=O.472) 
Pooled rates 234 238 56.6 (3.1) 0.107357 59.5 (2.97) 0.1132 I 578.361 201.629 (SE) 
95%CI 50.6-62.6 53.7-65.4 
Z{P) 
--
AF. atrial fibrillation; PAF. paroxysmal atrial fibrillation; AFL. atrial flutter; PSVT. paroxysmal supraventricular tachycardia; SVT. supraventricular tachycardia; ST% (SE) and Sp% (SE). 
Kaplan-Meier estimates (% of patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of Sp; RD. risk 
difference; 95% CI; 95% confidence interval; • statistically significant (P<O.05); •• highly statistically significant (P<O.OI) 
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Table 4.11 Kaplan-Meier estimates for patients remaining in sinus rhythm, and individual RD at 6 months (continued) 
d. Sotalol nonrandomised clinical trials 
Study name Sotalol Control Sr(SE) W.Sr Sp (SE) W.Sp RD (%) Statistic for % Weight 
(no. of patients) (no. of patients, type of (95% CI) effect Assigned in 
control) 
I I I I Fixed Effects Random Effect. 
Crijns et al. 1991 53 127 Flecainide 43.4 (6.81) 0.02158 37 (4.3) 0.05448 6.4 0.79 NS 154.553 398.044 
( -9.4-22.2) (P=0.43) 
Crijns et al. 1991 53 34 Amiodarone 43.4 (6.81) 0.02158 35.3 (8.2) 0.01489 8.1 0.76 NS 88.094 135.253 
(-12.8-28.98) (P=0.45) 
Antman et al. 1990 48 109 Propafenone 25 (6.3) 0.0256 27.5 (4.3) 0.05464 -2.5 -0.33 NS 147.328 562.33 
(-17.4-12.3) (P=O.72) 
Pooled rates (SE) 101 270 36.6 (3.8) 10.06876 32.6 (2.84) 0.124 416.98 1095.627 
95%CI 29.1-44.02 27.1-38.2 I I I 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AR... atrial flutter; PSVT. paroxysmal supraventricular tachycardia; SVT. supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier estimates (% of 
patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of Sp; RD, risk difference; 95% CI; 95% confidence interval; * statistically 
significant (P<O.05); ** highly statistically significant (p<0.0 I) 
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Table 4.11 Kaplan-l\Ieier estimates for patients remaining in sinus rhythm, and indi"idual RD at () months (continued) 
e. Flecaillide ralldomised clinical trials 
Study I/ame Fiecaillide COlltrol ST (SE) W,ST Sp(SE) W.Sp RD (%) I Statistic % Weight Assiglled iI/ 
(110. of patiellfS alld (I/O. of patients, t}pe (95% Cl) for effect 
type of arrhythmia) of cOl/trol) 
I Fixed Effects Random Effects 
Rasmussen et al. 28 chronic AF 28 Disopyramide 85.71 (6.6) 0.022867 46.43 0.01126 39.3 (16.72-61.9) 3.4** 75.44 37.58 
(abstract) 1988 (9.4) I 
Van-Gelder et al. 1989 \36 chronic AF 37 Placebo \58 (8.23) 0.014778 \49 (8.2) 0.01481 \9 (-13.8-3\.8) 0.77** 73.96 \37.21 
Anderson et al. 1989+ 48PAF 48 Placebo - - - - - - - -
Pritchett et al. 1991+ 42; 28 PAF, 14 PSVT 42; 28 PAF, 14 PSVT, - - - - - - - -
Placebo 
Henthorn et al. 1991 t 34 PSVT 34 Placebo - - - - - - - -
Pietersen el al. 1991 + 43PAF 43 Placebo - - - - - - - -
Lau et aI. 1992:1: 19PAF 15 Placebo - - - - - - - -
Lau el al. 1992:1: 19PAF 18 Quinidine - - - - - - - -
Chimienti el al. 1994 129; 77 PAF, 52 PSVT 136; 82 PAF, 54 PSVT, 81.6 (3.4) 0.08591 69.96 0.06471 2.2* 369.1 62.25 
Propafenone (3.9) (P=0.025) 
Pooled rates (SE) 379; 64 chronic AF, 215 401; 65 chronic AF, 234 79.54 (2.8) 0.12356 63.6 (3.3) 0.0908 518.484 137 
PAF, 100 PSVT PAF, 102 PSVT 
95%CI 73.96-85.1 57-70.13 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; *statistically significant (P<O.05); ** highly statistically significant (P<O.Ol) 
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Table 4.11 Kaplan-l\Jeier estimates for patients remaining in sinus rhythm, and individual RD at 6 months (continued) 
f. Flecaillide Ilollrandomised clinical trials 
--
_._--
Study name Flecaillide COlltrol SdSE) W.Sr Sp (SE) W.Sp RD (%) Statistic % Weight 
(110. of patiellts and (110. of patients, type (95% CI) for effect Assigned ill 
type of arrhythmia) of control) 
Fixed Effects RalJdom Effects 
eri jns et al. 1991 127 chronic AF 53 Sotalol 37 (4.3) 0.054478 43.4 (6.8) 0.02158 -6.4 (-22.2-9.4) -0.79 (NS) 154.56 11.5153 
erijns et aJ. 1991 127 chronic AF 34 A miodarone 37 (4.3) 0.05448 135.3 (8.2) 10.01489 1.7 (-16.4-19.84) 0.185 (NS) 116.93 111.2457 
Anderson et al. 1994 t 42; 25 PAF, 17 PSVT 42 Placebo; 25 PAF, 17 73.8 (6.8) 0.02173 16.7 (5.8) 0.0303 57.1 (39.7-74.6) 6.43** 126.43 11.3276 
PSVT 
Mary-Rabine et al. 55; 39 PAF, 16 PSVT 13 Amiodarone+flecainide; 69.1 (6.2) 0.0257 46.2 0.00523 22.94 (-6.8-52.7) 1.5 (NS) 43.479 9.6739 
1988 12 PAF, 1 PSVT (13.8) 
Leclercq et al. 1992 19PAF 33 Amiodarone+flecainide 68.42 (10.7) 0.008794 75.8 (7.5) 0.01797 -7.34 (-32.8-18.2) -0.56 (NS) 59.042 10.2767 
Pooled rates (SE) 243; 83 PAF, 127 chronic 175; 56 PAF, 87 chronic 48.5 (2.5) 0.165232 39.7 (3.3) 0.0899 500.429 54.04 
AF,33 PSVT AF,18PSVT 
95%CI I 43.7-53.3 33.2-46.2 I 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier estimates (% 
of patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of Sp; RD, risk difference; 95% eI; 95% confidence interval; * 
statistically significant (P<O.05); ** highly statistically significant (P<.O.O I) 
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Table 4.11 Kaplan-Meier estimates for patients remaining in sinus rhythm, and individual RD at 6 months (continued) 
g. Flecaillide uncolltroiled clinical trials 
Study name Flecainide Control Sr(SE) I W.ST Sp(SE) W.Sp RD (%) Statistic for effect % Weight (no. of patients and (no. of patients, type (95% Cl) Assigned in 
type of arrhythmia) of control) 
Fixed Effect. Random Effect. 
Berns et al. 1987 39; 5 chronic AF, 25 - 156.4 (7.9) 0.015861 157.7 (2.6) 0.152821-1.3 (-17.6-15.1) 1-0.155 (NS) 143.69 1198.247 
PAF,9 AT 
Zeigler et al. 1988 16PSVT - 50 (12.5) 0.0064 57.7 (2.6) 0.15282 1-7.7 (-32.7-17.3) 1-0.6 (NS) 61.43 169.61 7 
Sonnhag et al. 1988 20PAF - 55 (11.12) 0.008081 57.7 (2.6) 0.15282 1-2.7 (-25.1-19.7) -0.24 (NS) 76.75 89.974 
Zee-Cheng et al. 1988 15 PSVT - 46.7 (12.9) 0.006027 57.7 (2.6) 0.15282 -II (-36.8-14.7) -0.84 (NS) 57.98 65.223 
Anderson JL 1992 66; 55 PSVT, 41 PAF - 65.2 (5.9) 0.029069 57.7 (2.6) 0.15282 7.5 (-5.1-20) 1.16 (NS) 244.24 458.846 
Clementy et al. 1992 944PAF 
-
62.7 (1.6) 0.403693 57.7 (2.6) 0.15282 5.0 I (-0.87-10.9) 1.67 (NS) 1108.58 -987.209 
Pooled rates (SE) 1100; 1030 PAF; 65 
-
62.14 (1.5) 0.46913 57.7 0.92 13.5 (2.4) I 1692.67 -105.302 PSVT; 5 chronic AF (1.04) 
95%CI 59.3-65 55.7-59.8 -1.3-8.2 
11.43 (P=0.15) NS 1 1 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier estimates (% 
of patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of Sp; RD, risk difference; 95% CI; 95% confidence interval; * 
statistically significant (P<O.05); ** highly statistically significant (P<O.OI) 
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Table 4.12 Kaplan-l\leier estimates for patients remaining in sinus rhythm, and individual RD at 12 months 
a. Amiodarone ralldomised clinical trials 
--
------_ .. -
Study name Amiodarone Control SdSE) W,ST SI'(SE) W,SI' RD (o/~) Statistic for % Weight 
(no. of patients and (no. of patients, type (95% CI) effect Assigned in 
type of arrhythmia) of control) 
I I Fixed Effects Random Effects 
Vitolo et af. 1981 * 28 chronic AF 29 Quinidine 53.6(9.4) 10.01126 20.7 (7.5) 0.01767 32.9 12.7** 168 .77 1 18.4 (9.3-56.5) 
Martin et al. 1986* 43 PAF 22 Disopyramide 79.1 (6.2) 0.02598 54.5 (10.6) 0.00887 24.5 1.99* 66.144 18.2 
(0.4-48.6) (P=0.047) 
Bosi et al. 1990* 48 chronic AF 49 Placebo 72.9 (6.4) 0.02431 79.6 (5.8) 0.0302 -6.7 -0.77 NS 134.6 21.17 
(-23.6-10.2) 
Zehender et al. 1992* 12 chronic AF II Quinidine N erapamil - - - - - - - -
Jong et al. 1995* 39 chronic AF 25 Placebo - - - - - - - -
Pooled rates (SE) 170 136 71.97 0.061546 57.3 (4.2) 0.05672 269.514 57.77 (4.1) 
95%CI 64.1-79.9 49.1-65.6 
Z(P) 17.9** 13.6** I 
-
AF. atrial fibrillation; PAF. paroxysmal atrial fibrillation; AA... atrial flutter; PSVT. paroxysmal supraventricular tachycardia; SVT. supraventricular tachycardia; ST% (SE) and Sp% (SE). Kaplan-Meier estimates (% of 
patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST. weight of ST; W.S p, weight of S p; RD. risk difference; 95% CI; 95% confidence interval; * statistically 
significant (P<O.05); ** highly statistically significant (P<O.OI) 
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Table 4.12 Kaplan-l\leier estimates for patients remaining in sinus rhlthm, and imJiyidual RD at 12 months (continued) 
b. Amiodarolle Ullco1ltrolled clillical trials 
Sludy /lame I Amiodarolle I COlllrol I SdSE) III',ST Sp (SE) I W.Sp I RJ) ('k) ISlalislic I '7c Weighl 
(110. of patiellts alld (/10. (~f patiellt.\", (95'7c CI) jiJr effeft A.Higlled il/ 
type of arrhythmia) type of cOlltro/) 
I I I I I I I I I Fixed Effects I Ralldolll Effects 
Leak el al. 1979 14; 9 PSYT, 2 PAF, 3 1- 1 SO (13.4) 10.00S6 Iso.2 (2.6) 1 0.149202 -0.2 -O.OIS NS IS3.97 123 .8 PSYT+WPW (-26.87-26.5) (P=0.99) 
Podrid et al. 1981 26; 18 PAF, 8 PSYT - - - - - - - - -
Grasboys el al. 1983 121; 95 chronic AF , 21 
SYTand S SVT+AF 
- - - - - - -
- -
Blomstrom el al. 1984 21; 13 chronic AF, 8 - 47.6 (10.9) 0.00842 SO.2 (2.6) 0.149202 -2.6 -0.23 NS 79.7 27.7 
PAF (-24.5-19.4) 
Horowitz el al. 1985 38; II chronic AF - 52.6 (8.1) 0.015242 50.2 (2.6) 0.149202 2.4 10.29 NS 138.3 42.3 
27PAF (-14.2-19.1) 
Gold el al. 1986 68; 54 chronic or - \64.7 (5.8) \ 0.029776 50.2 (2.6) 0.149202 14.5 \2.3* 248.221 48.98 paroxysmal AF, 14 (2.1-26.9) 
chronic AF 
Blevins et ai. 1987 38; 17 chronic AF - 53.1 (8.8) 0.01285 50.2 (2.6) 0.149202 2.9 3.2** 118.312 40.26 
13 PAF (-15.1-20.9) 
Brodsky et al. 1987 28 chronic AF - 35.7 (9.1) 0.012196 50.2 (2.6) 0.149202 -14.5 -1.54 NS 112.7 30.88 (-32.9-4) (P=O.l24) 
Levy et al. 1991 102 chronic AF - 27.45 (4.4) 0.051216 50.2 (2.6) 0.149202 -22.7 -4.4** 381.283 52.6 
(-32.S_-12.7) 
Gossenlink et al. 1992 SOAFor AA... - 61 (5.4) 0.033627 50.2 (2.6) 0.149202 10.8 1.8 NS 274.425 49.9 (-0.01-22.6) 
Chun et al. 1995§ 110; 53 chronic AF or - 57.3 (4.7) 0.04495 50.2 (2.6) 0.149202 7.1 1.32 NS 345.44 37.88 
AA... and 57 PAF (-3.5-17.6) (P=0.187) 
Mostow et al. 1990 19; 9 AF, 1 AFL,6 - - - - - - - - -
P AF, 3 atrial arrhythmia 
Pooled rates (SE) 675; 470 AF, 205 PAF - 49.4 (2.2) 0.22857 50.2 1.34282 -0.5 1855.822 299.2 (0.86) 
95%CI 45.1-53.6 48.5-51.9 -5.2-4.2 
Z (P) -0.19 NS 
(P=O.85) 
ST (SE) and Sp (SE), Kaplan-Meier estimates for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of Sp; RD, risk difference; 95% CI; 95% confidence interval; 
§, retrospective uncontrolled study, which was grouped with uncontrolled studies; :t, NSR sustained, but it there may be a relapse during the NSR period and number of patients with AF or PAF was not stated; * 
statistically significant (P<O.05); ** highly statistically significant (P<O.O 1) 
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Table 4.12 Kaplan-l\leier estimates for patients remaining in sinus rhythm, and individual RD at 12 months 
(continued) 
c. Sotalol randomised clinical trials 
Study name Sotalol COlltrol SdSE) W.Sr Sp (SE) W.Sp RD (%) Statistic % Weight 
(110. of (110. of patiellts, (95% CI) for effect Assiglled ill 
patients) type of cOlltrol) 
Fixed Effects Random Effects 
luul-Moller et at. 1990* 95 79 Quinidine 1- - I- I- - 1- - -
Singhelat. 1991* 12 6 Placebo 
- - - 1- - - - 1-
Reirnold et at. 1993* 49 49 Propafenone 36.7 (6.9) 0.0231 30.6 (6.6) 0.0231 6.12 (-12.5-24.8) 0.643 NS 110.158 25.187 
(P=0.52) 
Kalusche et 01. 1994* 41 37 QuinidineJVerapamil 48.8 (7.8) 0.01688 67.6 (7.7) 0.01688 -18.8 (-40.3-2.7) -1.7 NS 83.218 23.4512 
(P=0.089) 
Carunchio et al. 1995* 20 20 Aecainide 60 (10.95) 0.009524 70 (10.3) 0.00953 -10 (-39.4-19.4) -0.67 NS 44.444 18.8235 
(P=0.5) 
Carunchio et al. 1995* 20 26 Placebo 60 (10.95) 0.0132 26.9 (8.7) 0.01322 33.1 (5.7-60.5) 2.37 NS 51.106 19.9234 
(p=0.018) 
Hohnloser et al. 1995 17 21 Quinidine - - - - - - - -
Pooled rates (SE) 110 132 47.5 (4.3) 0.062692 45.8 (4) 0.06269 288.768 87.3851 
95%CI 39.1-55.97 37.9-53.6 I 
ST (SE) and Sp (SE), Kaplan-Meier estimates for treatment group and controls. respectively with their standard errors; W.ST• weight of ST; W.Sp• weight of S p; RD. risk difference; 95% CI; 95% confidence 
interval; §. retrospective uncontrolled study. which was grouped with uncontrolled studies; :J:. NSR sustained. but it !here may be a relapse during !he NSR period and number of patients with AF or PAF was 
not stated; * statistically significant (P<O.05); ** highly statistically significant (P<O.O I) 
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Table 4.12 Kaplan-Meier estimates for patients remaining in sinus rhythm, and individual RD at 12 months 
(continued) 
d. Sotalol Ilonralldomised clinical trials 
Study name Sotalol Control Sr(SE) W.ST Sp(SE) W.Sp RD (%) I Statistic % Weight (no. of (no. of patients), (95% CI) for effect Assigned 
patients) type of control in 
I I I I Fixed Effect. Random Effects 
Crijns et al. 53 127 F1ecainide 24.5 (5.9) 0.02863 33.89 (4.2) 0.0567 -9.3 -1.29 NS 190.253 178.355 
1991 (-23.5-4.9) (P=0.197) 
Cri jns et al. 53 34 Amiodarone 24.5 (5.9) 0.02863 17.65 (6.5) 0.0233 6.9 0.78 NS 128.747 123.186 
1991 (-10.4-24.2) (P=0.435) 
Antman et al. 48 109 Propafenone 14.6 (5.1) 0.038534 20.18 (3.8) 0.067661 -5.6 -0.88 NS 245.514 226.055 
1990 (-18-6.91) (P=0.37) 
Pooled rates 101 270 20.53 0.09579 25.03 (2.6) 0.14777 -4 (4.21) 564.514 527.6 
(SE) (3.2) 
95%CI 14.2-26.9 19.9-30.13 -12.3-4.2 
Z (P) 1 6.36** 19 .6** -0.95 NS (P=0.34) 
-- -
ST (SE) and Sp (SE), Kaplan-Meier estimates for treatment group and controls, respectively with their standard errors; W,ST, weight of ST; W.Sp, weight of Sp; RD, risk difference; 95% CI; 
95% confidence interval; * statistically significant (P<.O.05); .. highly statistically significant (P<.O.OI) 
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Table 4.12 Kaplan-l\leier estimates for patients remaining in sinus rh}thm, and indiyidmll RDs at 12 months 
(continued) 
e. Flecaill;de ralldom;sed clinical trials 
--
Study lIame Flecail/ide COlltrol SrlSE) W.Sr Sp(SE) W.Sp RD (o/~) Statistic % Weight 
(110. of (110. of patiellts), (95% CI) for effect Assiglled ill 
patiel/ts alld type of cOl/trol 
type of 
patiel/ts) 
Find Effect. Ralldom Effects 
Rasmussen et al. 28 chronic AF 28 Disopyramide 85.7 (6.6) 0.022867 46.4 (9.4) 0.01126 39.3 (16.7-61.9) 3.4** 75.436 43.62 
(abstract) 1988 
Van-Geldcr et al. 36 chronic AF 37 Placebo 49 (8.3) 0.04405 36 (7.9) 0.0161 13 (-9.5-35.5) 1.13 (NS) 75.94 43.8 
1989 
Anderson et al.:j: 148 P AF 48 Placebo - - - - 1- - - -1989 
Pritchett et aU 42;28 PAF, 42; 28 PAF, 14 - - - - - - - -
1991 14PSVT PSVT, Placebo 
Henthorn et al. t 34PSVT 34 Placebo - - - - - - - -
1991 
Pietersen et at.:j: 43PAF 43 Placebo - - - - - - - -
1991 
Lau et a/.:j: 1992 19PAF 15 Placebo - - - - - - - -
Lau et al.:j: 1992 19PAF 18 Quinidine - - - - - - - -
Chimienti et al. 129; 77 PAF, 136; 82 PAF, 54 77.4 (3.7) 0.073717 63.8 (4.1) 0.05888 13.6 (2.8-24.4) 2.5* 327.348 78.58 
1994 52PSVT PSVT, Propafenone (P=0.012) 
Pooled rates 379;64 401; 65 chronic AF, 75.42 (3) 0.112 56.4 (3.4) 0.0862 478.72 165.98 
(SE) chronic AF, 234 PAF, 102 PSVT 
215 PAF, 100 
PSVT 
95%CI 69.5-81.3 49.7-63 I 
--
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), 
Kaplan-Meier estimates (% of patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W,ST, weight of ST; W.Sp, weight of Sp; RD, 
risk difference; 95% CI; 95% confidence interval; * statistically significant (P<O.05); •• highly statistically significant (P<.O.O 1) 
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Table 4.12 Kaplan-l\leier estimates for patients remaining in sinus rhythm, and individual RDs at 12 months 
(continued) 
f. Flecaillide llonrandomised clinical trials 
Study name Flecainide Control ST(SE) W,ST Sp(SE) W.Sp RD (%) Statistic '7D Weight 
(no. of patients (no. of patients, type (95% CI) for effect Assigned in 
and type of of control) 
arrhythmia) 
I I 1 Fixed Effects 
Crijns et al. 1991 127 chronic AF 53 Sotalol 33.86 (4.2) 0.056711 24.5 (5.9) 0.02863 19.3 (-4.9-23.5) 1.29 (NS) 1 190.3 
Crijns et at. 1991 127 chronic AF 34 Amiodarone 133.86 (4.2) 0.056711 17.7 (6.5) 0.0234 16.2 (0.98-31.4) 2.1* 165.6 
Anderson et al. 1994 t 42; 25 PAF, 17 42 Placebo; 25 PAF, 17 73.81 (6.8) 0.021727 16.7 (5.7) 0.03024 57.14 (39.7-74.6) 6.43** 126.43 
PSVT PSVT 
Mary-Rabine et al. 55; 39 PAF, 16 13 Amiodarone+flecainide; 69.1 (6.23) 0.025755 46.2 0.00523 22.9 (-6.8-52.7) 1.5 (NS) 43.48 
1988 PSVT 12 PAF, I PSVT (13.8) 
Leclercq et al. 1992 19PAF 33 Amiodarone+flecainide 68.42 (10.7) 0.008794 75.8 (7.4) 0.01797 -0.56 (NS) 59.1 
Pooled rates (SE) 243; 83 PAF, 127 175; 56 PAF, 87 chronic 46.1 (2.4) 0.169696 30.6 (3.1) 0.11 584.577 
chronic AF, 33 AF, 18 PSVT 
PSVT 
95%CI 41.4-50.9 24.5-36.6 
Random Effects 
19.5 
19.2 
18.53 
14.5 
15.9 
87.57 
AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE), Kaplan-Meier 
estimates (% of patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of Sp; RD, risk difference; 95% CI 95% 
confidence interval; • statistically significant (P<O.05); ** highly statistically significant (P<O.O I) 
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Table 4.12 Kaplan-l\leier estimates for patients remaining in sinus rhythm, and indhidual RDs ~lt 12 months 
(continued) 
g. Flecaillide ullco1ltrolled clillical trials 
Study name Flecainide COlltrol SdSE) W.ST Sp (SE) W.Sp RD (%) Statistic % Weight 
(no. of patiellts alld (110. of patiellts, (95% CI) for effect Assiglled ill 
type of arrhythmias) t)'Pe of cOlllrol) 
Fixed Effects Random Effects 
Berns et al. 1987 39; 5 chronic AF. 25 - 56.4 (7.9) 0.015861 50.2 (2.6) 0.14920 6.2 (-10.2-22.6) 0.74 (NS) 143.367 94.3 
PAF,9 AT 
Zeigler et al. 1988 16PSVT 50 (12.5) 0.0064 50.2 (2.6) 0.14920 -0.2 (-25.2-24.8) -0.016 (NS) 61.368 50.189 
Sonnhag etal. 1988 20PAF - 55 (11.1) 0.008081 50.2 (2.6) 0.14920 4.8 (-17.6-27.2) 0.42 (NS) 76.656 59.972 
Zee-Cheng et al. 15 PSVT 
-
33.33 (12.2) 0.00675 50.2 (2.6) 0.14920 -16.9 (-41.3-7.5) -1.36 (NS) 64.578 52.317 
1988 
Anderson JL 1992 66; 55 PSVT, 41 PAF 
-
65.2 (5.9) 0.02907 50.2 (2.6) 0.14920 15 (2.4-27.5) 2.33- 243.293 129.205 
Clementy et al. 1992 944PAF 
- - - - - - - -
Pooled rates (SE) 1100; 1030 PAF; 65 
-
57.1 (3.9) 0.066 50.2 0.746 6.4 (4.12) 589.262 385.983 
PSVT; 5 chronic AF (I.I 6) 
95%CI 49.5-64.7 49.5-64.7 -1.64-14.5 
Z (P) 1.56 (P=O.1I9) NS 
-------
AF, atrial fibrillation; PAF. paroxysmal atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular tachycardia; ST% (SE) and Sp% (SE),Kaplan-Meier 
estimates (% of patients remaining in sinus rhythm) for treatment group and controls, respectively with their standard errors; W.ST, weight of ST; W.Sp, weight of S p; RD, risk difference; 95% CI 95% 
confidence interval; * statistically significant (P<O.05); ** highly statistically significant (P<O.OI) 
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Figure 4.5 Pooled percentages of patients (and 95%CI, bars) in amiodarone group, other comparator antiarrhythmic drugs' group, and placebo group remaining in sinus rhythm at 
3,6, and 12 months after cardioversion are depicted for randomised controlled trials (RCTs). Standard reference quinidine values (obtained from recent meta-analysis) are 
represented for comparison at each time interval. The number of trials (N) included in analysis, and total number of patients at risk at the begining of the follow-up (n) are shown. 
The number of patients remaining in sinus rhythm at 6 and] 2 months in the placebo group was only reported in one trial (n=49), as a result meta-analytic pooled percentages could 
not be obtained. However, since quinidine was compared to placebo, and amiodarone have showed better efficacy than quinidine, the results of this trial may be due to chance. 
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Figure 4.6 Direct comparison of sotalol. other antiarrhythmic drugs (quinidine. 
quinidine+verapamil. propafenone. and flecainide). and placebo for maintenance of sinus 
rhythm. Pooled percentages of patients remaining in sinus rhythm (Pt) at 3. 6. and 12 
months are represented for each treatment group in RCTs (N=6). In addition. the pooled 
percentages of patients free of attack obtained from sequential NonRCTs are depicted for 
comparison at the three time intervals. The sotalol Pt was significantly higher in RCTs 
than NonRCTs (P<O.05). 
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Figure 4.7 Pooled percentages of patients of (and 95% CI, bars) in amiodarone, flecainide, sotalol groups remaining 
in sinus rhythm at 3, 6, 12 months prior to cardioversion are represented for (A) randomised control trials (RCTs) and 
for (B) nonrandomised control trials (NonRCTs). The results obtained from our meta-analysis are compared to 
standard quinidine pooled percentages in RCTs and nonrandomised trials (Reimold et ai, 1992). 
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Figure 4.8 Indirect comparison of arniodarone, sotalol, and flecainide for treatment of chronic atrial 
fibrillation (CAF). The pooled percentages of patients remaining in sinus rhythm at 3, 6, and 12 months 
prior to cardioversion are depicted for (A) randornised clinical trials (RCTs) and (B) nonrandomised 
clinical trials (NonRCfs). 
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4.3.4 Mortality and Proarrhythmia 
During the follow-up, a total of 456 patients (out of 3937 patients) discontinued use of 
medication due to intolerable adverse effects which included conduction disturbances, 
severe bradycardia, skin photosensitivity, sleeping disturbances, gastrointestinal 
irritation during amiodarone (77 patients, 8.7%), neurologic disturbances, 
proarrhythmia during sotalol (23 patients, 7%), visual disturbances, and palpitation 
during flecainide (263, 15.1 %). Furthermore, 24 (6.2%) during placebo, and 69 
(10.8%) during other comparative drugs were withdrawn due to other complications. 
In the amiodarone trials (all trial designs, N = 18), the unadjusted crude mortality rate 
for all amiodarone-treated patients and all control groups was 2.6% (23/877) and 3.9% 
(7/179) respectively. The causes of death in the arniodarone-treated group included 
myocardial infarction (n = 3), sudden death (n = 1), ventricular fibrillation (n = 1), 
cerebrovascular accident (n = 3), pneumonia (n = 2), carcinomatosis (n = 1), renal 
failure (n = 1), leukaemia (n = 2), hepatic disorders (n = 2), congestive heart failure (n 
= 2), vascular disease (n = 1), and intolerable skin photoallergy (n = 1). In the 
comparative drug group, the cause of mortality was myocardial infarction (n = 1), 
carcinoma (n = 1), cancer (n = 1), pulmonary embolus (n = 1), torsades de pointes (n = 
1), and unknown cause (n = 1). 
In sotalol clinical trials (RCTs and NonRCTs, N = 8), the unadjusted crude mortality 
rate for all sotalol-treated patients and all control groups was 0.84% (3/358) and 0.79% 
(4/504) respectively. The causes of death in the sotalol-treated group included 
myocardial infarction (n = 3), and cardiac arrest (n = 2). The cause of death in the 
comparative drug group was myocardial infarction (n = 3), and cerebral embolism (n = 
1 ). 
In flecainide clinical trials (all trial design, N = 16), the unadjusted crude mortality rate 
for all flecainide-treated patients and all control groups was 0.34% (6/1791) and 0.2% 
(11587) respectively. The causes of death in the flecainide-treated group included 
myocardial infarction (n = 2), cardiac arrest (n = 1), sudden death (n = 2), and 
pulmonary carcinoma (n = 1). The one event in the comparison group was acute 
myocardial infarction. 
Since patients allocated to active treatment in one trial should only be compared directly 
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with patients allocated to the control group in the same trial and not with patients in any 
other trial, and due to the unavailability of placebo control group in most included trials, 
calculating pooled summary estimates of death risk versus active control group in the 
same trial was considered appropriate. 
The summary statistics for mortality in the full-exposure groups in the RCTs and 
NonRCTs are given in Table 4.13 for amiodarone, Table 4.14 for sotalol, and Table 
4.15 for flecainide. 
As shown in Table 4.13. the difference between observed and expected value (O-E) 
was less than zero in three of the four amiodarone studies, and equal to 1.01 in one 
trial, and thus manifesting lower trend toward mortality in the amiodarone group. 
However. these differences were not significant in any of the trials (P>0.05). Overall. 
the typical pooled OR (Peto's method) was 0.91 (95% CI, 0.31 to 2.69; Z = -0.18; 
P=0.88). A test for heterogeneity between the various trial results was not significant 
(Q, 2.87; df=3, P=0.239). The summary OR calculated by Mantel-Haenszel method 
was 0.92 (95% CIt 0.5 to 1.7; Z= -0.27, P=0.8), the RD calculated by DerSimonian 
and Laird method was -4.628% (95% CI -12.3 to 3.04. P=0.238). and RR (Fleiss et 
al. method. 1993) was 1.02 (95% CI 0.42 to 2.48; P=0.97). All the previous 
summary estimates. although not statistically significant, implied lower incidence of 
mortality on amiodarone compared to other drugs. 
For the sotalol clinical trials, the study specific values of OR. RD, RR, as well as the 
overall meta-analytical estimates of these statistics. are shown in Table 4.14. The 
typical OR was 0.85 (95% CI 0.815 to 3.945; Z= -0.2, P=0.84; Q. 4.385, df = 6, 
P=0.223). The Mantel-Haenszel OR, RD, RR were 0.99 (0.97). -0.79 (0.34), and 
0.954 (0.94) respectively (P>0.05). 
Table 4.15 illustrates mortality data in the flecainide clinical trials. The deaths were 
stated in seven placebo-controlled trials and four comparative studies. The O-E value 
was equal to zero in seven studies (5 placebo-controlled, and 2 comparative studies). 
In one nonrandomised trial, comparing flecainide to amiodarone, the O-E value was-
0.3665 indicating lower incidence in flecainide. The overall pooled OR (Peto's 
method) versus other drugs was 1.9 (95% CIO.3 to 2.5; Z=0.7, P=0.5), and versus 
placebo was 7.5 (95% CI 0.8 to 72.6; Z=1.7. P=0.08). All the other statistics for the 
difference between flecainide and the active drugs were not significant. However, the 
Mantel Haenszel OR versus placebo was highly statistically significant (ORMH. 1.8; 
120 
95% CI, 1.2 to 2.7; Z=3.1. P=0.002), strongly suggesting increased mortality in the 
flecainide-treated group. However, the RD and RR versus placebo were 2.1 (95% CI, 
-0.5 to 4.8; Z=1.6, P=0.12), and 1.7 (95% CI, 0.4 to 6.5; Z=0.7, P=0.5) 
respectively. 
The insufficient reporting of data regarding the age, sex. left atrial diameter, duration of 
AF, or cardiac diagnosis, hindered the estimation of adjusted mortality rates. 
Furthermore, the time of death was not consistently reported. Hence, a survival meta-
analysis could not be performed. 
The proarrhythmic events reported in the amiodarone, sotalol, and flecainide clinical 
trials are given in Table 4.16. All forms of proarrhythmic reactions considered by the 
principal authors to be drug-induced pro arrhythmic effects, were included in the 
analysis. 
The incidence rate of proarrhythmia in amiodarone-treated group in all study designs, 
ranged from 0% to 15% in the individual studies. The crude total incidence rate from 
all studies was 0.7% (6/857) in amiodarone treated patients as compared with 5.1 % in 
the active control group. The nature of the presenting arrhythmia induced by 
amiodarone was severe symptomatic sinus bradycardia (n = 6). In the comparative 
drug group, proarrhythmia was in the form of prolongation of QT interval (n =1, 
receiving quinidine plus verapamil), ventricular arrhythmia (n = 6, receiving bepridil), 
and torsade de pointes (n = 2, receiving bepridil). Table 4.16 shows pooled estimates 
of proarrhythmia incidence in RCTs of amiodarone. As shown, the results of ORpeto , 
ORMH, and RR suggest a trend towards decreased incidence of pro arrhythmia with 
amiodarone when compared to other drug Classes. 
The incidence rate of proarrhythmia in the sotalol-treated group in the RCTs and 
NonRCTs, ranged from 1.03 % to 6% in the individual studies. The crude total 
incidence rate from all studies was 1.96% (7/358) in the sotalol-treated group versus 
1.5% (8/528) in the active control group. Sotalol-induced proarrhythmia was in the 
form of ventricular arrhythmia (n = 2), nonsustained ventricular tachycardia (n = 1), 
and supraventricular proarrhythmia (n = 1). In the control group, the proarrhythmic 
events were ventricular fibrillation (n = 2; 1 receiving quinidine, and 1 receiving 
propafenone), torsade de pointes (n = 3, receiving quinidine), sustained ventricular 
tachycardia (n = 1, receiving quinidine), and nonsustained ventricular tachycardia (n = 
1, receiving propafenone). The pooled estimates for the incidence of proarrhythmia on 
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sotalol as compared to other drugs suggested nonsignificant difference (Table 4.16). 
The incidence rate of pro arrhythmia in the flecainide-treated group in the individual 
studies ranged from 1.5% to 20.5%. The crude total incidence rate from all studies 
was 1.7% (32/1884) in flecainide treated patients as compared with 0.3% in the active 
control group. The nature of flecainide-induced pro arrhythmia was primarily 
supraventricular proarrhythmia (53.13% of the total events). In the control group, the 
two proarrhythmic events which occurred were symptomatic sustained ventricular 
tachycardia (receiving propafenone), and supraventricular proarrhythmia (receiving 
sotalol). On the contrary to amiodarone and sotalol, the overall pooled ORpeto, ORMH, 
RR were highly significant as compared to the combined estimates of other drugs and 
placebo (Q = 0.6, 0.1, 0.6 respectively). Recalculating the same statistics against other 
drugs did not show significant difference. However, against placebo, the difference 
was highly significant (P<O.O 1). 
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Table "',13 ,l\lortality data and statistical analysis of full-exposure group in randomised clinical trials of' amiod3l'one 
Study lIame Basic data Peto M-H method D-L metlwd Fleiss et 
(No method af (1993) 
dead/No 
fOllowed 
up) 
Amiodarolle Control O-E Var (O-E) OR statistic OR statistic RD(%) statistic RR statistic for 
group group (95% CI) for for (95% CI) for (95% CI) effect 
effect effect effect 
Vitolo et al. 1981 0128 0126Q 0 0 , 0.8 (NS) 0.93 -0.04 0 0.8 (NS) 0.931 -0.036 (NS) 
(NS) (0.019-45.3) 
Martin eta/. 9/43 4127D 1.01429 2.545 1.489 0.64 (NS) 1.42 0.58 6.12 0.662 (NS) 1.3434 0.5692 (NS) 
1986 (0.44-5. \) (NS) (-11.98-24.21) (0.486-3.713) 
Zehender et al. 0/20 1120Q+V -0.5 0.25 0.135 -I (NS) 0.32 -0.69 -5 -1.025 (NS) 0.333 -0.6851 (NS) 
1992 (0.002-6.82) (NS) ( -14.55-4.55) (0.014-7.724) 
Perelman et al. 0/10 2114 B -0.833 0.465 0.1666 -1.22 (NS) 0.24 -0.89 -14.29 ,1.53 (NS) 0.2727 -0.8676 (NS) 
1987 (0.09-2.95) (NS) (-32.62-4,05) (0.0145-5.13) 
Pooled rates vs 9/101 7/87 -0.319 3.26 0.91 -0.18 (NS) 0.92 -0.27 -4.628 -1.18 (NS) 1.01522 0.033 (NS) 
other drugs (0.31-2.69) (P=0.88) (0.5-1.7) (NS) (-12.3-3.04) (P=0.238) (0.415-2.482) (P=0.97) 
(P=0.8) 
Q statistic (P) 2.87 , - 2.45 1.546 
(P=0.239) NS (P=0.4887) NS (P=0.67) NS 
Pooled random- 1.01 0.013 (NS) - -0.0731 -2.4· , 
-
effects ( -0.938-0.95) (P=0.98) (-0.131_ -0.015) (P=0.02) 
Pooled rates vs NA - - NA - NA , 
placebo (SE) 
O-E. observed minus expected deaths; Var (O-E). variance of (O-E); OR (95% CI). odds ratio and its 95% confidence interval; M-H method. Mantel and Haenszel method; D-L method. DerSimonian and Laird method; 
RD (95% CI). rate difference and its 95% confidence interval; RR (95% CI). relative risk and its 95% confidence interval; Q. quinidine; Pro propafenone; D. disopyramide; Q+V. quinidine+verapamil; B. bepridil; * 
statistically significant (P<D.05); .* highly statistically significant 
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THbie 4.14 l\fortHlity dHta and stHtistical HnHlysis of full-exposure group in rHndomised dinical trials of sotHlol 
Stlldy "ame Basic {lata Feto M-H method lJ-L Flei.H et 
(No method method af (/993) 
dead/No 
followed 
IIp) 
Sotalol Control O-E Var (O-E) OR statistic OR statistic RD(%) statistic RR statistic 
grollp grollp (95% Cl) for effect for effect (95% Cl) for effect (95% Cl) for 
effect 
Juul-Moller et ai. 1/97 1/86Q -0.06011 0.4954 0.88575 -0.0854 (NS) 0.886 0.76 (NS) -0.131 -0.085 (NS) 0.8878 -0.1 (NS) 
1990 (-3.2-2.9) (0.09-8.38) 
Reimold et ai. 2150 0/50 Pr I 0.4949 7.5414 1.42141 (NS) 5.2 2.02* 4 1.44 (NS) 5 1.05 (NS) 
1993 (-1.4-9.4) (0.25-101.4) 
Kalusche et al. 0/41 OI37Q+V 0 0 - - 0.9 -0.05 (NS) 0 - 0.91 -0.05 (NS) 
1994 (0.018-44.5) 
Crijns et al. 1991 0/53 21127 F -0.5889 0.41317 0.24044 -0.916 (NS) 0.47 -0.486 (NS) -1.57 -1.426 (NS) 0.474 -0.48 (NS) 
(-3.7-0.6) (0.023-9.7) 
Crijns et al. 1991 0/53 1134 A -0.61 0.238076 0.0774 -1.248 (NS) 0.21 -0.95 (NS) -2.94 -1.015 (NS) 0.216 -0.95 (NS) 
(-8.6-2.7) (0.009-5.1 ) 
Antrnan et al. 0/48 0/109 Pr 0 0 - - 2.3 0.41 (NS) 0 
-
2.245 0.41 (NS) 
1990 (0.05-109.9) 
Hohnloser et ai 0/25 0125Q 0 0 - - 1 o (NS) 0 - I o (NS) 
1995 (0.68-48.5) 
Pooled rates vs 3/314 4/468 -0.2582 1.6416 0.855 -0.2015 (NS) 0.99 -0.036 (NS) -0.79 -0.96 (NS) 0.954 -0.078 (NS) 
other drugs (0.185-3.945) (P=0.84) (0.65-1.52) (P=0.97) (-2.4-0.8) (P=0.337) (0.29-3.11 ) (P=O.94) 
Q statistic (P) 4.385 - 4.224 2.4 
P=0.223 (NS) P=0.646 (NS) (P=O.879) 
Pooled random- - - - - - 1.5 0.4 (NS) 
effects (0.2-11.1) (P=0.7) 
Pooled rates vs NA - - NA - NA -
placebo (SE) 
O-E, observed minus expected deaths; Var (O-E), variance of (O-E); OR (95% CI), odds ratio and its 95% confidence interval; M-H method, Mantel and Haenszel method; D-L method, DerSimonian and Laird method; 
RD (95% CI), rate difference and its 95% confidence interval; RR (95% CI), relative risk and its 95% confidence interval; Q, quinidine; P, placebo; Pr, propafenone; D, disopyramide; Q+V, quinidine+verapamil; B, 
bepridil; F, flecainide; A, amiodarone; * statistically significant (P<O.05); ** highly statistically significant 
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Table .... 15 l\lortalit~1 data and statistic~ll anal)'sis of full .. exposure group in randomiscd clinical trials of flecainide 
Study llllme Basic {Iatll Peto M-H metllOd D-L Fleiss et {II 
(No method method (1993) 
dead/No 
followed 
lip) 
Flecainide Control O-E Var (O-E) OR statistic OR statistic RD(%) statistic RR statistic 
group group (95% CI) for effect for effect (95% CI) for effect (95% CI) for 
effect 
Van-Gelder et al. 0/36 0137 P 0 0 - - 1.03 0.013 (NS) 0 - 1.03 (0.02-50) 0.013 (NS) 
1989* 
Rasmussen et al. 1/30 01300 0.5 0.25 7.4 1 (NS) 3.1 0.7 (NS) 3.3 (-3.1-9.8) 1.02 (NS) 3 (0.13-71) 0.7 (NS) 
1988* (0.14-365) 
Anderson et al. 1/64 0/64 P 0.5 0.25 7.4 1 (NS) 3.1 0.7 (NS) 1.6 (-1.5-4.6) I 1.01 (NS) 3 (0.13-72) 0.7 (NS) 
1989* (0.14-365) 
Pritchett et al. 1991 * om omp 0 0 - - 1 0 0 I - 1 (0.02-49) 0 
Henthorn et al. 1991 * 0/48 0/48 P 0 0 - - I 0 0 - I (0.02-49) 0 
Pietersen et al. 1991 * 2148 0/48 P 1 0.494737 7.548 1.42 (NS) 5.2 1.07 (NS) 4.2 (-1.5-9.8) 1.44 (NS) 5 (0.24-99) 1.05 (NS) 
(0.46-121.5) 
Lau et aI. 1992* 0119 0/18Q 0 0 - - 0.95 -0.03 (NS) 0 - 0.95 (0.02-45) -0.03 (NS) 
Lau et al. 1992* 0/19 0/15 P 0 0 - - 0.8 -0.11 (NS) 0 - 0.8 (0.02-36.6) -0.11 (NS) 
ehimienti et aI. 0/169 O/I66Pr 0 0 - - 0.98 -0.009 (NS) 0 
-
0.98 (0.02-49) -0.008 (NS) 
1994* 
Anderson et al. ** 0/49 0/49P 0 0 - - I 0 0 - 1 (0.02-49) 0 
1994 
erijns el al. 1991 ** 21127 0/53 S 0.58889 0.413173 4.15904 0.92 (NS) 2.13 0.5 (NS) 1.6 (-0.5-3.7) 1.43 (NS) 2.11 (0.1-43) 0.5 (NS) (0.2-90) 
erijns el al. 1991 ** 21127 1/34 A -0.36646 0.493502 0.47589 (0.03-8.2) 
-0.52 (NS) 0.45 -0.8 (NS) -1.4 (-7.4-4.7) -0.44 (NS) 0.46 (0.1-3.3) -0.8 (NS) 
Pooled rates vs 6/663 11635 2.22243 1.9014 3.2 1.6 (NS) 1.4 (1.04-1.9) 2.2* (P=0.03) 1.7 (0.1-3.3) 2.1 * (P=0.04) 1.3 (0.5-3.2) 0.5 (NS) 
otherst (0.78-13.3) (P=O.II) (p=0.6) 
Pooled rates vs 7.5 (0.8-72.6) 1.7 (NS) 1.8 (1.2-2.7) 3.1** 2.1 (-0.5-4.8) 1.6 (NS) 1.7 (0.4-6.5) 0.7 (NS) 
placebo (SE) (P=0.08) (P=0.002) (P=0.12) (P=0.5) 
O-E, observed minus expected deaths; Var (O-E), variance of (O-E); OR (95% el), odds ratio and its 95% confidence interval; M-H method, Mantel and Haenszel method; D-L method, DerSimonian and Laird method; 
RD (95% el), rate difference and its 95% confidence interval; RR (95% el), relative risk and its 95% confidence interval; Q, quinidine; P, placebo; Pr, propafenone; D, disopyramide; Q+V, quinidine+verapamil; B, 
bepridil; F,llecainide; A, amiodarone; S, sotalol; * statistically significant (P<O.05); ** highly statistically significant; t, including placebo and other antiarrhythmics 
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-t.16 Pooled estimates of proarrh}thmic incidence in randomised clinical trials 
Amiodarone clinical Trials 
- ----
-~-
-- -----
Study name Basic data Peto M-H method D-L Fleiss et 
(No method method (II (1993) 
events/No 
followed 
up) 
Amiodarone Control O-E Var (O-E) OR statistic OR statistic RD(%) statistic RR statistic 
group group (95% CI) for effect for (95% CI) for effect (95% CI) for effect 
effect 
Vitolo el al. 0/28 0126Q -0.01786 0.24968 0.9311 I -0.0357 (NS) 0.93 -0.036 -0.1 I -0.036 (NS) 0.93 -0.036 (NS) 
1981 (0.0184-47) (NS) (-7-6.8) (0.02-45.3) 
Martin el aI. 0/43 0I27D -0.1111 0.23765 0.62655 I -0.2279 (NS) 0.63 -0.228 -0.6 -0.218 (NS) 0.64 -0.228 (NS) 
1986 (0.01-0.029) (NS) (-6-5) (0.013-31) 
Bosi el al. 1990 0/48 0/49 P 0.00505 0.24997 1.0204 0.01 (NS) 1.02 0.01 0.02 0.01 (NS) 1.02 0.01 (NS) (0.02-51.4 ) (NS) (-4-4) (0.02-50.4) 
Zehender et al. 3/20 II20Q+V 1.25 1.02896 3.36967 1.232 (NS) 4 1.175 11.9 1.27 (NS) 3.5 1.148 (NS) 
1992 (0.488-23.3) (NS) (-6-30) (0.4-29.7) 
Jong el al. 1995 0/44 0/43 P -0.00562 0.24997 0.97778 -0.01124 (NS) 0.98 -0.01 -0.025 -0.011 (NS) 0.98 -0.0113 (NS) (0.019-49.3) (NS) (-4.4-4) (0.019-48) 
Perelman et aI. 0110 8/14 B -3.31 1.49 0.12 -2.7** 0.036 -2.15* -52 -0.25 (NS) 0.08 -1.8 (NS) 
1987 (0.022-0.54) (-80_-24) (0.005-1.25) 
Pooled rates vs 3/193 9/179 - 2.19 3.49 0.53626 -1.2 (NS) 0.554 -2.6** -0.3 -0.25 (NS) 0.8557 -0.2396 (NS) 
other drugs (0.19-1.5) (P=0.23) (0.357-0.86) (P=0.009) (-3-2) (P=0.8) (0.24-3.1) (P=0.8) 
Q statistic (P) 7.5 14.97** 4.6 
(P=O.184) (P=O.OI) (P=O.5) NS 
NS 
Pooled random- - - -0.9 -0.38 (NS) - -
effects (-0.059-0.04) (P=0.7) 
Pooled rates vs NA - NA 
-
NA -
placebo 
* Statistically significant; O-E, observed minus expected deaths; Var (O-E), variance of (O-E); OR (95% CI), odds ratio and its 95% confidence interval; M-H method, Mantel and Haenszel method; D-L method, 
DerSimonian and Laird method; RD (95% CI), rate difference and its 95% confidence interval; RR (95% CI), relative risk and its 95% confidence interval; Q, quinidine; P, placebo; Pr, propafenone; D, disopyramide; 
Q+V, quinidine+verapamil; B, bepridil; F, fJecainide; A, amiodarone; * statistically significant (P<O.05); ** highly statistically significant 
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4.16 Pooled estinultes of proarrh,)'thmic incidence in randomised clinical trials (continued) 
Sotalol clinical trials 
----
-~~ 
----- --
Basic data Peto M-H method D-L 
(No lIIelhod melhod 
evelltslNo 
followed 
up) 
Amiodarolle COlltrol O-E Var (O-E) OR statistic OR statistic RD(%) statistic 
group group (95% CI) for effect for (95% CI) for effect 
effect 
1/97 1/86Q -0.08919 
\ 
0.739 0.89 -0.1 (NS) 0.886 \ -0.1 (NS) -0.2 I -0.1 (NS) (0.1-8.7) (-4-3.5) 
0/24 0110 P -0.19444 0.2122 0.39 -0.42 (NS) 0.43 -0.42 (NS) -3 -0.37 (NS) 
(0.005-28) (-16-12) 
3/50 2150 Pr 0.5 1.426 1.42 0.42 (NS) 1.43 0.42 (NS) 2 0.42 (NS) 
(0.28-7.3) (-7-11) 
0/41 0141 Q+V 0 0.25 I o (NS) 1.07 0.035 (NS) 0 o (NS) 
(0.02-50) (-5-5) 
0/20 0/26P 0.0625 0.2461 1.289 0.13 (NS) 1.293 0.13 (NS) 0.5 0.125 (NS) 
(0.03-66) (-7.7-8.8) 
1/53 0/127 F 0.91 0.415 8.885 1.4 (NS) 7.2 0.98 (NS) 2.4 1.04 (NS) 
(2.4-186) (-2-6.9) 
2148 1/109Pr 1.2673 0.8366 4.548 1.385 (NS) 3.9 0.83 (NS) 3.7 1.123 (NS) 
(0.53-38) (-2.8-10) 
0/25 4125Q -2 1.152 0.176 -1.86 (NS) 0.094 -2.3* -15 -1.93 (NS) 
(0.03-1.1 ) ( -31-0.08) 
0/20 0/20F 0.0122 0.249 1.05 0.024 (NS) I o (NS) 0.12 0.025 (NS) 
(0.021-52.1 ) (-9-9.6) 
1153 0134 A 0.28652 0.472 1.835 0.4 (NS) 1.97 0.412 (NS) 1.4 0.449 (NS) 
(0.11-32) (-5-7) 
7/358 81528 0.752 6 1.133 0.3 (NS) 1.13 0.613 (NS) 0.7 0.69 (NS) 
(0.51-2.5) (P=0.8) (0.8-1.64) (P=0.5) (-1.2-2.6) (P=0.49) 
7.83 6.19 
(P=O.551) (P=O.72) (NS) (NS) 
NA 
-
\ 
NA -
FIl'i.~s ('I 
al (1993) 
RR statistic 
(95% CI) for effect 
0.89 I -0.1 (NS) (0.09-8.4) 
0.44 -0.42 (NS) 
(0.01-20.7) 
1.4 0.42 (NS) 
(0.29-6.7) 
I 0 
(0.02-49) 
1.29 0.127 (NS) 
(0.027-62) 
7.1 1.21 (NS) 
(0.29-171) 
3.74 1.295 (NS) 
(0.51-27.5) 
0.11 -1.5 (NS) 
(0.006-1.96) 
l.l 0.025 (NS) 
(0.02-50.4) 
1.94 0.41 (NS) 
(0.08-46.4) 
1.32 0.65 (NS) 
(0.57-3.04) (P=0.52) 
5.5 
(P=0.79) 
(NS) 
NA I -
O-E, observed minus expected deaths; Var WoE), variance of WoE); OR (95% Cl), M-H method, Mantel and Haens:rel method; D-L method, DerSimonian and Laird method; RD (95% CI), rate difference and its 95% confidence interval; RR (95% CI), reialive 
risk and its 95% confidence interval; Q, quinidine; p, placebo; Pr, propafenone; 0, disopyramide; Q+V, quinidine+verapamil; B, bepridil; F, flecainide; A, amiodarone; * statistically significant (P<O.05); ** highly statistically significant 
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I 
4.16 Pooled estimates of proarrh)'thmic incidence in randomised clinical trials (continued) 
Flecaillide clinical trials 
- - ------ ---------
-_ .. _---------
Stlldy nallle Ba ... ic data Peto M-H method D-L method Fleiss 1'1 ({f 
(No method (/993) 
events/No 
followed 
up) 
Flecaillide COlltrol O-E Var (O-E) OR statistic OR statistic RD(%) statistic RR statistic 
group group (95% CI) for effect for (95% CI) for effect (95% CI) for 
-
effect effect 
Van-Gelder et al. I 4/36 1 0/37 P 1 2.033 1 1.182 5.6 (0.9-33.9) 1 1.9 (NS) 1 10.4 1.5 (NS) 10.8 (-0.2-21.9) 1 1.9 (NS) 9.2 (0.5-165.5) 1.5 (NS) 1989* 
Rasmussen el al. 1988* 0/30 0/30D 0 0.25 I (0.02-50.4) 0 I 0 0(-6.2-6.2) 0 I (0.02-48) 0 
Anderson et al. 1989* 3/64 O/64P 1.5 0.9767 4.7 (0.6-33.8) 1.5 (NS) 7.34 1.3 (NS) 4.6 (-1.3-10.5) 1.54 (NS) 7 (0.4-132.8) 1.3 (NS) 
Pritchett et al. 1991 * 3m 0173 P 1.5 0.9796 4.6 (0.6-33.5) 1.5 (NS) 7.3 1.31 (NS) 4.1 (-1.1-9.2) 1.5 (NS) 7 (0.4-133) 1.3 (NS) 
Henthorn et al. 1991 * 2151 0/51 P I 0.7354 3.9 (0.4-38.3) 1.17 (NS) 5.2 I.J (NS) 3.8 (-2.5-10) 1.2 (NS) 5 (0.3-101.6) I.J (NS) 
Pietersen et al. 1991 * 4/48 0/48 P 2 1.1984 5.3 (0.9-31.8) 1.83 (NS) 9.8 1.5 (NS) 8.2 (-0.4-16.7) 1.9 (NS) 9 (0.5-162.4) 1.5 (NS) 
Lau et al. 1992* 3/19 0/18 P 1.449 0.9205 4.8 (0.6-37.2) 1.5 (NS) 7.9 1.3 (NS) 14.9 (-3.3-33) 1.6 (NS) 6.7 (0.4-120) 1.3 (NS) 
Lau et al. 1992* 3/19 0/15 P 1.278 0.903 4.12 (0.5- 1.345 (NS) 6.6 1.22 (NS) 14.4 (-4.3-33.1) 1.5 (NS) 5.6 (0.3-99) 1.2 (NS) 
32.4) 
Anderson et al. 1994 ** 0/49 0/49P 0 0.25 I (0.02-50.4) 0 I 0 0(-3.9-3.9) 0 I (0.02-49) 0 
Leclercq et al. 1992** 2119 0/33 F+A 1.89 0.67319 7.9 (0.75-90) 1.7 (NS) 9.6 1.43 (NS) II (-4-26) 1.4 (NS) 8.5 (0.43-168.2) 1.4 (NS) 
Mary-Rabine et al. 0/55 0113 F+A -0.3 0.16 0.2 (0.001- -0.75 (NS) 0.2432 -0.7 (NS) -2.6 (-12.7-7.3) -0.5 (NS) 0.25 (0.006-12) -0.7 (NS) 
1988** 20.7) 
Chimienti eta!. 1994* 0/169 11166 Pr -0.51 0.49847 0.4 (0.02-5.8) -0.72 (NS) 0.33 -0.6 (NS) -0.6 (-2.3-1) -0.72 (NS) 0.33 (0.01-7.9) -0.7 (NS) 
Crijns et al. 1991* 0/127. 1153 S -0.91 0.415 0.1 J3 (0.005-
2.4) 
-1.41 (NS) 0.14 -1.2 (NS) -2.4 (-6.9-2) 
-1.04 (NS) 1 0.14 (0.005-3.4) -1.2 (NS) 
Crijnsetal.I99I* 01127 0/34 A 0.107 0.08457 3.6 (0.004- 0.37 (NS) I 0 0.4 (-0.7-1.5) 0.71 (NS) I 0 
2980) 
Pooled rates vs otherst 21n40 21684 10.54 9.2272 3.1 (1.6-5.98) 3.5** 3.37 (2.4-4.7) 7.3** 0.5 (-0.4-1.3) 1.08 (NS) 2.9 (1.24-7) 2.44· 
(P=0.OO04) (P<O.OI) (P=0.3) (P=0.014) 
Pooled rates vs placebo 4.5 (2-9.8) 3.7** 6.7 (4.23-10.6) 8.1 ** 3.42 (1.1-5.8) 2.9** 5.9 (1.9-18.6) 3.1*· 
(SE) (P=0.0002) (P<O.OI) (P=O.004) (P=O.OO2) 
O-E, observed minus expected deaths; Var (O-E), variance of (O-E); OR (95% CI), odds ratio a~d its 95% confidence interval; M-H method, Mantel and Haenszel method; D-L method, DerSimonian and Laird method; 
RD (95% Ct), rate difference and its 95% confidence interval; RR (95% CI), relative risk and tts 95% confidence interval; Q, quinidine; P, placebo; Pr, propafenone; D, disopyramide; Q+V, quinidine+verapamil; B, 
bepridil; F, flecainide; A, amiodarone; S, sotalol; * statistically significant (P<O.05); •• highly statistically significant; t, including placebo and other antiarrhythmics 
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4.3.5 Assessment of Publication Bias 
To assess whether the highly significant effects seen in the present meta-analysis, 
regarding the superiority of amiodarone and flecainide over other drugs, were merely 
due to publication bias in favour of positive results, the graphical techniques explained 
in Chapter 3 were applied to our data. The results are presented below. 
A funnel plot of the amiodarone clinical trials was plotted (Figure 4.9). This overall 
funnel plot follows the shape of an "inverted funnel" indicating no obvious publication 
bias. Furthermore, Figure 4.10 shows a similar funnel graph, but with the effect 
estimates (RDs) plotted as a function of the weight assigned for each individual trial. 
Again, this plot yielded a funnel-shaped scatter with a decrease in the scatter of results 
as precision increases. This supported the previous evidence of low retrieval bias. In 
addition, for demonstrating the absence of publication bias, a strong positive correlation 
between sample size and the weight of individual effects should exist (Mullen, 1989). 
This was presented in Figure 4.11. 
All the preceding graphical techniques were also performed for flecainide clinical trials. 
Figure 4.12, and Figure 4.13 illustrate two scatterplots of RDs versus the sample size 
. and versus the weights respectively. Although Figure 4.12 follows a funnel-shape 
plot, its peak is entirely dependent on only one large study (Clementy et al., 1992). 
This figure indicate a deficiency of large studies in this meta-analysis which may not be 
ascribed to publication bias, since the results of small negative as well as small positive 
were incorporated in this meta-analysis. Figure 4.14 presents the relationship between 
the sample sizes and the weights assigned for various individual clinical trials of 
flecainide. This graph does not imply a strong positive correlation (as that shown 
previously in Figure 4.11), due to the high degree of scatter between the results of the 
small sample size studies with different design characteristics. However, these studies 
were subgrouped in our analysis into various strata depending on their design 
categories. 
In addition to the graphical techniques for detecting the presence or absence of 
publication bias, numerical methods were developed for estimating the number of 
additional unpublished studies with null results (zero treatment difference), which 
would be needed to reverse the results of the significant meta-analysis to nonsignificant 
level. This was addressed by application of Rosenthal (1979) formula (fail-safe N) to 
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Figure 4.9 Funnel plot of amiodarone clinical trials (N = 17). The ligurc 
illustrates the relationship between the study sample size and its effect estimate (RD) at 3 (N= 17),6 
(N=14), and 12 (N= 12) months for the 17 individual studies included in the analysis. This scatter 
plot has yielded approximately a funnel-shaped graph, where both the results of small negative as 
well as large positive trials were included. Therefore, indicating a slight evidence of puhlication 
bias. 
l000~--------------------------------------~ 
800-
600-
400-
200-
04-------------r-----------r-----------~1----------.-1---------~ 
-40 -20 0 20 40 60 
800~------------------------------------------_..~ 
• 
• 
• • 
~ • 
• • • • • 0~---------------r-1-------------r-1-------------~1-------------1 
-40 -20 0 20 40 
400~----------------------------------------------------------~ 
• 
300-
200-
100 -
• 
• 
• 
• 
• 
• 
• 
• 
• 
• • 
O~------~Ir-------,-I-------~I-------~I-------r-I-------r-I---~ 
-30 -20 -10 0 10 20 30 40 
Rate Difference (RD) 
• 6 ll10nt hs 
II 12 Illonths 
Figure 4.10 Rate difference vs. weight for amiodarone clinical trials 
(N =17). This figure illustrates the relationship between a tri.al's weight (a measure of the 
precision of the results) and its effect estimates at 3, 6, and 12 months for the 18 individual studies. 
This figure shows that large sample size studies where more precise estimates (less variance), and 
small sample size studies with less precise estimates were incorporated in this analysis. Thus 
eliminating probability of publication bias. 
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Figure 4.12 Funnel plot of f1ecainide clinical trials (N=19). The figure illustrates 
the relationship between the study sample size and its effect estimate (RD) at 3 (N= 19), 6 (N= 14). and 12 
(N=13) months for the 19 individual studies included in the analysis. This scalier plot has yielded 
approximately a funnel-shaped graph, where both the results of small negative as well as large positive trials 
were included. Therefore, indicating a slight evidence of publication bias. 
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Figure 4.13 Rate difference vs. weight for flecainide clinical trials (N=19). 
This figure illustrates the relationship between a trial's weight (a measure of the precision of the results) and 
its effect estimates at 3, 6, and 12 months for the 19 individual studies. This figure shows that large sample 
size studies with more precise estimates (less variance), and small sample size studies with less precise 
estimates were incorporated in this analysis. Thus eliminating probability of puhlication hi as. 
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Figure 4.14 Sample size vs. weight (Flecainide trials). This figure 
illustrates the relationship between a trial's weight and its sample size for the 19 
trials of flecainide: a positive curvilinear correlation does not exist. The pattern 
shown in this figure implies possible evidence of publication bias. 
assess the robustness of the statistically significant results obtained from the meta-
analyses of mortality and proarrhythmia data. It was found that a total of six studies 
with null results are required to reverse the significant pooled RD, favouring lower 
mortality rate in amiodarone-treated group to nonsignificant (Table 4.11). Similarly, 
fifteen trials were needed to negate the positively significant OR of death on flecainide 
as compared to placebo (Table 4.13). Overall, these findings suggest the statistically 
significant results obtained from meta-analysis of mortality data have a high level of 
robustness, since it can only be reversed to nonsignificance by a large number of 
hypothetical null trials (nearly double the number of included studies). Furthermore, 
for proarrhythmia, 10 studies were required to reverse the negatively significant OR of 
proarrhythmia on amiodarone as compared to other drugs. Similarly, 17 null trials 
were required to reverse the significance of ORpeto of pro arrhythmia on flecainide as 
compared to placebo (Table 4.14). These large numbers of studies again definitely 
imply that the observed significant difference is not due to publication bias. 
4.4 DISCUSSION 
Patients with chronic atrial fibrillation are heterogenous with respect to underlying 
cardiac or other disease, functional status, age, and subjective symptoms. 
Electrocardioversion to sinus rhythm is frequently successful, but the choice of the 
subsequent treatment is difficult. The strategy for treatment of atrial fibrillation differs 
greatly between countries, since no antiarrhythmic agent was thought to be ideal in this 
context. Moreover, evidence that one agent is more effective than another for a certain 
category of patient was not established due to differences between published studies. 
Recently published studies and meta-analyses suggest that a re-evaluation of the 
standard approach to the pharmacological suppression of atrial fibrillation is warranted 
from the standpoints of both drug efficacy and safety, since these studies have shown a 
significant increase in mortality, particularly due to sudden death (Coplen et al., 1990; 
Reimold et al., 1992; Zarembski et al., 1995). However, the risks of these agents must 
be carefully weighed against their essential benefits for the treatment of atrial 
fibrillation. These benefits include alleviation of symptoms, such as palpitation and 
angina. In addition, they may eliminate the need for warfarin and avoidance of the 
latter's haemorrhagic complication. 
As apparent from this review, many studies are more than 10 years old. Some studies 
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are not controlled, while others have small number of patients or short term of follow-
up. Some of the individual placebo-controlled trials failed to show significant treatment 
benefit over placebo (Bosi et al., 1990, for amiodarone; Carunchio et al., 1995, for 
sotalol; Van-Gelder et al., 1989, for flecainide). Therefore, the value of prophylactic 
therapy for the maintenance of sinus rhythm following cardioversion is uncertain. 
The present meta-analysis shows clearly that amiodarone is significantly more effective 
than sotalol and quinidine for maintenance of sinus rhythm prior to cardioversion. 
However, it suggests that amiodarone and flecainide had similar efficacy for chronic 
AF patients at all time intervals, and for paroxysmal AF at 6 and 12 months. 
Amiodarone was superior to all drugs at 3 months, during which time the rate of 
relapse to AF is considered the highest. Two previous meta-analyses have been 
conducted to evaluate the efficacy and safety of quinidine for maintenance of sinus 
rhythm (Coplen et al., 1990; Reimold et aI., 1992). A comparison of weighted pooled 
estimates produced by the present meta-analysis to those of previous meta-analyses 
suggests a statistically significant difference in favour of amiodarone and flecainide 
over quinidine, but not in favour of sotalol. 
Unfortunately, in the present meta-analysis, only four placebo-controlled trials for 
amiodarone and sotalol were retrieved (2 for amiodarone, and 2 for sotalol). 
Nevertheless, the pooled estimates for treatment arms were further compared to 
quinidine data, which were previously compared to placebo controls. 
Pooling the available mortality data showed significant difference in favour of flecainide 
compared to other Class I (quinidine, disopyramide), Class II (sotalol, amiodarone) 
antiarrhythmic agents, and placebo (ORMH= 1.4, P<0.05). 
Comparison of the pooled estimates of mortality rates in patients treated with flecainide 
versus placebo and estimates obtained for quinidine versus placebo in a published meta-
analysis; (ORpeto of flecainide = 7.5, P=0.08) versus (ORpeto of quinidine = 2.98, 
P<0.05), and (ORMH of flecainide = 1.8, P=3.1) versus (ORMH of quinidine = 3.51, 
P=0.05), suggests more significant effect of quinidine treatment as compared to 
flecainide. One explanation of this result could be due to employment of cross-over 
design with placebo control as a second or first part in the flecainide clinical trials, 
which would increase the observed benefit on placebo as compared to the placebo 
group in the quinidine parallel design trials. As a result, this may negatively bias the 
estimates (OR, RD) calculated from the crossover design trials of flecainide compared 
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to placebo. 
Furthermore, examining the mortality data on amiodarone compared to other drugs 
(direct comparison) have shown a trend towards decreased mortality on amiodarone, 
which was statistically significant using the Dersimonian Laird method (RD = -7%, z= 
-2.4, P=O.02). 
In general, this meta-analysis involved trials that included heterogenous patient groups 
with regard to, for example, different pattern of AF (chronic AF, PAF, PSVT), and 
underlying cardiac diagnoses (Table 4.6). However, as shown in Table 4.6 no 
significant difference was found with regard to some clinical variables which were 
identified as significant predictive factors of response to therapy (Levy, 1994; Crijns et 
at., 1991), such as age (P=O.566), total duration of AF (P=O.2511), and left atrial 
diameter (P=O.864). 
Despite the application of stratified analysis in this study, evidence of heterogeneity still 
existed in some subgroups. This may have occurred exclusively due to one or more of 
the following confounders: 
(1) As shown in Table 4.6, the distribution of cardiac diagnoses were significantly 
different among the separate treatment groups compared in our meta-analysis 
procedures. All categories of diagnosis were significantly different (P<O.OOOl) except 
patients with congenital heart diseases (P=O.078). Moreover, the different drugs' trials 
enrolled patients with significantly different distributions as confirmed in Table 4.7. 
(2) Some trial protocols permitted the use of concomitant medications, such as digoxin, 
verapamil, B-blockers, heparin, anticoagulants, or other ventricular rate regulating 
agents. Others have instructed discontinuation of all active treatment 4 to 5 weeks 
before randomisation. This would falsely cause more observed benefit in the treatment 
groups receiving such medications as compared to others, who were only taking the 
investigated drug in the trial. 
(3) In the present meta-analysis, patients with chronic AF refractory to other 
antiarrhythmic drugs were included, as well as patients who had never received 
treatment, while the previous amiodarone meta-analysis (Zarembski et al., 1995) 
enrolled only patients resistant to Class I antiarrhythmic drugs or sotalol hydrochloride. 
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On the basis of available data, a meta-analysis estimating the effect of the previous 
confounding variables on the response, and explaining the potential sources of 
heterogeneity was not feasible. 
The results of this meta-analysis were further strengthened by the assessment of 
publication bias using graphical and numerical methods which showed low evidence of 
its existence. 
4.5 CONCLUSIONS 
In conclusion, the present meta-analysis has yielded a statistically significant results in 
terms of effectiveness of amiodarone and flecainide in maintenance of sinus rhythm 
prior to cardioversion. However, efficacy is not the only issue. Other factors should 
be taken into consideration to decide the strategy of treatment after CV, such as drug 
safety profile, local therapy tradition that guide the doctors in individual patient cases, 
as well as theoretical aspects concerning the mechanism of actions and pharmacokinetic 
properties of a drug. For instance, amiodarone has an unusual property of long half 
life taking from weeks to months. In addition, it has some other characteristic severe 
adverse effects such as sleeping disturbances, tremor, ataxia, corneal deposits, 
cutaneous changes, and impaired thyroid and liver functions. Also it increases the 
concentration of digitalis in serum, with a consequent risk of digitalis intoxication 
(Wheeler et ai., 1979). 
All the previously mentioned factors may hinder amiodarone from being the first drug 
choice for treatment of AF. However, as shown in this study, it has very low 
arrhythmogenic tendency as compared to other drugs, which may be due to its negative 
inotropic effect. Consequently, this may increase its benefit-risk ratio for treatment of 
selected types of patients with severe structural ventricular myocardial damage. Also, it 
was noted in this review, that the number of withdrawals during the follow-up due to 
intolerable side effects, was not significantly different in the amiodarone-treated group 
(8.7%), as compared to other groups (sotalol, 7%; flecainide, 15.1 %; placebo, 6.2%; 
and other comparatives, 10.8%). In addition, amiodarone has an anti anginal effect, 
and this may be of value in patients with coronary artery disease (Heger et aI., 1984). 
Furthermore, this study has shown that sotalol has an equal prophylactic effect to 
quinidine. However, due to the unavailability of sufficient proarrhythmia and mortality 
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data regarding sotalol compared to placebo, its value for maintenance of sinus rhythm 
remains undetermined. Secondly, it was shown in our meta-analysis of its RCTs and 
NonRCTs (sequential treatment) that sotalol fared better in RCTs than in serial 
treatment trials. This has negated the theory which advised that sequentially changing 
the type of drug after a recurrence may improve arrhythmia prognosis, as each drug 
exerts its beneficial effect in suppressing atrial fibrillation by a different mechanism of 
action (Crijns et aI., 1991; Antman et ai., 1990; Bauernfeind et aI., 1990). 
Some questions are, however, left unanswered by this study. For example, whether 
the various pattern of AF, or the different dosage regimes employed (fixed single dose 
versus titrated) can influence the likelihood of relapse. In fact, the percentages of 
patients remaining in sinus rhythm reported in the published trials were not stratified on 
the basis of these factors. In addition, other secondary efficacy endpoints such as the 
control of ventricular rate during the chronic AF or P AF attacks, time to the first attack, 
and intervals between attacks, were not consistantly reported in the trials. This 
obstructed the application of meta-analysis. The former end point was thought to be 
attained through the use of digoxin, beta-blocking agents, and calcium antagonists as an 
alternative to Class I or Class III agents. However, this strategy was not tested in any 
of the trials. A further issue that has not been solved in the meta-analysis of this 
chapter is which agent is a good choice for rapid conversion of acute AF to sinus 
rhythm. Nevertheless, this issue will be addressed in the next chapter. 
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CHAPTER FIVE 
ANTIARRHYTHMIC DRUGS FOR RECENT-
ONSET ATRIAL FIBRILLATION. WHICH IS 
THE BEST DRUG FOR RAPID AND SAFE 
CONVERSION TO SINUS RHYTHM ? 
A META-ANALYSIS 
5.1 INTRODUCTION 
Acute atrial fibrillation (AF) is usually defined as of recent onset within 24-48 hours 
(Sopher et al., 1996). It may be associated with both cardiovascular or 
noncardiovascular medical conditions (Kannel and Wolf, 1992). In addition, it is a 
common disorder after open heart surgery, particularly coronary bypass surgery, with 
an incidence ranging between 11 % and 100% (Groves et aI., 1991). This type of acute 
AF was thought to develop due to surgically-induced atrial enlargement, and local 
surgical trauma associated with increase in sympathetic activity (Boyden and Hoffman, 
1981). It usually occurs 24 to 60 hours after surgery, causing a lengthening in hospital 
stay from 9.9 to 11.4 days, thus increasing resource utilisation (Rubin et al., 1987). 
Although, this type of arrhythmia frequently reverts spontaneously, it may cause 
subsequent serious complications including sustained atrial fibrillation, embolic 
cerebrovascular accidents, and postoperative stroke (Waldo et al., 1978). Furthermore, 
atrial fibrillation is frequently associated with atrial flutter, and they may alternate with 
each other in the same patient (Tunick et aI., 1992). Atrial flutter, however, is found to 
be more challenging after surgery, since it is nonresponsive to medical therapy and it 
may require electrical pacing (Podrid and Kowey, 1995). 
Both atrial flutter and atrial fibrillation are associated with a rapid ventricular response 
rate which is difficult to control, and is primarily responsible for the associated 
symptoms, such as palpitation, lightheadedness, faintness and even syncope in some 
cases (Switzer et al., 1990). Most of these symptoms arise from the decline in cardiac 
output and the sustained decrease in blood pressure. Within the normal physiologic 
range, the heart rate ranges between 40-50 and 160-170 beats/min (Podrid and Kowey, 
1995). Although this variation in heart rate in normal individuals has little impact, in 
supraventricular arrhythmia this frequently leads to hemodynamic compromise with 
ischemia due to increase in oxygen demands. Furthermore, if the duration of the rapid 
ventricular response rate is prolonged, it may lead to ventricular dilation and congestive 
heart failure (Clark and Cotter, 1993; Sopher and Camm, 1996). Eventually, it may 
precipitate disabling stroke or even death (McAlister et al., 1990). 
5.2 EVOLVING STRATEGIES FOR 
MANAGEMENT OF ACUTE AF 
Strategies for acute AF treatment vary widely across institutions (Faniel et al., 1983; 
142 
Campbell, 1985; McAlister et ai., 1990; Sopher and Camm, 1996; Talajic et aI., 1996). 
Recently, a strong debate was introduced over whether to strive to convert patients to 
sinus rhythm or only to provide treatment for controlling the ventricular response 
"rhythm versus rate" (Sopher and Camm, 1996). In spite of considering the control of 
the ventricular rate as a chief target of therapy for acute AF (specifically in patients who 
initially fail to convert to sinus rhythm, nonconverters), due to improvement of 
ventricular function and alleviation of associated symptoms, drugs directed only 
towards control of the ventricular rate (such as digoxin, B-blockers, and Ca blockers) 
are considered imperfect, since further risk of thromboembolism due to continuous 
fibrillation can possibly arise (Sopher and Camm, 1996). Consequently, a number of 
authors have recommended that ventricular rate regulating agents should not be the 
first-line treatment for acute AF. Furthermore, they suggested that more aggressive, 
invasive therapy should be initiated for rapid cardioversion to sinus rhythm (Biasi et 
aI., 1995). 
Whether cardioversion to sinus rhythm, control of ventricular rate, or both are chosen 
as the desired therapeutic goal, rapidity of action of a particular drug will nevertheless 
still remain the key indicator of clinical effectiveness. Textbooks reflect no consensus 
on optimum ventricular rate control criteria (Zipes, 1992). Sopher and Camm (1996) 
have claimed that comparing ventricular rates during AF to rates during sinus rhythm 
may not be essential. However, since most trials have defined a supraventricular 
arrhythmia of> 100 beats per minute as clinically significant and requiring treatment 
(Butler et ai., 1993; Hou et ai., 1995), a treatment reducing the ventricular rate below 
this limit may be considered effective. Other authors of clinical trials have reported a 
reduction of> 20 beats/min in heart rate as a significant cut off point (Chapman et ai., 
1993). 
The ideal treatment of recent-onset atrial fibrillation is still questionable (Groves and 
Hall, 1991; Gentili et ai., 1992; Clark et ai., 1993; Madrid et ai., 1993; Dhala et ai., 
1994; Ollitrault et ai., 1994). Although numerous clinical trials have been performed, 
the high spontaneous conversion rate of recent-onset AF (39% to 48% of patients 
within 8 hours) makes controlled trials essential (Capucci et aI., 1992; Capucci et ai., 
1994). For many years, digoxin was used classically to decrease the ventricular rate, 
and to improve the hemodynamics, but usually this takes a long time and it may be only 
achieved by combination with a Ca antagonist or a B-blocker (Zoble et ai., 1987; Vecht 
et aI., 1986). In addition, these agents are infrequently effective for instant 
cardioversion to sinus rhythm (Lown et aI., 1987; Gentili et ai., 1992). 
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Electrical cardioversion is highly efficient for all patients, but this requires general 
anaesthesia and anticoagulation before and after application to avoid thromboembolic 
complications (Clark and Cotter, 1993). In addition, after unsuccessful cardioversion, 
a new lethal ventricular arrhythmia may develop, particularly if the plasma level of 
digoxin is above the therapeutic range. It has even been shown that normal mechanical 
function of the atria takes a long time to be restored. As a result, little improvement in 
either exercise tolerance or cardiac output is shown prior to electrical cardioversion 
(Lewis, 1990). 
Class lA antiarrhythmic drugs (particularly quinidine) have been widely used for 
pharmacological cardioversion to sinus rhythm. Nevertheless, they possess no effect 
on the ventricular response rate. On the other hand, they may sometimes increase it due 
to facilitation of A V node conduction (Halpren et al., 1980; Ollitrault et aI., 1994). As 
a result, many cardiologists tend to prescribe digoxin in conjunction with quinidine or 
disopyramide to reduce the ventricular rate (Campbell et al., 1985; Gavaghan et al. , 
1988; Halinen et al., 1995). However, the results of trials conducted in this area were 
not always promising and have added uncertainty. Moreover, the utility of quinidine 
for cardioversion has been questioned, due to the latest meta-analysis showing 
increased mortality relative to placebo in patients randomised to quinidine for 
maintenance of sinus rhythm (Coplen et ai., 1990). Furthermore, intravenous 
quinidine requires in-hospital drug titration which is time consuming making the 
therapy more expensive than other antiarrhythmic drugs. Although oral quinidine 
would provide a cheaper alternative, it is less effective and is associated with serious 
gastrointestinal complications (Crijns et ai., 1988). 
Class 1 C antiarrhythmic drugs, including flecainide and cibenzoline, have shown 
theoretical ability to control the ventricular rate as well as to suppress the atrial 
arrhythmia by prolonging the effective refractory period in the atria and slowing the 
atrioventricular node (A V) conduction (Connolly et ai., 1987; Ollitrault et al., 1994; 
Ravi-Kishore and Camm, 1995). However, these agents are contraindicated in critical 
heart diseases, since they possess a negative inotropic effect which may be 
arrhythmogenic or may even diminish the beneficial hemodynamic effect obtained by 
heart rate reduction (Gentili et ai., 1992). 
A number of clinical trials have been undertaken to test the effect of new intravenous 
and oral antiarrhythmic treatment with Class I and Class III activity on rapid ventricular 
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control as well as rapid cardioversion, in an attempt to define "best protocol" for 
management of acute AF associated with organic heart disease or cardiac surgery 
(McAlister et al., 1990; Groves and Hall, 1991). However, the results remain 
controversial (Talajic et al., 1996). 
A recent meta-analysis was conducted to test the value of prophylactic B-blocker, 
verapamil, and digoxin prior to bypass surgery to prevent the development of AF 
(Andrews et al., 1991). However, this meta-analysis did not address the efficacy for 
prompt cardioversion of postoperative atrial arrhythmias, and although the efficacy for 
controlling the ventricular rate was tested, the data were pooled at a single particular 
time point. 
In addition to choice of treatment, the probability of successful conversion to sinus 
rhythm may be influenced by a number of parameters, such as concomitant use of other 
antiarrhythmic drugs, left atrial size, underlying aetiology of arrhythmia (for example, 
rheumatic mitral valve disease), duration of the atrial fibrillation, and age of the patients 
(Sopher et al., 1996). However, no consensus view among the studies which tested 
the significance of these variables on successful conversion to sinus rhythm have been 
reached. Dalzell et al. (1990) and Dittrich et al. (1989) reported that left atrial size was 
not a significant predictor for successful cardioversion, while it was usually regarded to 
be important in older studies (Goy et al., 1988; Goldman et al., 1975). 
It was clear from the above review that data on antiarrhythmic therapy for this 
indication were mixed. Therefore, reanalysis of the data was undertaken; 
• To estimate the relative efficacy of flecainide, amiodarone and sotalol for conversion 
of acute medical atrial fibrillation and atrial fibrillation following cardiac surgery 
(using oral or intravenous dosage schedules). 
• To evaluate the differences between the three drugs in the time delay necessary to 
convert acute atrial fibrillation (AP) to sinus rhythm (estimate rapidity of action). 
• To evaluate their effect in controlling the ventricular rate when reversion to sinus 
rhythm has failed. 
• To evaluate the probability of incidence of major and minor side effects due to their 
use in this particular indication. 
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5.3 METHODS 
5.3.1 Definition of Inclusion Criteria 
5.3.1.1 Design of Primary Studies 
Prospective, published clinical trials of all design categories (detailed earlier in section 
4.2.1.1) were eligible for inclusion if they provided adequate delineation of treatments, 
dose, route of administration, number of patients included, and outcome measures of 
concerns to this chapter. In addition, the protocol of a trial had to include continuous 
electrocardiographic monitoring of cardiac rhythm. Unlike the previous meta-analysis 
(Chapter 4), the long-term follow-up postcardioversion (> 3 months) was not a crucial 
element for inclusion of a trial in the primary analysis, since outcomes of interest were 
mostly measured within 1 to 24 hours after administration of a trial intervention. 
5.3.1.2 Diagnostic Criteria and Type of Patients Included 
Patients of any age, of either sex, and with established diagnosis of acute 
supraventricular arrhythmia of any pattern (including atrial fibrillation, atrial flutter, or 
paroxysmal supraventricular tachycardia) were included. The arrhythmia was 
considered to be acute if it was stated by the author of the trial to be of recent-onset 
(mostly between 30 minutes and 72 hours), and/or presenting with a rapid ventricular 
response rate of ~ 100 beats/min. The time of onset of supraventricular attacks is to be 
ascertained by documented electrocardiograms in hospitalised patients or by an abrupt, 
clear onset of relevant symptoms (such as palpitation, chest discomfort, or dyspnea) 
either in the emergency room or outpatient clinic. 
Patients who developed supraventricular arrhythmia after they underwent cardiac 
surgery were also included. However, all patients with previously documented 
dysrhythmia of ~ 6 months duration were excluded from the analysis. 
5.3.1.3 Types of Intervention 
Interventions involved comparisons of single or multiple doses of oral, intravenous, 
and intravenous plus oral treatment with flecainide, sotalol, or amiodarone versus 
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placebo and/or any other antiarrhythmic agents for rapid conversion to sinus rhythm. 
5.3.1.4 Study Parameters and Outcomes 
Trials were included if they reported data concerning the following primary therapeutic 
end points: 
1. Rapid conversion to sinus rhythm, which has to be defined as documented 
conversion to sinus rhythm within a maximum of 8 hours after initiation of 
treatment, and sustained for the subsequent trial duration period. This cut-off point 
was thought to be mandatory to avoid misinterpretation of efficacy due to 
spontaneous conversion to sinus rhythm. A trial was still included if other time 
point measurements were reported for the purpose of comparison of relative efficacy 
of different drugs. 
2. An acceptable control of the ventricular rate is another therapeutic goal of interest, 
particularly in nonconverted patients. It is usually defined as slowing of the 
ventricular rate of > 20 beats/min, or achievement of a rate of < 100 beats/min 
maintained throughout the subsequent 24 hour period. 
Other secondary end points include the following: 
1. Incidence of adverse effects that required initiation of other active treatments (such 
as atropine if hypotension develops due to antiarrhythmic effects). 
2. Persistence of arrhythmia that required application of direct current cardioversion 
(DCC). 
3. Incidence of withdrawals due to major side effects. 
4. Incidence of other serious cardiovascular side effects of concern such as 
proarrhythmia and death. 
Exclusion was considered appropriate if there was any uncertainty regarding the trial 
design and number of patients included, or if the definition of the outcome measure 
deviates from the above delineated criteria. 
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5.3.2 Data Identification and Selection of Primary 
Trials 
A literature search was conducted through all available database sources (as detailed in 
Chapter 4) to identify all published trials addressing the use of flecainide, sotalol, and 
amiodarone in acute conversion to sinus rhythm. The following pertinent keywords to 
this chapter were combined with each drug under investigation cited in title and/or 
abstract: acute atrial fibrillation, atrial flutter, supraventricular arrhythmia, 
antiarrhythmic agents, cardiac surgery, coronary surgery, CABO, postoperative 
complications, cardioversion, and sinus rhythm. 
5.3.3 Data Extraction 
Data concerned with any of the following subheadings were extracted from text, tables, 
and figures (after scanning and magnifying them) in the clinical trial reports. 
5.3.3.1 Study Design Characteristics 
Clinical trials identified for each drug (flecainide, amiodarone, sotalol) were classified 
into the six study design categories described in section 4.2.3.1. For each trial the 
following information regarding execution and protocol was extracted: 
• Name of the first author 
• Publication status (full report! abstract! unpublished data) 
• Publication date 
• Design features (parallel or crossover; double-blind, single-blind, or open) 
• Number of patients enrolled 
• Number of patients randomised and received study medication 
• Number of patients included in the analysis 
• Number of patients allocated in each treatment group 
• Type of control (active [name of drug] or placebo) 
• Dosage regimens: for intravenous intervention it was reported as mg/Kg, mg/min, or 
mg/day, and for oral intervention as mg/day 
• Previous medications 
• Concomitant drugs administered such as ventricular rate regulating agents (digoxin, 
beta-blockers, and calcium-channel blockers) and anticoagulants 
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• Type of monitoring techniques 
• Duration of monitoring period (study duration) 
• Duration of follow-up (months) 
5.3.3.2 Population Characteristics of the Included Studies 
In addition to details of patients' demographic criteria which was mentioned in Chapter 
4, other relevant diagnostic criteria for this chapter were extracted as follows: 
: DefInition of supraventricular arrhythmia in the trial 
• Onset of acute AF (hours) 
• Cause of supraventricular arrhythmias categorised into medical or surgical 
• Baseline mean ventricular rate together with its standard error, or standard deviation 
for each treatment group 
• Baseline mean blood pressure together with its standard error, or standard deviation 
for each treatment group 
5.3.3.3 Outcome Measures 
The following data essential for analysis of effIcacy and adverse effects were extracted 
• Definition of conversion to sinus rhythm 
• The number of patients converted to sinus rhythm at all available time points in each 
of the study groups 
• The cumulative number of patients converted and nonconverted to sinus rhythm in 
each of the study groups at the end of the monitoring period. Each study at least 
reported the number of patients converted at one time point 
• Mean ventricular rate together with its standard error, or standard deviation for each 
treatment group at all available time points during the trial monitoring period, for both 
converted and nonconverted patients in each of the study groups. When data were 
reported for individual patients, the mean ventricular rate and its standard deviation for 
both category of response were calculated 
• In addition some studies reported the mean/median time of conversion to sinus rhythm 
with its standard error, or standard deviation for each treatment group, as a result its 
extraction was deemed appropriate for further analysis 
• The cumulative incidence of adverse effects and events described earlier in section 
5.3.1.4, on an intension-to-treat basis 
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All the previous efficacy end points were stratified whenever possible according to the 
route of administration (oral, IV, or oral plus IV), pattern of the arrhythmia (AF, AFL, 
or PSVT), medical or surgical etiology, and duration of the arrhythmia « 24 hours, or 
> 24 hours). 
5.3.4 Statistical Analysis and Data Synthesis 
5.3.4.1 Conversion to Sinus Rhythm 
Two different techniques of meta-analysis were employed for estimation of efficacy for 
conversion to sinus rhythm: 
1. Calculation of pooled odds ratio (OR) according to Peto' s method for each of the 
following time intervals: 0·3 hours, 3-8 hours, and 8-24 hours. 
In the present meta-analysis, this allows testing (for each time interval) of the 
hypothesis zero that the probability of conversion to sinus rhythm not due to treatment 
effect by comparing the observed number of converted patients (0) in a treatment 
group with the number of patients that would have been expected to be converted (E) in 
the same group if the number of converted were equally distributed among the treatment 
and control group. 
2. Calculation of meta-analytic weighted pooled percentages of patients converted to 
sinus rhythm at any time point reported in the trial. 
Due to the unsatisfactory reporting of all time measurements in some trial reports, an 
adjustment assumption was made. If the initial observation was not reported at time 
zero, it was assumed that there was no conversion until the first time point reported. 
The individual trials' percentages (Pt) were pooled separately at each time, using a 
weight proportional to the inverse of the variance of the percentage as follows (Gardner 
and Altman, 1986; Andrews et al., 1991): 
p.(1-p.) 
Variance of p. = ----N. 
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and hence the weight for each individual trial is: 
The pooled percentage = 
The formulas given for the variance of the percentage is not applicable for proportions 
outside the range 0.1 to 0.9. As a result, percentages of 0% or 100% were substituted 
by 0.5 and 99.5 respectively. A random-effects model was employed if heterogeneity 
existed. 
Indirect comparisons of pooled percentages from different treatment arms were 
performed as described in Chapter 4 (section 4.2.5.1). This test was also used for 
comparisons of subgroups of each treatment arm according to arrhythmia duration, 
type, pattern, and etiology. 
5.3.4.2 Effect on the Ventricular Response Rate 
To test the effect of antiarrhythmic treatment on the ventricular rate the following 
parameters estimates were calculated to allow direct and indirect comparisons between 
treatment groups: 
5.3.4.2.1 Absolute Mean Ventricular Rate 
For pooling the absolute ventricular rate in each treatment arm (VRi) in the identified 
clinical trials, two meta-analytic methods were employed: 
a. Pooled mean ventricular rate weighted by the inverse of the variance if the SEM 
(standard error of the mean), or SD (standard deviation of the mean) was reported in 
the original trials. 
Where SEM = SD / JD. ; n = number of patients in a particular treatment group. 
The variance of VRj = (SEM)2, and W j = 1 / (variance of VRj). Hence, the pooled 
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mean ventricular rate is calculated according to the formula adopted by Andrews et al. 
(1991): 
Mean VR = -----
and its SEM = F.' with approximate 95% CI of the mean given by: 
[Wi 
Mean VR ± 1.96 . SE 
The pooled VR was estimated at all time points starting from baseline. However, if a 
trial did not provide VR at a particular time point, the value of the previous time point 
was pooled. The Q statistic (Chi-square test) was calculated at each time point to 
estimate the degree of variability among the trials, and if heterogeneity existed, the 
pooled VR was recalculated using the random-effects model. 
B. Pooled mean ventricular rate weighted by number of patients in each individual trial. 
Some trials did not report the SD or SE of the mean VR, though they provided the 
values at all the time points. As a result, to pool the data from these trials as well, 
another macro containing the following equation was executed: 
MeanVR = 
where the Ni is the number of patients in a particular treatment group in each individual 
trial. 
5.3.4.2.2 Weighted Mean Effect on Ventricular Rate 
The weighted mean effect on ventricular rate was defined as mean change from the 
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baseline (Gansevoort et at., 1995). For each treatment arm (for example, flecainide) in 
each individual study, the mean change from baseline was calculated by subtraction of 
mean VR baseline from mean VR at a certain time point as follows: 
D. treatment = VRT- VRBaseline' where VRT is the ventricular rate at time point T. 
However, since many studies did not provide SE or SD of VRT or VRBaseline' the 
standard deviation of the change (S D. treatment) in each study was estimated according 
to an upper boundary assumption for paired data (Gardner and Altman, 1986; 
MacMahon et at., 1987; Cappuccio et aI., 1989) as follows: 
Nd1 S --'" Treatment - K 
where n= number of patients in each treatment group, d= D. treatment, and K is a 
constant equal to the square of the sum of the standardised normal deviates for a and 
S, with a = 0.05 (two-tailed) and S = 0.10 (one-tailed). Then the SE of the change in 
this paired case is given by: 
SE = 
",treatment 
S 
'" treatment 
N 
Thus the pooled mean treatment effect is calculated as: 
Pooled mean effect = 
where d= D. treatment, and Wi is proportional to the inverse of the variance of the 
change. Q statistic (Chi-square test) was performed at each time point to estimate the 
degree of variability among the trials, and if heterogeneity existed, the pooled weighted 
mean effect on ventricular rate was recalculated using the random-effects model. 
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5.3.4.2.3 Effect Size on Ventricular Rate Compared to Placebo 
To calculate the individual effect size at each time point, the mean treatment effect was 
calculated using the equations in section (4.3.4.3), as well as the placebo mean effect 
(estimated using the same procedures) were employed. The pooled SD of the 
individual effect size was calculated using the two S 6. treatment (as was shown in the 
previous section 4.3.4.3) of active treatment and placebo groups as follows: 
pooled SDi = SD j = 
(NT- 1).(ST)2 + (N c- 1).(Sc)2 
NT+Nc- 2 
Effect size was calculated according to Hedges (1982): 
A -A ESi =C (m) T C, i= 1, .... , k 
SPooled 
where m = nti + nci - 2, C(m) is given approximately by: 
3 
C (m) = 1 - 4m _ 1 
Hedges showed that if the assumption for t test between means are met in each study, 
then the sampling variance of ESi is approximately 
Consequently, the standard error ofESi is 
SEi = ...jvi 
Pooled ES is estimated as follows: 
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----, with weight calculated as Wi = 1 / Vi' 
5.3.4.3 Mean Conversion Time 
The individual trials' estimates of mean conversion time (Ti) were pooled for each 
treatment and control group separately, if the standard deviation or standard error was 
reported, using the following equation: 
Pooled mean conversion time = ---, where, Wi = 1 / (variance of Tj) 
Furthermore, a weighted average difference between a two treatment group was 
calculated using the method of Dersimonian and Laird, which was also explained by 
Andrews et ai. (1991). 
5.3.4.4 Incidence of Adverse Effects and Mortality 
The incidence of all types of adverse effects, described earlier in section 5.3.1.4 in this 
chapter, was estimated for flecainide, amiodarone, and sotalol treatment arms by 
calculation of weighted percentages (probabilities) detailed in section 5.3.4.4. This 
allowed the indirect comparison between the three drugs after adjusting for each drug 
trials separately the interstudy heterogeneity and variations due to design and patient 
populations. The incidence was further stratified according to the route of 
administration for each drug, and again an indirect comparison between similar groups 
for the three drugs was performed. 
Furthermore, direct comparisons were carried out by calculation of the pooled relative 
risk (RR) according to methods described in Chapter 3. 
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5.4 RESULTS 
5.4.1 Description of Trials Identified 
Literature search between 1966 and July 1996 identified a total of 70 published studies 
of amiodarone (25), sotalol (20), and flecainide (26) examining their efficacy for rapid 
conversion of acute SV As to sinus rhythm. Only 42 (Appendix 5.1) of these studies 
were trials that satisfied the inclusion criteria (19 for amiodarone, 9 for sotalol, and 14 
for flecainide). The remaining 28 studies (6 for amiodarone, 9 for sotalol, and 13 for 
flecainide) were omitted from analysis (Appendix 5.1) due to the following reasons: the 
trial was designed to test the efficacy for conversion of established chronic AF patients 
only (4 for amiodarone [3,4,5, 6], 2 for sotalol [1, 7]); the study was designed to 
evaluate the prophylactic use for prevention of SV As development postoperatively and 
the treatment was initiated few hours prior to surgery (2 for amiodarone [1,2], 3 for 
sotalol [3, 5, 8], 1 for flecainide [2]); invasive electrophysiologic studies (3 for 
flecainide [10, 12, 13],2 for sotalol [2,9]); the study was published in abstract format 
which did not contain sufficient information to allow the use of meta-analytic 
techniques (3 for flecainide [1, 4, 11]); the trial was a duplicate publication (3 for 
flecainide [7, 8, 9]); and data were reported in the form of retrospective review (2 for 
the flecainide [3,5]), or case report (1 for sotalol [6]); phase II efficacy study (1 for 
sotalol [4]); and study involved different patient population (1 for flecainide [6]). 
Characteristics of the randomised controlled and uncontrolled trials of flecainide, 
amiodarone, and sotalol included in the analysis, are summarised in Tables 5.1.1, 
5.1.2, and 5.1.3 respectively. As shown !or flecainide, 12 studies were RCTs, and 4 
trials were uncontrolled. For amiodarone, 17 studies were RCTs, and 2 trials were 
uncontrolled. For sotalol 7 studies were RCTs, and 2 trials were uncontrolled. 8 RCTs 
employed placebo comparisons (2 for amiodarone, 3 for sotalol, and 4 for flecainide), 
and 25 employed head to head comparisons to various antiarrhythmic drugs. 17 RCTs 
adopted an open-label, parallel design (6 for flecainide, 11 for amiodarone, and 2 for 
sotalol) and two employed open-label crossover (1 for amiodarone, and 1 for sotalol). 
6 RCTs were double-blind, parallel design (3 for flecainide, 2 for amiodarone, and 3 
for sotalol), and one RCT (for sotalol) was a double-blind, crossover design. 4 RCTs 
had single-blind, parallel design (3 for flecainide, and 2 for amiodarone), and one 
another trial for flecainide had additional single-blind, crossover period for patients 
who did not convert to sinus rhythm during the first drug (Madrid et a/., 1993). 
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Tahle 5.1.1 Chancte.-istics of randomised controlled and uncontl'olled trials of flecainide included in ~lI1alysis 
ROl/domised COl/trolled 
------ .. - -
- ._-
-- ---
Study name No. of /Jesign Treatment Type of colltrol /Jose of f1ecaillide Route No. COllcomitallt No. of Previous /Juration of 
patients features allocation (mg/Kg) of drugs patients medications study 
ellrolled; ( Flecainidel doses receiving 
randomised Control) cOllcomi· 
tallt drugs 
Borgeat et al. 1986 60;60 P,C 30/30 Quinidine 50 mg infusion over 10 IV+O M - 0/0 Digoxin; 18/24 NS 
mins; 
followed by a bolus up 
to a maximum of 2 
mg/Kg; 
I then 200 or 300 
mg/day 
Gavaghan et al. 58;56 P,C 29/27 Digoxin+Disopyramide 2 mg/Kg over 20 mins; IV+O M Digoxin 0127 6-blockers I month 
1988 followed by continuous preoperatively; 
infusion of 0.2 20121 
mg/Kglhr for 12 hrs; 
then 200 mg/day for 
the rest of the study 
Suttorp et al. 1989 40;40 P,C 20120 Verapamil 2 mg/Kg over 10 mins IV S - 0 Digoxin I month 
6-blockers 
Wafa et al. 1989 84;29 P,C 15/14 Digoxin or Digoxin 1 mg/Kg over 10 mins; IV M Verapamil 6/14 NS 24 hours 
+Verapamil followed by infusion of Digoxin 0/14 
1.5 mg/Kglhr for 1 
hour and then by 0.25 
mg/Kglhr for the rest 
of the 24 hour study 
period 
Suttorp et al. 1990 50;50 P,C 25125 Propafenone 2 mg/Kg over 10 mins IV S Digoxin 3/4 Class IA agents 11.4±5.2 hours 
B-blockers 6/3 
Calcium antagonist 4/1 
Anticoagulants 9/6 
------ '------ -- -
DB, double-blind; SB, single-blind; P, parallel; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study 
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Table 5.1.1 Characteristics of randomised controlled and uncontrolled trials of f1ecainide included in analysis (continued) 
Randomised controlled 
Study name No .. of Design Treatment Type of Dose of j7ecaillide Route No. Concomitant No. of Previous Duration of 
patients features allocation control (mg/Kg) of drugs patiellts medications study 
enrolled; (Flecaillide/ doses receiving 
ralldomised Control) concomi-
tant drugs 
Villani er at. 1990 37; 37 P, PI 19/18 Placebo 200 mg followed by 0 S NS 0/0 NS NS 
100 mg if AF 
persists 
Donovan erato 1991 104; 102 DB, P, C,PL 51/51 Placebo+Digoxin 2 mg/Kg over 30 IV S Digoxin 51/51 NS 6 hours 
mins; maximum 150 Patients receiving 8-
mg blockers or calcium 
channel blockers 
were not excluded 
Capucci et at. 1992 62;62 SB,P,C,PL 22119121 19 Amiodarone 300 mg/day 0 S - 0/0 NS 24 hours 
21 Placebo 
Madrid er al. 1993 80;80 SB,P,C,CO 40/40 Procainamide 1.5 mg/Kg over 15 IV M - - - NS 
mins; 
followed by 1.5 
mg/kg over I h 
Capucci et al. 1994 181; 181 SB,P,C,PL 58/61/62 61 Propafenone 300 mg/day 0 S - - - 8 hours 
62 Placebo 
-
DB, double-blind; SB, single-blind; P, parallel; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study 
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Table 5.1.1 Characteristics of randomised controlled and uncontrolled trials of flecainide included in analysis (continued) 
Ullcolltrolled 
-
Study name No. of Treatment Dose of flecainide Route No. Concomitant No. of patients Previous Duration of study 
patients allocation (mgIKg) of drugs receiving concomitant medications 
enrolled (Flecainidel doses drugs 
Control) 
Goy et af. 1985 50 50 50 mg infusion over 10 mins; followed O+IV M Digoxin 34 B-blocker; I 48 hours 
by a bolus up to a maximum of 2 
mg/Kg; 
then 200 or 300 mg/day 
Crozier et af. 1987 50 50 2 mg/Kg or 150 mg IV S Digoxin 7 - 45 mins 
Nathan et af. 1987 21 21 2 mg/Kg infused over 5-10 mins IV S - - - NS 
Crijns et al. 1988 (a) 20 20 200 mg, if sinus rhythm was not 0 M Digoxin 3 - 24 hours 
restored within 1 hr; Verapamil 7 
another 100 mg given if necessary; 
then a final dose of 100 mg administered 
3h from the start of treatment 
Crijns et af. 1988 (b) 20 20 2 mg/Kg infused over 10 mins IV S Digoxin 4 - 24 hours 
Verapamil 5 
- '-- ---- -
DB, double-blind; S8, single-blind; P, parallel; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study 
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Table 5.1.2 Char:lctt',-istics of randomised cont rolled and uncontJ-olkd trials of amiodarone indudt'd in <lila lysis 
Rondomised controlled 
--
Study /lame No. of Desigl/ Treatmel/t Type of Dose of Route No. COl/comital/t No. uf Previuus Duratiol/ 
patiel/ts features allocatiol/ Amiodarol/e cOl/trol (mg/Kg) of drugs patiel/ts medicatiol/s of study 
el/rolled; (Amiodarol/e doses receiving 
ralldomised / cOl/comi-
Control) tallt drugs 
Posada et af. 1988 76;36 P,C 14/22 Quinidine+Amiodarone 2 boluses of 150 mg IV M Quinidine 14/22 NS 10 hours 
vs Quinidine followed by an infusion 
of 600 mg over 6 hours 
Bertini et af. 1990 39;39 P,C 15124 Propafenone 5 mg/Kg over 30 sec; if IV;O M NS - NS 5 days 
the arrhythmia persists 
the dose was repeated at 
an infusion rate of 10 to 
15 mg/min; 
followed by oral therapy I 
of 200 mg/day for 2 
days and 400 mg for the 
next 5 days 
McAlister et al. 1990 83; 80 CO,C 41139 Quinidine 5 mg/Kg over 20 min IV S Digoxin 41139 NS 16 hours 
Propranolol 16/6 
Andrivet et al. 1990 46;46 P,C 21125 Cibenzoline Either orally, with a 0 S Digoxin 21125 Digoxin; 3/0 24 hours 
single dose of 30 Amiodarone; 
mg/Kg/24 h; or 211 
or IV loading dose of 5 Class I; 7/2 
to 7.5 mg/Kg over 30 IV M 6-blocker; 3/6 
mins; 
followed by continuous 
IV of 10 to 15 
mg/Kg/24 h 
Bellandi et al. 1993 196; 196 P,C 98/98 Propafenone A bolus of 5 mg/Kg (3 
min); 
IV M NS - NS 1 year 
followed by 15 
mg/Kg/24 hr 
DB, double-blind; SB, single-blind; P, parallel; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study 
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Tahle 5.1.2 Chanlcteristics of nmdomist.'d controlled and uncontrolled trials of amiodarone included in analysis (continued) 
Randomised contro/led 
Stl/dy lIame No. of Desigll Treatmellt l)'pe of Dose of ROllte No. COllromitallt No. of Previolls Duratioll of 
patients feafllres al/oratioll Amiodarolle (mg/Kg) of drugs patiellts mediratiolls stlldy 
ellrolled; (AlIliodarolle cOl/trol doses receivillg 
ral/dol1lised / cOllcomitall( 
COl/trol) drugs 
Chapman et 01. 1993 26;24 P,C 10/14 Procainamide 3 mg/kg infused over IV M Digoxin 8/12 Digoxin 72 hours 
15-20 min followed by B-blockers 
10 mg/Kg/24 h, and if 
no response was 
documented by I h, 3 
mglkg 
Cesar et al. 1994 60;60 P,C 16123/21 Quinidine+Digoxin; 2 5 mg/Kg infused over IV S Digoxin 0/21 QIPrc23 NS 4 hours 
Procainamide 10 min 
+Digoxin; 23 
Cochrane et al. 1994 30;30 P,C IS/IS Digoxin A loading dose of 5 IV M - 0 B-blocker; 817 24 hours 
mg/Kg (max 400 mg), 
infused IV over 30 
min, followed by 25 
mglh, and if VR 
uncontrolled, the 
infusion increased to 
40 mg/h 
Tre glia et al. 1994 71;54 P;C 27127 Propafenone 5 mg/Kg over 15 min IV M NS - NS 48 hours 
followed by. for non-
converting, infusion of 
15 mg/Kg over the 24 
hours 
Biasi et al. 1995 85;84 DB,P,C 46/38 Propafenone 5 mg/Kg over 15 min IV M - - - 24 hours 
followed by, for non-
converting, infusion of 
15 mg/Kg over the 24 
hours 
-----
DB, double-blind; SB, single-blind; P, parallel; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study 
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THbie 5.1.2 ChHracteristics of randomised controlled and uncontrolled trials of amiodal'one included in Hn'llysis (continued) 
ROl/domised cOl/trolled 
Stlldy nallle No. of Design Treatment Type of /Jose of Route No. Concomitant No. of Previous /Juration 
patients featllres allocation Amiodarolle (mg/Kg) of drugs patients medicatiolls of study 
enrolled; (Amiodaro cOlltrol doses receiving 
randomised net concomi· 
Control) tant drugs 
Chapman et al. 1993 26;24 P,C 10/14 Procainamide 3 mg/kg infused over 15-20 IV M Digoxin 8112 Digoxin 72 hours 
min followed by 10 B-blockers 
mg/Kg/24 h, and if no 
response was documented by 
I h, 3 mg/kg 
Cesar et al. 1994 60;60 P,C 16123/21 Quinidine+Digoxin; 2 5 mg/Kg infused over 10 IV S Digoxin 0/21 QIPrc23 NS 4 hours 
Procainamide min 
+Digoxin; 23 
Cochrane et al. 1994 30;30 P,C 15/15 Digoxin A loading dose of 5 mg/Kg IV M . 0 B-blocker; 8n 24 hours 
(max 400 mg), infused IV 
over 30 min; 
followed by 25mglh, and if 
VR uncontrolled, the 
infusion increased to 40 
mglh 
Treglia et al. 1994 71; 54 P;C 27/27 Propafenone 5 mg/Kg over 15 min; IV M NS - NS 48 hours 
followed by for non-
converting, infusion of 15 
mg/Kg over the 24 hours 
Biasi et al. 1995 85; 84 DB,P,C 46/38 Propafenone 5 mg/Kg over 15 min; IV M - - - 24 hours 
followed by for non-
converting, infusion of 15 
mg/Kg over the 24 hours 
DB, double·blind; SB, single-blind; P, parallel; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study 
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Table 5.1.2 Chanlcteristics of randomised controlled ~md uncontrolled trials of amiodarone included in analysis (continued) 
Ral/domised cOl/trolled 
-~ _ .. _----
------ - ---
~~----
Study lIame No. of Desigll Treatment Type of Dose of Route No. CO IICOIII ita lit No. of Previous Duration of 
patients features allocation Amiodarone (mgIKg) of drugs patients lIIedicatioll.~ study 
enrolled; (Amiodarone cOlltrol doses receiving 
randomised I concomi-
I Control) tallt drugs 
Donovan et al. 1995 98;98 DB, P, C, PL 32134/32 Flecainide; 34 7 mg/Kg over 30 mins IV S Digoxin 4/3/4 - 8 hours 
Placebo; 32 B-blockers 8/4/2 
Calcium antagonist 4/212 
Moran et al. 1995 42;42 P,C 21121 Magnesium 5 mg/Kg loading dose IV M Digoxin 1119 NS 24 hours 
sulfate over 15 to 20 mins Aminophylline 6/4 
followed by an infusion Sympathomimetics 1116 
of 10 mg/Kg/24 hrs 
Galve et aI. 1996 100; 100 P,PL,SB 50150 Amiodarone+ 5 mg/Kg over 30 mins; IV M Digoxin 50150 No previous 15 days 
Digoxin vs followed by 1200 mg antiarrhythmic 
Placebo+Digoxin diluted in 500 ml of therapy including 
saline over 24 hours digoxin 
*Larbuisson et al. 40;40 p,e 22118 Propafenone 2.5 to 5 mg/Kg infused IV M Digoxin 0/1 NS 1 week 
1996 over 10 mins; B-blockers 6/6 
if reversion was not Calcium antagonist 11110 
achieved in 20 min, Nitrates 6/3 
additional doses were 
given up to 900 mg/24 
hrs 
Capucci et al. 1992 62;62 SB, p,e, PL 19122121 22 flecainide 300 mg/day 0 S - 0/0 NS 24 hours 
21 Placebo 
DB, double-blind; SB, single-blind; P, parallel; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; e, comparative study 
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Table 5.1.2 Characteristics of randomised controlled and uncontrolled trials of amiodarone included in analysis (continued) 
Ralldomised COil trolled 
Study name No. of Design Treatment Type of Dose of Route No. Concomitant No. of Previous Duration of 
patients features allocation Amiodarone (mg/Kg) of drugs patients medications study 
enrolled; (Amiodarone control doses receiving 
randomised / concomi-
Control) tant drugs 
Hou et al. 1995 50;50 P,C 26124 Digoxin 5 mg/min for the first IV M Digoxin 0/24 - 24 hours 
hour, 3 mg/min for the Ca blockers 212 
next 3 hours, I mg/min B-blockers 1I2 
for another 6 hours and 
0.5 mg/min for the 
remaining 14 hours 
--
DB, double-blind; SB, single-blind; P, parallel; re, nonrandomised open-label trial; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study; VR, ventricular 
rate I 
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Table 5.1.2 Characteristics of randomised controlled, and uncontrolled trials of amiodarone included in analysis (continued) 
Ullcolltrolled 
Study lIame Year of No. of Treatment Dose of Route No. COllcomitant No. of patiel/ts Previous Arrhythmia Duratioll of 
publi- patiel/ts allocation Amiodarone of drugs receivillg medicatiolls mOllitorillg study 
catioll enrolled (Amiodarone (mg/Kg) doses concomitallt method 
I drugs 
Control) 
Faniel er al. 1983 26 26 Repeated boluses of 3 IV M - 0 Digitalis; 7 ECG 48 hours 
mg/Kg in 3 min, or 30 Verapamil; 4 
min infusion of 5 to 7.5 Digitalis+ 
mg/Kg; Verapamil; 2 
followed by continuous Hydroquinine; I 
infusion to a maximum 
of 1500 mg/24 h 
S trasberg et al. 1985 26 26 A slow bolus of 5 IV S - 0 Digoxin; 4 ECG 12 hours 
mg/Kg over 3 to 5 Quinidine; I 
mins 
Contini et al. 1993 61 61 A bolus of 300 mg; IV+O M - 0 - ECG 7 days 
followed by infusion of 
900 mg/24 h; 
then either IV or oral 
600 mg/24 h 
DB, double-blind; SB, single-blind; P, parallel; re, nonrandomised open-label trial; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study; YR, ventricular 
rate 
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Table 5.1.3 Characteristics of randomised controlled and uncontrolled trials of Sotalol included in analJsis 
Ralldol1lised COlltrolled 
Study lIame No. of Design Treatmellt Type of cO/lfrol Dose of Sotalol Route No. COllcomitant No. of Previous Duratioll of 
patiellts features af/ocatioll (mgIKg) of drugs patiellts medicatiolls study 
ellrolled; (Sotaloll doses receivillg 
ralldomised Co II trol) cOllcomi· 
tallt drugs 
Campbell et af. 42;40 C,P 20;20 Digoxin/ Disopyramide+Digoxin A bolus of Img/Kg; IV 0 . 0 B·blockers; 15115 24 hours I 
1985 and a further 0.2 I 
mg/Kg infused over 
12 hours 
Levy et al. 1986 23;23 CO,PL 23/23 Placebo 0.5 mg/Kg in 6 mins IV S - - - . 
Janssen et al. 1986 151; 130 C,P,PL 41/39/50 Metoprolol; 39 0.3 mg/Kg IV for IV+O S - 0 - 48 hours 
No therapy; 50 prevention of SV As; 
and 240 mg orally 
for acute treatment 
of SV As after 
CABG 
Suttorp et al. 1990 450;429 P,C 207/222 High dose Propranolol; 156 High; 40 mgl8 h 0 M . 0 B-blocker; 147/179 6 days 
Low dose Propranolol; 66 Low; 80 mgl8 h Digoxin; 9/14 
lordaens et al. 1991 43,43 DB,PL, 38/22 Placebo A bolus of 1.5 IV S - 0 0 I hour 
CO mg/Kg over IO mins 
Suttorp et al. 1991 303;300 DB, PL, P 1501150 Placebo Low; 80 mg/6 h 0 M - 0 B-blocker; 1181108 6 days 
Digoxin; 4n 
DB, double-blind; SB, single-blind; P, parallel; re, nonrandomised open-label trial; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study; VR, ventricular 
rate; 'I, the antiarrhythmic drugs were introduced as crushed tablets mixed in 100 mL of orange juice 
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Table 5.1.3 Chanlctcristics of randomised controlled and uncontnJlled trials of Sotalol included in analysis (continued) 
ROlldomised COil trolled 
Study name No. of Design Treatment Type of cOlltrol Dose of Sotalol Route No. COllcomitallt No. of Previous Duratioll of 
patients features allocatioll (lIIgIKg) of drugs patiellts medicatiolls study 
enrolled; (Sotaloll doses receivillg 
randolllised COlltrol) Concollli· 
tant drugs 
Hamer et al. 1993 6; 6 DB, CO, C 6/6/6 6 F1ecainide Sotalol; 2-2.9 mg/Kg 01 S - 0 Verapamil;(6/6/6) 4.5 hours 
6 Verapamil Flecainide; 2-3.3 mg/Kg Atenolol; (1/111) 
Nystrom et al. 1993 101; 101 C,P 50/51 Routine treatment Preoperatively, the first 0 M - 0 B-blocker; 42/40 6 days 
with other B- dose was 160 mg in the Digoxin; 3/1 
blockers morning of the day of the Calcium-channel 
operation; and blocker; 36/28 
postoperative a dose of 
320 mg/day 
Halinen et al. 1995 61; 61 DB,P,C 33/28 28 Quinidine 80 mg; then the same 0 M Digoxin 0/28 Digoxin; (5/1) 24 hours 
dose repeated after 2, 6, B-blockers; (6/13) 
10 hours if the Verapamil 
arrhythmia persisted (up lDiltiazem; (4/3) 
to a max of 320 mg) Diuretic; (1/8) 
Sung et al. 1995 93; 93 First part: 62133/29 62 Sotalol 1.5 I mg/Kg or 1.5 mg/Kg IV S or NS 0 
- I hour 
DB, PL, P mg/Kg infusion over 10 mins M 
Second part: 33 Sotalol I mg/Kg 
Open-label, 29 Placebo 
uncontrolled 
--
DB, double-blind; SB, single-blind; P, parallel; re, nonrandomised open-label trial; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study; VR, ventricular 
rate 
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Table 5.1.3 Characteristics of randomised controlled and uncontrolled trials of Sotalol included in analysis 
Uncontrolled 
Study name No. of Treatment Dose of Sotalol Route No. Concomitant No. of patients Previous medications Duration of study 
patients allocation (mg/Kg) of drugs receiving 
enrolled (Sotaloll doses concomitant drugs 
Control) 
Teo et al. 1985 29 29 A bolus of 30 mg at a rate of 2 IV S - 0 Digitalis; (8) 48 hours 
mg/min, or infusion of 100 mg over Disopyramide; (4) 
120 mins Sotalol; (2) 
Propranolol; (I) 
Atenolol; (I) 
Denis eta/. 1988 20 20 One to three injection of 0.5 mg/Kg IV M NS - NS NS 
DB, double-blind; SB, single-blind; P, parallel; re, nonrandomised open-label trial; CO, crossover; PL, placebo-controlled; S, single; M, multiple; IV, intravenous; 0, oral; C, comparative study; VR, ventricular 
rate 
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The included trials enrolled a total of 2528 patients, however; 2383 patients were 
randomised and received trials' treatment: 533 patients received flecainide, 610 patients 
received amiodarone, 272 patients received sotalol, 368 patients received placebo, and 
733 patients were receiving other antiarrhythmic drugs as active control (of which 140 
patients received quinidine; 22 received quinidine plus amiodarone; 47 patients received 
disopyramide; 77 patients received procainamide; 273 patients received propafenone; 21 
received cibenzoline; 39 patients received metoprolol; 21 patients received magnesium 
sulfate; and 93 patients received digoxin, verapamil or combination of the two). The 
sample size of each study ranged from 6 to 196 patients, with a mean of 58 patients 
over all the studies. 
The arrhythmia monitoring technique throughout the trials' observation period was a 
continuous 24-hour Holter monitoring (11 trials); continuous 12-lead electrocardiogram 
every hour which was recorded as soon as the patient convert to sinus rhythm (24 
trials), and/or recording of the symptoms. The average study duration was 86±43 
hours (range 45 minutes to 1 month), for flecainide trials 196±306 hours (range 45 
minutes to 1 month), for amiodarone trials 39.5±45 hours (range 4 hours to 7 days), 
and for sotalol trials 21±20.6 hours (range 1 hour to 48 hours). 
30 trials tested intravenous interventions (9 for flecainide, 14 for amiodarone, and 6 for 
sotalol), 6 trials tested oral interventions (5 for flecainide, and 2 for sotalo!), and 7 trials 
tested oral plus intravenous interventions (3 for flecainide, 3 for amiodarone, and 1 for 
sotalol). For intravenous interventions, the dosages and rates of infusion varied across 
the studies. Flecainide dosage employed varied between 1 to 2 mg/Kg infused over 10 
to 30 minutes, and in some studies followed by a continuous infusion of 0.2 to 1.5 
mg/Kg/hr for the rest of the study, or untill conversion to sinus rhythm was achieved. 
Amiodarone initial intravenous dose was mostly 5 mg/Kg over 3 to 30 mins, followed 
by 10 to 15 mg/Kglhr. Sotalol dosage varied between 0.5 to 1.5 mg/Kg over 10 mins. 
5.4.2 Population Characteristics of the Included 
Studies 
~he mean age of the patients actoss all studies, which reported the age (34 studies), 
was 58.57±7.85 years (range 23 to 71). In the 41 studies reporting gender, there was 
a total of 808 women and 1490 men, with a mean of 36 men and 20 women in the 
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sample. The mean onset of the arrhythmia was reported in 29 studies with an average 
overall mean of 160±538 hours (range 15 minutes to 4.6 months). The left atrial 
diameter was mentioned in 15 studies with a mean of 4 1.63±5. 1 mm (range 32.9 to 
55). 
Tables 1,2, and 3 of Appendix 5.2 show the characteristics of populations included in 
flecainide, amiodarone, and sotalol individual trials respectively. Table 5.2 summarises 
the mean characteristics of patients treated with amiodarone, sotalol, flecainide, and 
placebo groups. Patients characteristics for each type of treatment group were tabulated 
separately. Continuous data were compared using unpaired t-test, and one way 
analysis of the variance. Discrete variables were compared using chi-square test. The 
comparison of mean age have revealed that patients allocated to amiodarone were 
significantly older than other groups (ANOVA=5.48; P=0.0023). The time elapsed 
since the first onset of arrhythmia and left atrial diameter were not significantly different 
among the treatment groups (P=0.3911 and 0.524 respectively). Patients of medical or 
surgical etiology were not equally distributed among the groups (P=O). Furthermore, 
the comparisons of baseline mean heart rate and systolic blood pressure were not 
considered significant (P=0.35, and 0.449 respectively). 
Cardiac diagnoses were reported for a total of 1971 patients. Table 4, 5, and 6 of 
Appendix 5.2 show the different cardiac diagnoses of patients enrolled in flecainide, 
amiodarone, and sotalol clinical trials respectively. The distribution of the assorted 
diagnoses was tabulated, and examined with respect to various treatment groups (Table 
5.2), as well as different drugs' trials popUlations (Table 5.3). The valvular heart 
disease was the primary diagnosis in 16% of the population enrolled in amiodarone 
clinical trials, 4.8% of the patients in the sotalol trials, and 6.5% of the patients in 
flecainide trials (P<O.OOOI). Hypertension was found in 10.5% of the amiodarone 
trials' populations, 18% of sotalol trials' popUlations, and 18.43% of flecainide 
populations (P<O.OOOl). The proportion of patients with ischemic heart diseases and 
cardiomyopathy was more significant in amiodarone and sotalol clinical trials than 
flecainide trials (P<O.OOOI). Patients with ischemic heart diseases were equally 
distributed among the groups (P=0.06). Patients with congestive heart failure and 
cardiomyopathy existed more in amiodarone clinical trials than sotalol and flecainide 
trials. However, patients with lone fIbrillator were more common in flecainide trials 
(P<O.OOOI). In additiori, examination of distribution of the same diagnoses across 
individual treatment groups as shown in Table 5.2 (patients receiving amiodarone, 
sotalol, flecainide, placebo, and active control separately), has confirmed significant 
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statistical differences in all diagnoses categories (P<O.OOOI) except cardiomyopathy 
and pericarditis (P=0.08 and 0.27 respectively). 
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Table 5.2 l\Iean characteristics of all study groups included in the analysis 
-
Varia hies All groups Amiod:lrone Sotalol I Flecainide I'laccho Test of significance I'-value 
Study groups (N) 26 20 l) I 17 10 I - I -
I 
~ ~ 
-
Patients (II) 1783 610 272 533 368 - -
Age 58.57±7.85 62.7±5.3 50.3±12.5 
I 
55.74±l).6 53.l)l)±7.l)7 ANOVA P=O.0023** 
F=5.4745 
Male 1131 410 163 337 221 
Female 635 200 98 193 144 
Arrhythmia pattern 
Acute AF (n) 1254 531 73 416 234 )(2=104.3 P=O.OO 
AFL (n) 222 102 33 38 9 X2=53 P=O.OO 
PAF (n) 117 34 34 30 19 X2=17 P=O.OO 
PSVT (n) 159 18 96 21 24 )(2=253.7 P=O.OO 
Onset of arrhythmia (hours) 160±538 49.38±53.02 120.7±274.75 283.62±671 19.24±11.83 ANOVA P=0.391I 
F=1.0296 
Left atrial diameter (mm) 41.63±5.09 43.6±6.24 - 40.84±4.23 42.62±22.93 ANOVA P=0.5243 
F=0.6694 
Baseline heart rate (Ventricular 14 1.1 7±14.04 140.94±12.26 I 47.46±20.14 134. 54± 13.48 140.8±19.15 ANOVA P=0.35 13 
response rate, beats/min) F=1.I213 I 
Systolic blood pressure (mm Hg) 125.02±12.3 123.27±12.63 114.74±9.66 118 119.5±9.66 ANOVA P=0.449 
F=0.8397 
Surgical etiology (n) 1079 236 217 374 252 )(2=352.8 P=O.OO 
Medical etiology (n) 699 482 36 106 75 )(2=423.1 P=O.OO 
Cardiac diagnosist (n) 1528 448 190 422 468 -
-
Valvular (n) 210 97 II 44 58 )(2=33.132 P=O.OOO 
Hypertension (n) 217 49 33 74 61 )(2=8.455 P=0.0375 
Ischemic heart disease (n) 320 137 23 99 61 )(2=42.209 P=O.OOO 
Thyroid (n) 11 0 4 5 2 X2=1O.1I4 P=O.O 1762 I 
Lone Jibrillator (n) 532 132 73 168 159 )(2=7.513 P=0.057221 
Congenital heart disease (n) 6 I 3 0 2 )(2=8.81 P=0.031952 
Pericarditis (n) 15 5 I 7 2 )(2=3.919 P=0.270296 
Alcohol-associated (n) 28 7 8 3 IO )(2=9.175 P=0.027051 
CHF (n) 115 50 10 20 35 )(2=13.512 P=0.00365 
Cardiomyopathy (n) 37 17 2 11 7 )(2=6.675 P=0.083015 
Miscellaneous (n) 151 43 13 57 38 )(2=8.896 P=0.031 
AF. atrial fibnUaLion; AFL. atrial tluucr. PAF. paroxysmal atrial fibnlJauon; PAT. paroxysmal atrialliU:hycanha; PSVT, pamxysmaJ suprdvcnLncular lachycanha ANOVA, One-way Analysis oj the vanance; X2. ChI-square leSt; t.lolal number of patients for whom cardiac diagnosIS was 
reponed; CHF. congestive heart failure 
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Table 5.3 Distribution of cardiac diagnoses in amiodarone, sotalol, and flecainide clinical trials 
Diagnosis Amiodarolle clinical Sotalol clinical Flecainide clinical Chi-square test P-value 
trials trials trials 
n (%) n (%) n (%) 
Valvular heart 153 (16%) 12 (4.8%) 50 (6.5%) 44.717 p<o.ooo 
disease 
Hypertension 100 (10.5%) 45 (18%) 141 (18.43%) 21.011 P<0.OOO27 
Ischemic heart 196 (20.5%) 33 (13.2%) 140 (18.3%) 5.762 P=0.056065 
disease 
Thyroid 0(0%) 4(1.6%) 5 (0.65%) 12.173 P=0.002274 
Lone fibrillator 263 (27.5%) 74 (29.6%) 315 (41.2%) 25.04 P<O.OOO 
(no heart disease) 
Congenital heart 1(0.1%) 3(1.2%) I (0.13%) 10.119 P<0.OO643282 
disease 
Pericarditis 6 (0.63%) 1 (0.4%) 7 (0.92%) 0.882 P=O.OOO 
Alcohol associated 7 (0.73%) 12 (4.8%) 3 (0.39%) 35.25 P=O.OOO 
CHF 121 (12.7%) 10 (4%) 57 (7.5%) 21.282 P=0.05 
Cardiomyopathy 27 (2.8%) 2 (0.8%) 11 (1.44%) 6.157 P=0.3991 
Miscellaneous 64 (6.7%) 13 (5.2%) 59 (7.7%) 6.837 P=1 
Total 956 250 765 - -
X2, Chi-square test; CHF, congestive heart failure 
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5.4.3 Efficacy 
5.4.3.1 Conversion to Sinus Rhythm 
Different trials considered various time intervals as the end-point for successful 
conversion to sinus rhythm depending on the dose and route of administration 
employed. The definition of conversion success rate was stated in 30 studies (Table 
5.4). A total of 11 clinical trials reported the percentage of patients converted to sinus 
rhythm, in the form of curves, for different treatment arms at various time points during 
the study observation period. This varied between 6 to 24 hours (listed in Table 
5.5.1). 30 trials reported the incidence of successful conversion in the text at one or 
more time points (listed in Table 5.5.2). 
5.4.3.1.1 Direct Comparisons 
Flecainide Clinical Trials 
Table 5.6.1 displays the results of flecainide estimated effects (individual odds ratios), 
compared to direct control groups in individual trials at the three time-intervals specified 
in section 5.3.4.1. rn all the 5 placebo-controlled trials the differences between 
flecainide and placebo were statistically significant at the end of the three hour-interval. 
Furthermore, flecainide absolute efficacy relative to placebo was confirmed by pooling 
as shown in Figure 5.1. The typical pooled OR at 3 and 8 hours was highly 
statistically significant (OR3 hrs, 7.2; 95% cr, 4.7 to 11.12; Z=8.9; and ORg hrs, 5.5; 
95% cr, 3.6 to 8.4; Z=7.85). The test of heterogeneity among trials was not 
significant at 3 hrs, but was at 8 hrs. Despite application of random-effects model, 
flecainide was still superior to placebo at 8 hrs. 
Head to head comparisons of flecainide to other drugs from different classes in 10 
RCTs were not consistently significant (Figure 5.2). Pooling the data from two 
amiodarone controlled trials (of a total of 56 vs 51 patients) demonstrated superior 
conversion rate with flecainide at 3 hours, as well as at 8 hours (OR3 hrs, 3.44; 95% 
cr, 1.6 to 7.3; Z=7.8; and ORg hrs, 3.02; 95% CI, 1.4 to 6.6; Z=2.7). In addition, the 
pooled effect estimate expressed as RD was highly statistically significant (RD3 hrs, 
34%; 95% cr, 16.7% to 51.5%; Z=3.9, and RDg hrs, 29.6%, 95% cr, 12.7% to 
46.5%; 2=3.4). However, the results at 8 hours should be interpreted with caution as 
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Table 5.4 Definition of AF and successful conversion to sinus rhythm (CSR) emplo~'ed in individual trials 
Trial Drug treatment(s) Definition of AF Definition of CSR 
Goy et al. 1985 I Flecainide AF lasting at least 1 day but less than 3 Reversion to sinus rhythm not more than 48 hours 
months after the treatment is begun 
Borgeat et al. 1986 F1ecainide vs Quinidine INS INS 
Crozier et al. 1987 I F1ecainide I Acute SVT (within 24 h) Reversion to sinus rhythm within 45 min after the 
start of the infusion 
Nathan et at. 1987 I Flecainide INS INS 
Crijns et at. 1988 I F1ecainide Recent-onset AF <24 h, and chronic Reversion to sinus rhythm within 5h (oral) or within 
AF>24 h 30 min (intravenous regimen) 
Gavaghan et at. 1988 F1ecainide vs Atrial tachyarrhythmia developing after NS 
Digoxin+Disopyramide bypass grafting surgery or valve 
replacement surgery 
Suttorp et al. 1989 F1ecainide vs Verapamil AF or AFL < 6 months and ventricular Reversion to sinus rhythm within 1 hour after the 
rate> 100 bpm and no signs of heart start of the infusion 
failure 
Wafaetal. 1989 F1ecainide or F1ecainide Atrial tachyarrhythmia developing in Reversion to sinus rhythm within 45 mins, or within 
+Verapamil vs Digoxin or the first 96 hours after bypass grafting 1 hour if verapamil was added at 45 mins (due to 
Digoxin +Verapamil surgery and lasting for at least 15 mins persistence of AF), and maintained for 24 hours 
The treatment was also considered successful if it 
control the ventricular response rate 
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Table 5.4 Definition of AF and successful conversion to sinus rhythm (CSR) employed in individual trials (continued) 
-- --- --- ---- _. --- --
Trial Drug treatmellt(s) Defillition of AF Definition of CSR 
Suttorp et af. 1990 Flecainide vs Propafenone AF or AFL < 6 months and ventricular Reversion to sinus rhythm within I hour after the 
rate> 100 bpm and no signs of heart start of the infusion 
failure 
Donovan et af. 1991 Flecainide+Digoxin vs Placebo Recent-onset AF ~30 mins and $72 Early reversion: stable sinus rhythm within 1 hour 
+Digoxin hours of starting the medication and maintained until the 
end of the 6-hour monitoring period 
Late reversion: reversion between 1 and 6 hours 
Capucci et al. 1992 Flecainide vs Placebo vs Recent-onset AF ~7 days NS 
Amiodarone 
Villani et af. 1990 Flecainide vs Placebo Recent-onset PAF ~8 hours and ~ 24 NS 
hours 
Madrid et af. 1993 Flecainide vs Procainamide Paroxysmal atrial fibrillation lasting Reversion to sinus rhythm within 1 hour after the 
<24 hours start of the infusion 
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Table 5.4 Definition of AI" and successful conversion to sinus rhythm (CSR) employed in individual trials (continued) 
Trial Drug treatment(s) Definition of AF Definition of CSR 
Faniel et at. 1983 Amiodarone AF or AFL with rapid ventricular Reversion to sinus rhythm within 24 h, maintained 
response that had been unsuccessfully for more than 48 h 
treated by drugs (other than amiodarone) 
and/or DC shock 
Strasberg et af. 1985 Amiodarone Recent-onset AF or P AF NS 
Posada et al. 1988 Amiodarone+Quinidine vs Recent-onset AF ($7 days) Reversion to sinus rhythm over 10 hours 
Quinidine 
Bertini et al. 1990 Amiodarone vs Propafenone AForSVT Acute reversion: Reversion to sinus rhythm within 2 
hours via intravenous therapy at home 
Late reversion: Reversion to sinus rhythm within 1-2 
days after hospitalisation via oral therapy 
Noc et al. 1990 Amiodarone vs Verapamil I PAF Reversion to sinus rhythm within 3 hours I 
McAlister et af. 1990 Amiodarone vs Quinidine AF or AFL sustained for more than 2 Reversion to sinus rhythm within 8 hours, sustained 
hours after cardiac operation, and for at least 4 hours 
refractory to digoxin therapy or atrial 
pacing 
Andrivet et 01. 1990 Amiodarone vs Cibenzoline Sustained atrial tachyarrhythmia; lasting Reversion to sinus rhythm over 24 hours 
for at least 3 hours 
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Table 5.4 Definition of AI" and successful conversion to sinus rhythm (CSl~) emplo)'ed in individual trials (continued) 
Trial Drug trea tm e 11 t( s) Definitioll of AF Definition of CSR 
I 
Be Ilandi et al. 1993 I Amiodarone vs Propafenone I Stable AF of recent onset I Reversion to sinus rhythm over 24 hours 
Chapman et al. 1993 Amiodarone vs Procainamide AT sustained for at least I h (including Conversion to sinus rhythm by I hr (or slowing of 
AF, AFL, and SVT), and whieh failed ventricular rate> 20 beats/min) 
to respond to correction of possible 
precipitating factors 
Contini et al. 1993 Amiodarone AF developed after CABO Reversion to sinus rhythm over 48 hours 
Cesar et al. 1994 Amiodarone vs Acute AF ~ 7 days NS 
Quinidine+Digoxin vs 
Procainamide+Digoxin 
Cochrane et al. 1994 Amiodarone vs Digoxin AF developed due to open heart surgery Reversion to sinus rhythm over 24 hours with 
and persisted for more than 20 min with subsequent sustain throughout the study observation 
systolic blood pressure of 85 mmHg or period 
above without inotropic support 
Treglia et al. 1994 Amiodarone vs Propafenone Recent-onset AF (~7 days) Reversion to sinus rhythm over 48 hours 
Biasi et al. 1995 Amiodarone vs Propafenone AF or AFL lasting for at least 15 min Reversion to sinus rhythm within the 24-hour study 
prior to cardiac surgery and ventricular period and sustained at least 3 hours 
rate more than 100 beats/min I 
I 
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Table 5.4 Definition of AF and successful conversion to sinus rhythm (CSR) employed in individual trials (continued) 
------ ----------
Trial Drug treatment(s) Definition of AF Defil/ition of CSR 
Hou et af. 1995 Amiodarone vs Digoxin Persistent atrial fibrillation or flutter Reversion to sinus rhythm over 24 hours 
with ventricular rates above 130 
beats/min for less than 10 days 
Moran et al. 1995 Amiodarone vs Magnesium Sustained atrial tachyarrhythmia of;::: I Reversion to sinus rhythm over 24 hours 
sulfate hr duration, with a ventricular rate of 
120 beats/min 
Donovan et al. 1995 Amiodarone vs F1ecainide vs Recent-onset AF ;:::30 mins and ..:;,72 Early reversion: stable sinus rhythm within I hour 
Placebo hours of starting the medication and maintained until the 
end of the 6-hour monitoring period 
Late reversion: reversion between 1 and 6 hours 
Larbuisson et al. 1996 Amiodarone vs Propafenone Atrial fibrillation or flutter with a Efficacy was termed as: 'Success' (if sinus rhythm 
ventricular rate> 120 beats/min within was achieved within 20 mins after first dose and 
1 week after cardiac surgery hemodynamic parameters were improved by more 
than 20%) or as 'Improvement' (if sinus rhythm 
achieved within 24 hours and hemodynamic 
parameters were improved by more than 10%) 
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Table 5.4 Definition of AF and successful conversion to sinus rhythm (CSR) employed in individual trials (continued) 
Trial Drug treatI1lellt(s) Defillitioll of AF Definitioll of CSR 
Campbell et al. 1985 Sotalol vs Atrial tachyarrhythmia developing after NS 
Digoxin+Disopyramide bypass grafting surgery or valve 
replacement surgery 
Teo et al. 1985 Sotalol Acute or chronic, persistent or Reversion to sinus rhythm within 1 hours 
intermittent AF, AFL, or PSVT 
Levy et al. 1986 Sotalol vs Placebo Recent-onset AF, AFL, or junctional NS 
tachycardia, with ventricular rate> 120 
beats/min 
Janssen et al. 1986 Sotalol vs Metoprolol vs no AF developed after CABG NS 
treatment 
Denis et al. 1988 Sotalol Recent-onset AF, AFL, or junctional Reversion to sinus rhythm within 30 mins 
tachycardia 
10rdaensetal.1991 Sotalol vs Placebo Spontaneous or induced PSVT of~ 15 Reversion to sinus rhythm within 30 mins 
mins duration and a ventricular rate of> 
120 beats/min 
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Table 5.4 Definition of AF and successful conversion to sinus rhythm (CSR) employed in individual trials (continued) 
Trial Drug treatment(s) Definition of AF Definition of CSR 
Hamer et al. t 993 Sotalol vs Verapamil vs PSVT normally controlled by NS 
Flecainide antitachycardia atrial pacemaker 
Halinen et af. 1995 Sotalol vs Quinidine + Digoxin PAF lasting than 48 hours with heart Reversion to sinus rhythm over 24 hours 
rate> 80 beats/mins, and systolic blood 
pressure ~ 120 mm Hg 
Sung et al. 1995 Sotalol vs Placebo SVT, AF, or AFL of> 5 mins and < 7 Reversion to sinus rhythm within 30 mins 
days duration with ventricular rate of ~ 
120 beats/min (spontaneous or induced 
in the electrophysiology laboratory) 
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Table 5.5.1 Trials reporting curves with percentage of patients 
converted to sinus rhythm 
Trial Treatment Control Time interval 
Cochrane et al. 1994 Amiodarone Digoxin 0-24 hrs 
Hou et al. 1995 Amiodarone Digoxin 0-24 hrs* 
Donovan et al. 1995 Amiodarone I Placebo 0-8 hrs 
Flecainide 
Larbuisson et al. 1996 Amiodarone I Propafenone 0-24 hrs* 
Galve et al. 1996 Amiodarone I Digoxin+Placebo 0-24 hrs 
Posada et al. 1988 Amiodarone Quinidine 0-10 hrs 
+Quinidine 
Donovan et al. 1991 Flecainide+Digoxin Placebo+Digoxin 112-6 hrs 
Wafa et al. 1989 Flecainide Digoxin alone or with 0-24 hrs 
Verapamil 
Gavaghan et al. 1988 Flecainide Digoxin+Disopyramide 1-12 hrs 
Campbell et al. 1985 Sotalol I Digoxin+Disopyramide 1-12 hrs 
Halinen et ai. 1995 Sotalol Quinidine+Digoxin 0-24 hrs 
* Censored end points (the analysis was performed on an intention to treat basis) 
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Trial Treatment Control Time interval 
Chapman et af. 1993 Amiodarone Procainamide 1 h, and between 1 and 12 
hrs 
McAlister et af. 1990 Amiodarone Quinidine 0-2, 2-4, 4-6, 6-8, 10-12, 
12-4, and 14-16 hrs 
Cesar et af. 1994 Amiodarone Quinidine mean conversion time 
Procainamide 
Treglia et af. 1994 Amiodarone Propafenone 5, 24, and 48 hrs 
Biasi et af. 1995 Amiodarone Propafenone 1, and 24 hrs 
Bellandi et af. 1993 Amiodarone Propafenone mean conversion time 
Bertini et af. 1990 Amiodarone Propafenone 24 hrs 
Noc et af. 1990 Amiodarone Verapamil 20 mins, 40 mins, 1, 1.5, 
2.3, and 3 hrs 
Moran et af. 1995 Amiodarone Magnesium 1,2,4, 12, and 24 hrs 
Sulfate 
Andrivet et af. 1993 Amiodarone Cibenzoline 24 hrs 
Contini et af. 1993 Amiodarone - 1, 12, and 24 hrs 
Strasberg et af. 1985 Amiodarone 
-
Individual pts data; 10 mins 
to 8 hrs 
Faniel et af. 1983 Amiodarone - Individual pts data; 10 mins 
to 13 hrs 
Crozier et af. 1987 Flecainide 
-
0-45 mins 
Nathan et af. 1987 Flecainide - 2-15 mins 
Goy et aJ. 1985 flecainide 
-
Individual pts data, 2mins 
to 26 hrs 
Suttorp et af. 1990 Flecainide Propafenone 1 hr 
Capucci et af. 1992 Flecainide Placebo 3, 8, 12, and 24 hrs 
Amiodarone 
Villani et af. 1990 Flecainide No treatment mean conversion time 
Capucci et af. 1994 Flecainide Propafenone 3, and 8 hrs 
Madrid et al. 1993 flecainide Procainamide 1 hr 
Borgeat et af. 1986 flecainide Quinidine 1,4, and 8.20 hrs 
Crijns et al. 1988 flecainide 
-
1,3, and 8 hrs 
Suttorp et af. 1989 flecainide Verapamil 1 hr 
Sung et af. 1995 Sotalol Placebo 30 mins, and 1 hr 
Jordaens et aJ. 1991 Sotalol Placebo 30 mins 
Hamer et aJ. 1993 Sotalol 
flecainide 
Verapamil 60, 65, 45, and 85 mins 
Denis et af. 1988 Sotalol 
- Individual pts data, 2min to 
26 hrs 
Levy et af. 1986 Sotalol Placebo Individual pts data, 5 min 
to 40 mins 
Teo et af. 1985 Sotalol 
- 1, and 24 hrs 
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Trial (Comparison group) 
Time interval (0-3 hrs) 
Villani et al 1990 
Donovan et al 1991 
Capucci et al 1992 
Capucci et al 1993 
Donovan et al1995 
Pooled OR Peto's (Fie vs Placebo) 
Time inten'al (up to 8 hrs) 
Villani et al 1990 
Donovan et al 1991 
Capucci et al 1992 
Capucci et al 1993 
Donovan et al1995 
Pooled OR (Fixed-effects model) 
Pooled OR (Random-effects model) 
Total CSR up to 24 hrs 
Villani et al 1990 
Favours Placebo Favours Flecainide 
.--l-' 
I 
• 
I " " I " I I I III 
0.1 1 10 100 1000 
OR (Log scale) 
Figure 5.1 OR of conversion success rates (CSR) in the flecainide treatment groups 
as compared to direct placebo groups in RCTs. The results are represented 
stratified into 3, 8, and 24 hour-intervals. 
Trial (Comparison group) 
Time interval (0-3 IITs) Favours Comparative drug Favours Flecainide 
Borgeat et al 1986 (Quinidine) 
Gavaghan et al1988 (Disopyrarnide+Digoxin) 
Suttorp et al 1989 (Verapamil) 
Wafa et al1989 (Verapamil+Digoxin) 
Suttorp et al 1990 (Propafenone) 
Capucci et al1992 (Amiodarone) 
Capucci et al 1993 (Propafenone) 
Hamer et al 1993 (Sotalol) 
Hamer et al1993 (Verapamil) 
Madrid et al 1993 (Procainamide) 
Donovan et al1995 (Amiodarone) 
Pooled OR Peto's (Fie vs Propafenone) 
Pooled OR Peto's (Fie vs Amiodarone) 
Pooled OR Peto's (Fie vs Verapamil) 
Pooled OR Peto's (FIe vs Class IA) 
Time interval (up to 8 Ilrs) 
Borgeat et al 1986 (Quinidine) 
Gavaghan et al 1988 (Disopyramide+Digoxin) 
Wafa et al1989 (Verapamil+Digoxin) 
Capucci et al 1992 (Amiodarone) 
Capucci et al 1993 (Propafenone) 
Donovan et al1995 (Amiodarone) 
Pooled OR Peto's (FIe vs Amiodarone, Fixed-effects 
Pooled OR Peto's (FIe vs Amiodarone, Random-effect 
Pooled OR Peto's (FIe vs Class IA) 
Total CSR up to 24 IIrs 
Borgeat et al 1986 (Quinidine) 
Gavaghan et al1988 (Disopyramide+Digoxin) 
Wafa et al1989 (Verapamil+Digoxin) 
Capucci et a11992 (Amiodarone) 
Pooled OR Peto's (FIe vs Class IA) 
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Figure 5.2 OR of conversion success rates (CSR) in flecainide treatment groups 
as compared to direct control groups in RCTs. The results are represented 
stratified into 3, 8, and 24 hour-intervals. 
Q statistic was significant (P=0.02). A possible explanation for the heterogeneity in the 
treatment effect is the employment of different routes of administration in the two 
studies. Donovan et al. (1995) trial compared intravenous flecainide versus intravenous 
amiodarone, while Capucci et al. (1992) compared single oral loading dose with the 
intravenous amiodarone. Comparison of flecainide with another Class III agent sotalol 
was performed in one trial, and there was no significant difference in outcome (OR, 1; 
95% CI; 0.12-8.7). Nevertheless, due to the crossover design, and the small sample 
size of the study, a definite conclusion regarding their relative efficacy could not be 
drawn. 
Pooling the data was possible at 3 hours for only two propafenone controlled trials, and 
it showed no significant difference in the conversion rate between the two Class IC 
drugs, although a positive trend was evident in favour of flecainide (as shown in Figure 
5.2; OR3 hrs, 1.73; 95% CI, 0.87 to 3.4; Z=1.6; and RD3 hrs, 14; 95% CI, -2.4 to 
30.4; Z=1.7). Comparing the results at 8 hours in Capucci et al. (1994) trial only, the 
insignificant rate difference was still present (ORg hrs, 1.4; 95% CI, 0.5-3.89, and RDg 
hrs, 6; 95% CI, -11.7-23.9; Z=0.7). 
Furthermore, the pooled estimate for flecainide in two verapamil controlled trials (of a 
total of 41 vs 26 patients) suggests highly significant efficacy for flecainide over oral or 
intravenous verapamil (OR3 hrs, 9.3; 95% CI, 3.5-25; Z=4.4; Q=0.7, P=NS). In fact, 
the very high significant difference between the two agents has confirmed that the use 
ofverapamil is of no proven value for acute conversion of AF (Pt, 63.6% vs 6%). In 
another RCT (Wafa et al., 1989), flecainide was even superior to the digoxin I 
verapamil combination in cardioversion efficacy up to 6 hrs (OR, 6.5; 95% CI, 1.5-
29). 
Three identified RCTs (Borgeat et al., 1986; Gavaghan et al., 1988; Madrid et al., 
1993) compared flecainide to three different Class IA antiarrhythmic agents (quinidine, 
disopyramide, and procainamide). The ORs of each individual trial were all highly 
statistically significant (P<O.OI) at three hours (OR3 hrs was 15.6, 4.1, and 5.5 
respectively). Pooling the data at this time point has also yielded a highly significant 
difference in favour of flecainide without significant evidence of heterogeneity (pooled 
OR3 hrs, 6.7; 95% CI, 3.7 to 12.6; Z=6 (P<O.OI); Q=3.2, df=2, P=0.2). However, 
by 8 as well as by 24 hours, there was no significant difference in individual and 
pooled estimates (ORg hrs, 1.5; 95% CI, 0.7-3.3; and OR24 hrs, 1.1; 95% CI, 0.5-2.7). 
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Table 5.6.1 Results of conversion success rate (CSR) in individual clinical trials (randomised and uncontrolled) of flccainide 
- ----
Trial No. of CSR at ::; 3 h; OR"et" CSR at::; 8 h ORreto CSR up to OR"et" 
patients (N) (95% CI) (N) (95% CI) 24 h (N) (95% CI) 
randomised 
(Rx/Con-
trol) 
Rx Control Rx Control Rx Control 
Goy et ill. 1985§ 50 20/50 - - 23150 - - 36/50 - -
Borgeat et ill. 19X6 30130Q 17/30 0130 15.6 (5-47.4) 20/30 18/30 1.33 (0.5-3.76) 20/30 18/30Q 1.3 (0.5-3.8) 
Crozier et ill. '987§ 50 38/50 - - - - - 38/50 -
-
Nathan et ill. 1987§ 21 11121 - - - - - 11/21 - -
Crijns et ill. (a) 1988§ 20 10120 - - 11120 - - 11120 - -
Crijns et ill. (b) 1988§ 20 13120 - - - - - 13/20 - -
Gavaghan et ill. 1988 29/27 Dig+D 19/29 8127 4.1 (1.5-12) 22129 17127 1.8 (0.59-5.6) 25/29 24127 Dig+D 0.8 (0.2-3.8) 
5ut\orp et aI. 1989 20120 V 23/35 1120 11.3 (3.6-33) - - - - - -
WafaetaI.1989 15/13 V+Dig 11/15 3112 6.5 (1.5-29) 13115 4112 9.1 (1.9-42.3) 14115 10114 V+Dig 4.4 (0.7-29.3) 
Su\torp et aI. 1990 25125 Pr 19125 13125 2.8 (0.9-9) 19125 13125 - - - -
Villani et aL 1990 19/18 PL 18/19 0118 40 (11-148) 18/19 0118 40 (11-148) 18/19 5118 PL 15.9 (4.3-59) 
Donovan et aI. 1991 51/51 PL+Dig 29/51 7151 6.5 (3-14.8) 34/51 18/51 3.5 (1.6-7.5) - - -
Capucci et aI. 1992 22119N21 PL 15122 3119A 7.97 (2.5-27) 20/22 7/19A 10.4 (2.9-37.5) 21122 17/19A 2.3 (0.3-24.3) 
6121 PL 4.7 (1.5-14.9) 10121 PL 7.4 (2-26.9) 10121 PL 10.2 (2.7-38) 
Capucci et aI. 1993 41143 Pr/61 PL 23/41 21143 Pr 1.3 (0.5-3) 33/41 32143 Pr 1.4 (0.5-3.9) 
- - -
8/61 PL 7.5 (3.3-18) 17161 PL 8 (3.7-17.7) 
Hamer et aL 1993 6/6516 V 3/6 3/6 S I (0.12-8.7) . - - - -
-
116 V 4 (0.4-39.4) 
Madrid et aI. 1993 40/40 Pre 37/40 25/40 5.47 (1.9-15.5) -
- - - - -
Donovan et aI. 1995 34132 N32 PL 20134 13/32 A 2.1 (0.8-5.34) 23/34 19/32 A 1.4 (0.5-3.9) - - -
8/32 PL 3.9 (1.5- 10.3) 18/32 PL 1.6 (0.6-4) 
Pooled tates (%) in Refs; (95% Cl) 69.3% (59-79.5) Others#; 25% 79.3% Others#; 58.6% 85.5% Others#; 92.7% 
(19.4-30.6) (71.5-86.7) (51.4-65.9) (76-95) (78.5-95) 
PL; 16.3% PL; 37.3% 
(10.7-21.8) (30-44.5) 
Pooled tates (%) in Uncont; (95% CI) 58.9% (5 I. 7-66.2) 
-
61.3% 
-
68.7% 
(54.1-68.6) (61.7-75.7) 
Pooled OR 7.2 5.5 
-(AevsPL) 
95% CI for the OR 4.7-11.12 3.6-8.4 
-
ZIP) 8.9*· 7.85" 
-
Q statistic (P) 9.1 (0.06) NS 17.8* (0.0014) 
-
-
CSR; conversion success rate = no. of patients converted to sinus rhythm I no. of patients at risk at the beginning of the interval; §, uncontrolled trials (Uncont); FIe, Flecainide; PL, Placebo; #, including other 
antiarrhythmic drugs; A, Amiodarone; Dig, Digoxin; D, Disopyramide; Pr, Propafenone; Pre, Procainamide; Q, Quinidine; S, Sotalol; V, Verapamil; * statistically significant (P<O.05); ** highly statistically 
significant (P<O.O I) 
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From this analysis, it can be concluded that flecainide is more effective than a Class IA 
drug for prompt cardioversion, particularly in the first few hours. 
The percentage of patients converted to sinus rhythm with flecainide in the individual 
RCTs varied between 65.4% to 75.1 % at 3 hrs (with a weighted pooled percentage, 
Pt= 70.2%), and between 74.95% and 83.7% at 8 hrs (with P t= 79.3%). These 
estimates were not significantly different from corresponding estimates in the 
uncontrolled trials (Pt=58.9%; 95% CI, 51.7-66.2, and Pt=61.3%; 95% CI, 54-68.6, 
at 3 and 8 hrs respectively). 
Subgroup Analyses of Flecainide RCTs 
Figure 5.7 and Table 7.a of Appendix 5.2 display the stratified analysis of flecainide 
direct comparisons in RCTs. The subanalysis according to cause, onset of the 
arrhythmia, and route of administration did not show any change in the previous 
conclusions. Noteworthy, flecainide demonstrated very limited value for conversion of 
AFL compared to AF; the RD compared to verapamil and propafenone was 0, and -20 
(95% CI, -75 to 35) respectively. 
Amiodarone Clinical Trials 
Figure 5.3 displays the individual and pooled ORs for conversion efficacy versus 
placebo. The analysis was performed first by pooling the data from the three placebo-
controlled trials at 3 and 8 hour intervals, which has demonstrated nonsignificant 
difference from placebo (OR3 hrs, 1.3; 95% CI, 0.7-2.4; Q=2.4, df=2, P=0.3; and ORs 
hrs, 1.034; 95% CI, 0.6-1.8; Q=0.7, df=2, P=0.7). A second sensitivity analysis was 
later undertaken by excluding Galve et ai. (1996) trial, in which intravenous digoxin 
was given to both amiodarone and placebo arms. The later analysis did not alter the 
conclusion. Data at 24 hours was available only in one trial (Galve et al., 1996), and 
again it was statistically nonsignificant (OR, 1.3; 95% CI, 0.6-2.8). 
Direct head to head comparisons to other antiarrhythmic agents in different classes are 
displayed in Figure 5.4 and Table 5.6.2. At 3 hours amiodarone had displayed 
conversion efficacy which was only superior to digoxin (pooled OR3 hrs, 2.04; 95% 
CI, 1.1-3.9; Q=3.2, P=0.2), and to verapamil in one trial of a total of 24 patients (OR3 
hrs, 12; 95% CI, 3.3-44). Nevertheless, no significant difference in the conversion rate 
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Trial (Comparison group) Favours Placebo Favours Amiodarone 
Time interval (0-3 hrs) 
Capucci et III 1992 ¥ 
• 
Donovan et III 1995 3 . 
Galve et III 1996 
• 
Pooled OR ~ 
· 
Pooled OR (excluding Galve et III, 1996) ~ 
· 
Time inten'al (3-8 hrs) 
Capucci et aI 1992 -'-. 
Donovan et III 1995 I. I" 
Galve et III 1996 I~ I" 
Pooled OR 
Pooled OR (excluding Galve et aI, 1996) 1 
Total CSR up to 24 hrs 
Glllve et III 1996 , 
• 
0.01 0.1 10 
OR (Log scale) 
Figure 5.3 OR of conversion success rates (CSR) in the amiodarone 
treatment groups as compared to direct placebo groups in RCTs. The 
results are represented stratified into 3, 8, 24 hour-interval. 
Trial (Comparison group) 
Favours Comparative drug Favours Amiodarone 
Time interval (0-3 hrs) 
Cochrane et al 1994 (Digoxin) 
Hou et all99S (Digoxin) 
Galve et 01 1996 (Digoxin+Pla<ebo) 
Pooled OR (Am YO Digoxin) 
Posada et al1988 (Quinidine) 
McAlisler et al1990 (Quinidine) 
Cesar et all994 (Quinidine) 
Pooled OR (Am VI Quinidine) 
Chapman et all993 (Procainamide) 
Cesar et all994 (Procainamide) 
Pooled OR (Am YO Procainamide) 
Bertini ct 01 1990 (Prop'fenone) 
Biasi et 01 1995 (Propafenone) 
Larbuisson ct all9% (Propafenone) 
Pooled OR (Am vs Propafenone) 
C,pucci el all992 (FIecainide) 
Donovan ct all99S (FIecainide) 
Pooled OR (Am VI Aecainide) 
Noc ct al1990 (Verapamil) 
Moran et all99S (Mg Sulfale) 
Time inten'al (up to 8 hrs) 
Posada et al1988 (Quinidine) 
McAlisler et 01 1990 (Quinidine) 
Bertini et 011990 (Prop,fenone) 
Treglia et 01 1994 (Propafenone) 
Larbuisson et al 1996 (Propafenone) 
Pooled OR (Am vs Propafenone) 
Capucci et all992 (FIecainide) 
Donovan et all99S (FIecainide) 
Pooled OR (Am vs Aecainide) 
Cochrane et all994 (Digoxin) 
Hou et all99S (Digoxin) 
Galve et all996 (P1acebo+Digoxin) 
Pooled OR (Am vs Digoxin) 
Moran ct 01 1995 (Mg Sulfate) 
Total CSR up to 24 hrs 
Capucci ct all992 (FIecainide) 
Andrivel el all993 (Cibenzoline) 
Bellandi et all993 (Prop.fenone) 
Chapman ct all993 (Procainamide) 
Biasi et all99S (Propafenone) 
Larbuisson et all996 (Prop,fenone) 
Pooled OR (Am VI Propafenone) 
Cochrane et al 1994 (Digoxin) 
Hou el all99S (Digoxin) 
Galve ct 01 19% (Digoxin + Placebo) 
Pooled OR (Am VI Digoxin) 
Moran et all99S (Mg Sulfate) 
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Figure 5.4 OR of conversion success rates (CSR) in amiodarone treatment groups as 
compared to direct control groups in RCTs. The results are represented stratified into 
3, 8, and 24 hour-intervals. 
Table 5.6.2 Results of conversion success rate in individual clinical trials (randomised and uncontrolled) of Amiodarone 
Trial No, of CSR at ~ 3 h; ORI'"'' (:SR at ~ !I h ORI'"I .. eSR up to 24 ORI'"I .. 
patients (N) (95% el) (N) (95% CI) h (N) (95% el) 
randomised 
(Rx/Con-
t rol) 
Rx Control Rx Control Rx Control 
Faniel ", al. 19X3§ 26 14/26 - - 18126 - - 19126 - -
Strasberg el al. 1985§ 26 16/26 -
-
- - - - - -
Posada el al. 19X8 14 Q+Af22 Q 5/14 4/22 2.5 (0.5-11.4) 6/14 12122 0.64 (0.17-2.4) - - -
Bertini el al. 1990 15/24 Pr 6/15 21124 0.1 (0.03-0.5) 6/15 21/24 0.11 (0.03-0.5) - - -
Andrivet et al. 1993 21125 C - - - - - - 15/21 18125 e 0.97 (0.3-3.5) 
Noc el al. 1990 24/14 V 17124 1/14 12 (3.3-44) - - - - - -
McAlister el al. 1990 53/63 Q 13/53 10163 1.72 (0.7-4.3) 22/53 37/63 0.5 (0.24-1.05) - - -
eapucci el al. 1992 19/22 FI2I PL 3/19 15/22 F 0.13 (0.04-0.4) 7119 20/22 F 0.1 (0.03-0.34) 17119 21122 F 0.4 (0.04-4.3) 
6/21 PL 2 (0.7-5.7) 10121 PL 0.65 (0.19-2.3) 10/21 PL 6.4 (1.7-23.8) 
Bellandi el al. 1993 98/98 Pr - - - - - - 79/98 89/98 Pr 0.4 (0.2-0.97) 
Chapman elal. 1993 10/14 Pre 5/10 7/14 1 (0.2-4.9) - - - 7/10 10114 0.94 (0.2-5.4) 
Contini el aL 1993§ 61 33/61 - . . - - 47/61 - · 
Cesar el 01. 1994 16121 P/23 Q 8116 11123 P 1.1 (0.3-3.8) 
-
. . 
-
. 
-15121 Q 0.4 (0.11-1.6) 
Cochrane el aI. 1994 15115 Dig 4115 3/15 1.4 (0.3-7.6) 9/15 9115 I (0.24-4.22) 13/15 12115 Dig 1.6 (0.3-10.5) 
Treglia el aI. 1994 27/27 Pr 0127 0127 - 3127 13127 -1.7 (0.05-0.6) 13127 18127 0.8 (0.3-2.7) 
Biasi el 01. 1995 46/38 Pr 9/46 17/38 0.3 (0. H).8) 
- - -
38/46 26/38 Pr 2.2 (0.8-5.9) 
Donovan elal. 1995 32134 F/32 PL 13/32 8132 PL 0.5 (0.11-2.1) 19/32 18/32 PL 1.1 (0.4-3.04) -
- -
20134 F 0.5 (0.2-1.3) 23/34 F 0.7 (0.3-1.9) 
Hou el aI. 1995 26/24 Dig 14126 4124 4.9 (1.6-15.3) 19126 10124 3.5 (1.2-10.8) 24126 17124 4.2 (1-17.4) 
Moran el aL 1995 21121 M 6121 7121 0.8 (0.2-2.9) 7121 10121 0.6 (0.2-1.89) 7121 14121 M 0.3 (0.08-0.89) 
Galve el aI. 1996 5<V50 PL+Dig 15150 12150 1.3 (0.56-3.3) 26/50 24/50 1.2 (0.54-2.6) 28/50 25150 1.3 (0.58-2.8) 
Larbuisson el aL 1996 22118 Pr 4122 8118 0.3 (0.01-1.1) 12122 10118 0.96 (0.28-3.3) 17122 12118 1.7 (0.4-6.7) 
Pooled rates (%) in RCTs; (95% ell 32.5% (21.5-43.5) PL; 26.3% 45.5% (33.5-57.6) PL; 52.9% 75.3% (65.7-84.9) PL; 16.3% 
(14.5-38.2) (39.5-66.3) (10.7-21.8) 
Pooled rales (%) in Uncont; (95% el) 55.8% (46.7-64.9) - 62.8% (54-71.6) - 75.3% (67.4-83.3) 
Pooled OR (A vs PL) 1.3 1.034 
· 
95% CI for the OR 0.71-2.4 0.6-1.8 
· 
Z(P) 0.85 NS 0.12 NS 
-
Q statistic (P) 2.4 (0.3) 0.7 (0.7) 
-
--
eSR; conversion success rate = no. of patients converted to sinus rhythm I no. of patients at risk at the beginning of the interval; §. uncontrolled trials (Uncont); Fie. Flecainide; PL. Placebo; #. including other antiarrhythmic drugs; A. Amiodarone' Dig 
Digoxin; D. Disopyramide; Pr. Propafenone; Q. Quinidine; S. Sotalol; V. Verapamil; • statistically significant (P<O.05); •• highly statistically significant (P<O.Ol) • • 
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between amiodarone and digoxin was noted after pooling the data at 8, and at the end of 
the 24 hour-interval (pooled ORs hrs, 1.6; 95% CI, 0.9-2.8; Q=2.97, P=0.2; and 
pooled OR24 hrs, 1.7; 95% CI, 0.87-3.2; Q=2, P=O.4). 
Pooling the data from two Class IA agents trials (4 RCTs; 2 vs quinidine, and 2 vs 
procainamide) did not reveal significant difference in the rapidity of action. The pooled 
OR3 hrs versus quinidine was 1.3 (95% CI, 0.6-2.6) and versus procainamide was 1.1 
(95% CI, 0.4-2.8). In addition, the results of another trial of 10 hour duration (Posada 
et ai., 1988), which compared oral quinidine plus intravenous amiodarone combination 
to oral quinidine only, did not show significant increase in the number of patients 
converted, or even a significant decrease in the time required for cardioversion (OR3 
hrs, 2.5; 95% CI, 0.5-11.4; and ORs hrs, 0.64; 95% CI, 0.17-2.4). 
However, pooling data from two Class IC agents (4 RCTs; 2 vs flecainide, and 2 vs 
propafenone) has demonstrated a highly significant difference in favour of Class IC, 
particularly at 3 hours. The pooled OR3 hrs versus flecainide was 0.3 (95% CI, 0.14-
0.6) and versus propafenone was 0.24 (95% CI, 0.13-0.5). 
It is clear from our present meta-analysis (particularly the three placebo-controlled 
trials), that although intravenous amiodarone is widely used in Europe for emergency 
conversion of SV As to sinus rhythm, it is not effective for prompt effect, and thus it is 
of no value for this indication. Surprisingly, the results of uncontrolled trials (4 trials; 
Faniel et ai., 1983; Strasberg et ai., 1985; Contini et ai., 1993; Vietti-Ramus et ai., 
1992) have concluded very high efficacy of intravenous amiodarone in all recently 
occurring SVAs (at 3 hrs: Pt=55.8%; 95% CI, 46.7-64.9; at 8 hrs: Pt=62.8%; 95% CI, 
54-71.6; at 24 hrs: 75.3%; 95% CI, 67.4-83.3). These estimates were significantly 
different from corresponding estimates in amiodarone RCTs (2=3.4, P<O.OI), but not 
from those obtained in uncontrolled trials of flecainide (2=0.4, P>0.05). However, 
results from uncontrolled trials should be interpreted with caution due to unavailability 
of any control group. 
Subgroup Anaiyses of Amiodarone RCTs 
Figure 5.8 and Table 7.b of Appendix 5.2 display the stratified analysis of RCTs in 
which amiodarone was directly compared to placebo or other antiarrhythmic drugs. 
This subanalysis did not alter the previous conclusions. 
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Sotalol Clinical Trials 
Table 5.6.3, Figure 5.5, and Figure 5.6 display the individual and pooled ORs for 
conversion efficacy from sotalol RCTs. All individual ORs for intravenous sotalol 
versus placebo were highly significant and ranged between 6.04 and 14.3 (Figure 5.5). 
The pooled OR at 1 hour was 8.8 (95% CI, 4.7-16.5; Z=6.8; Q=1.53, P=0.5). 
Direct head to head comparison of sotalol to other active drugs was only available in 
four trials (Figure 5.6). However, due to different control groups, pooling was 
initially not justified. Intravenous sotalol was superior to intravenous combination of 
digoxin plus disopyramide for up to 2 hours (Campbell et al., 1985), displaying a more 
prompt effect. The individual ORs at 1 and 2 hours were 4 (95% CI, 1.2-13.9; Z, 2.2, 
P=0.03), and 4.8 (95% CI, 1.4-16.2; Z, 2.4, P=0.008) respectively. However, the 
individual OR of this trial did not reach the level of statistical significance at 3 hours 
(OR3 hrs, 2.8; 95% CI, 0.8-10). In another trial (Halinen et al., 1995) of oral 
intervention, quinidine plus digoxin combination was superior to oral sotalol with 
regard to the time required for conversion (OR3 hrs, 0.3; 95% CI, 0.1-0.9), as well as 
the total efficacy rate (OR24 hrs, 0.47, 95% CI, 0.1-2.4). An attempt for pooling the 
data from the previous two Class IA controlled trials was made (OR3 hrs, 0.8; 95% CI, 
0.34-1.9), nevertheless the results were heterogenous (Q=7.1, P<O.Ol). The most 
probable explanation is the employment of different routes of administration. 
Consequently, the results of this pooling was neglected. 
Comparison of sotalol to another beta-blocker, metoprolol, has shown superior effect 
in favour of the former, particularly at 3 hours (Figure 5.6). 
Subgroup Analyses of Sotalol RCTs 
Figure 5.9 and Table 7.c of Appendix 5.2 display the stratified analysis of sotalol's 
direct comparisons in RCTs. This subanalysis, according to the type of SV As, 
showed very high efficacy rate for the drug for termination of PSVT (pooled RD3 hrs, 
58.5; 95% CI, 32.9-84) and AF (pooled RD3 hrs, 26.4; 95% CI, 5.9-46.9, Z=2.5), as 
compared to placebo. However, it was not effective for AFL (pooled RD3hrs, 12.97; 
95% CI, -22.2-48.1, Z=0.7). 
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Trial 
Favours Placebo Favours Sotalol 
Time interval (0-3 hrs) 
Levy et al 1986 
lordaens et al 1991 
Sung et al 1995 
Pooled OR (Sot vs Placebo) 
0.1 1 10 100 
OR (Log scale) 
Figure 5.5 Pooled OR of conversion success rates (CSR) in the 
Sotalol treatment groups as compared to direct placebo groups in 
RCTs. The results are represented at 3 hours only. 
Trial (Comparison group) Favours Comparative drug Favours Sotalol 
Time interval (0-1 hrs) 
Campbell et al1985 (Disopyramide+Digoxin) 
• 
, 
Halinen et al1995 (Quinidine+Digoxin) . 
Time interval (0-2 hrs) 
Campbell et al1985 (Disopyramide+Digoxin) , 
• 
Halinen et al1995 (Quinidine+Digoxin) 
• 
Time interval (0-3 hrs) 
Campbell et al1985 (Disopyrarnide+Digoxin) 
Janssen et al 1986 (Metoprolol) ~ 
Hamer et al1993a (Flecainide) 
Hamer et al1993b (Verapamil) 
Halinen et al1995 (Quinidine+Digoxin) I 
Time interval (up to 8 hrs) 
Campbell et al1985 (Disopyrarnide+Digoxin) I. 
Janssen et al 1986 (Metoprolol) 
Halinen et al 1995 (Quinidine+ Digoxin) 
• 
, 
Total CSR up to 24 hrs 
Campbell et al 1985 (Disopyramide+Digoxin) 
Janssen et al1986 (Metoprolol) • 
Halinen et a\ 1995 (Quinidine+Digoxin) ..-----t----
"" .,," 
0.001 0.01 0.1 10 100 1000 
OR (Log scale) 
Figure 5.6 OR of conversion success rates (CSR) in sotalol treatment groups as 
compared to direct control groups in RCTs. The results are represented stratified into 3, 
8, and 24 hour-intervals. 
Table 5.6.3 Results of conversion success rate in individual clinical trials (randomised and uncontrolled) of Sotalol 
Trial No. of patients CSR at :S 3 h; o Rpeto CSR at :S 8 h ORpeto CSR at :S 24 h ORpeto 
randomised (N) (95% CI) (N) (95% CI) (N) (95% CI) 
(Rx/Control) 
Rx Control Rx Control Rx Control 
Campbell etal. 1985 20120D+Dig 15120 10/20 2.83 (0.8-10) 17/20 16120 1.4 (0.28-7.02) 17/20 17/20 D+Dig 1(0.2-5.6) 
Teo el al. 1985§ 29 16129 - - - - - 19129 - . 
Levy et al. 1986 23123 PL 7123 0123 10.1 (2-49.4) - - - - - -
Janssen et al. 1986 11/4MT 8/11 014 15.3 (1.7-140) 10/11 214 10.9 (0.7-172.5) 10111 414MT 0.26 (OJXl3-21.5) 
Denis et aI. 1988§ 20 8/20 - - - - - - - -
Jordaens et al. 1991 36122 PL 29/36 3122 14.3 (5-41) - - - - - -
Hamer et al. 1993 6/6 Fl6 V 3/6 3/6 F I (0.1-8.7) - - - - - -
1/6 V 3.96 (0.4-39.4) 
Halinen et al. 1995 33128Q+Dig 4133 10128 0.3 (0.1-0.9) 8/33 20128 0.15 (0.01-0.4) 16/33 24128Q+Dig 0.2 (0.07-0.6) 
Sung el al. 1995 64128 PL 38/64 4128 6.04 (2.5-14.6) - - - - - -
Pooled rates (%) in Refs; 49.6% (43.7-55.5) Others#; 38.2% 75.3% Others#; 65.2% 67.6% (61.6-73.7) Others#; 72.7% 
(95%CI) (26-50) (65.7-84.9) (54.7-75.8) (61.3-84) 
PL; 14% (4.4-23.6) 
Pooled rates (%) in Uncont; 48.9% (35-62.7) - 48.9% (35-62.7) - 55.5% (42-68.9) -
(95%CI) 
Pooled OR 8.8 
- -(S YS PL) 
95% CI for the OR 4.7-16.5 
- -
ZIP) 6.8" 
- -
Q statistic (P) 1.53 (0.5) NS . . 
Pooled OR 1.32 0.77 0.62 
(S YS others#) 
95% CI for the OR 0.64-2.7 0.43-1.4 0.4-1.1 
ZIP) 0.75 (0.05) NS -0.9 (0.4) NS -1.8 (0.072) NS 
Q statistic (P) 13.9 (0.001)** 3.02 (0.22) NS 3.24 (0.2) NS 
CSR; conversion success rate = no. of patients converted to sinus rhythm I no. of patients at risk at the beginning of the interval; §, uncontrolled trials (Uncont); Fie, Flecainide; PL, Placebo; #, including other 
antiarrhythmic drugs; A, Amiodarone; Dig, Digoxin; D, Disopyramide; Pr, Propafenone; Q, Quinidine; S, Sotalol; V, Verapamil; * statistically significant (P<O.05); ** highly statistically significant (P<O.OI) 
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Type of comparison Favours Comparator 
(c) Route of administration 
ii. Versus placebo 
IV route only (0-3 hrs, 2) 
IV route only (3-8 hrs, 2) 
Orally (0-3 hrs, 3) 
Orally (3-8 hrs, 3) 
Orally (8-24 hrs, 3) 
ii. Versus others 
l.Versus Amiodarone 
IV route only (0-3 hrs, 1) 
IV route only (3-8 hrs, 1) 
Orally (0-3 hrs, 1) 
Orally (3-8 hrs, 1) 
Orally (8-24 hrs, 1) 
2. Versus Quinidine 
IV +Orally (0-3 hrs, 1) 
IV +Orally (3-8 hrs, 1) 
3. Versus Verapamil 
IV only (0-3 hrs, 1) 
Orally (0-3 hrs, 1) 
4. Versus Propafenone 
IV only (0-3 hrs, 1) 
Orally (0-3 hrs, 1) 
Orally (3-8 hrs, 1) 
(d) Onset (duration) of a"hythmia 
i. Versus placebo 
> 24 hrs (0-3 hrs, 1) 
> 24 hrs (3-8 hrs, 1) 
< 24 hrs (0-3 hrs, 2) 
< 24 hrs (3-8 hrs, 2) 
ii. Versus others (all) 
> 24 hrs (0-3 hrs, 7) 
> 24 hrs (3-8 hrs, 7) 
> 24 hrs (8-24 hrs, 7) 
< 24 hrs (0-3 hrs, 3) 
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Figure 5.7 Summary of subgroup analyses of Flecainide RCTs (continued). 
The dark points represent the pooled estimates of subgroups' RDs and bars 
represent the 95% CI. Time intervals and number of trials in each subgroup are 
shown in brackets. 
Type of comparison 
(a) Type of arrhythmia 
i. Versus placebo 
AF (0-3 hrs, 3) 
AF (3-8 hrs, 3) 
AF (8-24 hrs, I) 
ii. Versus others 
l. Versus Digoxin 
AF (0-24 hrs, 3) 
AFL (0-24 hrs, I) 
2. Versus Quinidine 
AF(O-l hr, I) 
3. Versus Procainamide 
AF (0-24 hrs, I) 
AFL (0-24 hrs, I) 
psvr (0-24 hrs, 1) 
4. Versus Propafenone 
AF (0-3 hrs, 2) 
AF (3-8 hrs, 2) 
AFL or AFL (0-3 hrs, 2) 
AFL or AFL (3-8 hrs, 2) 
AFL or AFL (8-24 hrs, 2) 
s. Versus Flecainide 
AF (0-3 hrs, 2) 
AF (3-8 hrs, 2) 
AF (8-24 hrs, 1) 
(b) Cause of arrhythmia 
i. Versus placebo 
Cardiac surgery group (0 trials) 
Noncardiac surgery (medical) group (0-3 hrs, I) 
Noncardiac surgery (medical) group (3-8 hrs, 1) 
ii. Versus others 
1. Versus Digoxin 
Cardiac surgery group (0-3 hrs, 1) 
Cardiac surgery group (3-8 hrs, 1) 
Cardiac surgery group (8-24 hrs, 1) 
2. Versus Quinidine 
Noncardiac surgery (medical) group (0-3 hrs, 1) 
3. Versus Procainamide 
Noncardiac surgery (medical) group (0-3 hrs, 1) 
4. Versus Propafenone 
Cardiac surgery group (0-3 hrs, 2) 
Cardiac surgery group (3-8 hrs, 2) 
Noncardiac surgery (medical) group (0-3 hrs, 2) 
Noncardiac surgery (medical) group (3-8 hrs, 2) 
Noncardiac surgery (medical) group (8-24 hrs, 2) 
S. Versus flecainide 
Noncardiac surgery (medical) group (0-3 hrs, 1) 
Noncardiac surgery (medical) group (3-8 hrs, 1) 
Noncardiac surgery (medical) group (8-24 hrs, 1) 
Favours Comparator Favours Amiodarone 
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Figure 5.8 Summary of subgroup analyses of amiodarone RCTs. The dark 
points represent the pooled estimates of subgroups' RDs and bars represent the 
95% CI. Time intervals and number of trials in each subgroup are shown in 
brackets. 
Type of comparison 
(c) Route of administration 
i. Versus Placebo 
IV route only (0-3 hrs, 2) 
IV route only (3-8 hrs, 2) 
IV route only (8-24 hrs, I) 
Orally (0-3 hrs, I) 
Orally (3-8 hrs, I) 
ii. Versus others 
Versus F1ecainide 
IV route only (0-3 hrs, I) 
IV route only (3-8 hrs, I) 
Orally (0-3 hrs, 1) 
Orally (3-8 hrs, 1) 
Orally (8-24 hrs, 1) 
{. (d) Onset (duration) of a"hythmi 
i. Versus placebo 
> 48 hours (0-3 hrs, 1) 
> 48 hours (3-8 hrs, 1) 
< 48 hrs (0-3 hrs, 1) 
< 48 hrs (3-8 hrs, 1) 
ii. Versus others 
I. Versus Digoxin 
> 48 hours (0-3 hrs, 1) 
> 48 hours (3-8 hrs, 1) 
> 48 hours (8-24 hrs, 1) 
< 48 hrs (0-3 hrs, 1) 
< 48 hrs (3-8 hrs, 1) 
< 48 hrs (8-24 hrs, 1) 
2. Versus Propafenone 
> 48 hours (0-24 hrs, 1) 
< 48 hrs (0-3 hrs, 2) 
< 48 hrs (3-8 hrs, 2) 
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Figure 5.8 Summary of subgroup analyses of amiodarone RCTs 
(continued). The dark points represent the pooled estimates of subgroups' 
RDs and bars represent the 95% CI. Time intervals and number of trials in each 
subgroup are shown in brackets. 
Type of comparison 
(a) Type of arrhythmia 
i. Venus placebo 
AF (0-3 hrs, 2) 
AFL (0-3 hrs, 2) 
PSVT (0-3 hrs, 3) 
ii. Versus others 
AF (0-3 hrs) 
1. Venus Disopyramide+Digoxin (1) 
2. Venus Metoprolol (I) 
3. Versus Quinidine+Digoxin (I) 
AF (3-8 hrs) 
1. Venus Disopyramide+Digoxin (I) 
2. Venus Metoprolol (I) 
3. Versus Quinidine+Digoxin (I) 
AF (8-24 hrs) 
1. Versus Disopyramide+ Digoxin (\) 
2. Venus Metoprolol (I) 
3. Versus Quinidine+Digoxin (I) 
AFL (0-3 hrs) 
1. Versus Digoxin+Disopyramide (\) 
PSVT (0-3 hrs) 
1. Venus Flecainide (I) 
1. Versus Verapamil (\) 
(b) Cause of arrhythmia 
i. Venus placebo 
Cardiac surgery (0 trials) 
Noncardiac surgery (medical) group (0-3 hrs,3) 
ii. Versus others 
Cardiac surgery group (0-3 hrs) 
1. Versus Disopyramide+Digoxin (I) 
2. Venus Metoprolol (I) 
Cardiac surgery group (3-8 hrs) 
1. Versus Disopyramide+ Digoxin (\ ) 
2. Versus Metoprolol (\) 
Cardiac surgery group (8-24 hrs) 
1. Venus Disopyramide+ Digoxin (I) 
2. Versus Metoprolol (\) 
Noncardiac surgery (medical) group (0-3 hrs) 
1. Venus Flecainide (I) 
2. Versus Verapamil (I) 
3. Venus Quinidine+Digoxin (I) 
Noncardiac surgery (medical) group (3-8 hrs, 3) 
1. Versus Flecainide (1) 
2. Versus Verapamil (1) 
3. Venus Quinidine+Digoxin (1) 
Noncardiac surgery (medical) group (8-24 hrs, 3) 
1. Versus Hecainide (I) 
2. Versus Verapamil (1) 
3. Versus Quinidine+Digoxin (\) 
Favours Comparator Favours Sotalol 
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Figure 5.9 Summary of subgroup analyses of sotalol RCTs. The dark 
points represent the pooled estimates of subgroups' RDs and bars represent the 
95% CI. Time intervals and number of trials in each subgroup are shown in 
brackets. 
Type of comparison 
(c) Route of administration 
i. Versus placebo 
IV route only (0-3 hrs, 3) 
Orally (0-3 hrs, 0 trials) 
ii. Versus others 
IV route only (0-3 hrs, 1) 
1. Versus Disopyrarnide+Digoxin 
IV route only (3-8 hrs, 1) 
1. Versus Disopyrarnide+Digoxin 
IV route only (8-24 hrs, 1) 
1. Versus Disopyrarnide+Digoxin 
Orally (0-3 hrs, 3) 
1. Versus Metoprolol (1) 
1. Versus Flecainide (1) 
2. Versus Veraparnil (1) 
3. Versus Quinidine+Digoxin (1) 
Orally (3-8 hrs, 3) 
I. Versus Metoprolol (I) 
I. Versus Flecainide (1) 
2. Versus Veraparnil (1) 
3. Versus Quinidine+Digoxin (1) 
Orally (8-24 hrs, 3) 
I. Versus Metoprolol (1) 
I. Versus Flecainide (1) 
2. Versus Veraparnil (1) 
3. Versus Quinidine+Digoxin (I) 
(d) Onset (duration) of arrhythmia 
i. Versus placebo 
< 24 hours (0-3 hrs, 3) 
> 24 hours (0-3 hrs, 0 trials) 
ii. Versus others 
< 24 hours (0-3 hrs, 3) 
I. Versus Metoprolol (1) 
I. Versus Flecainide (1) 
2. Versus Veraparnil (1) 
3. Versus Quinidine+Digoxin (1) 
< 24 hours (3-8 hrs, 3) 
1. Versus Metoprolol (1) 
I. Versus Flecainide (1) 
2. Versus Veraparnil (1) 
3. Versus Quinidine+Digoxin (1) 
< 24 hours (8-24 hrs, 3) 
I. Versus Metoprolol (1) 
1. Versus Flecainide (1) 
2. Versus Verapamil (I) 
3. Versus Quinidine+Digoxin (1) 
> 24 hours (0-3 hrs, 1) 
1. Versus Disopyramide+Digoxin 
> 24 hours (3-8 hrs, 1) 
I. Versus Disopyrarnide+Digoxin 
> 24 hours (8-24 hrs, 1) 
1. Versus Disopyramide+Digoxin 
Favours Comparator Favours Sotalol 
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Figure 5.9 Summary of subgroup analyses of sotalol RCTs (continued). The dark 
points represent the pooled estimates of subgroups' RDs and bars represent the 95% 
CI. Time intervals and number of trials in each subgroup are shown in brackets. 
5.4.3.1.2 Indirect Comparisons 
Tables 5.7.1 and 5.7.2 show the weighted pooled percentages of patients converted to 
sinus rhythm in all treatment arms at any available time point using fixed and random-
effects models respectively. Figure 5.10.1 displays the indirect comparison between 
the three drugs and placebo up to one hour, which has shown superior effect for 
flecainide over the other two drugs and placebo under the fixed-effects model. 
However, underthe random-effects model (Figure 5.10.2) sotalol and flecainide were 
equally effective, and amiodarone was more effective than placebo. The same results 
were obtained at 10 hours after commencement of treatment (Figure 5.11). At 24 
hours, all the drugs were equally effective and superior to placebo (Figure 5.12). 
The indirect comparisons stratified by the route of administration has demonstrated 
equal efficacy of intravenous flecainide and sotalol at 3,8, and 24 hours (Figure 5.13). 
In addition, they demonstrated the very low efficacy of intravenous arniodarone (Figure 
5.13). However, oral flecainide was more effective than oral sotalol at all the time 
points (Figure 5.14). 
5.4.3.2 Mean Conversion Time 
The mean conversion time with its standard error or standard deviation was reported in 
22 trials: 10 for flecainide (Goy et al., 1985; Borgeat et al., 1986; Crijns et al., 1988; 
Suttorp et al., 1989; Suttorp et al., 1990; Villani et al., 1990; Donovan et al., 1991; 
Capucci et al., 1992; Capucci et al., 1993; Madrid et al., 1993), 7 for amiodarone 
(Posada et al., 1988; McAlister et al., 1990; Bellandi et al., 1993; Cesar et ai., 1994; 
Treglia et ai., 1994; Donovan et ai., 1995; Galve et al., 1996), and 5 for sotalol 
(Campbell et al., 1985; Levy et ai., 1986; Janssen et al., 1986; Denis et al., 1988; 
Halinen et al., 1995). The pooled means of conversion time for flecainide, 
amiodarone, and sotalol were 120.6±11.3, 315.6±33.3, and 27.2±5.3 minutes 
respectively, thus, indicating more rapid effect for sotalol. 
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Table 5.7.1 Weighted pooled percentages in different treatment groups in RCTs included in meta-analysis calculated using fixed-effects model 
Time iI/lerval I PT. I'lacelm (SE) PT. F1ecai"ide Pr. Qui"idi"e PT. Sola/ol (.'IE) PT. AlIli(~daro"e I PT. I'ro~}~re"Olle I'T. Q+A (.'IE) Pr. 1J+lJi~ (.'IE) Pr. ~'RRA (.'IE) 
(.'IE) (.'IE) (S/~) (Sl~) 
0-2lllins 0 1.6 (0.6) 0 0 I () 0 0 0 I 0 
2-5 mins 0 1.79 (0.6) 0 1.5 (0.8) I 0 0 0 0 0 
6 mins 0 1.79845 (0.6) 0 1.5 (08) 0 0 0 0 0 
7 mins 0 1.81 (0.6014) 0 1.5 (0.8) 0 0 0 0 0 
10 mins 0 1.89237 (0.61) 0 1.544 (0.78) 1.4484(5.95) 0 0 0 0 
12 mins 0 1.89237 (0.61) 0 1.5598 (0.78) 1.44845 (5.95) 0 0 0 0 
13 mins 0 1.89237 (0.61) 0 1.5598 (0.78) 1.46986 (0.598) 0 0 0 0 
15 mins 0 1.983 (0.61) 0 1.59997 (0.79) 1.46986 (0.598) 0 0 0 0 
16mins 0 1.983 (0.61) 0 1.6 (0.79) 1.46986 (0.598) 0 0 0 0 
18.2 mins 0 1.983 (0.61) 0 1.63 (0.79) 1.46986 (0.598) 0 0 0 0 
22.2 mins 0 2.03 (0.61) 0 1.64 (0.79) 1.533 (0.61) 0 0 0 0 
26mins 0 2.03 (0.61) 0 1.66 (0.8) 1.533 (0.61) 0 0 0 0 
27 mins 0 2.03 (0.61) 0 1.67 (0.8) 1.533 (0.61) 0 0 0 0 
30 mins 1.9959 (0.96) 2.35 (0.64) 0 8.6 (1.33) 1.954 (0.65) 0 0 0 0 
45 mins 1.9959 (0.96) 3.899 (0.72) 0 8.6 (1.33) 2.068 (0.656) 0 0 0 1.58931 (1.l4) 
50 mins 1.9959 (0.96) 3.92 (0.72) 0 8.6 (1.33) 2.068 (0.656) 0 0 0 1.58931 (1.14) 
1 hr 2.045 (0.962) 15.32 (1.2) 1.54 (0.9) 37.3 (2.5) 5.18 (0.95) 1.213 (0.62) 7.1 (6.9) 3.403 (2.51) 1.58931 (1.l4) 
1.5 hr 2.045 (0.962) 15.32 (1.2) 1.54 (0.9) 38.2 (2.5) 5.23 (0.95) 1.213 (0.62) 7.1 (6.9) 3.403 (2.51) 1.58931 (1.l4) 
2 hrs 2.084 (0.96) 16.19 (1.207) 8.7 (1.9) 48.1 (2.8) 13.54 (1.5) 1.928 (0.63) 28.6 (12.1) 3.55 (2.52) 9.37 (2.6) 
2.5 hrs 2.084 (0.96) 16.19 (1.207) 8.7 (1.9) 48.1 (2.8) 13.64 (1.45) 1.928 (0.63) 28.6 (12.1) 3.55 (2.52) 9.37 (2.6) 
2.7 hrs 2.084 (0.96) 22.34 (1.24) 8.7 (1.9) 48.1 (2.8) 14.1 (1.45) 1.928 (0.63) 28.6 (12.1) 3.55 (2.52) 9.37 (2.6) 
3 hrs 8.2 (1.8) 66.73 (2.1) 9.3 (1.93) 49.5 (2.8) 16.94 (1.56) 2.44 (0.683) 35.7 (12.8) 37.41 (6.91) 10.8 (2.8) 
4 hrs 8.348 (1.84) 67.24 (2.05) 10.88 (2) 54.6 (2.8) 18.21 (1.57) 2.44 (0.683) 42.9 (13.2) 53.31 (7.23) 11 (2.8) 
5 hrs 8.54 (1.84) 67.59 (2.042) 11.5 (2) 54.6 (2.8) 26.7 (1.87) 2.73 (0.71) 42.9 (13.2) 58.4 (7) 11.6 (2.8) 
6 hrs 9.15 (1.85) 69.82 (2) 13.6 (2) 58.2 (2.7) 27.4 (1.88) 2.73 (0.71) 42.9 (13.2) 62.3 (7) 16.9 (3.1) 
7 hrs 9.15 (1.85) 70.2 (2) 14 (2.03) 59.4 (2.8) 27.84 (1.87) 2.73 (0.71) 42.9 (13.2) 66.9 (6.8) 16.9 (3.1) 
8 hrs 11.1 (1.9) 74.4 (1.9) 14 (2.03) 60.4 (2.8) 29.66 (1.89) 3.14 (0.71) 42.9 (13.2) 71.8 (6.4) 17.4 (3.1) 
8.20 hrs 11.1 (1.9) 74.4 (1.9) 53.3 (3.72) 60.4 (2.8) 29.66 (1.89) 3.14 (0.71) 42.9 (13.2) 71.8 (6.4) 17.4 (3.1) 
9 hrs . 11.1 0.9) 74.7 (1.89) 56.82 (3.7) 61.8 (2.8) 29.66 (1.89) 3.14 (0.71) 50 (13.4) 71.8 (6.4) 17.4 (3.1) 
10 hrs 11.1 (1.9) 74.7 (1.89) 61 (3.52) 61.8 (2.8) 29.87 (1.888) 24.14 (0.62) 50 (13.4) 81.4 (5.7) 18.96 (3.1) 
II hrs 11.1 (1.9) 74.95 (1.9) - 62.3 (2.8) 29.87 (1.888) 24.14 (0.62) - 85.1 (5.2) 18.96 (3.1) 
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Table 5.7.1 Weighted pooled percentages in different treatment groups in RCTs included in meta-analysis calculated using fixed-effects model 
(continued) 
- -
Time interval Pc. Placebo (SE) PT. Flecainide PT .Quinidine PT .Sotalol (SE) PT. Amiodarone PT Propafenone PT. Q+A (SE) PT. D+Dig (SE) PT. VRRA (SE) 
(SE) (SE) (SE) (SE) 
12 hrs 11.1 (1.9) 78.27 (1.77) - 62.3 (2.8) 32.1 (1.88) 24.14 (0.62) - 87.5 (4.8) 20(3.11) 
13 hrs 11.1 (1.9) 78.27 (1.77) - 62.8 (2.8) 32.41 (1.88) 24.14 (0.62) 
-
87.5 (4.8) 20 (3.11) 
14 hrs 11.1 (1.9) 78.52 (1.77) - 62.8 (2.8) 32.41 (1.88) 24.14 (0.62) - 87.5 (4.8) 20(3.11) 
16 hrs 11.1 (1.9) 78.86 (1.77) 
-
63.2 (2.8) 32.41 (1.88) 24.14 (0.62) 
-
87.5 (4.8) 24.2 (3.04) 
17 hrs 11.1 (1.9) 78.86 (1.77) - 63.9 (2.8) 32.41 (1.88) 24.14 (0.62) - 87.5 (4.8) 24.2 (3.04) 
18 hrs 11.1 (1.9) 79.34 (1.75) - 64.63 (2.8) 32.41 (1.88) 24.14 (0.62) - 87.5 (4.8) 24.2 (3.04) 
19 hrs 14.5 (2.18) 79.45 (1.75) - 64.63 (2.8) 32.41 0.88) 24.14 (0.62) - 89.4 (4.5) 24.2 (3.04) 
20 hrs 
-
79.45 (1.75) - 64.63 (2.8) 33.2 (1.87) 24.14 (0.62) - 92.6 (3.8) 21.5 (3.1) 
24 hrs - 79.9 (1.7) - 66.4 (2.8) 68.6 (2.152) 24.423 (0.62) 
-
93.8 (3.5) 25.9 (3) 
25 hrs - 80 (1.7) - - 68.6 (2.2) 24.423 (0.62) - 93.8 (3.5) -
26 hrs - 80.13 (1.7) 
- -
68.6 (2.2) 24.423 (0.62) 
-
93.8 (3.5) 
-
29 hrs - - - - 68.6 (2.2) 24.423 (0.62) - 99.4 (1.14) 
-
48 hrs 
- -
- - 69.7 (2.1) 24.494 (0.62) - 99.4 (1.14) -
32 hrs - - - - 85.5 (1.5) - - 99.4 (1.14) -
72 hrs 
- - -
- - - - 99.6 (0.94) -
Q statistic for PT 21.7 «0.0013)** 59.6 (0)** 28 (0)** 43 (0)** 52.7 (0)** 3.9 (0.6) 
-
0(1) 90 (0) 
(P) 
Total No.of trials 7 16 5 9 13 6 1 2 6 
Total No. of pts 57/205 3421468 931164 150/242 256/402 115/255 7114 46/47 441120 
(events/total 
included) 
RD vs Placebo (%) 
-
51.3 (47.5-55)** 33.7 (26-41.2)** 38.6 (32.7- 40.2 (35.5-44.95)** 26.5 (22.7-30.4)** 22.5 (-4.4-49) 71.4 (66-76.8)** 0.42 (-6.2-7) NS 
(95% CI) RE; 47.5 (40.2- RE; 33.9 (15.6- 44.6)** RE; 37 (26.7- RE; 34 (-10.2-78.2) NS RE; 9.2 (-17.9-
54.7)** 52.4)** 36 (22.7-49.5)** 47.3)** NS 36.4) NS 
PT, meta-analytic pooled percentage of patients converted to sinus rhythm; FIe, Flecainide; PL, Placebo; #, including other antiarrhythmic drugs; A, Amiodarone; Dig, Digoxin; D, Disopyramide; Pr, Propafenone; 
Q, Quinidine; S, Sotalol; V, Verapamil; * statistically significant (P<0.05); ** highly statistically significant (P<O.OI); RE, random-effects model 
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Table 5.7.2 Weighted pooled percentages in different treatment groups in RCTs included in meta-analysis calculated using random-effects model 
Time interval Pc. Plaffbo (SE) Pr. Flaainide Pr .Quinidine Pr .Sotallll (SE) Pr. Amilldarlllle Pr Propafelllllle Pr. Q+A (.'IE) Pr. n+/)ig Pr. l'RRA (SE, 
(.'IE) (.'IE) (.'IE) (SE) (.'IE) 
0·2 mins 0 1.6 (0.6) 0 I 0 I 0 0 0 0 I 0 
2-5 mins 0 1.79 (0.6) 0 1.5 (0.8) 0 0 0 0 0 
6 mins 0 1.79845 (0.6) 0 1.5 (0.8) 0 0 0 0 0 
7 mins 0 1.81 (0.6014) 0 1.5 (0.8) 0 0 0 0 0 
10mins 0 2.77 (1.016) 0 1.544 (0.78) 1.4484(5.95) 0 0 0 0 
12 mins 0 2.77 (1.016) 0 1.5598 (0.78) 1.44845 (5.95) 0 0 0 0 
13 mins 0 2.77 (1.016) 0 1.5598 (0.78) 1.46986 (0.598) 0 0 0 0 
15 mins 0 3.83 (1.34) 0 1.59997 (0.79) 1.46986 (0.598) 0 0 0 0 
16mins 0 3.83 (1.34) 0 1.6 (0.79) 1.46986 (0.598) 0 0 0 0 
18.2 mins 0 3.83 (1.34) 0 1.63 (0.79) 1.46986 (0.598) 0 0 0 0 
22.2 mins 0 4.465 (1.4845) 0 1.64 (0.79) 1.533 (0.61) 0 0 0 0 
26 mins 0 4.465 (1.4845) 0 1.66 (0.8) 1.533 (0.61) 0 0 0 0 
27 mins 0 4.465 (1.4845) 0 1.67 (0.8) 1.533 (0.61) 0 0 0 0 
30 mins 1.9959 (0.96) 7.1 (1.887) 0 8.6 (1.33) 4.75 (1.545) 0 0 0 0 
45 mins 1.9959 (0.96) 17.492 (3.38) 0 8.6 (1.33) 6.536 (1.885) 0 0 0 1.58931 (1.14) 
50 mins 1.9959 (0.96) 17.759 (3.41) 0 8.6 (1.33) 6.536 (1.885) 0 0 0 1.58931 (1.14) 
1 hr 2.045 (0.962) 42.09 (7.5) 1.54 (0.94) 37.3 (2.5) 18.16 (3.85) 9.17 (3.26) 7.1 (6.9) 11.546 (11.42) 1.58931 (1.14) 
1.5 hr 2.045 (0.962) 42.09 (7.5) 1.54 (0.94) 38.2 (2.5) 18.5 (3.898) 9.17 (3.26) 7.1 (6.9) 11.546 (11.42) 1.58931 (1.14) 
2 hrs 5.007 (2.3) 46.524 (7.85) 23.2 (8.95) 48.1 (2.8) 29.33 (5.49) 27.96 (6.55) 28.6 (12.1) 14.18 (13.97) 9.37 (2.6) 
2.5 hrs 5.007 (2.3) 46.84 (7.889) 23.2 (8.95) 48.1 (2.8) 29.651 (5.55) 27.96 (6.55) 28.6 (12.1) 14.18 (13.97) 9.37 (2.6) 
2.7 hrs 5.007 (2.3) 53.1 (9.74) 23.2 (8.95) 48.1 (2.8) 30.7 (5.83) 27.96 (6.55) 28.6 (12.1) 14.18 (13.97) 9.37 (2.6) 
3 hrs 11.796 (3.489) 63.72 (4.25) 27.1 (9.92) 52.613 (9.398) 34.1 (6.4) 38.195 (10.64) 35.7 (12.8) 37.41 (6.91) 10.8 (2.8) 
4 hrs 12.7 (3.8) 64.4 (4.187) 32.879 (12.12) 55.376 (9.3) 37.35 (6.87) 38.195 (10.64) 42.9 (13.2) 53.31 (7.23) 11 (2.8) 
5 hrs 13.634 (4.14) 64.797 (4.156) 35.999 (13.07) 55.376 (9.3) 38.99 (6.9) 46.74 (17.84) 42.9 (13.2) 58.4 (7) 11.6 (2.8) 
6 hrs 16.2 (5.144) 67 (3.959) 42.82 (15.77) 57 (9.15) 40.38 (7.1) 46.74 (17.84) 42.9 (13.2) 62.3 (7) 22.84 (7.67) 
7 hrs 16.2 (5.144) 67.4058 (3.859) 43.575 (16.174) 57.48 (8.75) 40.97 (7.2) 46.74 (17.84) 42.9 (13.2) 66.9 (6.8) 22.84 (7.67) 
8 hrs 21.77 (6.7) 71.17 (3.87) 43.575 (16.174) 57.92 (8.4) 43.82 (7.53) 51.07 (19.54) 42.9 (13.2) 71.8 (6.4) 24.04 (8.17) 
8.20 hrs 21.77 (6.7) 71.17 (3.87) 55.46 (7.68) 57.92 (8.4) 43.82 (7.53) 51.07 (19.54) 42.9 (13.2) 71.8 (6.4) 24.04 (8.17) 
9 hrs 21.77 (6.7) 71.41 (3.8665) 58.85 (8.24) 58.77 (7.88) 43.82 (7.53) 51.07 (19.54) 50 (13.4) 71.8 (6.4) 24.04 (8.17) 
10 hrs 21.77 (6.7) 71.41 (3.8665) 61.43 (9.64) 58.77 (7.88) 29.87 0.888) 53.24 (27.562) 50 (13.4) 81.4 (5.7) 26.81 (9.612) 
11 hrs 21.77 (6.7) 71.654 (3.8786) - 59.18 (7.67) 44.28 (7.59) 53.24 (27.562) - 85.1 (5.2) 26.81 (9.612) 
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Table 5.7.2 Weighted pooled percentages in different treatment groups in RCTs included in meta-analysis calculated using random-effects model 
(continued) 
Time interval Pc. Placebo (SE) PT. Flecainide PT .Quinidine PT .Solalol (SE) PT. Amiodarone PT Propafenone PT. Q+A (SE) PT. D+Dig (SE) PT. VRRA (SE) 
(SE) (SE) (SE) (SE) 
12 hrs 21.77 (6.7) 73.03 (4.1) - 59.18 (7.67) 46.5 (8.12) 53.24 (27.562) - 87.5 (4.8) 30.1 (10.25) 
13 hrs 21.77 (6.7) 73.03 (4.1) - 59.59 (7.49) 46.8 (8.197) 53.24 (27.562) - 87.5 (4.8) 30.1 (10.25) 
14 hrs 21.77 (6.7) 73.391 (3.962) - 59.59 (7.49) 46.8 (8.197) 53.24 (27.562) - 87.5 (4.8) 30.1 (\ 0.25) 
16 hrs 21.77 (6.7) 73.92 (3.815) - 59.99 (7.34) 46.8 (8.197) 53.24 (27.562) - 87.5 (4.8) 33.18 (\2.9) 
17 hrs 21.77 (6.7) 73.92 (3.815) - 60.776 (7.1) 46.8 (8.197) 53.24 (27.562) - 87.5 (4.8) 33.18 (12.9) 
18 hrs 21.77 (6.7) 74.2 (3.84) - 61.535 (6.89) 46.8 (8.197) 53.24 (27.562) - 87.5 (4.8) 33.18 (12.9) 
19 hrs 25.9 (7.57) 74.35 (3.8) - 61.535 (6.89) 46.8 (8.197) 53.24 (27.562) - 89.4 (4.5) 33.1802.9) 
20 hrs 
-
74.35 (3.8) 
-
61.535 (6.89) 47.83 (8.374) 53.24 (27.562) - 92.6 (3.8) 31.62 (\ 1.3) 
24 hrs - 74.92 (3.696) - 63.566 (6.765) 65.13 (4.89) 60.24 (27.61) - 93.8 (3.5) 36.694 (13.67) 
25 hrs - 75.1 (3.7) - - 65.13 (4.89) 60.24 (27.61) - 93.8 (3.5) -
26 hrs - 75.26 (3.64) - - 65.13 (4.89) 60.24 (27.61) - 93.8 (3.5) -
29 hrs 
-
- - -
65.13 (4.89) 60.24 (27.61) 
-
99.4 (1.14) 
-
48 hrs - - - - 66.75 (4.68) 61.47 (27.598) - 99.4 (1.14) -
32 hrs - - - - 85.45 0.5) - - 99.4 (1.14) -
72 hrs - - - - - - - 99.6 (0.94) -
Total No.of trials 7 16 5 9 13 6 I 2 6 
Total No. of pts 57/205 3421468 93/164 150/242 256/402 115/255 7114 46/47 44/120 
(events/total 
included) 
PT, meta-analytic pooled percentage of patients converted to sinus rhythm; FIe, F1ecainide; PL, Placebo; #, including other antiarrhythmic drugs; A, Amiodarone; Dig, Digoxin; D, Disopyramide; Pr, Propafenone; 
Q, Quinidine; S, Sotalol; V, Verapamil; * statistically significant (P<0.05); ** highly statistically significant (P<O.OI); RE, random-effects model 
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Figure 5.10.1 Indirect comparison of the efficacy of flecainide, amiodarone, sotalol, quinidine, and placebo 
treatment arms for acute conversion to sinus rhythm within 1 hour (Fixed-effects model): the figure depicts the 
weighted percentages (probabilities) of patients converted to sinus rhythm at each follow-up time point during the first hour after 
administration oftreatment. The error bars show the 95% confidence intervals (=1.96.SEM). 
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administration of treatment. The error bars show the 95% confidence intervals (= 1.96.SEM). 
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Figure 5.11 Indirect comparison of the efficacy of fie cain ide, amiodarone, sotalol, and placebo treatment arms for 
acute conversion to sinus rhythm during the 10 hours after commencement of treatment (Fixed-effects model): the 
figure depicts the weighted percentages (probabilities) of patients converted to sinus rhythm at each follow-up time point during the 10 hours 
after administration of treatment. The error bars show the 95% confidence intervals (= 1.96.SEM). The P values shown next to legands 
express the significance of the absolute effect of each treatment arm as compared to placebo. 
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Figure 5.12 Indirect comparison of the efficacy of flecainide, amiodarone, sotalol, and placebo treatment arms for 
acute conversion to sinus rhythm during 24 hours (Fixed-effects model): the figure depicts the weighted percentages 
(probabilities) of patients converted to sinus rhythm at each follow-up time point during the 24 hours after administration of treatment. The 
error bars show the 95% confidence intervals (= 1.96.SEM). The P values shown next to legands express the significance of the absolute 
effect of each treatment arm as compared to placebo. 
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Figure 5.13 Indirect comparison of intravenous flecainide, sotalol, and 
amiodarone treatment arms in all trial designs for conversion to SR 
(Fixed-effects model). The figure depicts the weighted percentage 
(probabilities) of patients converted to sinus rhythm at 3, 8, and 24 hours. 
The error bars show the 95% CI (=1.96.SEM). 
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Figure 5.14 Indirect comparison of oral flecainide, and sotalol treatment 
arms in all trial designs for conversion to SR (Fixed-effects model). The figure 
depicts the weighted percentage (probabilities) of patients converted to sinus 
rhythm at 3,8, and 24 hours. The error bars show the 95% CI (=1.96.SEM). 
5.4.3.3 Effect on Ventricular Response 
Figure 5.15.1 displays the pooled weighted mean effects of placebo, flecainide, sotalol 
and amiodarone on the ventricular rate, compared to the baseline. For the placebo 
treatment arm, data regarding the ventricular rate in converted and nonconverted 
patients was reported in 3 trials. Pooling the data did not show statistically significant 
change from baseline during the 8 hours in converted and unconverted patients. 
For converted patients in the flecainide treatment group, the pooled mean decrease in 
the ventricular rate (from 5 trials) was statistically significant (dmean = -9.12; 95% CI, 
-2 to -16.2) at 1 and 2 hours, and reached clinically significant limits at 3 hours (dmean 
= -17.7; 95% CI, -4.8 to -26.6). This remained significant throughout the 24 hours 
(>20 beats/min decrease). Furthermore, for unconverted patients, the mean ventricular 
rate slowed significantly after 1 hour and remained significant up to the end of the 24 
hours (dmean = -19; 95% CI, -32.2 to -5.8). 
For sotalol, the data was only available from one trial for converted patients (Levy et 
al., 1986) and one for unconverted (Sung et al., 1995), and the change was not 
statistically significant at any time point. 
For amiodarone, the mean treatment effect was statistically and clinically significant 
compared to the baseline after 1 hour in converted (dmean = -26.5; 95% CI, -46.5 to-
6.5; Z = 2.6), as well as unconverted patients (dmean = -28.6; 95% CI, -50 to -7; Z = 
2.6). 
Pooling the data from two verapamil trials did not show any statistically significant 
effect compared to the baseline, either in converted (dmean = -13.2; 95% CI, 2.8 to-
29; Z = 1.6) or in nonconverted (dmean = -53.5; 95% CI, 0.5 to -107; Z = 1.9) (Figure 
5.15.2). The same results were obtained for propafenone. 
A direct comparison with placebo was performed in six trials; two for flecainide 
(Capucci et aI., 1992; Donovan et al., 1995), two for sotalol (Levy et al., 1986; Sung 
et al., 1995), and two for amiodarone (Capucci et aI., 1992; Donovan et aI., 1995). As 
shown in Figure 5.16, the effect size of flecainide versus placebo was not statistically 
significant at any time point for both converted and unconverted patients. For a sotalol 
trial with 23 patients (Levy et aI., 1986), the effect size in all patients was statistically 
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Figure 5.15.1 Effect of various treatment arms on the ventricular response as compared to the 
baseline. The figure depicts the weighted pooled treatment effect compared to baseline (expressed as 
weighted mean difference with 95% el) at each follow-up time point. The results for each drug are 
stratified into three groups: 1. all patients after excluding unconverted if it was reported in the original 
trial; and 2. unconverted patients only. The number of trials included for each subgroup is shown in 
brackets. Random-effects model was employed if heterogeneity existed. 
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Figure 5.15.2 Effect of various treatment arms on the ventricular response in all patients included. 
The figure depicts the weighted pooled treatment effect compared to baseline (expressed as weighted 
mean difference with 95% el) at each follow-up time point. The results for each drug are stratified 
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Figure 5.16 Effect of tlecainide, sotalol, and amiodarone on ventricular response as 
compared directly to placebo (included 3 RCTs). The figure depicts pooled effect size 
estimates at different time points with their associated 95% CI (Fixed-effects model). The 
results for each drug are stratified into two patients groups: 1. all patients (after excluding 
unconverted if possible); 2. unconverted patients only. Also the number of trials included in 
each subgroup is shown in brackets. Random-effects model was employed if heterogeneity 
existed. 
and clinically significant (ES, 20.7; 19.6-21.7). Another trial evaluated the effect in 
nonconverted patients (Sung et aZ., 1995). The results were significant starting at 2 
minutes with the maximum effect size reached at 20 minutes (ES, 5.8; 5.1-6.5). For 
amiodarone, the effect size was statistically significant at all time points from 1 to 8 
hours, with a highly significant difference, from the clinical point of view, at 1 hour 
(ES, 13.96; 12.8-15.2). In nonconverted patients the effect was significant at 20 
minutes to 1 hour. However, there was no significant difference after 3 hours. 
Indirect comparison using the pooled mean ventricular rate weighted by the number of 
the patients is depicted in Figure 5.17. There was a significant difference between 
flecainide and placebo, while amiodarone and sotalol has displayed more prompt effect 
for controlling the ventricular response. However, the indirect comparison, using the 
pooled mean weighted by the inverse of the variance (Figure 5.18), did not show any 
significant difference between the three drugs. 
5.4.4 Side Effects 
Common side effects of antiarrhythmic drugs can be classified into cardiovascular and 
noncardiovascular toxicities. Cardiac side effects include bradycardia (heart rate 
consistently < than 50 beats/min), conduction disturbances (for example, second or 
third degree A V block), worsened or new congestive heart failure, severe hypotension 
(blood pressure < 90 mm Hg), drug-induced proarrhythmia (such as conversion of AF 
to AFL with more rapid ventricular response rate, also called 1: 1 A V conduction), and 
sudden cardiac death. Noncardiac side effects may be minor or major. Minor 
noncardiac side effects include gastrointestinal disturbances (nausea, vomiting, and 
diarrhea), and those of the central nervous system (dizziness, light-headedness, and 
drowsiness). Major noncardiac side effects are those associated with amiodarone, such 
as thyroid dysfunction, and pulmonary fibrosis. Minor side effects can usually be 
eliminated by decreasing the dose. However, major side effects generally require 
discontinuations of the drug. The frequency of side effects is dose related and also 
duration related, thus increasing over time. Some of the previous side effects appear to 
be more common with one drug than the other. Flecainide, for example, is associated 
with visual disturbances which include blurred vision, difficulty in focusing, and spots 
before the eyes. Sotalol adverse effects are those related to B-blocker activity such as 
dyspnea and those associated with QT prolongation (due to its Class III effect), 
especially torsade de pointes. 
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In this review, 14 flecainide clinical trials (4 uncontrolled and 10 RCTs) involving a 
total of 434 patients reported the incidence of side effects. Four of these trials (Villani 
et ai., 1990; Capucci et aI., 1992; Donovan et ai., 1991; Capucci et aI., 1994) were 
randomised placebo-controlled (3 also compared to active control), and 6 were 
comparative studies without placebo (Borgeat et ai., 1986; Gavaghan et al., 1988; 
Suttorp et at., 1989; Wafa et al., 1989; Suttorp et at., 1990; Madrid et al., 1993). 
For amiodarone, 13 trials (3 uncontrolled and 11 RCTs) involving a total of 347 
patients provided data concerning adverse effects. Two trials were placebo-controlled 
(Capucci et aI., 1992; Donovan et aI., 1995) and 9 were randomised comparative 
studies (Bertini et aI., 1990; McAlister et al., 1990; Adrivet et aI., 1990; Bellandi et at., 
1993; Chapman et at., 1993; Cesar et at., 1994; Cochrane et at., 1994; Treglia et at., 
1994; Biasi et ai., 1995). One RCTs in which quinidine plus amiodarone was 
compared to quinidine (Posada et ai., 1988) was excluded from the analysis. 
For sotalol, 8 trials (two uncontrolled and 6 RCTs) including a total of 373 patients 
described the incidence of adverse effects. Three of them were placebo-controlled 
(Levy et al., 1986; 10rdaens et ai., 1991; Sung et al., 1995) and three were only 
comparative studies (Campbell et aI., 1985; Hamer et al., 1993; Halinen et aI., 1995). 
Table 5.8 shows the weighted pooled percentage incidence of adverse events in 
flecainide, amiodarone, and sotalol treatment groups separately. There was no 
significant difference in the incidence of cardiovascular side effects among the three 
treatment groups (P < 0.05). Although intravenous amiodarone is known to produce 
hypotension as a result of its peripheral systemic vasodilatory effects (Kopelman and 
Horowitz, 1989), this review of a limited number of patients (8 trials of 231 patients) 
shows that it was associated with a very low incidence of hypotension as compared to 
flecainide (2.7%±1.1 vs 1O%±2). Extracardiac side effects occurred frequently at 
different rates with each drug but these were not serious. The commonest noncardiac 
problems in the flecainide group were nausea (2.42%), central nervous system side 
effects (dizzinesslheadache/drowsiness) with overall incidence rate of 1.9%, as well as 
paraesthesia and hyperthermia (1.85%). Amiodarone was frequently associated with 
rashes (1.45%) and sotalol with respiratory distress or dyspnea (1.89%). 
Nevertheless, the overall incidence of side effects requiring active therapy (such as 
infusion of intravenous fluids), direct current cardioversion (DCC), and withdrawals as 
a direct result of the drug toxicity, were not significantly different. 
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Table 5.8 Comparison of the overall incidence of adverse effects and dropouts among 
different treatment groups 
Group Flecalnlde Amlodarone Sotalol 
1. All routes of administration 
Total number of trials 14 13 8 
Total number of patients 434 373 234 
Cardiac adverse effects 
Hypotension 2.6 (1.18-4.1) 1.95 (0.51-3.4) 5.5 (3.2-7.8) 
Bradycardia 1.7 (0.48-2.9) 1.8 (0.4-3.24) 1.9 (0.3-3.5) 
Proarrhythmia 2.28 (0.89-3.7) 1.4 (0.18-2.7) 1.52 (-0.04-3.1) 
New/Worse CHF 1.36 (0.27-2.5) 1.4 (0.18-2.7) 0 
Conduction disturbances 1.8 (0.57-3.1) 1.5 (0.2-2.7) 1.4 (-0.12-2.85) 
Death 1.73 (0.52-2.9) 1.48 (0.2-2.7) 0 
Noncardiac adverse effects 
Visual disturbances 1.49 (0.35-2.63) 1.5 (0.2-2.8) 0 
Respiratory distresslDyspnea 0 0 1.98 (0.2-3.8) 
Nausea 2.42 (0.9-3.9) 1.84 (0.4-3.23) 1.3 (-0.1-2.8) 
Diu.iness lHeadacheIDrowsiness 1.9 (0.65-3.2) 1.5 (0.2-2.7) 0 
Hyperthermia lParasthesialFatigue 1.85 (0.6-3.1) 0 0 
Superficial phlebitis 1.4 (0.3-2.5) 0 0 
Cold extremities 0 0 1.38 (-0.1-2.9) 
Rash 0 1.45 (0.2-2.7) 0 
ANAT 1.93 (0.65-3.2) 1.6 (0.3-2.83) 3.1 (0.95-5.2) 
DCC 2.1 (0.8-3.4) 2.64 (0.98-4.3) 2 (0.31-3.7) 
Dropouts 1.65 (0.5-2.8) 1.9 (0.5-3.3) 3.3 (1.2-5.5) 
2. Oral 
(single and multiple doses) 
Number of trials 4 2 2 
Number of patients 89 40 39 
Cardiac adverse effects 
Hypotension 1.7 (-0.97-4.4) 2.5 (-2-7.3) 33.5 (20-47) 
Bradycardia 1.7 (-0.97-4.4) 2.5 (-2-7.3) 33.5 (20-47) 
Proarrhythmia 3.34 (-0.4-7.1) 2.5 (-2-7.3) 11.4 (1.4-21.3) 
New/Worse CHF 1.98 (-0.9-4.84) 0 0 
Conduction disturbances 1.7 (-0.97-4.4) 4.34 (-1.9-10.6) 1.75 (-2.4-5.8) 
Death 0 0 0 
Noncardiac adverse effects 
Visual disturbances 0 0 0 
Respiratory distresslDyspnea 0 0 0 
Nausea 1.7 (-0.96-4.45) 2.5 (-2-7.3) 1.75 (-2.4-5.8) 
Diu.iness lHeadachelDrowsiness 1.9 (-0.9-4.7) 2.5 (-2-7.3) 0 
Hyperthermia lParasthesiaiFatigue 1.7 (-0.97-4.4) 0 0 
Superficial phlebitis 2 (-0.9-4.9) 0 0 
Cold extremities 0 0 0 
Rash 0 0 0 
ANAT 1.98 (-0.9-4.8) 2.5 (-2.34-7.33) 1.75 (-2.3-5.8) 
DCC 2.2 (-0.7-5) 2.S (-2.34-7.33) 28 (14.83-41.5) 
Dropouts 1.4 (-0.97-4.4) 2.5 (-2.34-7.33) 35.4 (21.9-48.9) 
The incidence rate is shown in te"'!ls of weighted pooled percentage (episodes per 100 patients) together with its 95% CI; 
ANAT. adverse effects needed active treatment; DCC; direct current cardioversion 
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Table 5.8 Comparison of the overall incidence of adverse effects and dropouts among 
different treatment groups (continued) 
Group Flecainide Amiodarone Sotalol 
3. IV 
(single and multiple doses) 
Number of trials 8 8 6 
Number Of patients 236 231 195 
Cardiac adverse effects 
Hypotension 10 (6.2-14.1) 2.7 (0.7-4.82) 4.7 (2.4-7) 
Bradycardia 1.7 (-0.04-3.4) 2.4 (0.47-4.4) 1.43 (-0.2-3.1) 
Proa"hythmia 3.3 (0.96-5.7) 1.6 (-0.03-3.2) 1.3 (-0.3-2.8) 
NewIWorse CHF l.5 (-0.1-3) 1.6 (-0.03-3.2) 0 
Conduction disturbances 1.7 (-0.03-3.35) 1.6 (-0.03-3.2) 1.3 (-0.3-2.9) 
Death 2 (0.23-3.8) 1.6 (O.oI-3.3) 0 
Noncardiac adverse effects 
Visual disturbances 0 1.7 (0.024-3.3) 0 
Respiratory distresslDyspnea 0 0 0 
Nausea 3.5 (1.03-5.9) 1.99 (0.21-3.8) 1.3 (-0.3-2.8) 
Dizziness IHeadacheIDrowsiness 2.8 (0.8-4.9) 1.6 (-0.04-3.2) 0 
Hyperthermia IParaesthesiaIF atigue 2.5 (0.6-4.4) 0 0 
Superficial phlebitis 0 0 0 
Cold extremities 0 0 1.32 (-0.3-2.9) 
Rash 0 0 0 
ANAT 2.1 (2.8-3.9) 1.8 (0.1-3.4) 3.5(1.1-6) 
DCC 2.3 (0.4-4.2) 2.5 (0.54-4.5) 1.6 (-0.14-3.3) 
Dropouts 1.7 (0.04-3.3) 2.5 (0.54-4.5) 2.5 (0.3-4.7) 
4. IV+Oral 
Number of trials 3 2 0 
Number of patients 109 76 0 
Cardiac adverse effects 
Hypotension 1.4 (-0.8-3.7) I (-1.23-3.2) 0 
Bradycardia 2.15 (-0.6-4.9) 1 (-1.23-3.2) 0 
Proa"hythmia 1.4 (-0.8-3.7) 1 (-1.23-3.2) 0 
NewIWorse CHF 0 0 0 
Conduction disturbances 3.2 (-0.OS-6.5) 1 (-1.23-3.2) 0 
Death 1.4 (-0.8-3.7) 0 0 
Noncardiac adverse effects 
Visual disturbances 1.S (-0.7-4.3) 0 0 
Respiratory distresslDyspnea 0 0 0 
Nausea 0 1 (-1.23-3.2) 0 
Dizziness IHeadachelDrowsiness 2.6 (-0.4-5.5) 1 (-1.2-3.3) 0 
Hyperthermia lParaesthesiaiF atigue 1.8 (-0.7-4.3) 0 0 
Superficial phlebitis 0 0 0 
Cold extremities 0 0 0 
Rash 0 1 (-1.23-3.23) 0 
ANAT 1.63 (-0.74-4) 1 (-1.23-3.2) 0 
DCC 1.4 (-0.S-3.7) 3.3 (-0.7-7.3) 0 
Dropouts 3.6 (0.13-7) 1 (-1.3-3.2) 
The incidence rate is shown in te~s of weighted pooled percentage (episodes per 100 patients) together with its 95% CI; 
ANAT. adverse effects needed acttve treatment; DCC; direct current cardioversion 
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As shown in the Table 5.8, further analysis of the incidence of side effects according to 
the route of administration did not reveal any important variation between the three 
drugs in intravenous and intravenous plus oral treatment trials. On the other hand, oral 
sotalol was associated with a very high incidence rate of hypotension and bradycardia, 
requiring drug discontinuation (35.4%; 95% CI, 21.9-48.9). However, the authors of 
the trial stated that all events were symptomless (Halinen et al., 1995). 
In general, the use of the three drugs for this indication was relatively safe and the 
incidence rates of proarrhythmia and death were very low. The cause of death of five 
patients in the flecainide group were neither attributed to treatment nor to AF (Donovan 
et al., 1991). However, one death in another flecainide trial occurred due to 
aggravation of the arrhythmia in a congestive heart failure patient who developed AF 
after repeated GABG surgery (Gavaghan et al., 1988). As a result, cautious 
monitoring of flecainide plasma concentrations is required, particularly in patients with 
heart failure due to its negative inotropic effect. In amiodarone group, two deaths were 
reported but it was not deemed due to therapy (McAlister et al., 1990). 
In addition to the indirect comparison of incidence of side effects among different 
groups, the pooled relative risk for the incidence of each adverse effect was estimated 
for the three drugs as compared directly to the control group in the same trial. Figures 
5.19, 5.20, and 5.21 depict the pooled log relative risk of cardiac, noncardiac side 
effects, adverse effects needed active therapy (ANAT) or direct current cardioversion 
(DCC), and those required withdrawals of treatment (dropouts) in fIecainide, 
amiodarone, and sotalol respectively. 
Four flecainide placebo-controlled trials (148 vs 165 patients) permitted the analysis 
(Figure 5.19). The meta-analysis has confirmed that none of the side effects reported 
occured at a significantly higher rate than placebo. Furthermore, pooling the data from 
two amiodarone controlled trials (56 vs 51), one compared to quinidine (30 vs 30), and 
one compared to disopyramide plus digoxin (29 vs 27), did not show any statistically 
significant difference for the incidence of side effects. On the contrary, the overall 
incidence of side effects was significantly higher with fIecainide than propafenone (2 
trials of 66 vs 68 patients) and digoxinlverapamil combination (2 trials of 35 vs 34 
patients). 
Two amiodarone placebo-controlled trials permitted the estimation of pooled relative 
risk of adverse effects (Figure 5.20). The pooling has shown that there was no 
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Flecainide side effects 
1. Versus Placebo (4; 148/165) 
Any side effects 
Cardiac side effects 
Hypotension 
Proanhythmia 
Conduction disturbances 
Death 
Noncardiac side effects 
Nausea 
Hot flushes/Superficial phlebitis 
HeadachelDizztnesslDrowsiness 
ANAT 
DeC 
Dropouts 
2. Versus Amiodarone (2; 56/51) 
Any side effects 
Cardiac side effects 
Hypotension 
Conduction disturbances 
Noncard,ac side effects 
Visual disturbances 
Nausea 
HeadachelDizzinesslDrowsmess 
Superficial phelibitis 
ANAT 
DCC 
Dropouts 
3. Versus Propafenone (2; 66/68) 
Any side effects 
Cardiac side effects 
Hypotension 
Conduction disturbances 
Proarrhythmia 
Noncardiac side effects 
HeadachelDizzmesslDrowsincss 
ParasthcsialHypcrthenniaiF atigue 
ANAT 
DeC 
Dropouts 
4. Versus DigoxinlVerapamii (2; 35/34) 
Any side effects 
Cardiac Side effects 
Hypotension 
Bradycardia 
Noncardiac side effects 
V isual disturbances 
Nausea 
ParasthesiaIHyperthenniaiFatigue 
HeadachelDizzinesslDrowsincss 
ANAT 
DCC 
Dropouts 
5. Versus Digoxin + Disopyramide (1; 29127) 
Any side effects 
Cardiac Side effects 
Hypotension 
Proarrhythmia 
Bradycardia 
Conduction disturbances 
Death 
Noncardiac side effects 
Urinary retension 
Nausea 
ANAT 
DeC 
Dropouts 
6. Versus Quinidine (1; 30/30) 
Any side effects 
Cardiac side effects 
Hypotension 
Proanhythmia 
Bradycardia 
Conduction disturbances 
Death 
Noncardiac side effects 
Nausea 
ANAT 
DCC 
Dropouts 
Favours control Favours flecaUaide 
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Figure 5.19 Flecainide cardiovascular and noncardiovascular side effects, as compared to direct 
control group (placebo or active control), in conversion to sinus rhythm. The figure depicts the 
relative risk of each side effect categorised into cardiac or noncardiac with the relatrive risk of 
ANAT, DeC, or dropouts displayed at the bottom for each comparison. The number of trial pooled 
and total number of patients included are shown in brackets. 
Amiodarone side effects 
I.Versus Placebo (2; 51/53) 
Any side effects 
Cardiac side effects 
Hypotension 
Proarrhythmia 
Noncardiac side effects 
Visual disturbances 
ANAT 
DCC 
Dropouts 
2. Versus Propafenone (2; 61/62) 
Any side effects 
Cardiac side effects 
Hypotension 
Proarrhythmia 
Conduction disturbances 
Bradycardia 
Noncardiac side effects 
Rash 
Dizziness 
ANAT 
DCC 
Dropouts 
3. Versus Quinidine (1; 41/32) 
Any side effects 
Cardiac side effects 
Hypotension 
Proarrhythmia 
Conduction disturbances 
Death 
Noncardiac side effects 
Nausea 
Diarrhea 
Rash 
ANAT 
DCC 
Dropouts 
4. Versus Cibenzoline (1; 21125) 
Any side effects 
Cardiac side effects 
Hypotension 
Proarrhythmia 
Conduction disturbances 
Bradycardia 
ANAT 
DCC 
Dropouts 
5. Versus Digoxin (1; 41/39) 
Any side effects 
Cardiac side effects 
Heart failure 
Proarrhythmia 
Death 
Noncardiac side effects 
Superficial phelibitis 
ANAT 
DCC 
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Figure 5.20 Amiodarone cardiovascular and noncardiovascular side effects, as compared to 
direct control group (placebo or active control), in conversion to sinus rhythm. The figure 
depicts the relative risk of each side effect categorised into cardiac or noncardiac with the 
relatrive risk of ANAT, DCC, or dropouts displayed at the bottom for each comparison. The 
number of trial pooled and total number of patients included are shown in brackets. 
Sotalol side effects 
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2. Versus Quinidine (1; 33/28) 
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DCC 
Dropouts 
3. Versus Flecainide (1; 6/6) 
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Diarrhea 
4. Versus Verapamil (1; 6/6) 
Any side effects 
Noncardiac side effects 
Nausea 
5. Versus Disopyramide + Digoxin (1; 20/20) 
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Figure 5.21 Sotalol cardiovascular and noncardiovascular side effects, as compared to direct 
control group (placebo or active control), in conversion to sinus rhythm. The figure depicts the 
relative risk of each side effect categorised into cardiac or noncardiac with the relatrive risk of 
ANAT, DCC, or dropouts displayed at the bottom for each comparison. The number of trial 
pooled and total number of patients included are shown in brackets. 
significant difference. Furthennore, amiodarone was associated with lower relative 
risk for the total incidence of side effects as compared to quinidine in a head to head 
comparison trial of 41 vs 32 patients (McAlister et ai., 1990). 
The comparison of incidence of adverse effects between sotalol and placebo was 
possible in three trials of 126 vs 93 patients. Neither cardiovascular nor 
noncardiovascular adverse events were significantly different from placebo (Figure 
5.21). The direct comparison of sotalol to quinidine and to disopyramide plus digoxin 
in two head to head comparison, displayed highly statistically significant incidence of 
hypotension in favour of sotalol (LnRR, 3.3 with 95% CI of 0.5 to 6.07; and 3.53 
with 95% CI of 0.78 to 6.3 respectively). However, the authors of these trials have 
claimed non severity of events in any patient and in 16 cases the blood pressure returned 
to pretreatment levels over one to two hours, although sotalol infusion was continued 
(Campbell et ai., 1985). 
5.5 DISCUSSION 
Rapid, reliable, and safe reestablishment of sinus rhythm is the major aim of 
pharmacologic treatment of acute atrial fibrillation. The previous analysis was 
performed in an attempt to answer the following questions: (1) which is the most 
effective agent 1, (2) which is the most quickly effective agent 1, and (3) which is the 
safest agent 1 
Flecainide is available in the United Kingdom for oral and intravenous use with very 
favourable pharmacokinetic features, achieving therapeutic plasma levels within 2-3 
hours. Thus it can be proposed for acute treatment of supraventricular arrhythmias. In 
both approaches employed in the present analysis (direct and indirect comparison), it 
was superior to placebo, amiodarone and Class IA agents (quinidine, disopyramide, 
and procainamide) in tenns of rapidity of action, and total efficacy for conversion to 
sinus rhythm. Although it has displayed significant efficacy when the analysis was 
carried out separately for AF complicating coronary artery bypass surgery, it was 
thought that it would be unlikely to be widely adopted for this indication, due to the 
concern about its use in patients with ischemic heart disease (Camm and Bashir, 1990). 
In addition, this analysis has revealed an interesting finding. Intravenous amiodarone 
was not significantly different in effect from placebo for conversion of acute AF, 
202 
particularly in the first few hours. This low efficacy of intravenous amiodarone might 
be explained in the light of its pharmacokinetic and electrophysiological properties. 
Although intravenous amiodarone was reported to have a faster onset of action after a 
small intravenous dose (1-30 minutes, with duration of effect of 1-3 hours) than oral 
amiodarone, which usually would take days to weeks to start working (Wellens et al. , 
1984; Ikede et at., 1984), it has been shown that the latter has more prominent effect on 
prolonging the effective refractory period in all cardiac tissues, particularly the atria 
(Vietti-Ramus et al., 1992). Thus intravenous amiodarone possess little if any efficacy 
for rapid cardioversion. 
However, the other Class III drug, sotalol, has shown very high efficacy compared to 
placebo in three trials. The indirect comparison between intravenous sotalol and 
intravenous flecainide suggest equal efficacy up to 24 hours. Nevertheless, further 
validation of this conclusion in large-scale direct comparison trials with flecainide and 
placebo is mandatory. 
Considering other data such as mean time of conversion which was pooled for 
flecainide, amiodarone, and sotalol treatment arms separately, one can conclude that 
sotalol is the most effective agent for rapid cardioversion. 
The other acceptable therapeutic end point was to achieve a sufficient decrease in the 
ventricular rate (less than 100 beats/min). Direct comparison of the three treatment 
effects (flecainide, amiodarone, and sotalol) on the ventricular rate to placebo was 
carried out in six trials. This comparison produced contradictory results relative to 
baseline, particularly for sotalol. This can be explained by the limited data available for 
sotalol effect on the ventricular rate (for only 23 converted, and 12 unconverted 
patients). The effect size of sotalol compared to placebo was statistically significant, 
indicating the existence of a sotalol effect on the ventricular rate which can be due to its 
beta-blocking effect on the atrioventricular node. 
The evidence was much stronger for amiodarone effectiveness in both methods of 
comparison due to the availability of more data (effect compared to baseline, 4 trials; 
and effect compared to placebo, 1 trial for converted, and 1 trial for unconverted). The 
effect was even evident if AF persists in unconverted patients. As a result its indication 
as an intravenous injection can be retained for cases which failed the cardioversion by 
other antiarrhythmic agent, to provide rapid improvement for the hemodynamic 
deterioration. 
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Finally, comparison of the three drugs with respect to incidence of any side effect, or 
stratified according to cardiac and noncardiac side effects did not reveal any serious 
difference in favour of treatment. In addition, dropout rates due to any cause or due to 
toxicity were not statistically significant. An important finding was that calculated 
relative risk for the incidence of death and proarrhythmia, due to this particular 
indication of antiarrhythmic drugs, was very low. As a result, the weight of evidence 
still supports the recommendation for their use in an emergency room for acute medical 
and surgical AF. 
5.6 CONCLUSION 
The meta-analysis described in this chapter suggested that, for patients presenting with 
acute AF, intravenous sotalol or intravenous flecainide should be tried first. 
Intravenous amiodarone should be retained for resistant unconverted cases for 
controlling the ventricular response to atrial fibrillation due to its salutory effects on the 
atrioventricular node by prolonging refractoriness and slowing of intranodal conduction 
(Donovan et ai., 1995). 
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CHAPTER SIX 
EFFECT OF ANTIARRHYTHMIC DRUGS ON 
EARLY AND LATE MORTALITY POST 
ACUTE MYOCARDIAL INFARCTION 
A META-ANALYSIS 
6.1 INTRODUCTION 
The prophylactic use of antiarrhythmic agents after acute myocardial infarction (AMI) 
was based on two major concepts. The first was the increased risk of developing 
potentially malignant ventricular fibrillation during the early acute phase of myocardial 
infarction, and the second was the increased risk of sudden death due to arrhythmia in 
patients who survived myocardial infarction (Toe et al., 1993). 
Many clinical and epidemiological studies have demonstrated that the two major risk 
factors of sudden cardiac death in patients who survived acute myocardial infarction, or 
who have advanced cardiac diseases (for example, congestive heart failure or 
cardiomyopathy) are the presence of left ventricular dysfunction and repetitive or 
complex forms of premature ventricular contractions (PVCs) (The Coronary Drug 
Project Research Group, 1973; Bigger, 1984; Lubsen, 1986). This observation has 
generated the hypothesis that suppression of PVCs with antiarrhythmic drugs, which 
does not possess a negative effect on left ventricular ejection fraction (L VEF), would 
potentially improve survival in patients with complicated cardiac diseases and prevent 
sudden cardiac death (Schaffer et al., 1975). 
As a result, numerous randomised clinical trials were conducted to determine whether 
antiarrhythmics reduced the incidence of sudden death and reinfarction in survivors of 
MI (Chamberlain et aZ., 1980; Ryden et al., 1980; Bell et aZ., 1982; Lubsen et al., 
1984; Impact Research Group, 1984; Smyllie et aZ., 1984). The Cardiac Arrhythmia 
Suppression Trials (CAST-I and CAST-II) showed increased mortality in patients 
treated with the Class IA (moricizine) and Class IC agents (encainide hydrochloride and 
flecainide) compared to placebo. This opened the possibility that antiarrhythmic drugs 
may actually have aggravated the arrhythmia which they were designed to treat (CAST 
Investigators, 1989; CAST Investigators II, 1992). 
A number of overviews were performed to analyze systematically the data from all 
randomised controlled trials that evaluated Class lA, IB, IC, II, and III agents to test 
whether this effect could be extrapolated to all antiarrhythmics (Furberg, 1983; Yusuf et 
aZ., 1988; Hine etaZ., 1989; Burckhardt et al., 1991; Lievre et ai., 1991; Nademanee et 
aI., 1993; Teo etal., 1993; Zarembski etaZ., 1993). Most of these reviews pooled 
together the results from all the available clinical trials of various classes, instead of 
performing a subgroup analysis for each class (particularly for all Class I 
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subdivisions). It was concluded that the routine use of Class I antiarrhythmic drugs 
after MI was associated with increased mortality, while beta-blockers showed a 
significant overall reduction in mortality. In fact, a meta-analysis of 6 trials of 
secondary prevention of MI by Class I antiarrhythmics, in which the antiarrhythmic 
effect was correlated with mortality, demonstrated that even before the evaluation of 
CAST, it was evident that suppression of arrhythmia criteria was a surrogate marker for 
a more relevant endpoint which is mortality (Lievre et aI., 1991). As a result, an 
alternative approach was suggested for explaining the cardioprotective effect of beta-
blockers, which was to minimize the ischemia by reducing oxygen consumption 
(Singh, 1991; Kjekshus, 1986). In addition, a shift toward other antiarrhythmic 
classes which would not act via depression of cardiac conduction, particularly Class 
III, was considered (Advani and Singh, 1995). 
Amiodarone, as a Class III agent with several mechanisms of actions (potassium 
channels blocking, as well as antianginal properties) demonstrated variable levels of 
efficacy for prevention of sudden death in several individual trials. Two recent meta-
analyses of its long-term prophylaxis confirmed its beneficial effects for reduction of 
both sudden cardiac death and total mortality (Teo et al., 1993; Zarembski et aI., 1993). 
However, the results were pooled at one time point without considering censored 
events in individual trials. New trials have been completed since publication of these 
studies necessitating an update. 
Sotalol, as a Class III agent with additional beta-blockade activity, was also examined 
in recent trials for treatment of acute and chronic myocardial infarction. However, the 
results were inconclusive. The d-sotalol is the dextrorotary optical isomer of racemate 
d,l-sotalol, which has a pure Class III action of lengthening the action potential 
duration, and devoid of beta-blocking properties (Advani and Singh, 1995). It was 
developed on the presumption that its clinical efficacy would approach that of 
arniodarone and sotalol (racemic), but without the serious toxicity profile of arniodarone 
and the risk of torsades de pointes (TDP) associated with beta-blockade action of 
sotalol. 
In thi!; chapter it was intended to review systematically the effectiveness of d,l-sotalol, 
d-sotalol, and amiodarone for patients with myocardial infarction in short-term 'early 
intervention' and long-term 'late intervention' trials, with the former indicating that 
treatment allocation was assigned within 72 hours of onset of symptoms, or as soon as 
possible after hospital admission, and the latter patients were enrolled at least 4 days 
214 
after MI (Furberg, 1983; Toe et aI., 1993). 
The primary objectives for analysis were as follows: 
• To review the role of intravenous or oral sotalol following myocardial infarction 
and to obtain data on various therapeutic end points (surrogate markers) 
employed in both RCTs for treatment of suspected acute MI (primary 
prevention RCTs), and RCTs following documented acute MI (secondary 
prevention RCTs). 
• To validate the beneficial impact of amiodarone on mortality of any cause in 
patients at high-risk by updating recent meta-analyses with further emphasis on 
pooling survival analysis from individual trials. 
• To test whether this effect of amiodarone in the first year (all previous analysis) 
would continue to improve the mortality in subsequent years. 
• To examine the toxicity of amiodarone treatment during its long-term use. 
6.2 METHODS 
6.2.1 Data Identification and Selection of Primary 
Trials 
A literature search was conducted through all available database sources as detailed in 
Chapter 4, to identify all published trials addressing the use of d-sotalol, d.l-sotalol, 
and amiodarone for treatment of myocardial infarction. The following pertinent 
keyword to this chapter were combined with each drug under investigation cited in the 
title and I or abstract: myocardial infarction, congestive heart failure, sudden death, and 
mortality. The search was completed for the period 1966 to 1997. Hard copies for all 
the clinical trials were obtained. A manual search for the references obtained 
complemented the computerised search. 
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6.2.2 Study Selection and Inclusion Criteria 
Trials were included provided they satisfied the following inclusion criteria: 
i. Trials were randomised, prospective and published trials. 
ii. Trials evaluated the use of sotalol for patients with suspected acute myocardial 
infarction (primary prevention of acute MI) or patients with documented acute 
myocardial infarction (secondary prevention of MI). 
lll. Sudden cardiac death, cardiac death, noncardiac death, or total mortality were 
the primary end points or secondary end points of the trials. Total mortality, 
however, was the preferred outcome, since it depend on a count without any 
possible bias in determining the cause of death. Moreover, it would permit 
direct comparisons across trials. 
IV. Abstracts and full length articles were included. 
v. Time of enrollment following AMI was specified in the trials. 
VI. Duration of treatment and follow up was continued for at least 6 months in the 
secondary prevention studies. 
6.2.3 Data Extraction 
6.2.3.1 Study Design Characteristics 
Data regarding the number of patients allocated in each treatment group, design, time of 
enrollment with regard to the acute event, time treatment started, dose of sotalol, route 
of administration, duration of exposure and follow up during the long-term studies 
were extracted from text, tables and figures. 
6.2.3.2 Population Demographic and Diagnostic Criteria 
In addition to details of patients' demographic criteria which was mentioned in Chapter 
4, other relevant diagnostic criteria for this chapter were extracted as follows: 
• Left ventricular ejection fraction (L YEF). 
• PVCs inclusion criteria, and/or baseline PVCs (mean or median ± SD/SE). 
• Number of patients with prior history of MI. 
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• Number of patients with congestive heart failure (CHF), together with its severity 
measurement according to New York Heart Association (NYHA). 
• Number of patients with coronary artery disease (CAD). 
• Number of patients receiving other B-blockers. 
• The major arrhythmic type and pattern in the subpatient popUlations. 
6.2.3.3 Outcome Measures 
Data regarding the following end points were extracted as number of events for 
dichotomous type, and mean or median together with its standard error or standard 
deviation for continuous type: 
• Conventional therapeutic end points employed in sotalol RCTs: heart rate, 
infarction size, arrhythmias, and non-fatal cardiovascular events 
• Short -term mortality data in acute trials 
• Long-term mortality data in chronic trials: 
6.2.4 
i. For trials which utilised survival analysis techniques, particularly Kaplan-
Meier product-limit method, to delineate life table curves, the actuarial 
percentages were deduced from the published curves which were scanned and 
read carefully at different time points by using Cricket Graph Computer 
Package. 
ii. For trials which did not report the published survival curves, the total 
number of deaths at the end of the follow-up interval, was extracted. 
Statistical Analysis and Data Synthesis 
6.2.4.1 Kaplan-Meier Product-Limit Method 
A survival curve for a group of patients is a graph representing the estimate of the 
probability of a dichotomous outcome (for example, death or reversion to sinus 
rhythm) at various times (Coldman and Elwood, 1979). This curve has a step-pattern. 
Kaplan-Meier Product-Limit Method is one of the methods employed for constructing 
such a curve, which requires knowledge of number of patients lost to follow-up at each 
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time point (censored observations). 
The procedures for calculation of Kaplan-Meier percentage can be summarised as 
follows (Kaplan and Meier, 1958; Coldman and Elwood, 1979): for the ith time 
interval, (i=O, .... K), with Rj being the number of patients actually remaining under 
follow-up in the trial at the beginning of the interval, let dj be the number of events 
during this interval, and let Cj be the number of patients lost to follow-up (censored 
observations) up to the end ofthe interval. The number of patients remaining at risk at 
the beginning of the interval (Nj) can be calculated by: 
N j= Rj-cj 
Then, the probability of surviving that interval (Pj) is estimated by: 
Pj = 1-( d/nj) 
Assuming the first cumulative survival curve estimate (So) as well as the probability of 
surviving at time zero (Po) to be equal to 1, the subsequent survival curve value is 
given by: 
The approximate variance of the survival curve estimate is obtained by: 
2 i I-P. 
VarianceofS j = (S) L -P J 
j=i jnj 
Where the summation sign implies summation over all intervals preceding the one (i) 
interval for which the calculation is being performed and including the latter. 
To combine the Kaplan-Meier survival percentages across various trials the following 
equation was employed (Coplen et aI., 1990; Messori and Rampazzo, 1993): 
Where WT is equal to the inverse of the variance of Sj. 
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6.2.4.2 Calculation of 'Log-rank' Odds Ratios of Meta-analysis 
This method is usually employed for pooling data from survival studies with censored 
end points to test the effect of time on the progress of outcome (Pignon et al., 1992; 
EBCTCG, 1990). It has the advantage of enabling the comparison of the overall 
difference between two treatments while taking the whole survival curves into account 
(Messori and Rampazzo, 1993). 
In the present meta-analysis this method allows testing (for each time interval) the 
hypothesis zero that the probability of death not due to treatment effect by comparing 
the observed number of converted patients (0) in a treatment group with the number of 
patients that would have been expected to be converted (E) in the same group if the 
number of converted were equally distributed among the treatment and control group. 
The value of (E) can be calculated as the product of the total number of deaths during 
the first interval (in both treatment and control groups) by the number of patients at risk 
(in the treatment group) at the beginning of the same interval which is equal to N i 
(equation I), divided by the total number of patients in the trial. The value of O-E 
would be expected to differ only randomly from zero if the death was not due to 
treatment. After calculations of the sum of (O-E) values, and pooled OR according to 
Peto's method as described in Chapter 3, the 'log-rank OR' of the second time interval 
is calculated from the overall grand total of the quantities (O-E) for the first plus the 
second time interval, and their corresponding variances to yield the overall 'log-rank 
OR' of death during the period from zero time to the end of the second interval (till 6 
months). The same procedures were repeated for calculation of 'log-rank OR' for the 
subsequent third interval (till 102 months). 
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6.3 RESULTS 
6.3.1 Description of Trials Identified 
6.3.1.1 Sotalol Clinical Trials 
A total of thirteen studies met the inclusion criteria. For the racemic sotalol, five trials 
were short-term 'early intervention' trials (Table 6.1), and seven were long-term 'late 
intervention' trials (Table 6.2). For d-sotalol, only one long-term trial was identified 
(SWORD Investigators, 1996). 
Short-term trials 
All five trials were randomised, placebo-controlled, parallel-design studies. The total 
number of patients included was 2165; 1088 received sotalol, 68 received placebo, and 
1009 received sotalol+aspirin. Three of the five used a double-blind design (Astrom et 
al., 1986; McGrath et al., 1986; Juul-Moller et al., 1992), except that in the Swedish 
Angina Pectoris Aspirin Trial (SAPAT), the employment of sotalol was open-label, 
since both, treatment (aspirin) group, and control (placebo) group were treated 
simultaneously with sotalol. Three trials evaluated intravenous intervention (Astrom et 
al., 1986; Lloyd et al., 1988; McGrath et al., 1986), one oral intervention (Juul-Moller 
et al., 1992), and one intravenous plus oral doses (Llewellyn et al., 1986). The length 
of treatment in the acute phase varied from 24 hours to 7 days. The enrollment of 
patients in the acute studies varied from 6 to 12 hours after the onset of pain, with the 
exception of SAPAT trial again, in which the treatment was initiated prior to the 
development of acute MI phase. 
All trials were designed to evaluate the therapeutic end points concerned with the 
beneficial effects of the early beta-blockade in acute MI phase, particularly 
heomodynamic effects on heart rate and blood pressure. In addition, one trial was 
designed to assess the effect on plasma and urinary catecholamine responses (McGrath 
et al., 1986). Another study tested the induced adverse effect of sotalol on increasing 
the left ventricular end-diastolic volume (Lloyd et al., 1988). Other therapeutic end 
points will be discussed later in detail in section (6.3.3.1.1). 
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Long-term Trials 
d,l-sotalol trials enrolled a total of 1744 patients; 1027 received sotalol, and 621 
received placebo, 18 received flecainide, 20 received timolol, 18 received encainide, 49 
received atenolol, 30 received amiodarone, and 17 received lignocaine. Three of the 
seven studies were randomised placebo-controlled (Myburgh et al., 1979; Julian et al., 
1982; Langbehn et al., 1985), while the remainder were randomised, active-controlled 
studies (Spielman et aI., 1985; Cobbe et al., 1988; Amiodarone vs Sotalol Study 
Group, 1989; Ho et at., 1994). Five trials used double-blind with crossover (Myburgh 
et at., 1979; Langbehn et aI., 1985, Cobbe et al., 1988; and Ho et at., 1994) or parallel 
design (Julian et aI., 1982) and two were open-label, parallel design (Spielman et al., 
1985; Amiodarone vs Sotalol Study Group, 1989). 
Four trials evaluated fixed oral dosage of 320 mg/day, while titration up to maximum 
tolerated level was permitted in two studies (Cobbe et aI., 1988; Spielman et aI., 1985). 
Only one study evaluated the acute effect of intravenous intervention in patients with 
remote MI admitted in emergency room (Ho et al., 1994). 
Patient enrollment varied between 5 days to 96 months post acute phase of MI. The 
intervention phases lasted 21 days to 23 months. The major arrhythmic type reported 
was of ventricular origin in all studies, and the antiarrhythmic effect of the treatment 
was provided in all trials except one (Julian et aI., 1982). 
The SWORD trial was multicenter, randomised, double-blind, placebo-controlled and 
parallel designed trial which evaluated oral dosage of 200 mg/day of d-sotalol, that was 
increased to 400 mg if required. It enrolled a total of 3121 patients (1549 sotalol-
treated, and 1572 placebo-treated). While racemic sotalol trials enrolled only patients 
with chronic MI, the SWORD trial enrolled patients with either a recent (6-42 days) MI, 
or a remote (> 42 days) MI. The duration of the follow-up was continued for 300 
days. 
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Table 6.1 Characteristics of randomised clinical trials of sotalol in treatment of recent or suspected acute myocardial infarction 'early 
intervention' 
Trial Design Dosage Enrollment No. of Treatmellt allocation Type of 
Sotalol/Colltroll patients (Flecainidel control 
randomised Control) 
Astrom et af. 1986 R,DB, PL, P IV 254 mglday Within 24 hours 20 10/10 Placebo 
(214-336) I 6±1.51l5±1.5 
Llewellyn et al. 1986 R,PL,P IV (120 mg) and oral Within 12 hour 50 22128 Placebo 
(320 mg) daily 
Lloyd et al. 1988 R,PL,P 40 mg IV over 10 mins, Less than 12 hours 30 15/15 Placebo 
if no side effects 5.3/5.9 
occurred two further 
doses of 40 mg were 
similarly given to a 
maximum total dose of 
120mg 
luul-Moller et al. 1992 DB, PL, R, P. 160 mg orally (40-480 Before the occurrence 2035 Sotalol+Aspirin; 1009 Sotalol+Pla-
The use of mg) I day ofMI cebo; 1026 
Sotalol was 
unblinded. 
McGrath et al. 1986 R,DB,PL, P Img/kg IV at 10 mg/min < 6 hours 30 15/15 Placebo 
followed by 160 mg/day 5.3±O.214.8±O.4 
for 7 days 
'Early intervention' indicates that treatment allocation was assigned within 72 hours of onset of symptoms or as soon as possible after hospital admission. 
Enrollment; the time elapsed after the incidence of index acute myocardial infarction. 
Primary end poillts Duration of 
treatment 
Infarction size, 48 hours 
arrhythmias, heart rate 
Heart rate, arrhythmias 24 hours 
Heart rate, blood pressure, 72 hours 
infarction size, 
arrhythmias 
All cause mortality, fatal 50 (range 23-76) 
and non-fatal myocardial months 
infarction, vascular events 
Infarction size, 7 days 
arrhythmias, heart rate, 
catecholamine level 
-- -
DB, double-blind; SB, single-blind; P, parallel; CO, crossover; PL, placebo-controlled; IV, intravenous; 0, oral; C, comparative study; 'I, mean time from onset of symptoms or pain to infusion start 
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Table 6.2 Randomised clinical trials of sotalol in treatment of myocardial infarction 'long-term interventions' 
Siudy Design Dose Roule N.randomised I 
(Reference) N.Colllil1ued The 
Study 
Myburgh et al. 1979 R, DB, PL,CO 320 mg/d for 28-day Oral 20/20 
period then an open 
phase in which the dose 
titrated for optimal 
requirements 
Julian et at. 1982 Multicenter, R, DB, 320 mg/day Oral I 456INS 
PL,P 
Langbehn et al. 1985 R, DB, PL,CO 320 mg/day Oral 18/18 
Spielman et al. 1985 R,C,P 320 mg/day Oral 55/55 
Cobbe et al. 1988 R,DB,CO 320 mg/day, titration Oral 103/103 
up to 480 mg/day was 
permitted 
Amiodarone vs Multicenter, R, P The initial dose was Oral 59/32 
Sotalol Study Group 256±77 (range 160-
1989 320) mg/day and that 
on which patients were 
stabilized was 491±163 
(range 160-640) 
mg/day 
Ho et al. 1994 R,DB,CO IV sotalol; 100 mg IV 33/33 
over 5 min 
Waldo and the Multicenter, R, DB, 200 mg or 400 mg of Oral 3121INS 
SWORD PL,P d-Sotalol daily 
investigators 1995 
Long-term 'late intervention' trials are those in which patients enrolled at least 4 days after MI. 
Enrollment; the time elapsed after the incidence of index acute myocardial infarction. 
Trealment Type of Enrollment 
allocation cOlltrol 
(Sotl 
Cant) 
20120 Placebo 6-96 months 
(mean 42 months) 
873/583 Placebo 5-14 days after MI 
18/18/18 Flecainide NS 
Placebo 
17/20/18 Timolol; 20 7-28 days post MI 
Encainide; 18 
54/49 Atenolol 7-10 days after 
admission 
29/30 Amiodarone 16 patients> I year 
after AMI 
10 patients between I-
12 months prior AMI 
9 patients between 1 
week and 1 month 
16/17 Lignocaine NS 
1549/1572 Placebo 2208 pts had remote 
MI(>42 days) and 91 I 
had AMI (6-42 days) 
Primary end poinls Duration of 
treatment 
Suppression of PVCs 6 months 
Mortality, reinfarction 12 months 
PVCs% suppression, 21 days 
blood pressure 
Arrhythmias, mortality NS 
Arrhythmia frequency, 12 months 
effect on QT-interval, 
deaths, reinfarction 
Termination of VT, 23 months 
deaths 
Termination of VT, 30 min 
deaths 
Mortality, reinfarction 300 days 
'-----
DB, double-blind; SB, single-blind; P, parallel; CO, crossover; PL, placebo-controlled; IV, intravenous; Com, comparative study; PVCs, premature ventricular contractions; V A, ventricular arrhythmia; VT, 
ventricular tachycardia; Sot, sotalol; Cont, control. 
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6.3.1.2 Amiodarone Clinical Trials 
Thirty three clinical trials were initially identified addressing the indication of 
amiodarone for prolonging the survival in patients at high risk for sudden death. 20 
trials were excluded from the analysis: seven due to employment of open-label, 
uncontrolled design (Cleland et al., 1987; Herre et aI., 1989; Strasberg et al., 1990; 
Kerin et al., 1991; Rodriguez et aI., 1992; Proclemer et al., 1993; Scheinman et al., 
1995); five were designed to evaluate different efficacy end points and long-term 
mortality data were not reported (McKenna et al., 1981; Schmidt et al., 1985; Novo et 
aI., 1988; Fournier et aI., 1989; Greco et aI., 1989; Mahmarian et aI., 1994); 4 were in 
the form of preceding abstract (Hamer et aI., 1988; Luna et al., 1990; Stewart et al., 
1989; Siebels et aI., 1992); and three were duplicate publications for the same trial 
(Singh et al., 1992; Singh et al., 1993; Massie et al., 1996). Only 12 trials satisfied the 
inclusion criteria, two of which, the Canadian Acute Myocardial Infarction Amiodarone 
Trial (CAMIAT) and the European Myocardial Infarction Amiodarone Trial (EMIAT), 
were still ongoing trials, with incomplete mortality data and were also excluded from 
analysis. 
The design characteristics of the remaining 11 trials are shown in Table 6.3. The trials 
collectively randomised 3229 patients: 1497 received amiodarone, 841 received 
placebo, 215 received Class I, 130 received metoprolol, and 542 acted as a control and 
did not receive any antiarrhythmic treatment. The sample size of each study varied 
between 34 to 674 patients, with a mean of 293 patients over all studies. 
Six trials employed randomised, double-blind, placebo-controlled, parallel design 
(Hockings et al., 1987; Hamer et al., 1989; Cairns et al., 1991; Nicklas et al., 1991; 
Ceremuzynski et al., 1992; Singh et aI., 1995). Four other randomised trials employed 
a control group, and allocation to treatment was single-blind (Garguichevich et al., 
1995), or on an open-label basis (Pfisterer et al., 1993; Navarro-Lopez et al., 1993; 
Doval et al., 1994; and Garguichevich et al., 1995). Another large trial compared 
amiodarone to conventional treatment with Class I agents (The CASCADE 
investigators, 1993). 
All trials employed an initial oral loading dose which varied between 400 to 1000 
mg/day for 5 to 28 days (mean 740±231 mg/day for a mean of 15 days), followed by a 
lower maintenance dose which varied between 200 to 600 mg (mean 330±11 mglday). 
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Table 6.3 Randomised clinical trials of amiodarone in treatment of myocardial infarction 'long-term interventions' 
Stlldy Design Dose ROllte N.randomised I 
(Reference) N.Continued Tile 
Study 
Hockings et al. 1987 R, DB, P, PL 600 mg/day for 4 weeks, Oral 100/100 
then 200 mg/day 
Hamer et al. 1989 R, DB, P, PL 600 mg/day for 2 weeks, Oral 16/14 
then 200 mg/day 
Cairns et al. 1991 (CAMIAT R, DB, P, PL Loading dose of 10 Oral 48/29 
pilot study) mg/Kg/day for 3 weeks, 
then a maintenance dose of 
300-400 mg/day, which 
was then tapered depending 
on the response 
Nicklas et af. 1991 R, DB, P, PL 400 mg for 4 weeks, Oral 49/52 
then a maintenance dose of 
200 mg/day 
Ceremuzynski et af. 1992 R, DB, P, PL Initial dose of 800 mg/day Oral 305/308 
for the first 7 days, 
thereafter, 400 mg for 6 
days a week for 12 months 
(decreased to 200 or 100 
mg/day if heart rate is <55 
beats/min) 
_._--
Long-term 'late intervention' trials are those in which patients enrolled at least 4 days after MI. 
Enrollment; the time elapsed after the incidence of index acute myocardial infarction. 
Type of Enrollment Primary end points 
co"trol 
Placebo < 8-10 days after AMI Suppression of arrhythmia, 
death 
Placebo - Beneficial effect of 
amiodarone on L VEF, exercise 
tolerance, side effects, and 
mortality 
Placebo Within 6-30 days after Arrhythmia suppression, 
AMI arrhythmic death, resuscitated 
VF, cardiac death, noncardiac 
vascular death, and 
nonvascular death 
Placebo - Sudden death, noncardiac, 
suppression of arrhythmia 
Placebo Between the 5th and Sudden cardiac death, 
7th days after mortality from any cause, and 
admission occurrence of serious V A 
Dllration of 
treatme"t 
6-42 months 
22 (3-30) months 
2 years 
12 months 
12 months 
DB, double-blind; S8, single-blind; P, parallel; C, controlled study; CO, crossover; PL, placebo-controlled; IV, intravenous; Com, comparative study; PVCs, premature ventricular contractions; VA, 
ventricular arrhythmia; VT, ventricular tachycardia; Am, amiodarone; Cont. control; AMI, acute myocardial infarction. 
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Tahle 6.3 Randomised clinical trials of amiodarone in treatment of myocardial infarction 'long-term interventions' (continued) 
Stlldy Vesigll Vose RO/lte Treatmellt 
(Referellce) al/ocatioll 
(A m/ 
COllt) 
The CASCADE investigators R,P,O,Com Initial loading dose of Oral 113/115 
1993 1200 mg/day for 10 days, 
then 200-800 mg/day 
(mean 600 mg) for 1-2 
months, then the dose was 
tapered to a maintenance 
dose of 100-400 mg/day 
Pfisterer et al. 1993 (BASIS) R,O,C,P A loading dose of 1000 Oral 98/114/100 
mg for 5 days, followed 
by 200 mg/day 
Navarro-Lopez et al. 1993 R,O,C,P A loading dose of 600 Oral 11511301123 
(SSSD) mg/day, followed by 200 
mg/day for the first week, 
then 400 mg/day the 
second week 
Doval et al. 1994 (GESICA) R,O,C,P 600 mg/day for 14 days, Oral 260/256 
then 300 mg/day for 2 
years 
Long-term 'late intervention' trials are those in which patients enrolled at least 4 days after Ml. 
Enrollment; the time elapsed after the incidence of index acute myocardial infarction. 
Type of ('olltrol Ellrol/mellt Primary elld poillts 
Conventional therapy with Within 6 months of Cardiac mortality, sudden 
other Class I drugs the index VF arrhythmic death, 
resuscitated out-of-hospital 
VF, and nonarrhythmic 
cardiac death 
Control (No antiarrhythmic Within 16±9 days Sudden cardiac death, 
treatment); 114 after the acute non sudden cardiac death, 
Class I; 100 phase of infarction noncardiac death, 
arrhythmic events, and 
effect on ventricular 
arrhythmia 
Metoprolol; 130 10-60 days after Sudden or non sudden 
Control (No antiarrhythmic AMI cardiac death, 
treatment); 123 Median time, cardiovascular or 
(36/37/47) noncardiovascular, nonfatal 
cardiac events 
Control (undefined) 
- Total mortality, sudden 
death, death due to 
progressive heart failure 
V/lratioll 
of 
treatmellt 
8 years 
72 (55-125) 
months 
3 years 
720 days 
DB, double-blind; S8, single-blind; p, parallel; C, controlled study; CO, crossover; PL, placebo-controlled; IV, intravenous; Com, comparative study; PVCs, premature ventricular contractions; VA, 
ventricular arrhythmia; VT, ventricular tachycardia; Am, amiodarone; Cont, control; AMI, acute myocardial infarction. 
226 
Table 6.3 Randomised clinical trials of amiodarone in treatment of myocardial infarction 'long-term interventions' (continued) 
Study Design Dose Route Treatment 
(Reference) allocation 
(AmI 
Cont) 
Garguichevich et aJ. 1995 (EPAMSA) R,SB,C,P A loading dose of Oral 57/49 
800 mg/day for 14 
days, 
then 400 mg/day for 
the rest of 12 months 
Singh et al. 1995 (STA TCHF) R,DB,PL,P 800 mg/day for 14 Oral 336/338 
days, 
then 400 mg/day for 
50 weeks, 
then 300 mg/day till 
the end of the study 
Long-term 'late intervention' trials are those in which patients enrolled at least 4 days after MI. 
Enrollment; the time elapsed after the incidence of index acute myocardial infarction. 
Type of control Enrollment Primary end points 
Control (No ~ 6 months after MI Sudden death, congestive 
antiarrhythmic heart failure death, other 
treatment); 49 cardiac death, noncardiac 
death 
Placebo 
-
Sudden death, congestive 
heart failure death, other 
cardiac death, noncardiac 
death, suppression of 
arrhythmia, effect on left 
ventricular ejection fraction 
Duration of 
treatment 
12 months I 
4.5 years 
DB, double-blind; S8, single-blind; P, parallel; C, controlled study; CO, crossover; PL, placebo-controlled; IV, intravenous; Com, comparative study; PVCs, premature ventricular contractions; V A, 
ventricular arrhythmia; VT, ventricular tachycardia; Am, amiodarone; Cont, control; AMI, acute myocardial infarction. 
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The patient enrollment varied between 5 days to 6 months post acute phase of MI. 
Four trials enrolled patients with congestive heart failure or serious coronary artery 
disease, with or without MI (Hamer eta/., 1989; Nicklas et al., 1991; Doval et al., 
1994; Singh et al., 1995). Inclusion of those trials was justified, since the 
overwhelming majority of those patients have the potential for development of MI with 
increased risk of sudden death (Teo et al., 1993). 
The duration of follow-up in the studies varied between 6 to 96 months, with a mean of 
34.33 months. 
6.3.2 Patient Demographic Criteria 
6.3.2.1 Sotalol Clinical Trials 
Table 6.4 shows details of patient characteristics in sotalol (racemic) trials. The mean 
age of the patients across all studies which reported the age (9 studies), was 
58.66±5.22 years (range 52.5 to 68). In the 7 studies reporting gender, there was a 
total of 1057 women and 1433 men. The total number of patients who had a previous 
history of MI attack before the index MI was 5 (3 sotalol-treated; and 2 control-treated) 
in short-term studies, and 183 (89 sotalol-treated; and 114 control-treated) in long-term 
studies. Data regarding the mean left ventricular ejection fraction (L VEF) was 
mentioned in 3 studies, with a total mean of 37.52±7 mm (range 32.04 to 43). The 
mean PVCslhr inclusion criteria varied significantly across the 6 studies reporting it 
from IIhr to 4061hr. 
In addition to MI, other associated cardiac complications were congestive heart failure 
in 44 patients (22 sotalol-treated, and 22-control-treated), angina in 2107 patients (1047 
sotalol-treated, and 1060 control-treated), and hypertension in 124 patients (65 sotalol-
treated, and 59-control-treated). Total number of patients receiving other beta-blockers 
was 61 patients (32 sotalol-treated, and 29-control-treated) in one trial (Cobbe et al., 
1988), zero in 8 trials, and not stated in two trials. Prognostic classification of the 
arrhythmia associated with patients included in this analysis was based primarily on the 
risk of sudden cardiac death according to the criteria discussed earlier in Chapter 2. 
Consequently, the ventricular arrhythmia was considered prognostic ally important or 
potentially lethal iIi eight studies (3410 patients), and malignant in two studies (1515 
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patients). 
Comparison between the trials' subgroups data regarding the age and left ventricular 
ejection fraction by using unpaired t-test and one way analysis of the variance, did not 
reveal a significant difference in distribution. 
6.3.2.2 Amiodarone Clinical Trials 
Table 6.5 delineates the details of patient characteristics in amiodarone trials. The mean 
age of the patients across all studies, which reported the age (10 studies), was 
61.44±3.5 years (range 56 to 70). In the 9 studies reporting gender, there was a total 
of 728 women and 2251 men. Data regarding the mean left ventricular ejection fraction 
(LVEF) was available in 9 studies, with a total mean of 30.63±9.3 mm (range 17 to 
46). The mean PVCslhr inclusion criteria ranged between 3.4 and 30 PVCs/min. 
Comparison of mean age and mean L VEF among treatment subgroups in individual 
studies by one way analysis of the variance suggested nonsignificant difference. 
In five trials (Cairns et al., 1991; The CASCADE investigators, 1993; Pfisterer et al., 
1993 ; Navarro-Lopez et al., 1993; and Singh et aI., 1995) the total number of patients 
concomitantly receiving beta-blocker therapy was 306 patients; 112 in amiodarone 
group, and 194 in control group (chi-square = 4.798, df=4, P=0.0285). Examination 
of the distribution of other dichotomous diagnostic variables, including the number of 
patients with a previous history of MI, coronary artery disease, and anterior or inferior 
MI, did not reveal significant difference (p>0.05). However, the male percentage was 
significantly higher in amiodarone-treated patients (chi-square = 16.8, P=0.000042). 
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Table 6.4 Population characteristics of included sotalol studies 
--- -- - --- -------
Study Meall Age±SD Gellder, MIF History oj AMI PVCs LVEF, No. NYHA No. Corollary No. patients Patiellts No. patiellt with 
illclusiotl meatl%±SD% CHF Class artery diseases with other Receivillg Cardiomyopathy 
criteria associated B-B/ocker 
cardiac diseases 
Myburgh et a/. 53 (38-65) - 20 15lhr - - - 20MI - 0 -
Julian et al. 55.4±7.9, 55.2±7.9 160/40 15,15 NS - 21122 - 873/583 MI 12. 13 hypertension 0 0 
28123 angina 
Spielman et al. - - 17 sotalol, 18 ~ IOlhr :S40 
encainide, 20 timolol 
- - 17/18120 MI - NS -
Astrom et al. 57±2.9, 64±3 
-
1,0 300lhr - - - 15115 AMI 0 0 -
Llewellyn et aI. - - - mean±SD; - - - - - NS -
S;206±284 
P;406±513 , 
Lloyd eta/. 5S.2 (37-70), 221S - 360lhr 48.7±16.5, - - - - 0 -
52.5 (34-69) 49.4±14.5 
Cobbeetal. 56.7±7.3, 53.7±9.4 93/10 5,5 > IIhr in 88 pIS - I/O - 515 MI 13, 3 hypertension 32,28 -
and> IIO/hr in 
13 pts 
Amiodarone vs SotaIol 59.8±14.6, 6O.8±12.2 48/11 18,20 NS 32.8± 12, 36± 16. - - 10/ II angina - 0 -
study group 
Juul-Moller et al. 67±8,67±8 1058/977 - NS - - - 100911026 angina 40, 43 hypertension 0 -
McGrath et al. 53±3,55±2 2614 2,2 NS - - - 15/15MI - 0 -
Hoe/al. 6S±6 (56-SO), 26/7 Old MI; 13, 15 NS 33±1O (IS-45), - - 14I16MI - 0, I 0, I 
61±IS (21-90) Acute MI; I, I 361 17(19-76) 
Waldo and SWORD 6O.4±IO, 59.9±9.8 26841437 527,503 NS 3IM.S. 30.8±7 IOS/126 Class 1 1549/1572 MI 573, 550 hypertension 511,503 
-
investigators 1115/1131 Class II 
341/330 Class 111 
The first data set represents a sotalol-treated group; second data set represents a control-treated group; AMI, acute myocardial infarction; CHF, number of patients with congestive heart failure; LVEF, left ventricular 
ejection fraction; NYHA class, New York Heart Association functional class; PVCs, premature ventricular contractions 
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Table 6.S Population characteristics of included amiodarone studies 
Study Meall Age±SJ) Gender, MIF History oj AMI PVc.~ LVEF, No. NYHA No. Corollary No. patients with Patiellts A IIteriorllnjerior 
il/c/usioll lIIeal/%±SJ)% CHI" Class artery diseases other associated Receivil/g MI 
criteria cardiac diseases B·Blocker 
Hockings et aJ. 19S7 . . . . . . . . . 
· 
57/34.5S/42 
Hameretal. 1999 70.66 . . . 19.17 413 II 8/10 8.4 cardiomyopathy 
· 
. 
11110 III 
III IY 
Caimsetal.I991 64.66 35113.2316 56148 ~IO PYCs/min . 13/9 - 27114 . 17.8 18/30.12117 
(CAMIAT pilot study) 
Nicklas et al. 1991 56±1.59±1 4118.4517 
-
204 PYCslhr 19±1.21±1 39144 III 25/28 -
· 
. 
1018 IV 
Ceremuzynski et aI. 59.4±12.3. 58.6±11.8 88/217.98/210 50/45 NS ~4O 154.155 - - - 132. 148 hypertension - 1561138. 1571136 
1992 
S4098.105 
The CASCADE 63±1O.62±1O 103110.99116 80172 ",10 PYCs/min 35±1O. 35±14 54148 I.II.IY 96192 17. 23 noncoronary 7.6 -
investigators 1993 artery disease 
pfisterer el aL 1993 61±7. 61±6 C. 60±8 79119.97117.9119 37/56136 ~IO PYCs/min 46±2. 42±2. 41±2 - - - 46. 50. 45 hypertension 35.49.46 31167. 50/64. 44156 
(BASIS) CI 
Navarro-Lopez el aI. 58±10. 59±1O M. 100115. 12317. 32126/25 8 PYCslhour 35±7. 34±7. 35±7 22117120 I. II - 37. 36. 32 hypertension 40.22.47 36129.42132.43/31 
1993 57±9C 108115 
Doval el al. 1994 58.5.60.1 211145. 198/62 98/103 ~IO PYCs/min 20. 19 52156 II - 102. 105 hypertension - -
(GESICA) 1231126 III 
81178 IV 
Garguichevich el aI. 62±8.6O±JO 82118.73127 25118 8OPYCs/min 27±7.27±7 - - 25118. MI 20. 19 cardiomyopathy 
- -
1995 (EPAMSA) 12. 12 chagasic heart 
disease 
Singh el al. 1995 65±8.5.66.1±8.1 333/3. 33414 - ~IO PYCs/min <30226.222 414 I 2421239 - 13.16 -(STATCHF) 30-40 110. 116 1791179 II 
135/144 III OIlY 
- - -
The first data set represents amiodarone-treated group; second data set represents control-treated group; C, control group; CI, class I; M, metoprolol; AMI, acute myocardial infarction; CHF, congestive heart failure; 
L VEF, left ventricular ejection fraction; NYHA class, New York Heart Association functional class; PVCs, premature ventricular contractions 
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I 
6.3.3 
6.3.3.1 
6.3.3.1.1 
6.3.3.1.1.1 
Efficacy 
Sotalol clinical trials 
Conventional therapeutic end points employed in 
short-term acute trials 
Infarct size 
Recent studies have demonstrated a significant correlation between infarct size and total 
creatine phosphokinase (CPK) into the circulation (Willerson et al., 1972; Norris et al., 
1980; International Collaborative Study Group, 1984). Hence, early therapeutic 
intervention, which can alter the enzyme release and consequently reduce the 
myocardial damage, were thought to be determinant for improving the prognosis of 
acute MI. Clinical trials frequently produce indirect measurement of infarct size as the 
percentage reduction in enzyme release or ECG changes (Yusuf et al., 1985). In this 
review, three short-term, placebo-controlled trials evaluated the effect of early 
intravenous sotalol for limiting infarct size in the acute phase of MI (A strom et al. , 
1986; McGrath et aI., 1986; Lloyd et al., 1988). The infarct size was determined by 
accumulated creatine kinase release and peak CK. Table 6.6 displays the results 
observed in these trials. Estimation of a pooled effect size was hindered by incomplete 
and inconsistent reporting of means together with their standard errors or standard 
deviations in individual trials. The treatment effect on the enzyme level was favourable 
in only one trial of 30 patients (Lloyd et al., 1988). However, further validation is 
required in a larger trial. 
Table 6.6 
Trial 
Astrom et al. 1986 
McGrath et al. 1986 
Lloyd et at. 1988 
CK, creatme kmase 
Summary of the effect of antiarrhythmic treatment with 
sotalol on serum enzyme release 
Enzyme Cumulated release p 
and/or peak value of 
the enzyme 
Rx Control 
CK 
-
- NS 
CK Peak CK (lUll); 113±13 Peak CK (lUll); 125±16 NS 
Cumulated release; 199±24 Cumulated release; 184±21 
CK Peak CK (lUll); 912 Peak CK (lUI\); 257 P< 
0.03 
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6.3.3.1.1.2 Effect on heart rate 
Heart rate was considered an important haemodynamic index which might predict, 
better than any other parameter the beneficial effect of beta-blockers in acute myocardial 
infarction with regard to mortality and nonfatal reinfarctions (Kjekshus et aI., 1986). 
This was explained by the possible decrease in oxygen requirement with a subsequent 
reduction in infarction size. This had supported the concept of the antiischemic rather 
than antiarrhythmic mechanism of action (Kjekshus et al., 1982). A previous overview 
of early intervention trials of beta-blockers has shown a close relation between 
reduction in heart rate of at least 15 beats/min during infarct evolution, and reduction of 
infarct size between 25% and 30% (Kjekshus et aI., 1986). It has also suggested that a 
reduction of the heart rate of < 8 beats/min has no effect or may even increase infarct 
size. 
In this overview, four sotalol placebo-controlled RCTs (of a total of 62 sotalol-treated; 
and 67 placebo-treated patients) examined the effect of sotalol on heart rate at different 
time points throughout the study period after intravenous infusions in the ICU unit. 
Mean heart rate at each time point together with its standard deviation, or standard 
error, were extracted from the published graphs (Astrom et al., 1986; McGrath et al. , 
1986), or tables (Llewellyn et al., 1986; Lloyd et al., 1988). 
The weighted mean change compared to baseline for sotalol and placebo treated groups 
(dt and dp respectively), individual trial effect sizes, and pooled effect sizes under fixed 
and random effects models are listed in Table 6.7. As shown in Figure 6.1, the pooled 
effect size was statistically significant at all time points under the fixed-effects model. 
However, due to heterogeneity of effect, random-effects model was employed at 30 
mins, 2, 4, and 6 hours. As a result, the pooled effect has not reached the level of 
significance at 2 and 4 hours. Correlation analysis between the effect on heart rate and 
the reduction in all cause mortality or morbidity (non-fatal reinfarctions) by reduction of 
infarct size was not feasible, since the later data were missing from most trial reports. 
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Time points 
30 mins (3, 47/52) 
Pooled (Fixed effects) 
Pooled (Random effects) 
2 hours (2, 25/24) 
Pooled (Fixed effects) 
Pooled (Random effects) 
4 hours (2, 25/24) 
Pooled (Fixed effects) 
Pooled (Random effects) 
6 hours (2, 25/24) 
Pooled (Fixed effects) 
Pooled (Random effects) 
12 hours (3, 40/39) 
Pooled (Fixed effects) 
24 hours (2,30/30) 
Pooled (Fixed effects) 
Favours Placebo Favours Sotalol 
uw:.;;w;; au pw uzwa ;au 
iie; niX;; ;;;;;UlWUW # Wi;;;;;;; ";;a:::;;;;::,";;;;;;" •• ;;":.;;",,".";;;;,, csua 
'P'" "",,",,!!, ., ' 
-1 o 1 2 3 4 5 
Effect Size 
Figure 6.1 Effect of early administration of intravenous sotalol on 
heart rate in acute myocardial infarction as compared to placebo. 
The number of trials pooled and total number of patients are 
shown in brackets. 
Table 6.7 l\leta-anal)tic estimates for the effect of sotalol on heart rate 
Trial Tillie No.pts Treatmellt effect Placebo effect Effect size Z (P) IlIfar£"( redudio" Mortality reductio" 
poi"t (SIC) (dt)§, (dp)§, (95% CI) (OR; P) 
(beats/mills):tSDp (beatsl", illS ):tSD p 
Llewellyn et al. 1986* 30 mins 22/28 -17±9.4 2±13.2 1.378 (0.8-1.98) 4.5** Not stated Not stated 
Astrom et al. 1986* 30 mins 10/9 -8±7.1318 -6±12 0.998 (0.15-1.9) 2.3** NS Not stated 
McGrath et al. 1986* 30 mins 15115 -20±19.02 1.6±5.2 3.65 (2.7-4.6) 7.2** NS OR; 0.5 (NS) 
Pooled 30 mins 47/52 - - FEs; 1.73 (1.3-2.2) 7.7** - -
REs; 1.97 (0.56-3.39) 2.7** 
Astrom et al. 1986* 2 hrs 10/9 -6.2±6.93 1±28.6423 0.76 (-0.08-1.59) 1.8 (NS) NS Not stated 
Lloyd etal. 1988* 2 hrs 15/15 -20.5±19.04 4±6 2.66 (1.7-3.6) 5.5** Significant compared Not stated 
to placebo 
Pooled 2 hrs 25/24 - - FEs; 1.59 (0.96-2.214) 4.97** - -
REs; 1.692 (-0.17-3.6) 1.78 (NS) 
Astrom et al. 1986* 4 hrs 10/9 -6.2±5.513 -2.74±28.8 0.54 (-0.28-1.37) 1.3 (NS) NS Not stated 
McGrath et al. 1986* 4 hrs 15/15 -20±19.02 S.2±5.8 3.1 (2-4.04) 6.3** NS OR; 0.5 (NS) 
Pooled 4 hrs 25124 - - FEs; 1.6 (0.99-2.2) 5** - -
REs; 1.8 (-0.69-4.3) 1.42 (NS) 
Astrom et al. 1986* 6 hrs 10/9 -S±5.5127 2.1±27.5 0.99 (0.14-1.834) 2.3** NS Not stated 
Lloyd etal. 1988* 6 hrs 15/15 -21.9±18.7 4±6.4 2.4 (1.5-3.34) 5** Significant compared Not stated 
to placebo 
Pooled 6 hrs 25/24 - - FEs; 1.6 (0.996-2.3) 5** - -
REs; 1.68 (0.29-3.1) 2.4** 
Astrom et al. 1986* 12 hrs 10/9 -6.4±7.3342 -3.67±14 0.64 (-0.19-1.5) 1.5 (NS) NS Not stated 
McGrath et al. 1986* 12 hrs 15/15 -19.67±17.6872 -15.4±7.9644 1.11 (0.23-1.98) 2.5** NS OR; 0.5 (NS) 
Lloyd et al. 1988* 12 hrs 15/15 -20.6±15.597 -3.1±26.964 0.85 (0.1-1.597) 2.2* Significant compared Not stated 
to placebo 
Pooled 12 hrs 40/39 - - FEs; 0.85 (0.4-1.3) 3.6** - -
McGrath et al. 1986* 24 hrs 15/15 -IS.49S±17.695 4.7±14.8472 0.61 (-0.13-1.35) 1.6 (NS) NS OR; 0.5 (NS) 
Lloyd et al. 1988* 24 hrs 15/15 -17.2±15.7519 0.7±26.9382 0.9 (0.13-1.64) 2.3* Significant compared Not stated 
to placebo 
Pooled 24 hrs 30/30 - - FEs; 0.74 (0.22-1.3) 2.76** - -
S, sotalol; C, control; §, Mean change compared to baseline; SOp, pooled standard deviation of the change; *, statistically significant; **, highly statistically significant; FEs, fixed-effects model; 
REs, random-effects model; NS, not significant. 
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6.3.3.1.1.3 Prevention and termination of arrhythmias 
Two placebo-controlled, short-tenn trials evaluated the efficacy of sotalol in preventing 
the development of various types of arrhythmia episodes post acute MI (McGrath et aZ., 
1986; Lloyd et al., 1988). Figure 6.2 and Table 6.8 display the meta-analytic ORs for 
prevention of PVCs, VT, and VF. The results were significant in favour of sotalol for 
prevention of PVCs only (OR, 0.229; 95% CI, 0.08-0.65; Z=-2.8, P<O.OI). 
However, three other trials have estimated the difference in the PVCs frequency (Table 
6.9) between sotalol and placebo (Llewellyn et al., 1986; Astrom et al., 1986) or 
another beta-blocker atenolol (Cobbe et aZ., 1988), and the individual trial results were 
not significant. Due to the inconsistent reporting of mean PVCs/24 hours in the three 
trials, a meta-analytic rate difference could not be estimated. 
Furthennore, the remedial action of sotalol for termination of various episodes of 
arrhythmia development during chronic MI was evaluated in long-tenn trials (Myburgh 
et ai., 1979; Langbehn et ai., 1985; Spielman et aZ., 1985; Hou et al., 1994). Although 
the data were reported in various fonns (for example, number of patients with a specific 
percentage of PVCs suppression), only the number of patients with complete VT and ~ 
70% suppression were included in the analysis. Table 6.10 and Figure 6.2 give the 
individual odds ratios for suppression of arrhythmia with various treatments. Due to 
variation in duration of treatment, route of administration, as well as employment of 
different control groups, pooling was not possible. In the placebo-controlled trial 
(Myburgh et al., 1979) sotalol displayed more efficacy than placebo in completely 
abolishing PVCs. However, this did not reach the conventional level of significance. 
It has also been shown to be more efficacious than timolol in suppressing PVCs and 
VT (Spielman et al., 1985) with OR equal to 9.7 (95% CI, 1.6-59.7). Furthennore, 
intravenous sotalol was superior to intravenous lignocaine for acute tennination of VT 
(Hou et aZ., 1994) and of comparable efficacy to flecainide and encainide (a two Class 
IC agents), with OR equal to 0.42 (95% CI, 0.12-1.5) and 0.45 (95% CI, 0.08-2.5) 
respectively. 
In spite of the previous estimations, a finn conclusion, with regard to sotalol' s efficacy 
relative to other drugs for termination of arrhythmia in patients at high risk, can not be 
drawn without a larger trial. In addition, validation of this efficacy criterion in the light 
of its effect on mortality and morbidity in MI patients is also essential. 
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Prevention of arrhythmia 
Versus placebo 
VT 
McGrath et al1986 (9/13) 
Lloyd et al1988 (IS/IS) 
Pooled (Fixed effects) 
Pooled (Random effects) 
VF 
McGrath et al1986 (9/13) 
Lloyd et al1988 (IS/IS) 
Pooled (Fixed effects) 
PVCs 
Lloyd et al1988 (IS/IS) 
Total (All arrhythmia types) 
Termination of arrhythmia 
VTand PVCs 
Myburgh et al1979 (Placebo, 20/20) 
Langbehn et al 1985 (Flecainide, 18/18) 
Spielman et al198S (Encainide, 11115) 
Spielman et al 19S5 (Timolol, IllS) 
Hou et al 1994 (Lignocaine, 16/17) 
SOlalol better 
I I 
SOlalol worse 
"" 
0.001 0.01 
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I 
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I I I 
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-
-
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I I I 
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Figure 6.2 Efficacy of sotalol for prevention or termination of arrhythmias 
in patients with acute or chronic myocardial infarction respectively. The 
figure depicts odds ratios with their 95% CI as compared to a direct 
control group in acute and long-term studies. 
Table 6.8 Prevention of arrhythmia incidence from sotalol short-term trials 
Study name Basic data Peto's method 
(no. arrhythmia event/llo. randomised) 
Sotalol group Control group O-E Var (O-E) OR (95% CI) Z statistic for effect (P) 
McGrath et al. 1986 VT; 8/9 7/13 1.864 1.21 4.6 (0.79-27.8) 1.7 (NS) 
VF; 1/9 1113 0.18182 0.46 1.48 (0.08-26.7) 0.27 (NS) 
Lloyd et al. 1988 pves 6/min; 15/15 15115 0 14.5 I (0.019-50.4) o (NS) 
pves, coupled; 4115 8/15 -2 6 0.34 (0.08-1.44) -1.5 (NS) 
pves, multiform; 0115 7115 -3.25 3.75 0.11 (0.02-0.54) -2.7 (NS) 
VT; 3115 14/15 -5.5 1.91 0.06 (0.014-0.23) -3.99** 
VF; 0/15 2115 -0.75 0.593 0.28 (0.02-3.6) -0.97 (NS) 
Pooled for VT 11/24 21/28 -3.636 3.12 FEs, 0.3 (0.1-0.95) -2* 
REs, 0.49 (0.01-37.8) -0.32 (NS) 
Pooled for VF 1124 3/28 -0.5682 1.05 FEs, 0.58 (0.086-3.9) -0.6 (NS) 
Pooled for pves No. events; 19 30 -5.25 3.6 FEs, 0.23 (0.08-0.65) -2.8** 
Pooled for all types No. events; 31 54 -10 6.4 FEs, 0.2 (0.097-0.5) 
-3.9** 
REs, 0.299 (0.05-1.9) 
-1.3 (NS) 
pves, premature ventricular contractions; VF, ventricular fibrillation; VT, ventricular tacchycard; *, statistically significant; **, highly statistically significant; FEs, fixed-effects model; REs, random-effects 
model; NS, not significant 
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Table 6.9 The sotalol effect on VPCs frequency in post MI trials 
Trial VPCs124 hrs Type of 
I 
Significance of the 
control difference 
Rx Control 
Llewellyn et af. 1986 Mean±SD; 206±284 406±S13 Placebo NS (P=O.07) 
Astrom et al. 1986 Not stated Not stated Placebo NS 
Cobbe et al. 1988 Median (range); Baseline,S (0-10429) Atenolol NS 
Baseline, ll.S (0-2226) 6 days, 8 (0-672) 
I 6 days, 16 (0-4202) 
PVCs, premature ventricular contractions 
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Table 6.10 Efficacy for termination of arrhythmias during chronic MI 
Trial No. of pts with terminated Peto's method 
arrhythmia/No. total 
Sotalol Control O-E Var (O-E) OR (95% CI) Z statistic for effect (P) 
M yburgh et at. 1979 PVCs, 4120 0120 PL 1.75 1.02404 5.523 (0.796-38.3) 1.73 (NS) 
Langbehn et al. 1985 PVCs, 7/18 11118 Flecainide -2 2.31429 0.42 (0.116-1.5) -1.3 (NS) 
Spielman et al. 1985 70% PVCs and VT, 7/11 12115, Encainide -1.04 1.29852 0.4495 (0.08-2.5) -0.9 (NS) 
0/8, Timolol 2.7 1.2 9.7 (1.6-59.7) 2.5* 
Hou et al. 1994 VT,11I16 3/17 Lignocaine 4.2 2.07622 7.61 (1.95-29.6) 2.9** 
--
PL, placebo; PVCs, premature ventricular contractions; VF, ventricular fibrillation; VT, ventricular tacchycard; *, statistically significant; **, highly statistically significant; FEs, fixed-effects model; 
REs, random-effects model; NS, not significant 
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6.3.3.1.1.4 Short-term Mortality 
Mortality data were classified into sudden cardiac (presumed arrhythmic), other cardiac, 
noncardiac, undefined, and total mortality (all cause) as shown in Table 6.11 for the 
acute short-term, and long-term trials (discussed in the subsequent section). 
Table 6.12 and Figure 6.3 provide the calculated odds ratios for total mortality on 
sotalol in both types of trials. When mortality was not reported, an assumption that no 
deaths occurred in either treatment groups was made. Unfortunately, short-term trials 
of oral or intravenous sotalol reported very limited data on mortality. Only in one acute 
trial (McGrath et al., 1986) of 30 patients (15 sotalol-treated and 15 placebo-treated), 
one death was reported in the placebo group. Another RCT (Juul-Moller et al., 1992) 
involving 2035 patients had a comparison of the effect of sotalol+placebo versus 
sotalol+aspirin for the prevention of all cause mortality as primary objective, and 
sudden death in patients with chronic unstable angina. The study demonstrated a 
significant reduction in sudden cardiac death when aspirin was added to sotalol but no 
conclusions could be drawn with regard to sotalol's absolute efficacy in reducing 
mortality (Figure 6.3). 
In general, the acute studies were very small in sample size and were not designed to 
examine short-term mortality. 
6.3.3.1.2 Chronic long-term trials 
6.3.3.1.2.1 Long-term mortality 
A total of six d,l-sotalol (racemic sotalol) long-term trials have reported on mortality 
(Myburgh etal., 1979; Julian etal., 1982; Spielman etal., 1985; Cobbe eta!., 1988; 
Amiodarone vs Sotalol Study Group, 1989; Hou et al., 1994). Only three of these 
were designed primarily to assess the effect of the drug on mortality (Julian et al., 
1982; Spielman et aI., 1985; Amiodarone vs Sotalol Study Group, 1989), and only one 
was placebo-controlled (Julian et al., 1982). Thus a meta-analytic pooled odds ratio 
was not calculated. 
Table 6.12 and Figure 6.3 display the individual odds ratio for total mortality in the six 
studies. As shown, no additional benefit for racemic sotalol over placebo, other beta-
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Total mortality (aU cause) 
Acute studies 
McGrath et al1986 (Placebo, 15/15) 
Juul-Moller et a11992 (S+A', 1026/1009) 
Long term studies 
Julian et al 1982 (Placebo, 873/583) 
Spielman et al1985 (Encainide, 17/18) 
Spielman et al 1985 (Timolol, 17120) 
Cobbe et al1988 (Atenolol, 54/49) 
Amiodarone vs Sotalol study group 1989 (Am', 29/30 
Hou et al1994 (Lignocaine, 16/17) 
SWORD investigators 1996 (Placebo, 1549/1572) 
Sudden cardiac death 
Acute studies 
McGrath et al 1986 (Placebo, 15/15) 
Juul-Moller et a11992 (S+A', 1026/1009) 
Long tenn studies 
Myburgh et al1979 (Placebo, 20/20) 
Julian et al1982 (Placebo, 873/583) 
Spielman et al1985 (Encainide, 17/18) 
Spielman et al1985 (Timolol, 17/20) 
Cobbe et al 1988 (Atenolol, 54/49) 
Amiodarone vs Sotalol study group 1989 (Am', 29/30 
Hou et al1994 (Lignocaine, 16/17) 
SWORD investigators 1996 (Placebo, 1549/1572) 
Other cardiac death 
Acute studies 
McGrath et al1986 (Placebo, 15/15) 
Juul-Moller et a11992 (S+A*, 1026/1009) 
Long term studies 
Myburgh et al 1979 (Placebo, 20/20) 
Julian et al1982 (Placebo, 873/583) 
Cobbe et al1988 (Atenolol, 54/49) 
Amiodarone vs Sotalol study group 1989 (Am', 29/30 
Hou et al 1994 (Lignocaine, 16/17) 
SWORD investigators 1996 (Placebo, 1549/1572) 
Noncardlac death 
Acute studies 
McGrath et al1986 (Placebo, 15/15) 
Long term studies 
Myburgh et al 1979 (Placebo, 20/20) 
Julian et al1982 (Placebo, 873/583) 
Hou et al 1994 (Lignocaine, 16/17) 
SWORD investigators 1996 (Placebo, 1549/1572) 
Undefined death 
Acute studies 
McGrath et al 1986 (Placebo, 15/15) 
Long tenn studies 
Myburgh et al1979 (Placebo, 20/20) 
Julian et al1982 (Placebo, 873/583) 
Spielman et al 1985 (Encainide, 17/18) 
Spielman et al1985 (Timolol, 17/20) 
Cobbe et al 1988 (Atenolol, 54/49) 
Amiodarone vs Sotalol study group 1989 (Am', 29/30 
Hou et al 1994 (Lignocaine, 16/17) 
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Figure 6.3 Odds ratios for total mortality, sudden cardiac death, other cardiac deaths, 
noncardiac death, and undefined death in sotalol short-term acute or long-term chronic 
interventions for treatment of myocardial infarction. Type of control and number of patients 
randomised in each group are shown in brackets. ·S+A, sotalol+aspirin; Am, amiodarone. 
Table 6.11 Mortality data reported in sotalol randomised clinical trials 
Study Sudden Cardiac Deaths Other cardiac Deaths Noncardiac deaths Undefined Deaths Total Mortality 
Myburgh et al. 0/20 S, 0/20 PL 0/20 S, 0/20 PL 0/20 S, 0/20 PL 0/20 S, 0/20 PL 0/20, 0120 PL 
Julian et al. 25/873 S, 14/583 PL 37/873 S, 36/583 PL 21873 S, 1/583 PL 1/583 PL 64/873 S, 52/583 PL 
Spielman et al. 6/17 S, 1118 E, 1/20 T NS NS 4/18 E, 3120 T 6/17 S, 5/18 E, 4/20 T 
Astrom et al. * 0/10 S, 0/9 PL 0/10 S, 0/9 PL 0/10 S, 0/9 PL 0/10 S, 0/9 PL 0/10 S, 0/9 PL 
Llewellyn et at. * 0/28 S, 0/28 PL 0/28 S, 0/28 PL 0/28 S, 0/28 PL 0/28 S, 0/28 PL 0/28 S, 0/28 PL 
Lloyd et al. NS NS NS NS NS 
Cobbe eta/. 1154 S, 0/49 A 2154 S, 0/49 A NS 10/54 S, 10/49 A 13/54 S, 10/49 A 
Amiodarone vs sotalol study 2129 S, 0/30 Am 1129 S, 0/30 Am NS 4/29 S, 8/30 Am 7/29 S, 8/30 Am 
group. 
Hou etal. 0/16 S, 1117 Lig 1/16 S, 1117 Lig 0/16 S, 0/17 Lig 0/16 S, 0/17 Lig 1/16 S, 1117 Lig 
luul-Moller el al.I 19/1009 S+As, 6611009 S+As, - - 8211009 S+As, 
31/1026 S+PL 85/1026 S+PL 10611026 S+PL 
McGrath et al. * 0/15 S, 1/15 PL 0/15 S, 0/15 PL 0/15 S, 0/15 PL 0/15 S, 1115 PL 0/15 S, 1115 PL 
Waldo and SWORD 56/1549,3211572 PL 17/1549, 13/1572 PL 5/1549,3/1572 PL 
-
78/1549 S, 48/1572 PL 
investigators 
* Early intervention trial; A, Atenolol; Am, Amiodarone; As, Aspirin, E, Encainide; Fie, Flecainide; PL, Placebo; Lig, Lignocaine; S, Sotalol; T, Timolol; 'I, The patients included 
in this study had chronic stable angina pectoris which can predispose to fatal or non-fatal myocardial infarction 
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Table 6.12 Total mortality data and statistical analysis of full-exposure group in randomised clinical trials of sotalol 
Study name Basic data Peto's method 
(No dead/No followed up) 
Sotalol group Control group O-E Var (O-E) OR statistic for effect 
(95% Cl) 
McGrath et al. * 1986 0/15 1/15 PL -0.25 0.3685 0.5075 (0.02-12.8) -0.4 
Julian et af. 1982 64/873 521583 PL -5.5522 25.6484 0.81 (0.6-1.19) -1.1 
Spielman et af. 1985 6/17 5/18 E 0.6571 1.9396 1.4 (0.34-5.7) 0.472 
4120 T 1.4054 1.8627 2.13 (0.5-8.9) 1.03 
Cobbe et al. 1988 13/54 10/49 A 0.9417 4.4992 1.23 (0.49-3) 0.44398 
Amiodarone vs sotalol study 7129 8/30 Am -0.3729 2.844 0.88 (0.3-2.8) -0.22 
group 1989 
Juul-Moller et af. 1992 106/1 026 PL+S 8211009 As+S -11.2147 42.676 0.77 (0.57-1.04) -1.72 
Hou et al. 1994 1116 1117 Lig 0.0303 0.4839 1.065 (0.064-17.8) 0.0436 
Waldo and SWORD 78/1549 48/1572 PL 15.4643 30.2363 1.67 (1.17-2.4) 2.812 
investigators 1996 
* Early intervention trial; A, Atenolol; Am, Amiodarone; As, Aspirin, E, Encainide; Fie, Flecainide; PL, Placebo; Lig, Lignocaine; S, Sotalol; T, Timolol; * statistically significant 
(P<0.05); ** highly statistically significant (P<O.OI) 
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blockers (timolol and atenolol), Class IC agent (encainide), another Class III drug 
(amiodarone), or lignocaine was demonstrated. 
Restricting the comparison to sotalol versus other beta-blockers, the pooled OR for total 
mortality and undefined deaths in two trials (of total 71 versus 69 patients) did not 
show any significant difference for the two treatments (ORtotaJ, 1.44; 95% CI, 0.67-
3.15; Q=0.39, P=0.53; and ORundefined, 0.72; 95% CI; 0.296-1.8; Q=1.05, P=0.31). 
On the other hand, the pooled results for prevention of sudden arrhythmic death 
suggested a statistically significant effect for other beta-blockers over sotalol (OR, 5.19; 
95% CI, 1.214-22.2; Q=0.54, P=0.46), indicating that beta-blocker activity may be the 
main protective mechanism against sudden arrhythmic death. 
The survival with oral d-sotalol (SWORD) trial was a large (3121 patients), 
multinational, multicenter, placebo-controlled, randomised, and double-blind trial of d-
sotalol designed to test the hypothesis that the preventive effect was mainly due to a 
Class III activity. However, this study was stopped abruptly as d-sotalol increased 
total mortality relative to placebo (OR, 1.7; 95% CI, 1.2-2.4; Z=2.8; P<O.OI). 
6.3.3.1.2.2 Non-fatal cardiovascular events 
Reduction of reinfarction in patients who survived an acute MI is one of the major aims 
of further treatment (Singh, 1991). The prevention of non-fatal reinfarction was 
examined in four trials. Three were for racemic sotalol (Julian et al., 1982; Cobbe et 
aI., 1988; Juul-Moller et al., 1992), and one for d-sotalol (SWORD investigators, 
1996). Due to employment of different control groups (placebo in Julian et al., 1982; 
atenolol in Cobbe et al., 1988; and sotalol+aspirin in SAPAT trial, 1992), pooling the 
data was not possible. 
d,l-sotalol was significantly more effective than placebo in preventing reinfarction 
(Table 6.13.1). However, when compared to atenolol, there was no difference in the 
preventive effect. Addition of aspirin to sotalol increased the efficacy of sotalol in 
preventing non-fatal reinfarction in patients with chronic unstable angina (Juul-Moller et 
at., 1992). 
As shown in the Figure 6.4, no significant effect on other non-fatal events was 
observed. Moreover, d-sotalol has been shown not to have any superior efficacy when 
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Non-fatal reinfarction 
Julian et al 1982 (Placebo, 873/583) 
SWORD investigators 1996 (Placebo, 1549/1572) 
Cobbe et al1988 (Atenolol, 54/49) 
Juul-Moller 1992 (Sotalol+Aspirin, 1572/1549) 
Stroke 
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SWORD investigators 1996 (Placebo, 1549/1572) 
CABG 
Cobbe et al1988 (Atenolol, 54/49) 
Juul-Moller 1992 (Sotalol+Aspirin, 1572/1549) 
SWORD investigators 1996 (Placebo, 1549/1572) 
Proarrhythmia 
Langbehn et al1985 (Flecainide, 18/18) 
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Figure 6.4 Odds ratios for non-fatal cardiac events in sotalol long-term chronic 
interventions for treatment of myocardial infarction. Type of control and number of 
patients randomised in each group are shown in brackets. 
Table 6.13.1 Nonfatal rcinfarction from long-term trials of sotalol 
Siudy lIame Basic dala Peto's melhod 
(II oil/alai 
rein/arctions/llo.randomised) 
Sotalol group Control group O-E Var (O-E) OR statistic for effect (P) 
(95% CI) 
Julian el al. 1982 24/873 PL,221583 -3.6 10.7 0.7 (0.39-1.3) -1.1 (NS) 
Cobbe et al. 1988 4/54 A,4/49 -0.1942 1.86 0.9 (0.22-3.8) -0.14 (NS) 
Juul-MoHer et at. 1992 S+PL,78/124 As+S, 7/81 26.5854 11.95 9.3 (5.3-16.3) 7.7 (NS) 
Waldo and SWORD 24/1549 PL,24/1572 0.17687 11.82 1.02 (0.6-1.8) 0.05 (NS) 
investigators 1996 
A, Atenolol; As, Aspirin; PL, placebo; S, Sotalol 
Table 6.13.2 Nonfatal reinfarction from long-term trials of amiodarone 
Study name Basic data Peto's method 
(nonfatal 
reinfarctionslno.randomised) 
Amiodarone group Control group O-E Var (O-E) OR statistic for effect I 
(95% CI) (P) 
Ceremuzynski et al. 1992 14/305 PL,IO/308 2.05873 5.77 1.43 (0.63-3.23) 0.86 (NS) 
Navarro-Lopez et al. 1993 7/115 C,61123 0.71849 3.083 1.26 (0.4-3.9) 0.41 (NS) 
M,5/130 1.36735 2.854 1.61 (0.5-5.2) 0.81 (NS) 
Am, Amiodarone; M, Metoprolol; C, control (no antiarrhythmic drugs or undefined); PL, placebo 
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compared to placebo in preventing any non-fatal cardiac complications (SWORD 
Investigators, 1996). 
6.3.3.2 Amiodarone Clinical Trials 
6.3.3.2.1 Suppression of Ventricular Arrhythmias 
The efficacy of amiodarone for suppressing ventricular ectopy was assessed in four 
trials, with respect to frequency of ventricular premature beats (Nicklas et ai., 1991; 
Navarro-Lopez et ai., 1993; Pfisterer et al., 1993; Singh et al., 1995). Frequency was 
defined by average number of ventricular premature beats per hour during the entire 20 
to 24 hours of ECG recording. 
Table 6.14 and Figure 6.5 display the results of treatment effect expressed as weighted 
mean change compared to baseline for amiodarone, placebo, comparative drug (Class I, 
and metoprolol), individual trial effect sizes, and pooled effect sizes at 1,3,6, and 12 
months. Generally, amiodarone was more effective than placebo at I, 3, 6, and 12 
months. However, it appeared as effective as Class I drugs in one trial (Pfisterer et al., 
1993). Similar results were obtained from the comparison to metoprolol in another trial 
(Navarro-Lopez et al., 1993). Regression analysis of the treatment effect and odds of 
sudden arrhythmic death (Table 6.14) suggest a positive linear trend. 
6.3.3.2.2 Analysis of Mortality Data 
6.3.3.2.2.1 Single point estimates 
A total of eleven trials reported mortality data at the end of the observation period, 
according to the previously mentioned death classifications (section 6.3.3.1.1.4). Raw 
mortality data are shown in Table 6.15. In addition, eight trials presented actuarial 
survival curves for total mortality. Furthermore, in three trials separate survival curves 
were provided for sudden death. 
The Peto method was applied to mortality data reported at the end of the follow-up 
intervals. Table 6.16 and Figure 6.6.1 display the individual odds ratios of total 
mortality in all eleven trials. As shown in the Figure 6.6.1, pooling the results from the 
six placebo-controlled trials has demonstrated a trend for beneficial effect of 
244 
Versus Placebo 
1 month 
Nicklas et al 1991 (49/52) 
Navarro-Lopez et al 1993 (115/123) 
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Figure 6.S Efficacy of amiodarone for arrhythmia suppression 
(PVCslhr) as compared to placebo, Class I, and metoprolol. The 
total number of patients included in each trial is shown in 
brackets. 
Table 6.14 Efficacy of amiodarone for arrh)'thmia suppression following myocardial infarction 
- -
-_._.-
Trial Time No.pts Treatment effect Control effect Effect size Z (P) Odds of sudden death 
poillt (AI C) (dt)§, (dp)§, (95% Cl) 
(mollths) (PVCs/hr ):1:SDp (PVCs/lzr):1:SDp 
Versus Placebo 
Nicklas et al. 1991 I 49/52 -160. 7±57.5 -13.7±49.4 2.95 (2.497-3.4) 12.7·· 2.4 
Navarro-Lopez et al. 1993 I 1151123 -20±37.72 -8±37.8 0.32 (0.06-0.58) 2.39·· 0.64 
Singh et al. 1995 I 336/338 -188±415.95 -I3±465.5 0.38 (0.22-0.53) 4.76·· 0.83 
Pooled I 500/513 FEs; 0.6 (0.44-0.69) 8.65·· 
-
REs; 1.2 (0.043-2.3) 2.033· 
Pfisterer et al. 1993 3 981114 -23±11O 20±33.3 1.29 (0.997-1.58) 8.7·· 0.4485 
Nicklas et al. 1991 6 49/52 -137.75±59 -25.2±50.6 2.2 (1.77-2.65) 9.82·· 2.4 
Navarro-Lopez et al. 1993 6 1151123 -19±41.4 1±40.8 0.49 (0.23-0.75) 3.65·· 0.64 
Pfisterer et al. 1993 6 981114 -7±105.6 -19±133.4 0.09 (-0.2-0.36) 0.65 (NS) 0.4485 
Pooled 6 262/289 FEs; 0.59 (O.4H).77) 6.7·· -
REs; 0.9 (-0.12-1.9) 1.7 (NS) 
Navarro-Lopez et al. 1993 12 1151123 -26±37 -11±37.4 0.4 (0.14-0.66) 3·· 0.64 i 
Pfisterer et al. 1993 12 981114 -32±107.7 -7±139.4 0.18 (-0.09-0.45) 1.28 (NS) 0.4485 
Pooled 12 2131237 FEs; 0.29 (0.1-0.483) 3.1" -
V.Tsa. Clas:r I 
Pfisterer et al. 1993 3 981100 -23±11O.5 -9±103.3 0.14 (-0.15-0.42) 0.94 (NS) 1.304 
Pfisterer et al. 1993 6 981100 -7±105.6 -13±93.85 0.064 (-0.22-0.34) 0.45 (NS) 1.304 
Pfisterer et aI. 1993 12 981100 -32±107.7 -26±96.15 0.0622 (-0.22-0.34) 0.45 (NS) 1.304 
Versas Me/opTalal 
Navarro-Lopez et aI. 1993 I 1151130 -20±37.72 -10±147.16 0.068 (-0.18-0.32) 0.53 (NS) 0.398 
Navarro-Lopez et al. 1993 6 1151130 -I 9±4 1.4 -7±149.35 0.08 (-0.17-0.33) 0.62 (NS) 0.398 
Navarro-Lopez et aI. 1993 12 115/130 -26±37 -25±144.I75 0.007 (-0.24-0.26) 0.054 (NS) 0.398 
A. amiodarone; C, control; §. Mean change compared to baseline; SOP. pooled standard deviation of the change; *, statistically significant; **, highly statistically significant; FEs. 
fixed-effects model; REs, random-effects model; NS. not significant. 
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Table 6.15 Mortality data reported in amiodarone randomised clinical trials 
Study Sudden Cardiac Deaths Other cardiac Deaths Noncardiac deaths Ulldefined Deaths Total Mortality 
Hockings et al. 1987 41100 Am, 3/100 PL 5/100 Am, 4/100 PL 3/100 PL 71100 Am, 11100 PL 16/100 Am, 111100 PL 
Hamer et al. 1989 0/19 Am, 4/15 PL 4119 Am, 2115 PL 2119 Am, 0/15 PL - 6/19 Am, 6/15 PL 
Cairns etal. 1991 (CAMIAT) 1/48 Am, 4/29 PL 4/48 Am, 1/29 PL 0/48 Am, 1129 PL . 5/48 Am, 6/29 PL 
Nicklas et al. 1991 12149 Am, 6/52 PL 2149 Am, 3/52 PL . . 14/49 Am, 9152 PL 
Ceremuzynski et al. 1992 10/305 Am, 20/308 PL 9/305 Am, 13/308 PL 21305 Am, 0/308 PL - 21/305 Am, 33/308 PL 
The CASCADE investigators 1993 13/113 Am, 191115 Class I 101113 Am, 131115 Class I 41113 Am, 21115 Class I 
-
381113 Am, 55/115 Class I 
Pfisterer et al. 1993 (BASIS) 10/98 Am, 24/114 C, 8/100 Class I 9/98 Am, 121114 C, 11100 Class I 5/98 Am, 111114 C, 11100 Class I 7/98 Am, 61114 C 31198 Am, 531114 C, 10/100 Class I 
Navarro-Lopez et al. 1993 31115 Am, 91130 M, 51123 C 11115 Am, 6/130 M, 41123 C 01115 Am, 21130 M, 01123 C 
-
41115 Am, 17/130 M, 91123 C 
Doval et al. 1994 (GESICA) 321260 Am, 39/256 C 441260 Am, 521256 C 41260 Am, 4/256 C 71260 Am, 111256 C 871260 Am, 1061256 C 
Garguichevich et al. 1995 4/57 Am, 10/49 C 2157 Am, 4/49 C 0/0 0/0 6157 Am, 14/49 C 
(EPAMSA) 
Singh et al. 1995 (CHFST AT) 64/336 Am, 75/338 PL 34/336 Am, 40/338 PL 221336 Am, 23/338 PL 111336 Am, 5/338 PL 1311336 Am, 143/338 PL 
---
Am, Amiodarone; M, Metoprolol; C, control (no antiarrhythmic drugs or undefined) 
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Table 6.16 Total mortality data and statistical analysis of full-exposure group in randomiscd clinical trials of amiodarone 
Study name Basic data Peto's method 
(No dead/No followed up) 
Amiodarone group Control group O-E Var (O-E) OR statistic for 
(95% CI) effect 
Hockings et af. 1987 16/100 111100 PL 2.5 5.868 1.5 (0.68-3.44) 1.03 
Hamer et al. 1989 6119 6/15 PL -0.706 1.9723 0.7 (0.174-2.8) -0.5 
Cairns et al. 1991 (CAMIAT) 5/48 6/29 PL -1.857 2.2427 0.44 (0.12-1.62) -1.24 
Nicklas et al. 1991 14/49 9152 PL 2.8416 4.48 1.89 (0.75-4.76) 1.34 
Ceremuzynski et al. 1992 211305 33/308 PL -5.8679 12.3306 0.62 (0.36-1.09) -1.67 
The CASCADE investigators 381113 551115 Class I -8.09 13.826 0.56 (0.33-0.94) -2.2 
1993 
Pfisterer et al. 1993 (BASIS) 31198 53/114 C -7.8302 12.67 0.54 (0.3-0.94) -2.2 
10/100 Class I 10.71 8.2 3.7 (1.87-7.4) 3.75 
Navarro-Lopez et al. 1993 4/115 171130 M -5.86 4.8 0.295 (0.12-0.7) -2.7 
(SSSD) 91123 C -2.2815 3.08 0.48 (0.16-1.5) -1.3 
Doval et al. 1994 (GES1CA) 87/260 106/256C -10.2481 30.3 0.71 (0.5-1.02) -1.9 
Garguichevich et al. 1995 6/57 14/49 C -4.7547 4.072 0.31 (0.118-0.82) -2.4 
(EPAMSA) 
Singh etal. 1995 (STATCHF) 131/336 143/338 PL -5.5935 40.7129 0.87 (0.64-1.2) -0.88 
M, Metoprolol; C, control (no antiarrhythmic drugs or undefined); * statistically significant (P<0.05); ** highly statistically significant (P<O.OI) 
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Figure 6.6.1 Odds ratios for total mortality, sudden cardiac death, and other cardiac 
deaths in amiodarone long-term chronic interventions for treatment of myocardial 
infarction. Number of patients randomised in each group are shown in brackets. 
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Figure 6.6.2 Odds ratios for noncardiac, and undefined deaths in amiodarone 
long-term chronic interventions for treatment of myocardial infarction. Number of 
patients randomised in each group are shown in brackets. 
amiodarone over placebo, but, the difference was not statistically significant. Pooled 
odds ratios of total mortality, sudden death, and death due to other cardiac causes were: 
0.77 (95% CI, 0.6-1.05; Z=-1.7), 0.88 (95% CI, 0.7-1.12; Z=-1.06), and 0.9 (95% 
CI, 0.6-1.3; Z=-0.62) respectively. However, combining the results of those trials 
with data from another three trials (The CASCADE Investigators, 1993; Pfisterer et al., 
1993; Navarro-Lopez et at., 1993), which employed a control group not receiving any 
antiarrhythmic treatment, has shown a highly significant effect in favour of amiodarone 
for reducing total mortality and sudden death, with pooled OR equal to 0.75 (95% CI, 
0.63-0.89; Z=-3), and 0.7 (95% CI, 0.6-0.89; Z=-2.96) respectively. The test of 
heterogeneity was nonsignificant (Q=14, df=9, P=0.12), confirming the validity of this 
. pooling. Pooling cardiac mortality data only did not show any significant effect for 
amiodarone on prevention of death due to other cardiac causes (OR, 0.82; 95% CI, 
0.63-1.07, Z=-1.5; heterogeneity Q=4, df=9, P=0.9). 
Pooling the results from two trials comparing amiodarone to Class I drugs (211 versus 
229 patients) did not show any significant difference for prevention of any type of 
deaths. Direct comparison of amiodarone with metoprolol in one trial (115 versus 123 
patients) suggested that the former was associated with a more favourable 3-year effect 
on total mortality (ORtotah 0.3; 95% CI, 0.13-0.7, Z=-2.7). Nevertheless, no 
significant difference in efficacy for prevention of sudden or other cardiac deaths was 
observed (OR sudden, 0.398, 95% CI, 0.13-1.3, Z=-1.6; and 0Rother cardiac, 0.26; 95% 
CI, 0.06-1.2, Z= 1.8). 
Further investigation for effect on noncardiac and undefined death did not detect any 
favourable trends with amiodarone (Figure 6.6.2). 
6.3.3.2.2.2 Meta-analytic survival analysis 
Table 1 and Table 2 of Appendix 6.2 display the raw actuarial survival data generated 
by the life-table method from eight published survival graphs for total mortality. As 
shown in Table 1 (Appendix 6.2), the data in four trials were considered completely 
censored due to the availability of the number of patients remaining at risk at the 
beginning of each time interval during the follow-up (Ceremuzynski et at., 1992; 
Navarro-Lopez et al., 1993; Pfisterer et at., 1993; Garguichevich et ai., 1995). For the 
other four trials (Nicklas et al., 1991; The CASCADE Investigators, 1993; Doval et al., 
1994; Singh et al., 1995), in which the number of patients at risk was not provided, 
total death events were approximated by calculations described earlier in section 
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6.2.4.1. 
Later on, the distribution of death events, and termination of follow-up over time was 
estimated by curve fitting using equation 4b of Kaplan-Meier method (1958), as shown 
in Table 3 of Appendix 6.2. 
For the three trials which contributed additional survival curves for sudden death only 
(Doval et al., 1994; Garguichevich et ai., 1995; Singh et ai., 1995), the actuarial 
estimates were generated using the previous sequence (Table 4, Table 5, and Table 6 of 
Appendix 6.2). 
The meta-analytic log-rank ORs for total mortality in trials with completely censored 
data yielded highly statistically significant results over the time interval from 
randomisation up to 102 months Table 7 (Appendix 6.2), indicating superior effect of 
amiodarone for prevention of total mortality as compared to placebo. With regard to the 
partially censored trials, the meta-analytic statistics conducted over the whole period, 
from randomisation to 36 months, produced nonsignificant ORs (Table 7: Appendix 
6.2). However, with respect to the subsequent 12 months (at the end of 4 years), the 
meta-analytic log-rank OR of 0.53 (95% CI, 0.3 to 0.9; Z = -2.28, P < 0.01) was 
highly significant. Concerning the meta-analysis of data generated by curve fitting in 
the same three trials, the results were not promising over the whole observation period. 
One trial was excluded from the primary direct comparison analysis due to the 
employment of Class I as a control group rather than placebo (CASCADE 
Investigators, 1993). 
A sensitivity analysis was performed by reconducting the pooling of the data from 
censored and partially censored trials (Analysis group 4, Table 7), then censored with 
those obtained by curve fitting (Analysis group 5, Table 7). The ORs of this repeated 
analysis were highly significant up to 102 months (8 years), which again suggested that 
amiodarone decreased the overall mortality rate compared to placebo. 
The analysis of the three trials, which contributed actuarial survival data for sudden 
death, involved a total of 1296 patients. This pooling demonstrated a marked reduction 
in sudden death for amiodarone, particularly during the first two years (P < 0.01). 
Separate pooling of completely censored data, and data generated by curve fitting, 
(Analysis group 1 and 3; Table 8) revealed evident beneficial effects of amiodarone 
only during the first two years but not thereafter (log-rank ORs were 0.66 [Z = -2.23, 
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Figure 6.9.2 Meta-analytic survival curve of sudden death reconstl1lcted 
from one trial with censored data and two trials with data generated by 
curve fit. The amiodarone displayed a highly significant effect for 
reduction of sudden death, as compared to placebo. 
P < 0.05] and 0.72 [Z = -2.1, P < 0.05] respectively). 
Table 9 and Table 10 of Appendix 6.2 displays the pooled survival rates together with 
their standard errors and the estimate of homogeneity which was consistently 
nonsignificant. Reconstructing the survival graph for the amiodarone treatment arm, by 
merging the life tables in the censored trials, censored pooled with no.ncensored trials, 
censored pooled with curve fitting trials, and curve fitting trials separately, 
demonstrated the significance of mixed meta-analytic pooling for providing more 
statistical power for detecting amiodarone effect (Figure 6.7). The indirect comparison 
of the whole profile of the four survival curves by log-rank test yielded a highly 
significant difference with respect to the curve obtained from censored and partially 
censored trials. Applications of the two techniques for reconstructing the survival 
curves for total mortality and sudden death in amiodarone and placebo treatment arms 
are presented in Figure 6.8 and Figure 6.9 respectively. The indirect comparison 
approach has confirmed that the conclusions of the previous direct comparison 
estimates favouring amiodarone efficacy. Notably, there was a greater difference 
between the whole curves of amiodarone and placebo for surviving sudden death, 
establishing a more marked effect of treatment on prevention of death due to 
arrhythmia. 
6.3.3.2.3 Non-fatal Cardiovascular Events 
The efficacy of amiodarone for prevention of non-fatal cardiovascular events was 
examined by combining the available data from trials which prospectively defined these 
events as primary or secondary end-points. Figure 6.10 displays the incidence 
calculated as individual and pooled odds ratios of non-fatal reinfarction, resuscitated 
sudden ventricular arrhythmia, proarrhythmia, congestive heart failure, stroke, 
syncope, angina, CABO, as well as any non-fatal cardiovascular events. Noticeably, 
although the results did not research the level of significance, amiodarone, like sotalol, 
did not show effectiveness for prevention of reinfarction, or development of new 
congestive heart failure. In fact, there were increased trends for reinfarction in 
amiodarone-treated patients in two trials (pooled OR, 1.37; 95% CI, 0.71-2.6; Z=0.9), 
and congestive heart failure in another two (pooled OR, 1.4; 95% CI, 0.88-2.4, 
Z=1.41). With the exception of resuscitated sudden VA, there was no significant 
difference in the occurrence of other types of events. 
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Figure 6.10 Odds ratios for non-fatal cardiac events in amiodarone long-term 
chronic interventions for treatment of myocardial infarction. 
6.3.3.2.4 Side Effects and Toxicity 
Table 6.17 and Figure 6.11 show the pooled relative risk of side effects, toxicity, and 
withdrawals in the long-term intervention trials of amiodarone. The reported adverse 
events were categorised into nine types: ocular, dermatological, gastrointestinal, 
neurological, hepatic, cardiovascular, pulmonary toxicity, thyroid toxicity, and 
withdrawals. As shown, the pooled relative risks of ocular, dermatological, 
gastrointestinal, neurological, hepatic, cardiovascular, and pulmonary toxicity events 
with amiodarone relative to placebo or class I antiarrhythmics, was not statistically 
significant. 
6.4 DISCUSSION 
The belief that suppression of premature ventricular contractions (PVCs) in survivors 
of acute myocardial infarction (AMI) can reduce the incidence of sudden death, has led 
the pharmaceutical industry to search for more effective antiarrhythmic agents for 
ventricular arrhythmia suppression in an attempt to improve the survival rate. 
Consequently, the number of antiarrhythmic drugs rose spectacularly throughout the 
1980s (Morganroth and Ooin, 1991). However, after the results of CAST (I & II) 
showing increased mortality with Class Ic agents, many physicians started in early 
1990s to appraise the use of other classes for treating potentially life-threatening 
ventricular tachyarrhythmias in MI survivors. The fact that beta-blockers prevent 
mortality in a variety of subsets of patients has led to a shift to more complex Class III 
molecules, which also possess sympatholytic activity. Today, despite the extensive 
research with Class III compounds, their precise role in prevention of sudden death 
remains questionable (Lazzara, 1996; Singh, 1996). 
The employment of intravenous beta-blockers, among many other interventions during 
the first few hours of AMI, is mainly considered for limitation of myocardial damage or 
mortality, or both (ACC I AHA Task Force, 1990). Beta-blockers act primarily by 
reducing the need for nutrients and oxygen by the ischemic myocardium (Yusuf et al., 
1985; Yusuf et al., 1988). Intravenous sotalol, which is a non-selective beta-blocker, 
may confer more benefit since it is devoid of unfavourable intrinsic sympathomimetic 
activity (Frishman and Cavusoglu, 1995). Review of available trials which assessed 
beneficial effects of early administration of sotalol in AMI, has revealed significant 
251 
Ocular side effects 
Versus Placebo 
Severe corneal microdeposits (2; 407/410) 
Other visual disturbances (3; 126/95) 
Dermatological side effects 
Versus Placebo (5; 768n64) 
Versus Class I (I; 99/101) 
Gastrointestinal side effects 
Versus Placebo (5; 980/978) 
Versus Class 1(1; 99/101) 
Neurological side effects 
Versus Placebo (4; 454/436) 
Hepatic dysfunction 
Versus Placebo (5; 552/534) 
Cardiovascular side effects 
Versus Placebo 
AV-Block (6; 110111095) 
Sinus bradycardia (4; 672/653) 
Symptomatic bradyarrhythmia (2; 106n9) 
Versus Clas I 
Sinus bradycardia (1; 99/1 0 1) 
Pulmonary toxicity 
Versus Placebo (5; 860/846) 
Versus Class 1(1; 113/115) 
Thyroid toxicity 
Versus Placebo (6; 839/865) 
Versus Class I (2; 213/230) 
Withdrawals 
Versus Placebo (8; 1174/1155) 
Versus Class I (2; 211/215) 
Versus Metoprolol (1; 1151130) 
Amiodarone better Amiodarone worse 
-
~ 
~ 
• '-+--0 
""'""*-
I e I 
I ~ 
."" 
-+-0 
0.1 10 100 1000 
Relative Risk (RR) 
Figure 6.11 Relative risk ofamiodarone toxicity and side effects as compared to 
placebo or active control in long-term intervention trials. The number of pooled 
trial and total number of patients included are shown in brackets. 
Table 6.17 Relative risk of amiodarone foxicity and side effects in long-term intervention tdals 
Category Comparison No. of trials No. of patients Pooled RR§ (95% C/) Z 
Ocular side effects 
Severe corneal microdeposits Versus placebo 2 407/410 8.4 (1.01-70.4) 1.97 
Other visual disturbances Versus placebo 3 126/95 3.08 (0.68-14) 1.5 
Dermatological side effects Versus placebo 5 768n64 1.24 (0.36-4.3) 0.34 
Versus Class I I 99/101 5.1 (0.25-104.9) 1.06 
Gastrointestinal side effects Versus placebo 5 980/978 1.22 (0.7-2.1) 0.7 
Versus Class 1 I 991101 3.1 (0.13-74.24) 0.7 
Neurological side effects Versus placebo 4 454/436 1.6 (0.885-2.7) 1.54 
Hepatic side effects Versus placebo 5 5521534 1.06 (0.44-2.6) 0.14 I 
Cardiovascular side effects 
AV-block Versus placebo 6 110111095 1.696 (0.87-3.32) 1.54 
Sinus bradycardia Versus placebo 4 6721653 2.99 (1.8-4.9) 4.3** 
Versus Class I 2 l06n9 5.1 (0.25-104.9) 1.06 
Symptomatic brady arrhythmia Versus placebo 1 99/101 2.04 (0.33-12.54) 0.77 
Pulmonary toxicity Versus placebo 5 860/846 2.33 (0.94-5.75) 1.83 
Versus Class I I 1131115 19.34 (1.4-328.3) 2.05 
Thyroid toxicity Versus placebo 6 839/865 4.5 (1.7-11.8) 3.1 
Versus Class 1 2 213/230 8.50.1-67.74) 2.03 
Withdrawals Versus placebo 8 1174/1155 1.08 (0.885-1.3) 0.74 
Versus Class I 2 2111215 1.43 (0.95-2.2) 1.73 
Versus Metoprolol I 115/130 1.4 (0.43-4.33) 0.52 
RR, relative risk 
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impacts on heart rate, infarction size, and suppression of PVCs (which are well-
established effects by all beta-blockers). Nevertheless, its definite value requires 
further validation in direct comparison of 'early intervention' studies, due to the 
confined reporting of short-term mortality data. In this analysis, comparison of sotalol 
to placebo did not show greater survival. Furthermore, direct comparisons have 
yielded superior effect for other beta-blockers compared to sotalol, which suggested 
that the additional Class III action of sotalol may not be solely responsible for the 
protective effect of ischemic myocardium against arrhythmic sudden death. In addition, 
this can be explained by sotalol being a Class III agent has exhibited a reverse use 
dependence phenomenon in which excess delay in repolarisation was produced at 
slower heart rate. This effect predisposed to torsades de pointes and proarrhythmias 
leading to excessive sudden death in sotalol-treatment group compared to placebo-
treatment group. Moreover, the results of SWORD trial evaluating the efficacy of pure 
Class III agent, d-sotalol has supported the findings of pharmacological studies which 
proved attenuated or nullified beneficial antifibrillatory effect of all pure Class III agents 
in the presence of high release of catecholarnines as in acute ischemia due to myocardial 
infarction (Singh, 1995). However, these studies did not demonstrate pronounced 
attenuation of Class TIl action when a drug was associated with additional beta-blocking 
activity such as arniodarone and racemic sotalol. 
Amiodarone is an extremely complex drug possessing the 4 electrophysiologic actions 
which are proposed by Vaughan Williams classification of antiarrhythmic mechanisms 
(Nademanee et al., 1993). The drug was first introduced as an antianginal vasodilator 
in 1962 (Singh and Vaughan Williams, 1970), and only recently it was found to have 
antiarrhythmic effects by blocking potassium channels, and thus lengthening the 
duration of action potential, but unlike other Class III agents, in a use-dependent 
fashion. In addition it depresses the sodium channel with a fast onset and offset 
kinetics. Consequently, it delays the conduction, particularly at faster heart rates and 
more often in diseased tissues rather than healthy tissues at normal heart rates. It also 
blocks the calcium channels in SA and A V nodal tissues, thereby slowing the phase 4 
depolarisation with subsequent decrease in the heart rate. More remarkablely, it is 
regarded as a potent anti adrenergic agent. 
The meta-analysis described in this chapter has produced a highly significant single 
point estimates of pooled ORs confirming amiodarone clinical effectiveness for 
prolonging the survival in patients with congestive heart failure or myocardial 
infarction. Furthermore, specific techniques for extracting actuarial survival data from 
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all published graphs in RCTs were employed to examine its long-term effect in 
congestive heart failure or AMI. The results of this survival meta-analysis support the 
previous conclusions based on single point estimates. The nonparametric log-rank 
odds ratios method was applied to raw actuarial data deduced from published Kaplan-
Meier graphs as well as data generated by curve fitting, using the original Kaplan-Meier 
equation to approximate the number of events and lost to follow-up (censored 
observations) in each study. Pooling each set of data separately has yielded highly 
significant log-rank ORs for total mortality in the first set of four censored trials (Iog-
rank OR at 102 months, 0.598; 95% CI, 0.43 to 0.83; Z = -3). However. log-rank 
ORs from data generated by curve fitting in a further three trials, were nonsignificant up 
to 48 months (log-rank OR, 0.87; 95% CI, 0.72 to 1.06, Z = -1.4). Merging of the 
two data sets has provided strong evidence of efficacy for improving survival in terms 
of both total mortality and sudden death. 
The precise link between the clinical evidence suggested by this overview of RCTs, 
regarding its superiority over other drug classes, and evidence contributed by the in 
vitro electrophysiological massive examinations remains uncertain. During ischemia. a 
rapid loss of intracellular potassium with over accumulation of extracellular potassium 
is reported to partially depolarise the membrane. Intracellular alteration of calcium ions 
concentrations will predispose to membrane depolarisation leading to abnormal 
automaticity and reentery (Nademanee etal., 1993). Amiodarone possesses the ability 
to block the potassium channels and may help to prevent the arrhythmias, due to 
ischemia. In addition, the binding of amiodarone to sodium channels was found to 
increase in depolarised tissues with subsequent increase of its effect on excitability of 
these tissues. Although this effect can be achieved by other Class III agents. such as 
sotalol (potassium channel blocking) and Class I agents (sodium channel blocking). 
amiodarone can also block calcium channels with a further inhibition of calcium-
mediated triggered activity inside the cells, such as accumulation of free fatty acids, 
causing arrhythmogenesis. Nevertheless, the effect of pure calcium c hanne I blockers 
on mortality appeared to be neutral or even deleterious (Teo et al., 1993). thus 
indicating that protective actions of amiodarone are essentially mediated by bcta-
blocking activity. Amiodarone, unlike other Class III agents, blocks the channels in a 
use-dependence manner without interfering with normal sinus rhythm. Therefore. it 
has a low proarrhythrnic potential which is an advantage over other agents. 
Prophylactic treatment with amiodarone should be initiated as early as possible post 
AMI, particularly within the first 6 months, during which time the risk of death was 
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highest (Zarembski et al., 1993; Pfisterer et al., 1992). In some individual trials 
(Pfisterer et al., 1993; Garguichevich et al., 1995) the two survival curves of 
amiodarone and control tended to diverge widely in the first 0-12 months period. then 
remained parallel thereafter without displaying any further significant difference. Yet. 
the pooled estimates of log-rank ORs yielded by the meta-analysis persisted significant 
throughout the follow-up period (mean of 34.33 months). This suggested the 
importance of continuation of arniodarone treatment for delaying of death. In fact. the 
beneficial effect of amiodarone was evident in some of the sensitivity subgroup 
analyses only after 6-12 months of treatment. 
It was reported that for a drug to significantly reduce the rate of ischemia-related deaths. 
it had to reduce either the incidence of recurrent MI or the associated fatal ventricular 
arrhythmias (Singh, 1991; Kjekshus, 1986). Yet in RCTs of sotalol and amiodarone 
reviewed in this meta-analysis, the pooled estimates for incidence of reinfarction. 
congestive heart failure, or any other non-fatal cardiovascular event. were not 
significantly different from placebo (Figure 6.4 & Figure 6.10). These events were not 
consistently employed as secondary outcome measures in all post MI trials making 
statistical analysis difficult. 
The ability of sotalol and arniodarone to suppress PVCs prior MI was also validated. 
However, a correlation of pooled effect size estimates at different time points to odds of 
mortality, did not display any dependent response or systematic relation. This 
confirmed that PVCs suppression criterion was merely a surrogate marker for mortality 
in this type of patients. 
Amiodarone-induced toxicity, was generally not serious possibly due employment of 
low doses (mean 330 mg/day within the range 200 to 600 mg/day). 
6.5 CONCLUSION 
The present study supports the recommendations of the World Health Organisation and 
Medicines Control Agency in the United Kingdom to restrict indication of racemic 
sotalol and d-sotalol to the treatment of ventricular arrhythmias or prophylaxis of 
supraventricular tachyarrhythmias, and to stop its use for secondary prevention after M I 
and for life-threatening ventricular arrhythmias (Committee on Safety of Medicines / 
Medicines Control Agency, 1996; WHO Drug Information, 1997). However, the 
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results strongly suggest that continued prophylactic use of amiodarone to prolong the 
survival in patients at high risk of sudden death due to arrhythmia complicating 
congestive heart failure or AMI is justified. 
Further validation of all the previous conclusions by updating this meta-analysis in the 
light of new data from trials which are still in progress is also recommended. 
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CHAPTER SEVEN 
GENERAL DISCUSSION, CONCLUSION, AND 
FUTURE DIRECTIONS 
7.1 DISCUSSION 
The general aim of this thesis was to undertake a systematic review of the use of 
antiarrhythmic agents in the management of cardiac arrhythmias. 
Three strategies are usually considered for conversion of acute atrial fibrillation: 
treatments directed at controlling the ventricular response rate while awaiting 
spontaneous conversion, pharmacological conversion, and electrical cardioversion 
(Talajic et al., 1996). Although several trials have suggested that class I or III agents 
are advantageous over others, it was not possible to identify the ideal drug class from 
the overall bulk of data. In addition, there was no published systematic overview 
covering the issue of pharmacological cardioversion by different antiarrhythmic drugs. 
Consequently, a systematic overview (Chapter 5) was undertaken including a total of 
42 trials which examined the efficacy and safety of the most frequently employed class 
I (flecainide), and class III (amiodarone and sotalol) drugs. Although some individual 
trials have concluded that intravenous amiodarone is superior to placebo for acute 
cardioversion and despite its increasing use in current clinical practice (Olshansky, 
1996), the present meta-analysis has failed to confirm its value for this indication. 
Data on the mean ventricular rate together with the associated standard deviation or 
standard error are not reported in most trials. In those cases, an upper bound 
assumption for calculating the standard deviation of mean difference in individual trials 
was employed (Cappuccio et al., 1989). The confidence interval of the individual 
effect sizes and the weighted mean change compared to baseline were therefore wider 
than would be the case with observed variances. Ventricular rate was considered a very 
important therapeutic end point. Yet, it was rarely provided for converted and 
unconverted patients separately. This made pooling and comparisons of response 
between these two subgroups impossible. 
The results of this meta-analysis has supported the high efficacy of intravenous and oral 
flecainide for prompt cardioversion. Although there was only limited data on oral and 
intravenous sotalol (3 randomised controlled trials), the pooled estimates at one hour 
confirmed the drug's superiority over placebo. Insufficient direct head to head 
comparison data were available to compare sotalol with flecainide. 
Patient diagnostic variables which are frequently identified in the literature as being 
important for successful conversion to sinus rhythm are: duration of arrhythmia, left 
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atrial diameter, age, and the presence and extent of structural heart diseases. 
Unfortunately, the relevant data are rarely reported and analysis of their impact on the 
efficacy of drug treatment could not be carried out. 
Although flecainide and sotalol are commonly employed in the United Kingdom, a new 
pure class III drug, ibutilide, was recently approved by FDA in the United States as a 
first line agent for pharmacoconversion mainly due to its apparent safety, rapid onset of 
action, and availability for intravenous administration for acute conversion. It was 
classed as a primary choice in The Adult Advanced Cardiac Life Support (ACLS) 
guidelines (Anderson, 1996). 
The issue of chronic treatment which should be initiated post-cardioversion for 
maintenance of sinus rhythm is still a controversial area in clinical practice due to the 
high relapse rate observed during long-term treatment following discharge. Unlike the 
use of amiodarone for acute cardioversion, the analysis in Chapter 4 has demonstrated 
improved benefit for amiodarone given orally on a chronic basis. The pooled 
percentage of patients maintaining sinus rhythm was consistently higher with 
amiodarone than with placebo and other traditional antiarrhythmic agents (quinidine, 
flecainide, or sotalol). This advantage was not associated with a higher incidence of 
pro arrhythmic events. 
It is important to emphasize that maintenance of sinus rhythm is not the only strategy 
for management of chronic atrial fibrillation and that Canadian Consensus Guidelines 
(Newman et al., 1996) propose two alternative strategies to prevent or reduce the 
symptoms associated with chronic relapse (dyspnea, palpitations, fatigue, and 
syncope), and to prevent serious thromboembolic complications. These strategies are 
heart rate control, and/or anticoagulation. However, none of the 42 clinical trials 
included in the meta-analysis has prospectively compared these strategies or evaluated 
the efficacy of antiarrhythmic drugs for reduction of thromboembolic complications. 
Therefore, the benefit obtained from maintenance of sinus rhythm may still have been 
introduced as a surrogate outcome measure in some patient categories, particularly 
those at highest risk for proarrhythmia, stroke, and systemic thromboembolism. Thus, 
although the meta-analysis undertaken had involved follow-up data concerning a total 
of 3937 patients for a mean of 16 months, a clear conclusion about the value of 
initiating antiarrhythmic therapy post-cardioversion can only be made by further 
investigation in larger trials which are precisely designed to compare the previously 
defined alternative approaches to the management of chronic atrial fibrillation. 
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The final part of the thesis involved a meta-analysis (Chapter 6) to assimilate the 
strongest evidence on the impact of antiarrhythmic drugs on mortality in patients at high 
risk of sudden death (post myocardial infarction and congestive heart failure). 
A meta-analysis based on pooling individual patient data from each study enables a 
more precise and less biased estimate of effect than can be achieved from a meta-
analysis of summary data (Clarke and Stewart, 1994). With such a method, it would 
have been possible to overcome the problems experienced in pooling censored outcome 
measures such as total mortality and sudden death, particularly in randomised clinical 
trials which employed the product-limit method to analyse the survival data. Moreover, 
the analysis based on time to each event would contribute greater statistical power than 
that produced using a limited number of time points with aggregate data. Although the 
authors of the individual trials which did not report individual length of follow-up for 
each patient, or total number of censored observations at each time point were 
contacted, they were all reluctant to share their data. 
An attempt was made to approximate the distribution of lost to follow-up and deaths by 
curve fitting. The pooled log-rank odds ratios as well as the single point pooled odds 
ratios confirmed the positive impact of amiodarone on prolonging the survival after 
acute myocardial infarction. 
Although curve fitting has been implemented by many authors to generate the number 
of events during follow-up duration (Pignon et al., 1992; Fine et al., 1993; Gregory et 
at., 1992; Messori etat., 1994), its application to any Kaplan-Meier survival curve to 
produce the final meta-analytic survival graph requires further validation. Its sensitivity 
to detect the censored estimates that should approximate the true original values remains 
to be determined by assembling larger numbers of randomised clinical trials which 
provided the raw actuarial data and reconducting the meta-analysis on original and 
curve fitting data separately. 
7.2 CONCLUSION 
The present meta-analyses suggest that amiodarone is a useful agent for maintenance of 
sinus rhythm. Overall, it is well tolerated and safe for this indication compared with 
other available agents such as flecainide and sotalol. 
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However, for acute conversion to sinus rhythm, the overall pooling of existing data has 
demonstrated optimal benefit and minimal risk with oral and intravenous flecainide, or 
intravenous sotalol. The lack of evidence supporting the use of intravenous 
amiodarone in the early period after cardiac surgery is important and impressive. The 
value of recently promoted pure class III agents for prompt cardioversion needs to be 
elucidated. 
The meta-analysis of survival curves supports the continuous indication of prophylactic 
antiarrhythmic therapy with oral amiodarone for improving survival in life threatening 
ventricular arrhythmias particularly in the setting of post myocardial infarction. The 
data from trials comparing d, I-sotalolor d-sotalol with placebo or other beta-blockers 
failed to show any prophylactic effect with respect to deaths. 
7.3 FUTURE DIRECTIONS 
1. To update the meta-analysis of amiodarone effect on survival (Chapter 6) 
by adding the results of two large-scale, multicentre, recently completed 
clinical trials (the Canadian Acute Myocardial Infarction Amiodarone Trial 
(CAMIAT) and the European Myocardial Infarction Amiodarone Trial 
(EMIAT). 
2. 
3. 
To validate the results of this meta-analysis by conducting another meta-
analytic approach based on individual patient data (in which the patient is 
the unit of analysis). This method would have several advantages as 
follows: (1) the ability to test the agreement between the two meta-analytic 
estimates, (2) the facility to examine the impact of confounding variables 
not investigated in the individual studies (such as patients diagnostic 
criteria, dose, and concomitant medications), and (3) the possibility to 
analyse the homogeneity of the patient populations. 
To undertake a systematic overview of randomised clinical trials 
addressing the efficacy and safety of Ibutilide (pure class III agent) which 
was recently approved by FDA for acute cardioversion. The results of this 
systematic evaluation would be further compared to pooled estimates of 
the efficacy and safety of flecainide and sotalol which were obtained in 
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4. 
5. 
this thesis (Chapter 5). 
To evaluate the impact of amiodarone on the quality of life of patients 
during long-term maintenance therapy by using a general health-status 
measure (the UK Sickness Impact Profile). 
A decision analytic approach to compare the various strategies for 
treatment of chronic atrial fibrillation would be worthwhile. Variables to 
be incorporated should include the following: 
• The meta-analytic estimates for the probability of maintenance of 
sinus rhythm or reversion to atrial fibrillation at 3, 6, and 12 
months. 
• The pooled relative risk for the incidence of proarrhythmia, stroke, 
any nonfatal toxicity, and sudden death during the three treatment 
strategies. 
The overall cost should include the costs of drug acquisition for I-year treatment, drug 
administration, routine medical care, adverse event management, and monitoring 
techniques for arrhythmia. 
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APPENDIX 4.2 
Appendix 4.2 
Table (1) Population Characteristics of the Included Studies (amiodarone clinical trials) 
Study name Age;mean years M:F Duration of AF Left atrial diameter, No. pts. chronic AF No. pts. paroxysmal No. pts with other forms of 
(range/±SD) (months) mm (range) or AFL AF supraventricular arrhythmias 
(Amiodarone/Con- (Amiodarone/Control) (AmiodaroneIControl) (AmiodaroneICon- (AmiodaroneIControl) 
trol) trol) 
Vitolo et al. 1981 * 52.6±1O.7 20:34 1.0I±O.97, 1.03±O.92 NA 54 AF (28/26) 0 0 
(54.7±1O.7, 
50.4±10.5) 
Martin et al. 1986* 75.6,74.1 29:41 NA NA 0 70 (43127) 0 
Bosi et al. 1990* 20-77 60:37 24 hours-30 days ~5 97 AF (48/49) 0 0 
Zehender et al. 1992· 59±5,57±6 23:17 6.l±3.7 (11-22), 4.8±3.9 (1-19) 50±5.2 (42-66), 40 AF (20/20) 0 0 
49±4.1 (43-64) 
Jong el al. 1995* 63±l2, 62±1l 74:13 18±12, 19±JO 50±l2, 5l± 13 7 AF (4/3) 0 0 
80 AFL (40/40) 
Perelman et al. 1987** 63.7 7:7 Ranged from 3 months to several NS 14AF 0 0 
years 
Leak et al. 1979*** 22-77 6:7 2 months-37 years NS 0 2 12PSVT 
Podrid et al. 1981 *** 56 (16-78) NA 1 to 61 years (average 9.9) NS 0 20 9PSVT 
Grasboys et al. 1983*** 5904-80) 82:39 Average 8 years NS 95AF 0 21 SVT 
5SVT+AF 
Blomstrom et al. 1984*** 61 47-73) 12:9 chronic AF 18.8 (1-62) months NS 13AF 8 0 
PAF 74 (4-180) months 
Horowitz et al. 1985*** 60 (26-78) 29:9 At least 3 months (4-108) 48 (32-90) II AF 27 0 
*Randomised controlled trials, **Nonrandomised controlled. ···Uncontrolled; NA, not available; AF. atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; SVT, supraventricular 
tachycardia; §, retrospective uncontrolled study, which was grouped with uncontrolled studies 
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Appendix 4.2 
Table (1) Population Characteristics of the Included Studies (amiodarone clinical trials), (continued) 
Study name Age; mean years M:F Duration of AF Left atrial diameter, No. pts. chronic AF or No. pts. paroxysmal No. pts with other forms of 
(rangeI:tSD) (mo) mm (range) AFL AF supraventricular arrhythmias 
(AmiodaroneIControl) (AmiodaroneIControl) (AmiodaroneIControl) (AmiodaroneIControl) (AmiodaroneIControl) 
Brodsky et al. 61 (32-87) 18:10 4 days to 215.37 months 57 (46-78) 228 AF 0 0 
1987*** 
Blevins et al. 1987*** chronic AF 62 (35-79) NS chronic AF 75 (0.5-360) chronic AF 44 (18-80) 25 AF 13 PAF 0 
PAF 60 (46-76) PAF 65 (18-120) PAF 39 (28-65) 
Gold et al. 1988*** 59 (25-75) 37:31 At least I year in 14 patients 42.2±8.9 (29-70) 68AF 68 PAF 0 
with chronic AF 
54 patients with PAF less 
than I year 
Mostow er al. 62.7 13:6 55 (0.1-324) months 45.7 9 AF, 1 AFL 6PAF 3 atrial tachycardia 
1990*** 
Levyetal.I99I*** NS NS At least 1 month NS 112 AF 0 0 
Gosselink et al. 63±1O 53:36 At least 2-350 months 48 89 AFor AFL 0 0 
1992*** 
Chun et al. 1995§ 6O±13 95:15 NS 44±9 53 AF or AFL 57PAF 0 
----
*Randomised controlled trials, **Nonrandomised controlled, ·**Uncontrolled; NA, not available; AF, atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; PAF, paroxysmal 
atrial fibrillation; SVT, supraventricular tachycardia; §, retrospective uncontrolled study, which was grouped with uncontrolled studies 
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Appendix 4.2 
Table (2) Population Characteristics of the Included Studies (sotalol clinical trials) 
Study name Age;mean years M:F Duration of AF Left atrial No.pts.chronic AF No.pts. paroxysmal No. pts with other Mean heart 
(range/±SD) (Sotalol/Control) diameter, mm or AFL AF forms of volume 
(Sotalol/Control) (range) (Sotalol/Control) (Sotalol/Control) supraventricular (Sotalol/Control) 
(Sotalol/Control) arrhythmias 
(Sotalol/Control) 
luul-Moller et al. 59±9,59±9 149:34 5.1±3.7,5.2±3.3 42±7,42±7 AF (98/85) DID DID 521±93,522±82 
1990* months 
(median 414.2 months) 
Singh et aJ. 1991 * 6O±14,61±9 24:10 3.4;e4.9, 4.1±5.7 44±4,43±6 AF (24110) DID DID NA 
years 
Reimold et al. 1993* 62±12,61±12 64:36 52±45, 66±96 46±8,46±8 AF (28125) 22125 DID NA 
(median 35.5, range 
0.25 to 504) months 
Kalusche et al. 1994* 63.5±5.4, 58.7±5.5 56:26 Mean 219 days NS AF (41141) DID DID NA 
Hohnloser et al. 1995* 62±1l; (60±1O, 18:32 44±56 (median 20 50±7 AF (25125) DID DID NA 
65±13) days); (49±63, 39±48) 
Carunchio et al. 1995· NS NS NS NS 0 20126 DID NA 
Crijnsetal.I99I** 60±12 65:62 22 months (0.1-300) 45±7 AF (531127/34) 0 0 NA 
Antman et al. 1990*· 63±13 70:39 24 (0.3-576) 44±9 53 56 0 NA 
·Randomised controlled trials, **Nonrandomised controlled, ·**Uncontrolled; NA, not available; AF, atrial fibrillation; AFL, atrial flutter; PSVT, paroxysmal supraventricular tachycardia; PAF, paroxysmal 
atrial fibrillation; SVT, supraventricular tachycardia; §, retrospective uncontrolled study, which was grouped with uncontrolled studies 
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Table (3) Population Characteristics of the Included Studies (flecainide clinical trials) 
Study name Age; mean years M:F Duration of AF Left atrial diameter, No. pts. chronic AF No. pts. paroxysmal No. pts with other forms of 
(rangel:tSD) (mo) mm (range) or AFL AF supraventricular arrhythmias 
(FlecainideIControl) (FlecainideIControl) (FlecainideIControl) (FlecainideIControl) ( FlecainidelControl) (FlecainideIControl) 
Van-Gelder el al. 1989* 60±11/57±14 42:31 12±14/21±27 months 45±7,43±8 AF (36/37) 0/0 0/0 
Rasmussen el al. 1988* 
- -
>2 weeks 
-
AF (30/30) 0/0 0/0 
Sonnhag et al. 1988*** 62 (44-73) 9:11 1 month to 20 years 
-
0 20 0 
(8±6 years) 
Anderson et al. 1989* 56±13 30:18 
- -
0/0 64/64 0/0 
Pritchett el al. 1991 * 54.1± 5.2 44:29 
- -
0/0 45/45 28128 PSVT 
Henthorn et al. 1991 * 50±15 11:23 
- -
0/0 0/0 51/51 PSVT 
Pietersen et al. 1991 * 53±13 23:20 
- -
0/0 48/48 010 
Clementyelal. 1992*** 65.3±l1 555:389 - - - 944 0 
Lau et aI. 1992* 59±8 17:12 
- -
0/0/0 19115 Placebo/I8 0/0/0 
Quinidine 
Crijns el af. 1991 ** 60±12 65:62 22 months (0.1-300) 45±7 AF (127/34/53) 0 0 
Berns el al. 1987*** 64±13 24:15 34±36 months 43±6 5 25 9 Ectopic atrial tachycardia 
(PAT) 
Zee-Cheng et al. 43 11:8 2-10 years 
-
0 0 15 PSVT 
1988*** 
Anderson JL 1992*** 53.4±5.5 38:28 
- -
0 41 25 PSVT 
Anderson elal. 1994** 55.64±5.2 26:23 
- -
0/0 25125 17117 PSVT 
Leclercq el al. 1992** 56.3±9.1 38:14 - - 0/0 19/33 0 
Mary-Rabine el al. 55±1 34:21 6 months-36 years - 0/0 39 16PSVT 
1988** (mean,5.6±1 years) 
Zeigler el aI. 1988*** 13 (1-32) - - - 0 0 16SVT 
Chimienti et al. 1994* - - > 4 months prior to study - 0/0 97/103 72163 PSVT 
*Randomised controlled trials. **Nonrandomised controlled, ***Uncontrolled; NA. not available; AF. atrial fibrillation; AFL. atrial flutter; PSVT. paroxysmal supraventricular tachycardia; PAF. paroxysmal 
atrial fibrillation; SVT. supraventricular tachycardia; §. retrospective uncontrolled study. which was grouped with uncontrolled studies 
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Table (4) Cardiac diagnoses in patients enrolled in randomised control, nonrandomised control, and uncontrolled trials (amiodarone clinical trials) 
Study name Patients Valvular Hypertension Ischemic heart Thyroid Lone Congenital Pericarditis Cardiac surgery CHF Cardiomyopathy Miscellaneous (n) (Amio/Cont) (Amio/Cont) disease (Amio/Cont) fibrillator heart disease (Amio/Cont) (Amio/Cont) (NYHA class) (Amio/Cont) (Amio/Cont) (Amio/Cont) (Amio/Cont) (Amio/Cont) (Amio/Cont) 
Vitolo et al 1981· 54 12112 010 16114 010 010 010 010 5/6 010 010 010 
Martin et al 1986· 70 NA NA NA NA NA NA NA NA NA NA NA 
Bosi et at 1990· 97 010 010 010 010 48/49 010 010 010 010 010 010 
Zehender et al 40 515 213 414 010 211 010 010 010 010 414 313 
1992· 
Jong et al 1995· 81 20116 116 3/4 010 8/13 311 010 9/6 010 010 010 
Perelman et al 14 416 010 010 010 213 010 010 010 010 314 III 
1987·· 
-Leak et at 1919'·· 14 NA NA NA NA NA NA NA NA NA NA NA 
Blomstrom et al 21 8 0 2 0 3 1 0 0 0 3 4 
1984··· 
Podridetal 29 NA NA NA NA 
1981··· 
NA NA NA NA NA NA NA 
Grasboys et aI 121 16 0 17 0 74 5 0 0 0 0 9 
1983·" 
Horowitz et al 78 II 0 13 0 
1985··· 
9 0 0 NS 10 10 0 
Gold et aI 1986·" 68 16 12 15 0 9 2 0 0 0 1 9 
Blevinetal 38 3 0 16 0 7 0 0 0 0 12 0 
1981··· 
Brodslcyetal 28 I3 0 5 0 0 I 0 0 0 II 3 
1987·" 
MOSIowetai 19 6 0 II 0 2 0 0 6 II 5 7 1990··· 
Levyeta/l99I··· 112 NS NS NS NS NS NS NS NS NS NS NS 
Gosselink el aI 89 69 18 33 0 9 2 0 II 89; class I 16. 10 0 
1992·" class II 44. class 
111 26. class IV 3 
OlUn et all995··· 110 14 15 36 0 24 I 0 0 0 19 0 
Sum (Amio) 881 192 54 111 0 195 15 0 31 110 84 35 
Sum (Placebo) 9S 16 6 4 0 62 I 0 6 0 0 0 
Sum (Others) 52 17 3 18 0 I 0 0 6 0 4 3 
Pooled (all). % 1089 225 (20.7%) 63 (5.8%) 193 (17.7%) 0 258 (23.7%) 16 (1.41%) 0 430.9%) 110(10.1%) 88(8.1%) 38 (3.5%) 
*Randomised controlled trials, **Nonrandomised controlled, ***Uncontrolled; NA, not availa.ble; CHF, c~nges~ive h~art failure; NYHA class, New York Heart Association class; (AmiolCont) the number of 
patients with a given cardiac diagnosis in amiodarone (Amio) and control (Cont) group; others, mcludmg patients In aclJve control group. ' 
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Table (5) Cardiac diagnoses in patients enrolled in randomised control, and nonrandomised control trials (sotalol clinical trials) 
Study name Patients (n) Valvular Hypertension Ischemic heart Thyroid Lone Congenital Pericarditis Cardiac surgery CHF Cardiomyopathy Miscellaneous 
(Sota/Cont) (Sota/Cont) disease (Sota/Cont) Jib rilla tor heart disease (Sota/Cont) (Sota/Cont) (NYHA class) (Sota/C ont) (Sota/Cont) 
(Sota/Cont) (Sota/Cont) (Sota/Cont) (Sota/Cont) 
Juul-MoUer et aI 183 113 26/22 16113 010 49/41 010 010 010 010 010 010 
1990· 
Singh et all99l· 34 NA NA NA NA NA NA NA NA NA NA NA 
Reimold et aI 1993" 100 12118 1211 1115 210 13/6 010 010 010 3/2 010 31 
KaJusche et aI 82 010 1419 215 010 15/11 010 010 010 010 1116 3/0 
1994" 
Carunchio el aI 66 NA NA NA NA NA NA NA NA NA NA NA 
1995" 
Hohnloser et aI 50 6/8 416 9/6 010 413 010 010 010 010 212 010 
1995" 
Crijnselall99I" 121 106 20 30 4 22 9 0 36 56 (class I) 6 0 
58 (class II) 
13 (class III) 
Sum (Sota) 608 131 76 68 6 103 9 0 36 130 15 34 
Sum (Placebo) 0 0 0 0 0 0 0 0 0 0 0 0 
Sum (Others) 189 29 44 29 0 61 0 0 0 2 18 0 
Pooled (all). % 642 160(24.9%) 120 (18.1%) 91 (15.1%) 6(0.9%) 170(26.5%) 9 (1.4%) 0 36 (5.6%) 132(20.6%) 33 (5.1%) 34 (5.3%) 
"'Randomised controlled trials, "''''Nonrandomised controlled, ""'Uncontrolled; NA, not available; CHF, congestive heart failure; NYHA class, New York Heart Association class; (Sota/Cont), the number of 
patients with a given cardiac diagnosis in SOlalol (Sola) and control (Cont) group, others, including patients in active control group. 
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& ... ", ...... , ..... --- .......... - ..... ·-h··v'-~- ................. ____ ~ ___ a ~.--- ••• - _ •• _.~ ••••. ", ___ ~ ____ ~_ 
_-v ... ____ ~. ___ ~ ___ ., .. __ .... _ _ .. _____ ~_. __ .1. __ - __ ._.~ , .. ___ •••. _ .... _._ ••• __ ...... _ •. , 
Sludy name Palients Valvular Hyperlension Ischemic heart Thyroid Lone Congenilal Pericardilis Cardiac surgery CHF Cardiomyopalhy Miscellaneous 
(n) (Fie/ConI) (Fie/ConI) disease (Fie/ConI) fibrillalor heart disease (Fie/ConI) (Fie/ConI) (NYHA class) (Fie/ConI) (Fie/ConI) 
(Fie/ConI) (Fie/ConI) (Fie/ConI) (Fie/ConI) 
Rasmussent't a/ 19MR· 60 O(() o(() O(() 010 0/0 010 ()(O ()(O 010 ()(O ()(O 
Gelder., 01198~ 73 ISlI2 314 H)(IO 010 518 212 010 ()(O Class I, 818 III (WO 
Class 1128129 
Anderson., 01 1989' 64 414 18118 Olll 010 12112 - - 010 Class I, 4 32132 
Class II, 4 
Pietersel1<'toll99I' 48 III 212 313 010 010 010 010 010 Class I, 42142 ()(O 010 
Henthornet 01 1991' 51 818 7n ()(O 010 U/O ()(O 0/0 010 U/O 414 818 
PrircOOllt'Ioll99l· 73 
- - - - - - -
laUd al 1992· 19 010 ()(O 010 0/0 19119119 ()(o (I/O 010 010 010 0/0 
AndcJ'5Ol1 IL 1992··· 66 2S 13 - 16 - - -
Ande"""",t 01 1994' 49 010 18118 313 010 010 010 010 ()(O Class I, 2 010 10 
Chimientirlol 1994· 335 
-
-
- - - - - -
CrijllMtall99I" 127 HJ6 20 30 4 22 9 0 36 56 (class I) 6 0 
58 (class II) 
13 (class III) 
1.ecIera¥' 0/1992" 52 3 0 3 0 - 0 0 0 0 2 35 
Mary-Rabinu,oI 55 2 0 10 0 40 I 0 0 0 0 , 
1988" 
Clement yet 01 1992'" 944 171 262 55 6S 435 - . . 0 23 54 
Zeiglern Q/ 1988··· 16 0 . . . 12 4 0 2 0 0 0 
_,011987'" 39 6 0 16 0 7 0 0 0 0 10 0 
ae.cben8'f tJl 19 4 0 I 0 0 0 0 0 0 0 13 
I'JKS··· 
Sonnhaget 01 1988'" 211 8 3 . 10 . . . 0 . I 
Sum (fie) 1952 320 363 147 69 578 16 0 31 217 46 158 
Sum (PbcdJo) 271 2S 4'J 16 0 39 2 0 0 'IS 5 40 
Sum (0lher5) 19 0 0 0 19 0 0 0 0 0 0 0 
Pooiod(aJl)," 2110 332 (15.75,*,) 367 (17.4,*,) 157(7.4~) 69(3.3~) 6I1S (28.7'1) 18(O.85~) 0 31 (1.8'1) 296(14~) 46 (2.2~) 1S8(7.s~) 
lUndumuc4crotrullcd tnaIJ" "Nonnoodomuc4CODtrulJcd. "'linwntrollcd; NA.llUla •• Jloblc;t:Hf,CODge>;II ._C .. _. .. ' ......... , ..... ., .. ~ He..nAiooc ,loso; Il'la:JCoot),lhe Dwnber 01 paucolS WItB • , .. en ""u...; ~ .. m IIeciuDlde (Fie) and <ootrollCoot) group. 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects model 
a. Amiodarone clinical trials 
Analysis Comparisons Time No. of No. of No. of Pooled effect (%) Fixed.effects Q statistic Random.effects 
group interval studies comparisons patients (P) 
Amiodarone Controls RD(%) Z RD(%) Z 
Pr(95% CI) Pc(95% CI) (95% CI) (95% CI) 
1 AIlRCfs 3 months 5 5 1701136 76.9 63.1 15.3 3.13·· 16.58'· 18.5 1.83 NS 
(70.7-83.1) (70.7 -83.1) (5.7-24.9) (P=(l.Ol) (-1.4-38.3) 
1 AlIRCfs 6 months 3 3 119/100 76.7 66.3 12.3 2.01· 10.15·· 17.32 1.22 NS 
(69.13-84.3) (57.6-74.95) (0.33-24.2) (P=O.04) (P=O.OO6) (- 10.5-45.1) (P=O.22) 
1 AlIRCfs 12 months 3 3 119/100 71.97 57.32 11.1 1.82 8.7· 15.8 1.2 NS 
(64.1-79.9) (49.1-65.6) (-0.9-23) (P=O.069) (P=O.013) (-10-41.5) (P=O.22) 
2 Amiodarone vs placebo 3 months 2 2 87n4 69.3 62.2 10.2 1.48 10.61·· 16.1 0.69 NS 
(59.6-78.9) (52.9-71.6) (-3.34-23.7) (P=O.139) (P=O.OOI) (-29.7-61.9) (P=O.49) 
2 Amiodarone vs placebo 6 months 1 1 48/49 72.9 79.6 -6.7 -0.77 - - -(60.4-85.5) (68.2-90.4) (-23.6-10.2) (P=1.56) 
2 Amiodarone vs placebo 12 months 1 I 48/49 72.9 79.6 -6.7 -0.77 
- - -(60.4-85.5) (68.2-90.4) (-23.6-10.2) (P=1.56) 
3 Amiodarone vs class IA 3 months 3 3 83/62 82.3 64.11 20.5 2.96·· 4.9 20.7 1.92 
(quinidine and disopyramide) (74.2-90.4) (53.5-74.7) (6.9-34.1) (P=O.088) (-0.49-41.9) 
NS 
3 Amiodarone vs class IA 6 months 2 2 71151 78.9 46.99 31.01 3.6·· 0.54 31.2 4.9 
(quinidine and disopyramide) (69.4-88.4) (33.4-60.6) (14.2-47.8) (P=O.46) (18.8-43.6) 
NS 
3 Amiodarone vs class IA 12 months 2 2 71151 71.4 32 28.8 3.3·· 0.24 29.1 6.98 
(quinidine and disopyramide) (61.2-81.5) (19.97-44) (11.9-45.7) (P=O.63) (20.9-37.2) 
NS 
4A Amiodarone vs quinidine 3 months S 5 1701373 76.9 69.4 7.6 2.3- 6.2 7.6 1.83 
standard (Refs) (70.7-83.1) (67.3-71.S) (0.98-14.1) (P=O.02) (P=O.19) (-0.6-15.8) 
NS 
4A Amiodarone vs quinidine 6 months 3 3 911373 76.7 57.7 19.02 4.6-· 0.48 19.11 11.4 
standard (Refs) (69.1-84.3) (54.8-60.6) (10.9-27.2) (P=O.79) (15.8-22.4) 
NS 
RO, risk difference; 95% CI; 95% confidence inlerval; PT and Pc, pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic, test of heterogeneity, * 
statistically significant P < 0.05; ** highly statistically significant P < 0.0 I; NS, nonsignificant 
273 
Appendix 4.2 
Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects model (continued) 
a. Amiodarone clinical trials (continued) 
Analysis Comparisons Time No. of No. of No. of Pooled effect ("10) Fixed-effects Q statistic Random-
group interval studies comparisons patients (P) effects 
Amiodarone Controls RD("1o) Z RD("1o) Z 
PT(95"10 el) Pc(95"1o CI) (95"10 CI) (95"10 CI) 
4A Amiodarone vs quinidine standard 12 months 3 3 119/373 71.98 50.2 21.5 4.97"" 4.7 19.9 2.94 
(ReTs) (64.1-79.88) (47.3-53) (13-29.95) (P=O.0967) (6.6-33.2) 
NS 
48 Amiodarone vs quinidine standard 3 months II II 512/373 81.8 69.4 9.7 5.2"" 53.8"" 17.7 0.38 NS 
(uncontrolled trials) (78.7-84.7) (68.1-70.8) (6.1-13.4) (P=O) (-7.5-11.03) 
48 Amiodarone vs quinidine standard 6 months II II 5121373 79.4 57.7 18 8.98"" 63.3** 7.7 1.03 NS 
(uncontrolled trials) (76.2-82.6) (56.2-59.2) (14.1-21.9) (P=O) (-3.7-19) 
48 Amiodarone vs quinidine standard 12 months 8 8 3911373 56.3 50.2 5.7 2.12** 8.3 5.3 1.75 NS 
(uncontrolled trials) (51.4-61.1) (48.5-51.9) (0.4-11) (P=O.31) (-0.6-11) 
5A Amiodarone vs quinidine standard 3 months 4 4 127/373 76.2 69.4 6.8 1.8 NS 6.027 7.13 1.29 NS 
(RCTs with chronic AF only) (68.9-83.4) (67.1-71.7) (-0.8-14.4) (P=O.072) (P=O.II) (-3.7-17.97) (P=O.2) 
NS 
5A Amiodarone vs quinidine standard 6 months 2 2 761373 75.2 57.7 17.6 3.3** 0.28 16.4 7.2** 
(RCTs with chronic AF only) (65.5-84.9) (54.2-61.2) (7.2-27.9) (P=O.597) (11.9-20.8) 
NS 
5A Amiodarone vs quinidine standard 12 months 2 2 761373 66.8 50.2 16.3 2.88** 2.6 14.3 1.5 NS (RCTs with chronic AF only) (56.4-77.2) (46.6-53.8) (5.2-27.3) (P=O.12) <-4.5-33.1) (P=O.I34) 
NS 
58 Amiodarone vs quinidine standard 3 months 8 8 273/373 70.3 69.4 0.4 12.1 ** 13.2 -2.1 
-0.47 
(uncontrolled trials with chronic (65-75.6) (67.8-70.96) (-5.4-6.1) (P=O.068) (-10.9-6.7) NS 
AFonly) NS 
58 Amiodarone vs quinidine standard 6 months 8 8 25&373 70.1 57.7 11.73 3.74** 9.4 9.4 2.11* (uncontrolled trials with chronic (64.6-75.7) (55.8-59.5) (5.6-17.9) (P=O.15) (0.7-18.14) (P=O.034) 
AFonly) NS 
58 Amiodarone vs quinidine standard 12 months 6 6 199/373 53.6 50.2 2.8 0.75 NS 8.41 0.25 0.05 NS 
(uncontrolled trials with chronic (46.8-60.3) (48.13-52.3) (-4.5-10) (P=O.45) (P=O.135) (-9.9-10.4) 
AFonly) NS 
RD, risk difference; 95% CI; 95% confidence interval; PT and pc, pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic, test of 
heterogeneity, * statistically significant P< 0.05; ** highly statistically significant P < 0.01 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects model (continued) 
a. Amiodarone clinical trials (continued) 
Analysis Comparisons Time No. of No. of No. of Pooled effect (%) Fixed-effects Q statistic Random-
group interval studies comparisons patients (P) effects 
Amiodarone Controls RD(%) Z RD(%) Z 
Pr(95% Cl) Pc(95% CI) (95% CI) (95% CI) 
6 Amiodarone YS quinidine standard 3 months 6 6 1261373 86.6 69.4 14.4 4.5** 26.8** -2.8 -0.28 NS 
(uncontrolled trials with PAF (81.3-91.9) (67.5-71.3) (8.1-20.8) (P=O.OOOI) (-22.5-16.9) 
only) 
6 Amiodarone YS quinidine standard 6 months 6 6 95/373 67.5 57.7 8.5 1.799 NS 17.2** -4.8 -0.4 NS 
(uncontrolled trials with PAF (58.8-76.1) (55.2-60.2) (-0.8-17.7) (P=O.07) (P=O.OOO6) (-31.1-21.5) 
only) 
6 Amiodarone YS quinidine standard 12 months 4 4 1461373 61.9 50.2 11.4 2.7** 4.4 NS 10.6 1.94* 
(uncontrolled trials with PAF (54.1-69.6) (47.7-52.7) (3.1-19.7) (P=O.OO7) (P=O.22) (-0.08-21.2) (P=O.05) 
only) 
RD, risk difference; 95% CI; 95% confidence interval; PT and PC, pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic, test of 
heterogeneity, * statistically significant P < 0.05; ** highly statistically significant P < 0.01 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects model (continued) 
h. Sotalol clinical trials 
Analysis Comparisons Time No. of No. of No. of Pooled effect (%) Fixed-effects Q statistic Random-effects 
group inter.al studies comparisons patients 
(P) 
Sotalol Controls RD(%) Z RD(%) Z 
Pr(95% CI) Pc(95% CI) (95% CI) (95% CI) 
I All trials 3 months 8 10 3351508 57.1 56.63 1.3 0.41 NS 14.15 1.31 3.3--
(RCfs and non-RCfs) (52.5-61. 7) (52.6-60.64) (-4.87-7.4) (1'=0.68) (P=O.1171) NS (-6.6-9.2) 
I All trials 6 months 8 10 3351508 48.8 45.5 3.6 1.13 NS 16.9 4.33 9.6--
(RCfs and non-RCfs) (44.12-53.5) (41.5-49.5) (-2.6-9.8) (P=O.26) (P=O.0503) NS (-4.5-13.2) 
I All trials 12 months 5 7 2111402 30.3 31.21 -2.23 -0.653 NS 11.996 -1.1 -0.21 NS 
(RCfs and non-RCfs) (25.23-35.4) (26.9-35.5) (-8.9-4.5) (P=O.5) (P=O.062) NS (-11.1-8.95) (P=0.8) 
2 AIIRCfs 3 months 6 7 2341238 63.5 69.84 1.5 0.37 NS 11.82 1.8 0.318 NS 
(51.8-69.3) (64.3-75.4) (-6.34-9.32) (P=0.1) (P=O.066) NS (-9.5-13) (1'=0.75) 
2 AIIRCfs 6 months 6 7 2341238 56.6 59.6 3.96 0.95 NS 15.94-- 5.32 0.76 NS 
(50.63-62.6) (53.1-65.4) (-4.2-12.1) (P=O.34) (P=O.014) (-8.5-19.1) (1'=0.45) 
2 All RCfs 12 months 3 4 1101132 41.5 45.8 1.24 0.21 NS 9.342- 2.11 0.197 NS 
(39.12-55.97) (37.9-53.6) (-10.3-12.8) (P=0.8) (P=O.0251) (-18.9-23.1) (1'=0.8) 
3 SotaJol vs placebo 3 months 2 2 32132 69.15 16.9 19.4 2.1 NS 4.25- 21.7 1.124 NS 
(RCfs) (54.3-83.99) (60.73-93.12) ( 1.3-37.5) (1'=0.04) (P=O.0394) (-16.1-59.5) (P=O.26) 
3 SotaJol vs placebo 6 months 2 2 32132 56.61 34.62 36 3.6-- 0.3156 35.95 6.4" (RCfs (39.9-73.34) (16.33-52.9) (16.32-55.7) (1'=0.5) NS (24.9-41) 
3 SotaJoi vs placebo 12 months I I 20126 60 26.9 1.96 2.36--
- - -(RCfs) (38.5-81.5) (9.87-43.973) (5.1-60.5) 
4 SoIaJol VI other 3 months 5 5 2221206 62.53 68.9 -2.6 -0.95 NS 2.97 -1.5 -0.41 NS 
antiarrltythmic drugs (56.3-68.8) (63-74.8) (-11.3-6.1) 
(RCfs) 
(1'=0.34) (P=O.5) NS (-8.6-5.7) (1'=0.7) 
4 SoIaJol VI other 6 months 5 5 2221206 56.6 62.4 -2.7 -0.58 NS 3.34 
-2.1 -0.5 NS 
antiarrltythmic drugs (50.2-63.02) (56.22-68.5) (-11.6-6.3) 
(RCfs) 
(P=O.56) (1'=0.5) NS (-10-5.9) (1'=0.62) 
4 SoIaJoJ vs other 12 months 3 3 1101106 45.3 50.8 -5.6 -0.9 NS 3.1 
-6.4 -0.78 NS 
antiarrhythmic drugs (36.1-54.4) (45-59.6) (-18.32-7.1) 
(RCfs) 
(1'=0.37) (1'=0.22) NS (-22.4-9.7) (1'=0.44) 
4A Sotalol vs Class IC 3 months 2 2 69/69 
- -
-3.4 
-0.5 NS 0.64 
- -(RCfs) (-18-11.3) (P=O.4) NS 
4A SotaIol vs Class IC 6 months 2 2 69/69 
- -
-1.2 
-0.13 NS 1.52 
- -(RCfs) (-17-14.9) (1'=0.22) 
RD, risk difference; 95% CI; 95% confidence interval; P-r and Pc, pooled percentages of patienlS remaining in sinus rhythm in trealment and control groups; Q statislic, test of 
heterogeneity, • statistically significant P < 0.05; •• highly statistically significant P < 0.01 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects model (continued) 
b. Sotalol clinical trials (continued) 
Analysi. Comparisons Time No. of No. of No. of Pooled effect (%) Fixed-effects Q statistic Random-effect. 
group interval studies comparisons patient. 
(P) 
Sotalol Controls RD(%) Z RD(%) Z 
Pr(95% CI) Pc(95% CI) (95% CI) (95% CI) 
4A Sotalol vs Class IC 12 months 2 2 69/69 
- -
1.5 0.2 NS 0.8 
- -(Refs) (-14.3-17.3) (P=0.4) 
4A Sotalol vs Oass IA 3 months 3 3 153/137 
- -
-2.2 -0.4 2.3 (0.3) 
- -(Refs) (-13-8.6) 
4A Sotalol vs Oass IA 6 months 3 3 153/137 - - -3.4 -0.62 1.8 (0.42) 
- -(Refs) (-14-7.4) 
5 Sotalol vs other 3 months 2 3 1011270 45.7 42.013 0.9 0.185 2.3 0.87 0.16 NS 
antiarrhythmic drugs (38.1-53.4) (36.2-47.83) (-8.96-10.83) NS (P=O.313) (-9.9-11.6) (P=0.9) 
(non-Refs) (P=O.85) NS 
5 Sotalol vs other 6 months 2 3 1011270 36.6 32.6 3.02 0.62 NS 0.94 2.03 0.671 NS 
antiarrhythmic drugs (29.1-44.02) (27.1-38.2) (-6.6-12.6) (P=O.5) (P=O.626) (-3.9-7.95) (P=0.5) 
(non-Refs) NS 
5 Sotalol vs other 12 months 2 3 1011270 20.6 25.03 -4.01 -0.953 2.1277 -3.95 
-0.91 NS 
antiarrhythmic drugs (14.2-26.86) (19.9-30.13) (-12.3-4.24) NS (P=O.345) (-12.5-4.6) (P=0.4) (non-Refs) (P=1.66) NS 
5A Sota1ol vs Oass IC 3 months 2 2 1011236 
- -
2.3 0.4NS 2.05 -
-(non-Refs) (-8.9-13.5) (P=O.2) 
SA Sota1ol vs Oass IC 3 months 2 2 1011236 
- -
1.7 0.3 NS 0.7 
- -(non-Refs) (-9-12.5) (P=O.4) 
SA Sota101 vs Oass IC 3 months 2 2 1011236 
- -
-7 -1.5 NS 0.15 
- -(non-Refs) (-16.6-2.2) (P=O.7) 
6A Sota1ol VI quinidine 3 months 6 6 2341373 61.54 69.4 -7.7 -2.34- 10.8 -7.13 
-1.38 NS 
standard (Refs, (55.5-67.6) (67.5-71.4) (-14.2_-1.24) (P=O.0557) (-17.2_2.96) (P=O.l7) 
NS 
6A Sota1ol VI quinidine 6 months 6 6 2341373 55.86 57.7 -1.6 -0.5 NS 8.3 
-0.592 
-0.13 NS 
standard (ReTs' (49.62-62.1 ) (55.7-59.7) (-8.2-5.2) (P=O.6) (P=O.1412) (-9.7-8.5) (P=O.897) 
NS 
RD. risk difference; 95% CI; 95% confidence interval; PT and Pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of 
heterogeneity.· statistically significant P < 0.05;·· highly statistically significant P < 0.01; NS. nonsignificant 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects model (continued) 
b. Sotalol clinical trials (continued) 
Allalysis Comparisons Time No. 0/ No. 0/ No. 0/ Pooled effect (%) Fixed-effects Q statistic Ralldom-effects 
group inter.al studies eomparison. patients 
(P) 
Sotalol Controls RD(%) Z RD(%) Z 
Pr(95% CI) Pc(95% CI) (95% CI) (95% CI) 
6A Sotalol vs quinidine 12 months 3 3 1101373 45.3 50.2 -4.7 -0.95 NS 3.238 -3.65 -0.57 NS 
standard (RCfs) (36-54.4) (47.3-53.13) (-14.3-5) (P=0.3) (P=O.198) (-16.2-8.94) (P=0.6) 
NS 
6B Sotalol vs quinidine 3 months 2 2 101/373 41.4 69.4 -27.9 -5.56" 6.5·· -27.5 -2.2 NS 
standard (32.14-50.7) (66.1-72.7) (-37.8_-18.1) (P=O.OI) (-52.6_-2.5) (P=O.028) 
(non-RCfs) 
6B Sotalol vs quinidine 6 months 2 2 101/373 33.4 57.7 -24.2 -4.9" 3.41 -23.7 -2.5S·· 
standard (24.4-42.4) (54.2-61.3) (-33.9_-14.5) (P=O.0638) (-41.7_-5.7) 
(non-RCfs) NS 
68 Sotalol vs quinidine 12 months 2 2 101/373 18.8 50.2 -31.2 -7.3" 1.33 -31.\ -6.3·· 
standard (11.3-26.4) (46.6-53.8) (-39.6_-22.9) (p=O.2486) (-40.8_-21.4) 
(non-RCfs) NS 
7 SotaIol VI quinidine 3 months 5 5 185/373 64.5 69.4 -4.7 -1.27 7.262 -3.98 -0.75 NS 
standard (57.7-71.2) (67.31-71.5) (-11.9-2.53) NS (p=O.1227) (-14.44-6.5) (p=O.45) 
(RCfs with chronic (P=0.2) NS 
AFonly) 
1 Sotalol vs quinidine 6 months 6 6 213/313 56.2 57.7 -1.3 -0.37 8.7 -0.643 -0.12886 NS 
standard (49.6-62.7) (55.1-59.1) (-8.3-5.7) NS (P=O.1225) (-10.4-9.13) (P=O.S97) 
(RCfs with chronic (P=O.1) NS 
AFonly) 
1 SotaIol VI quinidine 12 months 2 2 611373 52.6 50.2 2.5 0.37 NS 0.648 1.6 0.315 NS 
standard (40.1-65) (46.6-53.8) (-10.5-15.5) (P=O.1) (P=O.4209) (-8.2-11.3) (P=O.75) 
(RCfs with chronic NS 
-. 
I 
RD, risk difference; 95% CI; 95% confidence inlerval; Pr and Pc, pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic, test of 
heterogeneity, • statistically significant P < 0.05; •• highly statislically significant P < 0.0 I; NS, nonsignificant 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects model (continued) 
c. Flecainide clinical trials 
Anal,si. Comparisons Time No. of No. of No. of Pooled effect (%) Fixed-effects Q statistic Random-effects 
group interval studies comparison. patient. 
(P) 
Flecainide Controls RD(%) Z RD(%) Z 
Pr(95% CI) Pc(95% CI) (95% CI) (95% CI) 
1 All trials 3 months 12 14 6221533 60.9 (57.8-64) 29.6 (26.6·32.6) 21 (16.5-25.7) 9'- 94.6-- 22.2 (9.4-35.1) 3.4'-
(RCfs and non-RCfs) (P=O) 
I All trials 6 months 7 8 4361376 61.8 (58-65.4) 51.7 (47.1-56.3) 14.7 (S.5-20.8) 4.7** 39.9" 14.7 (8.5-20.S) 4.7" 
(RCfs and non-RCfs) (P=O) 
I All trials 12 months 7 S 4361376 57.7 (54-61.4) 42.2 (37.7-46.6) 19.4 (13-25.4) 6.33-- 2S.S'- 20.7 (7.7-33.7) 6.3'-
(RCfs and non-RCfs) (P=O.OOO2) 
2 A1IRCfs 3 months 8 9 379/401 65.S (61.8-69.7) 25.3 (21.9-2S.6) 25.5 (20-30.9) 9.3** 41.5" 2S.9 (16.1-41.8) 4.4" 
(P=O) 
2 AIIRCfs 6 months 3 3 1931201 79.5 (74-85) 63.6 (57-70) 15.3 (6.7-23.9) 3.5** 5.13 NS 18.5 (I.S-35.2) 2.2' (P=O.03) 
(P=O.OS) 
2 A1IRCfs 12 months 3 3 1931201 75.4 (69.5-SI.3) 56.3 (49.7-63) 17.5 (S.6-26.5) 3.S" 4.23 NS 
(P=O.1204) 
20.2 (5-35.4) 2.6** (P=O.OO9) 
3 Aecainide vs placebo 3 months 6 6 2221219 49.7 (43.8-55.6) 10.97 (6.9-15) 33.35 (26-40) 9.3** 24.S*- 33.7 (I7.S-49.6) 4.2" (RCfs) (P=O.OOO2) 
3 Aecainide vs placebo 6 months I I 36137 5S (41.9-74.1) 49 (32.9-65.1) 9 (-13.9-31.9) 0.77 -
- -(RCfs) (P=O.4) 
3 Aecainide vs placebo 12 months I I 36137 49 (32.7-65) 36 (20.5-51.5) 13 (-9.5-35.5) 1.133 
- - -(RCfs) (P=O.3) 
4 Aecainide vs other 3 months 3 3 1761IS2 79 (73.8-84 .. 6) 59 (52.9-65.34) 14.6 (6.2-22.9) 3.4** 5.34 NS IS.5 (1.4-35.6) 2.1· (P=O.0346) 
antiarrhythmic drugs (P=O.0693) 
(RCfs) 
4 Aecainide vs other 6mooths 2 2 157/164 82.5 (76.5-88.4) 66.5 (59.4-73.6) 16.3 (7-25.6) 3.4-· 4.S· 23.6 (-3.3-0.5) 1.72 NS 
antiarrllythmic drugs (P=O.03) (P=O.OS5) 
(RCfs) 
4 Aecainide vs other 12 months 2 2 1571164 79.4 (73.I-S5.7) 61 (53.6-68.4) 18.4 (S.6-2S.2) 3.7·· 4.05· 24.5 (-0.4-49) 1.93 NS 
antiarrllythmic drugs (P=O.04) (P=O.054) 
(RCfs) 
5 Aecainide vs otherst 3 months 3 3 1931201 82.3 (77-S7.6) 66.7 (60.3-73) 15.2 (6.9-23.5) 3.6" 5.2 NS 19.6 (3.1-36.2) 2.33* (P=O.OI9) 
RCfs (parallel design) (P=O.OS) 
RD. risk difference; 95% CI; 95% confidence interval; Pr and pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of 
heterogeneity. • statistically significant P < 0.05; •• highly statistically significant P < 0.01; t. including placebo and other antiarrhythmics; NS, nonsignificant 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects model (continued) 
c. Flecainide clinical trials (continued) 
Allalys;s Comparisons Time No. of No. of No. of Pooled effect (%) Fixed-effects Q statistic Random-effects 
group interval studies comparisolls patients 
(P) 
Flecainide Controls RD(%) Z RD(%) z 
PT(95% CI) Pc(95% CI) (95% CI) (95% CI) 
5 Flecainide vs otherst 6 months 3 3 1931201 79.5 (74-85) 63.6 (57-70) 15.3 (6.7-23.9) 3.5** 5.13 NS 18.5 (1.8-35.2) 2.2* (P=O.03) 
RCfs (parallel design) (P=O.OS) 
5 Flecainide vs otherst 12 months 3 3 1931201 75.4 (69.5-81.3) 56.3 (49.7-63) 17.5 (8.6-26.5) 3.8** 4.23 NS 20.2 (5-35.4) 2.6** 
RCfs (parallel design) (p=O.1204) (P=O.OO9) 
6 Flecainide vs Placebo 3 months 5 5 IS6IIS2 47.3 (41-53.7) S.4 (4.3-12.6) 35 (27.9-42.8) 9.3** 21.9** 36.9 (19.4-54.4) 4.14** 
RCfs (crossover (P=O.OOO2) 
design) 
6 Flecainide vs Placebo 6 months 0 - - - - - - - - -
RCfs (crossover 
design) 
6 Flecainide vs Placebo 12 months 0 -
- - - - - - - -
, 
RCfs (crossover 
design) 
7 Flecainide vs Gass IA 3 months 2 2 47/46 - - 25 (8.9-41.4) 3.04*· 3 (P=O.08) 
- -
SA Flecainide vs otherst 3 months 4 5 2431175 53.5 (48.6-58.4) 46.2 (39.6-52.7) 9.3 (0.4-IS.2) 2.1· 43.S*· 9.4 (-20.7-39.6) 0.6 NS (non-RCfs) (P=O.03) (P=O) 
8A Flecainide vs otherst 6 months 4 5 2431175 4S.5 (43.7-53.3) 39.7 (33.2-46.2) 14 (5.23-22.7) 3.13** 34.S** 13.7 (-13-40) 1.01 NS (non-RCfs) (P=O) 
SA Flecainide vs otherst 12 months 4 5 2431175 46 (41.4-50.9) 305 (24.5-36.6) 20.9 (12.8-29) 5.1" 24.2·· 20.2 (-0.7-41) 1.9 NS (non-RCfs) (P=O.OOOI) 
88 Flecainide VI 3 months 2 2 74146 68.9 (58.4-79.5) 69.1 (56.2-82) 5.5 (-13.9-25) 0.56 NS 2.3 NS 6.8 (-22.8-36.4) 0.5 NS 
Amiodarone+flecainide (P=O.l3) 
S8 Flecainide va 6 months 2 2 74146 68.9 (58.4-79.5) 69.1 (56.2-82) 5.5 (-13.9-25) 0.56 NS 2.3 NS 6.8 (-22.8-36.4) 0.5 NS 
Amiodarone+flecainide (P=O.l3) 
88 Flecainide vs 12 months 2 2 74146 68.9 (58.4-79.5) 69.1 (56.2-82) 5.5 (-13.9-25) 0.56 NS 2.3 NS 6.8 (-22.8-36.4) 0.5 NS 
Amiodarone+flecainide (P=O.13) 
9A Flecainide vs quinidine 3 months 8 8 3791373 65.8 (6I.S'()9.7) 69.4 (67.8-71) .() (-1O.7_-I.S) -2.S· 126·· -15.2 (-335-3.2) 
-1.6 NS 
SlaJldard (RCfs) (P=O.OO5) (P=O) 
9A Flecainide vs quinidine 6 months 3 3 1931373 79.5 (74-S5) 57.7 (54.8-<>0.6) 21 (14.6-27.8) 6.3·· 7.2·· 18.6 (4.6-32.7) 2.6" 
SlaJldard (RCfs) (P=O.03) (P=O.OO9) 
RD. risk difference; 95% CI; 95% confidence interval; Pr and pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of 
heterogeneity. • statistically significant P < 0.05; •• highly statistically significant P < 0.01; t. including placebo and other antiarrhythmics; NS. nonsignificant 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects model (continued) 
c. Flecainide clinical trials (continued) 
Analysis Comparison. Time No. of No. of No. of Pooled effect (%) Fixed-effects Q slalislic Random-effecls 
group inlltrpal studies comparisons patient. 
(P) 
Flecainide Controls RD(%) Z RD(%) Z 
PT (95% CI) Pc (95% el) (95% CI) (95% CI) 
9A F1ecainide vs quinidine 12 months 3 3 193/373 75.4 (69.5-81.3) 50.2 (47.3-53) 24.7 (17.8-31.5) 7.1·· 11.4·· 21.4 (3.5-39.4) 2.34· 
standard (RCfs) (P=O.OO3) (P=O.019) 
98 F1ecainide vs quinidine 3 months 4 4 243/373 58 (52.1-64) 69.4 (67.1-71.7) -10.4 (-17_-3.9) -3.13" 16·· -6.31 (-22.4-9.7) 
-0.8 NS 
standard (P=O.OOI) 
(non-RCfs) 
98 F1ecainide vs quinidine 6 months 4 4 243/373 54.2 (48.3-60.1) 57.7 (55.2-60.2) -2.1 (-8.6-4.5) -0.62 NS 25.6·· 3.7 (-16.5-24) 0.4 NS 
standard (P=O) 
(non-RCfs) I 
98 F1ecainide vs quinidine 12 months 4 4 243/373 52.3 (46.4-58.1) 50.2 (47.7-52.7) 3.8 (-2.7-10.3) 1.13 NS 30.84·· 10.5 (-11.7_32.6) 0.93 NS 
standard (P=O) 
(non-RCfs) 
9C F1ecainide vs quinidine 3 months 6 6 11001373 62.4 (59.5-65.3) 69.4 (67.5-71.3) -7.5 (-12_-2.9) -3.2" 1.71 NS -6.1 (-10.3_-17.9) -2.8·· 
standard (P=0.9) (P=O.OO5) (uncontrolled mals) 
9C F1ecainide vs quinidine 6 months 6 6 11001373 62 (59.3-65) 57.7 (55.7-59.7) 3.5 (-1.3-8.2) 1.43 NS 3.3 NS 3.2 
-
standard (P=O.15) (P=O.7) 
(uncontrolled mats) 
9C F1ecainide vs quinidine 12 months 5 5 1561373 57.1 (49.5-64.7) 50.2 (47.9-52.5) 6.44 (-1.6-14.5) 1.6 NS 5.6 NS 5 (-5-15) 0.97 NS 
standard (P=O.12) (P=O.2343) 
(uncontrolled bia1s) 
lOA F1ecainide vs Placebo 3mooths 4 4 1381134 33.6 (26-41.2) 6.3 (1.96-10.7) 27.8 (19.4-36.2) 6.5·· 7.4 NS 29.1 (15.7-42.4) 4.3" 
for PAF (RCfs) (P=O.06I) 
lOA F1ecainide vs Placebo 6 months 0 
- - - - - - - - -for PAF (RCfs) 
lOA F1ecainide VI Placebo 12 months 0 
- - -
. . . . . . 
for PAF (RCfs) 
108 Flecainide VI 0Iher 3 months 2 2 961100 75 (67.95-82.5) 51.3 (43.1-59.5) 14.2 (2.9-25.2) 2.48'· 0.1558 NS 22 . 
anliarrllythmics for (P=O.OI) (P=O.7) 
PAF(RCI's) 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects models (continued) 
c. Flecainide clinical trials (continued) 
Analysis Comparisons Time No. of No. of No. of Pooled effect (%) Fixed-effects Q statistic Random-effects 
group interval studie, comparisons patients 
(P) 
Flecainide Controls RD(%) Z RD(%) Z 
Pr(95% C1) Pc(95% Cl) (95% CI) (95% Cl) 
lOB Aecainide vs 6 months I I 77/82 84.5 (79.4-92.6) 69.6 (59.6-79.6) 14.9 (2.1-27.7) 2.3* - - -
Propafenone for P AF P=0.02 
(ReTs) 
lOB Aecainide vs 12 months I I 77/82 79 (69.9-88.1) 63 (52.6-73.5) 16 (2.14-29.9) 2.3* - -
-
Propafenone for PAF P=0.02 
(RCTs) 
lOe Aecainide vs Placebo 3 months 2 2 48/48 81.4 (70.4-92.4) 175 (6.9-28.14) 62.4 (46.9-77.9) 7.9*· 0.16 NS 71.03 
-
for PSVT (RCTs) (P=O.69) 
IOC Aecainide vs Placebo 6 months 0 
- - - - - - - -
I 
-
for PSVT (RCTs) 
100 Aecainide vs 3 months I I 52154 83.2 (73-93.4) 79.2 (68.4-90) 4 (-10.8-18.9) 0.53 
- -
-Propafenone for PSVT NS 
(RCTs) 
100 Aecainide vs 6 months 1 I 52154 77.3 (65.9-88.7) 70.5 (58.3-82.7) 6.8 (-9.9-23.5) 0.8 NS 
- - -Propafenone for PSVT 
(RCTs) 
100 Aecainide vs 12 months 1 I 52154 75 (63.2-86.8) 65 (52.3-77.7) 10 (-7.3-27) 1.1 NS 
- - -
Propafenone for PSVT 
(RCTs) 
lIA Aecainide vs Placebo 3 months 1 1 25125 68 (49.7-86.3) 12 (0.74-24.7) 56 (33.7-78.3) 4.93** 
- - -for PAF (non·RCTs) 
llA Aecainide vs Placebo 6 months I I 25125 68 (49.7-86.3) 12 (0.74-24.7) 56 (33.7-78.3) 4.93" 
- - -for PAF (non·RCTs) 
llA Aecainide vs Placebo 12 months 1 1 25125 68 (49.7-86.3) 12 (0.74-24.7) 56 (33.7-78.3) 4.93·· 
- - -for PAF (non-RCTs) 
lIB Aecainide vs 3 months 2 2 58/45 62.3 (49.9-74.7) 70.3 (57.3-83.3) -1.1 (-21.1- -0.1 NS 0.61 NS -2.3 (-17.1-12.5) 
-0.3 
Amiodarone+t1ecainide 18.9) (P=O.44) 
L- _____ ~or PAF (non-RCTs) 
RD. risk difference; 95% CI; 95% confidence interval; Pr and pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of 
heterogeneity. * statistically significant P < 0.05; *. highly statistically significant P < 0.01; t. including placebo and other antiarrhythmics; NS. nonsignificant 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects models (continued) 
c. Flecainide clinical trials (continued) 
Analysis Comparisons Time No. of No. of No. of Pooled effect (%) Fixed-effects Q statistic Random-effects I 
group interval studies comparisons patients : (P) 
Flecainide Controls RD(%) Z RD(%) z 
PT(95% CI) Pc (95% CI) (95% CI) (95% CI) 
liB Aecainide vs 6 months 2 2 58/45 62.3 (49.9-74.7) 70.3 (57.3-83.3) -1.1 (-21.1- -0.1 NS 0.61 NS -2.3 (-17.1-12.5) -OJ NS 
Amiodarone+f1ecainide 18.9) (P=O.44) 
for PAF (non-RCfs) 
liB Aecainide vs 12 months 2 2 58/45 62.3 (49.9-74.7) 70.3 (57.3-83.3) -1.1 (-21.1- -0.1 NS 0.61 NS -2.3 (-17.1-12.5) -OJ NS 
Amiodarone+f1ecainide 18.9) (P=O.44) 
for PAF (non-RCfs) 
IIC Aecainide vs otherst 3 months 2 2 33/18 90.3 (80.4- 23.5 (3.4-43.7) 88 (77.3-99) 15.9'- 5.4- 78.5 (44.6-1.12) 4.5--
for PSVT (non-RCfs) 100.3) (P=O.021) 
IIC Aecainide vs otherst 6 months 2 2 33118 90.3 (80.4- 23.5 (3.4-43.7) 88 (77.3-99) 15.9'- 5.4- 78.5 (44.6-1.12) 4.5--
for PSVT (non-Refs) 100.3) (P=O.021) 
IIC Aecainide vs otherst 12 months 2 2 33118 90.3 (80.4- 23.5 (3.4-43.7) 88 (77.3-99) 15.9·· 5.4· 78.5 (44.6-1.12) 4.5** 
for PSVT (non-Refs) 100.3) (P=O.021) 
12A Aecainide vs standard 3 months 4 4 10301373 62.3 (59.3-6S.2) 69.4 (67.1-71.7) -7.9 (-12.9_- -3.11'· 1.93 NS -1.9 
-
quinidine (uncontrolled 2.9) (P=O.59) 
trials for PAF only) 
12A Aecainide vs standard 6 months 4 4 10301373 62.2 (59.2-65.1) 57.1 (55.2-60.2) 3.45 (-1.7-8.6) 1.31 NS 2.2 NS 1 
-
quinidine (uncontrolled (P=O.535) 
trials for PAF only) 
12A Aecainide vs standard 12 months 4 4 10301373 62.2 (S9.2-65) 50.2 (47.7-52.7) 10.9 (S.7-16) 4.11" 2.2 NS 14.5 
-
quinidine (uncontrolled (P=O.536) 
trials for PAF only) 
12B Aecainide vs standard 3 months 4 4 65/313 70.2 (59.S-80.8) 69.4 (67.1-71.1) 0.7 HO.2- 0.12 NS 6.2 NS -0.5 (-16.4-15.4) -0.06 NS 
quinidine (uncontrolled 11.6) (P=O.I) 
trials for PSVT only) 
RD, risk difference; 95% CI; 95% confidence interval; P-r and Pc, pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic, test of 
heterogeneity, * statistically significant P < 0.05; ** highly statistically significant P < 0.01; t, including placebo and other antiarrhythmics; NS, nonsignificant 
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Table (7) Pooled RD of different analysis subgroups estimated under fixed-effects and random-effects models (continued) 
c. Flecainide clinical trials (continued) 
Allalysis Comparisoll' Time No. of No. of No. of I'ooled effect (%) Fixed-effect. Q statistic Ralldom-effects 
group illterval studies comparisolls patiellts 
(I') 
Flecaillide COlltrols RD(%) Z RD(%) Z 
1'T<95% C1) I'c(95% CI) (95% CI) (95% CI) 
12B Aecainide vs standard 6 months 4 4 65/373 67.9 (57.2-78.5) 57.7 (55.2-60.2) 10.03 (-0.9-21) 1.79 NS 8.6· 8 (-10.9-26.8) 0.83 NS 
quinidine (uncontrolled (P=ll.0734 ) (P=O.0357) 
trials for PSVT only) 
12B Aecainide vs standard 12 months 4 4 65/373 64.8 (54.3-75.4) 50.2 (47.7-52.7) 14.5 (3.6-25.3) 2.6" 13.3" 11.7 (-11.5-34.9) 0.99 NS 
quinidine (uncontrolled (P=O.OO4) 
trials for PSVT only) 
13 Aecainide vs standard 3 months 2 2 64/373 76.9 (66.9-86.9) 69.4 (66.1-72.7) 1.3 (-3.2-11.8) 1.4 NS 3.958· 5.9 (-15.34-21.2) 0.55 NS 
quinidine for chronic (P=O.047) 
AF(RCfs) 
13 Aecainide vs standard 6 months 2 2 64/373 74.8 (64.7-84.9) 57.7 (54.2-61.3) 16.8 (6.1-27.6) 3.1" 6.2" 14.6 (-12.6-41.7) 1.05 NS 
quinidine for chronic (P=O.OI3) 
AF(RCfs) 
\3 Aecainide vs standard 12 months 2 2 64/373 71.5 (61.4-81.7) 50.2 (46.6-53.8) 20.9 (10-31.7) 3.8" 10.7" 17.5 (-18.5-53.5) 0.954 NS 
quinidine for chronic (P=O.OOI) 
AF(RCfs) 
------
RD. risk difference; 95% CI; 95% confidence interval; Pr and pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of 
heterogeneity. * statistically significant P < 0.05; *. highly statistically significant P < 0.01; t. including placebo and other antiarrhythmics; NS. nonsignificant 
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Appendix 5.2 
Table (1) Population Characteristics of the Included Studies (Flecainide clinical trials) 
Study name Agejmean years Weight Male Female Onset of acute AF Left atrial Type of SVAj Cause of AF Mean Mean heart Mean blood 
(range/±SD) (Kg) (hours) diameter, mm Flecainide/Con- IIentricular rate at entery pressure 
( FlecainidelCon- (Flecainide/Con- (range) trol) ejection (beats/min) (mm I/g) 
tro/) trol) ( Flecainide/Con- fraction 
trol) 
Goy et al. 1985 64 (38-93) 
-
31 19 8.5 (days) 41.68 AF;39 Medical; 50 
- - -
Converted; 5.3±9.8 Converted; 40±11 AFL;6 
(days) Nonconverted;46±11 SVT;5 
Nonconverted; 
16.7±26.2 (days) 
Borgeat et al. 64 (16-92) 
-
39 21 95±41140±4 (days) 45±2I46±1 AF (30/30) Medical; (30/30) 
- - -
1986 
Crozier et al. 55 (18-89) 
-
31 19 < 24 hrs NS AF; 25 Medical; 50 
- - -
1987 SVT; 15 
AFUPAT with AV 
block; 10 
Nathan et al. 1987 49 (17-79) 
-
19 2 NS NS PAF (II) Medical; 21 
-
PAF; 156±1O -
PAFL (10) PAFL; 120±12 
Crijns et al. 1988 62±14 - 12 8 < 24 hr 14 NS AF (20) Medical; 20 - 117±26 -
(a) >24hr6 
Crijns et al. 1988 55±16 
-
14 6 <24hrI3 NS AF (20) Medical; 20 - 135±53 
-(b) >24hr7 
Gavaghan et al. 61.9±7.3/61.8±12.7 
-
24/20 5n 67 .6±41.4/61.8± 12.7 NS AF (25/24) CABG surgery; <0.5 in (5/4) 152±35.6 
-
1988 AFL (4/3) (26/23) II 68±44.4 
Valve replacement 
surgery; (3/4) 
Suttorp et al. 59±12 
-
19/13 In < 24 hr (12113) I 23±231I34±1 8 AF (17/17) Medical; (20/20) 
- I 23±231I34±1 8 -
1989 6O±13/58±11 > 24 hr (8n) AFL (3/3) 
Wafa et al. 1989 63±7 
-
15/11 013 58±19 (30-96) NS AF (15/12) CABG surgery; 
- 151±151144±1O -
61±8/66±5 AFL (0/2) (15/14) 
Villani et al. 1990 44.4±1.9/46.6±1.8 
-
12112 7/6 
-
42.6±3.4/43.5±4 PAF (19118) NS 
- 121±12I114±16 -
AF, atrial fibrillation; AFL, atrial flutter; CABG, coronary artery pypass surgery; PAF, paroxysmal atrial fibrillation; PAT, paroxysmal atrial tachycardia; PSVT, paroxysmal supraventricular tachycardia; SVA, 
supraventricular arrhythmia; The values are given as controVtreatment 
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Table (1) Population Characteristics of the Included Studies (Flecainide clinical trials; continued) 
Study name Age;mean years Weight Male Female Onset of acute AF Left atrial Type of SVA; Cause of AF Mean Mean heart Mean blood I 
(range/±SD) (Kg) (hours) diameter,mm Flecainide/Con- ventricular rate at entery pressure , 
(Flecainide/Con- (Flecainide/Con- (range) trol) ejection (beats/min) (mm Hg) 
trol) trol) (Flecainide/Con- fraction 
trol) 
Suttorp et al. 59±14 - 15/19 1016 < 24 hr (15116) 38±7/37±7 AF (20120) Medical; (25/25) - 137±25/141±21 -
1990 58±15/61±13 > 24 hr (10/9); the AFL (515) 
mean duration of AF 
(if >24 hrs) was 
100.8±57.61184.8±266 
Donovan et al. 60 (21-90) 
-
72 30 8.7±13n.3±9 - Recent-onset AF Cardiothoracic - 145±19/147±22 Systolic; 
1991 61±13/59±11 (51/51) surgery; (26/27) 118±17 
Cardiac disease; 1122±17 
(25/24) 
Capucci et al. 58±12I59±10/57±11 
-
14/10/11 819110 28±29.4/29.8±30.21 45±5/46±6/46±8 Recent-onset AF Medical; 
- 123±21/125±20 -
1992 27±26.8 (22119121) (22119/21) 11 22±14 
Capucci el al. 
- - - - - -
Recent-onset AF Medical; 
- - -
1993 (41143/61) (41/43/61) 
AF. atrial fibrillation; AFL. atrial flutter; CABG. coronary artery pypass surgery; PAF. paroxysmal atrial fibrillation; PAT. paroxysmal atrial tachycardia; PSVT, paroxysmal supraventricular tachycardia; SVA. 
supraventricular arrhythmia; The values are given as control/treatment 
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Table (2) Population Characteristics of the Included Studies (Amiodarone clinical trials) 
Study name Age; mean years Weight Male Female Onset of acute AF Left atrial Type of SVA; Cause of AF Mean Mean heart Mean blood 
(range/±SD) (Kg) (hours) diameter, mm Flecainide/Con- ventricular rate at entery pressure 
(Flecainide/Con- (Flecainide/Con- (range) trol) ejection (beats/min) (mm Hg) 
trol) trol) (Flecainide/C on- fraction 
trol) 
Faniel et al. 66.6 53 14 12 NS NS AF; 20 Medical; 26 - 142 -
1983 AFL;6 
Strasberg et al. 63 
-
16 10 15 mins-48 hrs 42±8 AF; 16 Medical; 26 - 143±17 129±31 
1985 PAF; 10 
Posada et al. 54.5156.9 - - - :5; 7 days 55±4/48±8 AF; (14/22) Medical; (14/22) - - -
1988 
Bertini et al. 68±7.35IPr62. - 7/9 8/15 60 min (25-840) NS AF; (12116) Medical; (15/24) - 145±25.911 Systolic; 
1990 58±11.54 SVT; (3/8) 148.5±30.73 139.33±20.6 
1135.65±23.07 
Diastolic; 
90±11.451 
83.9±11.96 
Noc et al. 1990 71±9.6 (51-85) - 15 9 20 mins-48 hrs NS PAF; 24 Medical; 24 - I 25±27 -
McAlister et al. 59±14/59± 19 
-
25/23 16116 103±711102±70 (hrs) Normal or mild T; AF; (29127) Surgical and ~40%; 1251124 Systolic; 
1990 (24/24) AFL; (819) medical; (41/39) (33127) 117/115 
Moderate or large T; AF/AFL; (4/3) Surgical only; < 40%; (212) 
(7/9) (35/36) Unknown; 
Unknown; (1016) (6110) 
Andrivet et al. 58.5±3/58±1.9 
-
12118 9n < 24 hrs; (12117) 42±1.8/36.7±1.3 AF; (11118) Medical; (21125) 
-
I 37±51130±5 
-
1993 > 24 hrs; (9/8) AFL; (5/2) 
AT; (212) 
AF+AFL; (0/2) 
AF+AT; (1/1) 
AFL+AT; (210) 
Chapman ef al. 7 I ±9/65± 13 
-
8110 214 Not less than 1 hr NS AF; (719) Medical; (10/14) 
- I 6O±231 I 6O±20 Systolic BP 
1993 AFL; (1/3) (SO) (SO); 
SVT; (212) 128±321123±18 
Contini et al. 61.9 (48-77) 
-
52 9 NS NS AF;61 Surgical; 61 > 50%;49 153.5±5.7 Systolic BP; 
1993 < 50%; 12 102±6.1 
Diastolic; 
64.5±2.7 
Bellandi et aI. 6 1.36± I 1.871 - 104 92 53.16±46.5 11 41.87±3.S7/42.18±3. AF; (98/98) Medical; (98198) - 13S.06±16. Systolic; 
1993 6S.15±11.89 S6.97±48.l3 72 3/1 38.04±1 9.2 138.31±20.4 
1141.6±21.06 
Diastolic; 
84.7±7.6I 
86.9±9. 
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Table (2) Population Characteristics of the Included Studies (Amiodarone clinical trials; continued) 
Study name Age; mean years Weight Male Female Onset of acute AF Left atrial Type of SVA; Cause of AF Mean Mean heart Mean blood 
(range/:tSD) (Kg) (hours) diameter,mm Flecainide/Con· ventricular rate at entery pressure 
(Flecainide/Con- (Flecainide/Con- (range) trol) ejection (beats/min) (mm Hg) 
trol) Irol) (Flecainide/Con- fraction 
tro/) 
Cesar et al. 1994 56.27±131 Q54.S±131 - 10/11114 6110/9 2.Sl±I.9/1.75±1.61 NS AF; (16/21123) Medical; - - -
Prc55A±12 2.75±2.5 (16/21/23) 
Cochrane et al. 60.2I65.S 
-
11110 4/5 54/49 (hrs) - AF; (15/15) CABO; (11110) - 1461144 I I 6.7±31I 26±2 
1994 Aortic valve 
replacement; (3/3) 
Mitral valvotomy; 
(110) 
Combined 
procedures; (0/2) 
Treglia et al. 56.6±9 .S/57 .8±1 0.2 - 10/13 17114 35.9±61.5/39.5±52.3 32.9±5A/34.5±4.6 AF; (27/27) Medical; (27/27) - 150A±19.31 IIOA±lS.61 
1994 153A±IS.l 100.2±IS.3 
Biasi et al. 1995 66.l±S/62.9±S 
-
36132 10/6 76.8±50A/84136 Enlarged; (13/11) AF or AFL; (46/38) Coronary surgery; ~40%; 131±231 98.5±10.71 
Unknown; (9/6) (31/23) (20/21) 139.4±22 95.38±12.3 
Valvular surgery; < 40%; (1/2) 
(15/15) Unknown; 
(916) 
Hou et al. 1995 70±Sn0±6 6O±111 22121 4/3 14/4 hrs 47±10/49±9 AF; (20119) Surgical; (3/4) 
-
157±201163±26 
-
61±11 AFL; (6/5) Medical; (23/20) 
Moran etal. 67±15 73±15 15/11 6110 ~ I hr NS AF; (11/15) Surgical; (11110) - 153±23/151±16 Systolic; 
1995 AT; (4/2) Medical; (10/11) 123±23/130±33 
AFL; (212) 
Reentry junctional 
tachycardia; (4/2) 
Donovan et al. 56±13/59±16I59±12 
- - -
11.5±13.618.8±8.21 NS AF; (32134132) CABO surgery; 
-
121±28/ Systolic; 
1995 8.9±13.6 (29) I 29±211134±22 I 20±1711 24±22 
Valve replacement 123±19 
surgery; (7) 
Medical; (62) 
Oalve et al. 1996 6O±13/61±11 
-
27128 13/11 25132118135 42±7/42±8 AF (50/50) Cardiac surgery; 34±7/32±7 I 47±24/1 4 I ±24 Systolic; 
(8/9) (SD) 138±25/128130 
Medical; (42141) 
Larbuisson et al. 67 (40-76)166 (58-75) 73.5n2 20117 211 Within one week after - AF or AFL; (22118) CABO surgery; 58 (32-78)1 
- -
1996 cardiac surgery (19116) 57 (30-80) 
Valve replacement 
surgery; (3/2) 
Medical; (8/10) 
- "-
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Table (3) Population Characteristics of the Included Studies (Sotalol clinical trials) 
Study name Age;mean years Weight Male Female Onset of acute AF Left atrial Type of SVA; Cause of AF Mean Mean heart Mean blood 
(range/:tSD) (Kg) (hours) diameter,mm (Sotalol/Control) ventricular rate at entery pressure 
(Sotalol/Control) (Sotalol/Control) (range) ejection (beats/min) (mm Hg) 
(SotalollControl) fraction 
Campbell et al. 60.5±9.1/63.5±5.2 - 19/15 115 54.4±16/55.11±27.7 NS AF; (19119) CABG surgery >50%; 163±241158±17 114±12I158±17 
1985 (hrs) AFL; (III) (17/16) (18/18) 
Valve replacement <50%; 
surgery (3/4) (2/2) 
Teo et al. 1985 43±I7 
-
9 4 Acute AF; 742.4 (hrs) NS Acute; AF, 3; AFL, Surgical; (4), 3 - - -
Chronic AF; 6.38 II;SVT, I valve replacement 
(years) surgery, and 1 
Chronic; AF, 8; thoracic surgery 
AFL, 2; SVT; 6 
Medical; (28) 
Levy et al. 1986 47 (10-77) 
-
16116 717 8.2 hrs NS AF; (9/9) Medical; (23/23) - 153.7 Systolic; 101.96 
AFL; (4/4) Diastolic; 69.4 
Junctional 
tachycardia; (1011 0) 
Janssen el al. 581 M 57.71 C59.6 
-
34/31/40 718/10 NS NS AF; (914 M) GABG; (1214) ~30% 141±29.61 
-
1986 AFL; (210) 135±23.8 
PAF; (1/0) 
Denis el al. 1988 65.8±14.3 - II 9 < 24 hrs NS AF; (8) Medical; (20) - - -
AFL; (5) 
Junctional 
tachycardias; (5) 
Systolic 
tachycardias; (2) 
Jordaens el al. 4L7±5.5 71±4.9 19 24 3.3 hrs NS AFL; (I) Medical; (43) 
- 180.5±6.7 Systolic; 118±61 
1991 AVNT; (30) Diastolic; 
CMT; (12) 83.8±S.7 
Hamer et al. 23-54 
-
3 3 NS NS PSVT;(6) Medical; (6) 
- - -
1993 
Halinen el al. 54.9±12.7153.2±15.3 
-
21119 1219 12.4±10.8Il 1.8±1 1.5 NS PAF; (33128) Medical; (33128) 
- 119/125 -
1995 (hrs); Median (9n.3) 
Sung el al. 1995 SVT; 42 ()9-72) 80.5 62 31 SVT; Median (range); NS SVT; (30114) Medical; (64129) 
- S; I mg/Kg; Systolic; 125 
AF; 63 (28-83) 0.25 (0.08-120) AF; (25/9) 135±7.S Diastolic; 78.9 
AF; 24 (0.08-144) AFL; (9/5) S; 1.5 mg/Kg; 
140±9.1 mg/Kg 
PL; 140±9.1 
----
• AF, atrial fibrillation; AFL, atrial flutter; CABG. coronary artery pypass surgery; PAF, paroxysmal atrial fibrillation; PAT. paroxysmal atrial tachycardia; PSVT, paroxysmal supraventricular tachycardia; SVA, 
supraventricular arrhythmia; The values are given as controUtrealmen; M, melOprolol; C, conlrol; A VNT. atrioventricular nodal tachycardia; CMT. circus movemenl tachycardia 
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Table (4) Cardiac diagnoses in noncardiac surgery patients (Flecainide clinical trials) 
Study name Patients Valvular Hyperten- Ischemic Thyroid Lone Congenital Pericarditis Alcohol- CHF Cardiomyopathy Miscel-
(n) (Fle/Cont) sion heart disease (Fle/Cont) Jibrillator hearl disease (Fle/Cont) associated (NYHA (Fle/Cont) laneous 
(Fie/Coni) (Fie/Coni) (Fie/ConI) (Fie/Coni) (Fle/Cont) class) (Fie/Coni) 
(Fie/Coni) 
Goy et aJ. 1985 50 12 4 8 0 21 0 2 0 0 4 0 
Borgeat et aL 1986 60 11 11 14 0 10 0 2 0 0 5 1 , 
Crozier et aJ. 1987 50 2 3 12 0 13 0 0 0 0 2 18 
Nathan et al. 1987 21 0 0 2 0 14 0 0 0 0 0 5 
Crijns et aJ. • (a) 1988 20 6 1 7 0 4 0 1 0 0 0 0 
Crijns et aL· (a) 1988 20 2 3 6 0 4 0 1 0 0 0 4 
SUllorp et aJ. 1989 40 012 5/4 614 0 9/9 WI 0 0 0 0 0 
WafaetaJ.I989 29 111 0 15/14 0 0 0 0 0 0 0 0 
SUllorp et aJ. 1990 50 413 212 7n 0 HV12 0 0 0 0 0 112 
Donovan et aL 1991 102 2 0 817 2 15 
-
I 3 
- -
23 
Capucci et aL 1992 62 0 7F/5pnA 0 0 15F/19A12IP 0 0 0 Oassl; 0 0 
2OF/18N19P 
Villani et aL 1990 37 
- - - - - - - - - - -
Madrid et aJ. 1993 4IY4O 4 17 9 3 42 0 0 0 0 0 S 
Capucci etaL 1994 181 0 21125Pr124P 51415 0 32132133 0 0 0 0 0 0 
NA. not available; CHF. congestive heart failure; NYHA class, New York Heart Association class; (AmioiCont). the number of patients with a given cardiac diagnosis in flccainide (FIe) and control (Cont) group; 
others. including patients in active control group 
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Table (5) Cardiac diagnoses in noncardiac surgery patients (amiodarone clinical trials) 
Study name Patients Valvular Hyperten. Ischemic Thyroid Lone Congenital Pericarditis Alcohol· CHF Cardiomyopathy Miscel· 
(n) (Am sion heart disease (Ami fibrillator heart disease (Amio/Cont) associated (NYHA (Amio/Cont) laneous 
io/Cont) (Am (Amio/Cont) o/Cont) (Amio/Cont) (Amio/Cont) (Amio/Cont) class) (Amio/Cont) 
io/Cont) (Amio/Cont) 
Faniel et al. 1983 26 4 0 4 0 4 I 1 0 1 2 II 
Strasberg et aI. 26 1 2 13 0 6 0 1 0 0 3 1 
1985 
Posada et al. 1988 36 819 V3 (lI2 0 112 0 0 0 0 012 3/3 
Bertini et al. 1990 15/24 0 6111 0 0 9113 0 0 0 0 0 0 
Noc el aI. 1990 NS . 
- - - - - - - - - -
McAlister et al. 41/39 21/19 0 19117 0 0 0 0 0 0 0 1/3 
1990 
Andrivet et aI. 1993 21125 3/5 111 0 0 16118 0 0 0 0 0 III 
Be\landi et at. 1993 98/98 23120 21119 2']J24 0 21124 0 0 0 0 516 615 
Chapman et at. 10114 0 212 3/3 0 6110 0 0 0 (lI2 010 0 
1993 
Contini et aI. 1993 24 0 0 M1;24 0 0 0 0 0 0 0 0 
Cesar et al. 1994 16121123 NS NS NS NS NS NS NS NS NS NS NS 
Cochrane et at. 0 0 0 0 0 0 0 0 0 0 0 0 
1994 
Treglia et at. 1994 54 NS NS NS NS NS NS NS NS NS NS NS 
Biasi et at. 1995 17 0 0 M1 inferior (614) 0 0 0 0 0 0 0 0 
MI anterior (314) 
Donovan et at. 62 6 S 18 0 15 0 0 7 0 0 11 
1995 
Hou et at. 1995 23/20 413 313 615 0 514 0 VI 0 II; (918) 212 112 
III; (315) 
IV; (14111) 
Moran O!'t at. 1995 42 0 0 110 0 V4 0 110 0 0 0 617 
Galve et at. 1996 SG'SO 27 0 18 . 2l!I2O 0 0 0 516 5 2 
Latbuisson O!'t at. NS . . 
- - - - - - - - -1996 
-
NA. not available; CHF, congestive heart failure; NYHA class, New York Heart Association class; (AmiolCont), the number of patients with a given cardiac diagnosis in amiodarone (Amio) and control (Cont) 
group; others, including patients in active control group 
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Table (6) Cardiac diagnoses in noncardiac surgery patients (Sotalol clinical trials) 
Study name Patients Valvular Hyperten- Ischemic Thyroid Lone Congenital Pericarditis Alcohol- CHF Cardiomyopathy Miscel-
(n) (Sot/Coni) sion heart disease (Sol/Cont) Jibrillator heart disease (Sot/Cont) associated (NYHA (Sot/Cont) laneous 
(Sot/Coni) (Sot/Cont) (Sot/Coni) (Sot/Cont) (Sol/Cont) class) (Sot/Cont) 
(Sol/Cont) 
Too et al. 1985 28 5 0 5 4 3 1 0 1 0 0 9 
Levy et al. 1986 23 5 0 1 0 10 2 1 0 0 2 4 
Jordaens et aL 1991 43 NS 
- - - - - - -
- - -
Hamer et al. 1993 6 0 0 0 0 6 0 0 0 0 0 0 
HaIinen et al. 1995 33124 111 11112 MI;2J3 0 9/1 0 0 7/4 0 0 0 
Angina;3n 
Sung et al. 1995 93 0 22 12 0 45 0 0 0 10 0 0 
NA, not available; CHF, congestive heart failure; NYHA class, New York Heart Association class; (Amio/Cont), the number of patients with a given cardiac diagnosis in sotalol (Sota) and control (Cont) group; 
others, including patients in active control group 
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Table 7.a Summary of subgroup analyses 
Flecainide clinical trials 
Type of comparison Time No. of No. of No. of PT (SE); Pc (SE); RD(%) z Q statistic RD('7~) Z 
interval trials compari- patients (950/0 CI) (95% CI) (95% CI) (P) (95% CI) 
(hrs) son 
(a) Type of active control 
FIe vs Propafenone 0-3 2 2 66/68 65.1 % (5.7); 50% (6.1); 14.1 (-2.4-30.4) 1.7 (NS) 0.96 (0.33) 
- -
(53.8-76.3 ) (38.1-61.9) 
FIe vs Propafenone 3-8 2 2 66/68 78.9% (5); 67.5% (5.5); 11.9 (-2.8-26.5) 1.6 (NS) 1.26 (0.26) - -
(69-88.7) (56.7-78.4) 
FIe vs Verapamil 0-3 2 2 41/26 63.6% (7.5); 6.1 (4.6); 57.4 (40.2-74.7) 6.5** 1.02 (0.3) 
- -(49-78.2) (-3-15.2) 
FIe vs Amiodarone 0-3 2 2 56/51 62.7% (6.02); 27.7% (6.02); 34 (16.7-51.5) 3.9** 3.7 (0.054) 34.97 2.05* 
(50-75.4) (15.9-39.6) ( 1.5-68.5) 
FIe vs Amiodarone 3-8 2 2 56/51 82.3% (4.9); 50.9% (6.8); 29.6 (12.7-46.5) 3.43** 7*(0.01) 30.9 1.4 (NS) 
(72.8-91.9) (37.4-64.2) (-13.9-75.8) 
FIe vs Amiodarone 8-24 1 1 22119 95% (4.4); 89.5% (7); 5.98 (-10.3-22.3) 0.72 
- - -(86.8-104.2) (75.7-103.3) (NS) 
FIe vs Quinidine 0-3 I I 30/30 56.7% (9) 0 56.7% (9) 6.3** 
- - -
FIe vs Quinidine 3-8 1 1 30/30 66.7% (8) 60% (8) 6.7 (-17-30.99) 0.5 (NS) 
- - -
Fie vs Digoxin+Disopyramide 0-3 1 1 29/27 65.5% (8.9) 29.6 (8.9) 35.9 (38.9-74.4) 2.9** 
- - -
FIe vs Digoxin+Disopyramide 3-8 1 1 29127 75.9% (7.9) 63 (9) 12.9 (-11.l-36.9) l.l (NS) 
- - -
FIe vs Digoxin+Disopyramide 8-24 1 ) 29127 86.2% (0.06) 88.9 (0.06) -2.7 (-19.9-14.6) -0.3 (NS) 
- - -
FIe vs Sotalol 0-3 ) ) 6/6 50% (20.5) 50% (20.5) 0(-56.6-56.6) o (NS) 
- - -
RD. risk difference; 95% CI; 95% confidence interval; PT and pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of heterogeneity. 
* statistically significant P < 0.05; ** highly statistically significant P < 0.01; NS. nonsignificant 
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Table 7.a Summary of subgroup analyses (continued) 
Flecainide clinical trials 
Type of comparison Time No. of No. of No. of PT(SE); Pc (SE); RD(ClD) z Q RD(%) Z 
interval trials comparison patients (95% CI) (95% CI) (95% CI) statistic (95% CI) 
(hrs) (P) 
(b) Type of 
arrhythmia: 
i. Versus placebo 
AF 0-3 5 5 1671183 72.6% 16.3% 67.3 18.7"" 56.9"" (0) 51.7 3.5"* 
(66.4-78.8) (10.7-21.8) (60.3-74) (22.7-80.7) 
AF 3-8 5 5 1671183 82.8% 37.3% 65.7 18.2"* 72 .... (0) 47.4 2.85"* 
(77 .4-88.3) (30-44.5) (58.7-72.9) (14.8-80.1) 
AF 8-24 1 1 19118 94.7% 27.8% 67 5.7** - - -
(84.7-104.8) (7.1-48.5) (44-90) 
AFL - - - - - - - - - - -
PSVT 
- - - - - -
- - - - -
ii. Versus others# 
Versus Propafenone 
AF 0-3 2 2 78/81 73.7% (4.7); 51.9% (5.5); 16.8 2.3* 2.9 (0.1) 
- -(64.6-82.9) (41-62.7) (2.15-31.4) 
AF 3-8 I I 58/61 77.6% (5.5); 72% (5.7); 5.5 0.7 (NS) 
- - -(66.9-88) (60.9-83.4) (-10-21) 
AFL 0-3 1 1 515 20% (17.9); 40% (21.9); -20 -0.7 (NS) 
- - -(-IS-55) (-2.9-83 ) (-75-35) 
Versus Verapamil 
AF 0-3 I I 17117 82.4% (9.2); 5.9% (5.7); 76.5 7** - - -
(64-100.5) (-5-17) (55.2-97.8) 
AFL 0-3 1 1 3/3 0% 0% 0 
- - - -
PSVT 0-3 1 
I 
I 6/6 50% (20.4); 16.7% (15.2); 33.3 1.3 (NS) 
- - -(10-90) (-13-46.5) (-16.6-83) 
Versus Quinidine 
AF 0-3 I 1 30/30 56.7% (9); 0% 56.7 6.3** -
- -(39-74) (38.9-74) 
AF I 3-8 I 1 30/30 66.7% (8.6); 60% (8.9); 6.7 0.54 - - -
I (49.8-83.5) (42.5-77) (-17.7-31 ) (NS) 
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Table 7.a Summary of subgroup analyses (continued) 
Flecainide clinical trials 
Type of comparison Time No. of No. of No. of PT (SE); Pc (SE); RD(7d z Q RD(O/~) Z 
interval trials compari- patients (95% Cl) (95% Cl) (95% Cl) statistic (95% Cl) 
(hrs) son (P) 
(c) Cause of arrhythmia 
• 
i. Versus placebo 
Cardiac surgery group 0-3 I I 26/27 61.5% (9.5); 18.5% (7.5); 43.2 3.5** 
- - -
(42.8-80.2) (3.9-33.2) ( 19.3-66.8) 
Cardiac surgery group 3-8 1 1 26/27 69.2% (9.1); 37% (9.3); 32.2 2.5** 
-
- -
(51.5-86.97) (18.8-55.3 ) (6.8-57.6) 
Noncardiac surgery (medical) 0-3 4 4 107/124 76.8% (3.7); 13.2% (3.2); 73.8 18.6** 41.6** (0) 56.3 3.3** 
group (69.7-84) (6.9-19.6) (66.1-8\.6) 
Noncardiac surgery (medical) 3-8 4 4 107/124 86.8% (3.1); 32.4% (4.5); 74.93 18.9** 38.9** (0) 56.6 3.5** 
group (80.6-92.9) (23.6-41.2) (67.2-82.7) 
Noncardiac surgery (medical) 8-24 4 4 1071124 86.8% (3.1); 31.7% (4.1); 50.4 9.2** 4.5** (0.2) 49.8 7.2** 
group (80.6-92.9) (23.6-39.8) (39.6-61.2) 
ii. Versus others# 
Versus Digoxin+Disopyramide 
Cardiac surgery group 0-3 1 1 29/27 65.5% (8.8); 29.6% (8.8); 35.9 2.9** 
- - -(48-82.8) ( 12.4-46.9) 01.5-60.3) 
Cardiac surgery group 3-8 1 1 29127 75.9% (7.9); 63% (9.3); 12.9 1.05 (NS) 
- - -(60.3-9\ ) (44.7-81.2) (-11-36.9) 
Cardiac surgery group 8-24 I 1 29127 86.2% (6.4); 88.9% (6); -2.7 -0.3 (NS) 
- - -(73.7-98.8) (77-100.1) (-19.9-14.6) 
Versus Quinidine 
Noncardiac surgery (medical) 0-3 I I 30/30 56.7% (9); 0% 56.7 6.3** - - -
group (39-74) (38.9-74) 
Noncardiac surgery (medical) 3-S I I 30/30 66.7% (8.6); 60% (8.9); 6.7 I 0.54 (NS) -
- -
group (49.S-83.5) (42.5-77) (-17.7-3)) 
- -
RD. risk difference; 95% CI; 95% confidence interval; PT and Pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of 
heterogeneity. * statistically significant P < 0.05; .. highly statistically significant P < 0.0 I; NS. nonsignificant 
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Table 7.a Summary of subgroup analyses (continued) 
Flecainide clinical trials 
Type of comparison Time No. of No. of 
interval trials comparison 
(hrs) 
(d) Route of administration 
ii. Versus placebo 
IV route only 0-3 2 2 
IV route only 3-8 2 2 
Orally 0-3 3 3 
Orally 3-8 3 3 
Orally 8-24 3 3 
ii. Versus otbers# 
Versus Amiodarone 
IV route only 0-3 I J 
IV route only 3-8 I 1 
Orally 0-3 I 1 
Orally 3-8 I I 
Versus Quinidine 
IV + Orally 0-3 I I 
IV + Orally 3-8 I I 
Versus Verapamil 
IV only 0-3 1 I 
Orally 0-3 1 I I 
No. of 
patients 
85/83 
85/83 
821100 
821100 
821100 
34/32 
34/32 
22119 
22119 
30/30 
30/30 
35120 
6/6 
Appendix 5.2 
Pr(SE); Pc (SE); RD(%) z Q statistic RD(%) Z 
(95% CI) (95'7'~ CI) (95% Cl) (P) (95% Cl) 
57.6% (5.4) 16.9% (4.1); 39.8 (26.5-53) 5.9** 0.43 (0.5) - -
(47.2-68.2) (8.9-24.9) 
67.1% (5.1); 43% (5.3); 23.7 (9.2-38.1) 3.2** 1.7 (0.2) - -
(57.1-77) (32.6-53.4) 
80.7% (3.9); 15.6% (3.96); 77.9 (69.7-86.3) 18.4** 33.7** 60.2 (\9.5-100.8) 2.9** 
(72.9-88.4) (7.8-23.4 ) 
89.5% (3.3); 32.2% (5.1); 79 (70.9-87) 19** 27** 64.7 (30-99.3) 3.7** 
(83-96) (22.2-42) 
89.5% (3.3); 31.3% (4.6); 54 (42.4-66) 9** 1.97 (0.372) 
- -
(83-96) (22.4-40) 
58.8% (8.4); 40.6% (8.7); 18.2 (-5.5-41.9) 1.5 (NS) 
- - -
(42.3-75.4) (23.6-57.6) 
67.6% (8); 59.4% (8.7); 8.3 (-14.9-31.4) 0.7 (NS) 
- - -(5 \.9-83.4) (42.4-76.4) 
68.2% (9.9); 15.8% (8.4); 52.4 (26.9-77.8) 4** 
- - -(48.7-87.6) ( -0.6-32.2) 
90.0% (6.\3); 36.8% (\ 1.1); 54.1 (29.3-78.9) 4.3** 
- - -(78.9-102.9) (\5.2-58.5) 
56.7% (9); 0% 56.7 (38.9-74) 6.3** 
- - -(39-74) 
66.7% (8.6); 60% (8.9); 6.7 (-17.7-31) 0.54 (NS) 
- - -(49.8-83.5) (42.5-77) 
65.7,* (8); 5% (4.9); 60.7 (42-79) 6.5** 
- - -
(50-81 ) (-4.6-14.6) 
50% 16.7% 33.3 (-16.6-83) 1.3 (NS) 
- - -
--
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Table 7.a Summary of subgroup analyses (continued) 
Flecainide clinical trials 
Type of comparison Time No. of No. of 
interval trials comparison 
(hrs) 
(e) Duration of arrhythmia: 
i. Versus placebo 
> 24 hrs 0-3 I 1 
> 24 hrs 3-8 1 1 
< 24 hrs 0-3 2 2 
< 24 hrs 3-8 2 2 
ii. Versus others# 
< 24 hrs 0-3 3 3 
> 24 hrs 0-3 7 8 
> 24 hrs 3-8 7 8 
> 24 hrs 8-24 7 8 
Overall analysis 
Versus placebo 0-3 5 5 
Versus placebo 3-8 5 5 
Versus placebo 8-24 5 5 
Versus others# 0-3 8 8 
Versus others# 3-8 8 8 
Versus others# 8-24 8 8 
No. of 
patients 
22121 
22121 
36/68 
36/68 
70/57 
, 
114/110 
114/110 
114/110 
1671183 
167/183 
167/18 
2151150 
215/150 
215/150 
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PT(SE); Pc (SE); 
(95% CI) (95% CI) 
68.2% 28.6% 
(48.7-87.6) (9.2-47.9) 
95.5% 47.62% 
(86.7-104.2) (26.3-68.98) 
57.7% 16.93% 
(47.2-68.2) (8.9-24.9) 
67.1 % 43% 
(57.1-77.1) (32.6-53.4 ) 
81.7% 45.6% 
(73.4-90.2) (31.4-59.8) 
64.5% 25.3% 
(56.1-72.9) (16-34.5) 
79.13% 47.6% 
(72.2-86) (38.7-56.4) 
87.8% 75.97% 
(69-82.9) (69-82.9) 
72.6% 16.3% 
(66.4-78.8) 00.7-21.8) 
82.8% 20.96% 
(77 .4-88.3) 05.7-26.2) 
82.8'* 36.3% 
<77.4-88.3 ) (29.5-43) 
63.7% 25% 
(57.7-69.6) (19.4-30.6) 
71.7% 58.6% 
(66.1-77.3) (51.4-65.9) 
82.5% 92.7,* 
(78-87) (78.5-95) 
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RD(%) z Q statistic RD(o;~) Z 
(95% CI) (P) (95% C/) 
39.6 (12.2-67) 2.8** - - -
47.8 (24.8-70.9) 4.1** - . -
39.8 (26.5-53.13) 5.9** 0.43 (0.5) 
- -
23.7 (9.2-38.14) 3.2** 1.74 (0.2) - -
63.3 (51.96-74.6) 10.96** 27.2** (0) 
- -
45.8 (35.1-56.5) 8.4** 5.8 (0.6) 
- -
27.98 (16.4-39.6) 4.7** 12.2 (0.09) 
-
-
7.1 (-1.9-16.1) 1.5 (NS) 3.2 (0.87) 
- -
67.3 (60.3-74) 18.7** 56.9** (0) 51.7 (22.7-80.7) 3.5** 
58.4 (66.2-53) 14.7** 53** (0) 46.9 (17.3-53) 3.11** 
42 (32.9-51.2) 9.02** 14** (0.007) 41.3 (23.9-58.7) 4.6** 
39.02 (31.2-46.82) 9.8** 25.3** (0.003) 36.3 (22.5-50. I} 5.1** 
26.3 (18.4-34.1) 6.5** 31.1 ** 25.9 (10.5-41.5) 3.3** 
(0.0003) 
15.8 (8.6-22.6) 4.4** 32.14** 16.4 (2.3-30.5) 2.3** 
(0.0002) 
~~--
Appendix 5.2 
Table 7.b Summary of subgroup analyses 
Amiodarone clinical trials 
Type of Time No. No. of No. of PT(SE); Pc(SE); RD(%) z Q RD(O/~) Z OR statistic Q statistic I 
comparison interval of compari- patients (95% CI) (95% CI) (95% CI) statistic (95% CI) (95% CI) for effect (P) 
(hrs) trials son (P) 
(a) Type of active 
I control 
Am vs Propafenone 0-3 4 4 110/107 6.8% (2.2); 16.6% (2.3); -6.5 -1.997* 16.7 -22 -1.95* 0.24 -4.2** 1.5 (NS) 
(2.5-11.3) (12-21.1) (-12.9_-0.1) (0.001) (-44.7-0.09) (0.13-0.5) 
Am vs Propafenone 3-8 4 4 110/107 22.5% (3.7); 63.8% (4.2); -29.1 -4.75** 5.45 - - 0.29 -4.3** 6.13 (NS) 
(15-29.8) (55-72) (-41.1_-17) (0.145) (0.16-0.5) 
Am vs Propafenone 8-24 4 4 1661154 80.8% (3.1); 86.7% (2.6); -3.6 -0.85 6.4 2.7 0.29 (NS) 0.92 -0.3 (NS) 6.9* (0.03) 
(74.8-86.8) (81.5-91.9) (-11.8-4.6) (NS) (0.04) (-15.6-20.9) (0.5-1.63) 
Am vs Digoxin 0-3 3 3 91/89 35.3% (4.9); 20.96% (4.3); 14.8 2.3* 4.5 - - 2 2.2* 3.23 (0.2) 
(25.8-44.9) (12.5-29.4) (1.98-27.6) (0.1) (1.07-3.9) 
Am vs Digoxin 3-8 3 3 91/89 60.3% (5); 48.3% (5.3); 11.6 1.6 (NS) 3.2 - - 1.6 1.5 (NS) 2.97 (0.23) 
(50.5-70.2) (38-58.7) (-2.7-25.9) (0.2) (-0.9-2.8) 
Am vs Digoxin 8-24 3 3 91189 80.7% (3.8); 62.8% (4.9); 11.76 1.8 (NS) 1.3 - - 1.7 1.5 (NS) 2 (0.4) 
(73.3-88) (53.1-72.5) ( -0.8-24.3) (0.5) .. (0.87-3.2) 
Am vs Flecainide 0-3 2 2 51/56 27.7% (6); 62.7% (6); -34 -3.9** 3.7 -34.97 -2.05* 0.3 -3.2** 2.9 (0.09) 
(15.9-39.6) (50-75.4) (-51.5_- (0.05) (-68.5_-1.5) (0.14-0.62) 
16.7) 
Am vs Flecainide 3-8 2 2 51156 50.7% (6.8); 82.3% (4.9); -29.6 -3.4** 6.9957 -30.9 -1.4 (NS) 0.3 -1.3 (NS) 5.8* (0.02) 
(37.4-64.2) (72.8-91.9) (-46.6_- (0.0096) (-75.8-13.9) (0.004-1.9) 
12.7) 
Am vs Flecainide 8-24 2 2 51156 77.5% (5.5); 88.9% (3.9); -6.7 -0.99 0.03 - -
(66.8-88.3) (81.3-96.5) (-20.1-6.6) (NS) (0.86) 
Am vs Quinidine 0-3 2 2 69/84 29.2% (5.3); 25.8% (4.2); 3.2 0.5 2.9 (0.09) - - 1.3 0.6 (NS) 3.9* (0.05) 
( 18.7-39.7) (17.6-34) (-10-16.5) (NS) (0.6-2.63) 
Am vs Quinidine 3-8 1 I 53/63 41.5% (6.8); 58.7% (6.2); -17.2 -1.9 - - - 0.67 -1.4 (NS) -
(28.2-54.8) (46.6-70.9) ( -35.2-0.8) (NS) (0.4-1.2) 
Am vs Procainamide 0-3 2 2 26/37 50% (9.8); 48.6% (8.2); 1.3 0.1 (NS) 0.007 (NS) - - 1.05 0.1 (NS) 0.007 (NS) (30.8-69) (32.5-64.7) (-23.7-26) (0.39-2.8) 
FIe vs Digoxin+Diso- 0-3 I I 29127 65.5% (8.9) 29.6 (8.9) 35.9 2.9** - - - 4.1 2.7** 
-
pyramide (38.9-74.4) (1.5- I2) 
Am vs Cibenwline 0-24 I I 21125 71.4% (9.8) 72% (0.1) -0.57 -0.04 - . - 0.97 -0.04 (NS) 
-(-26.7-25.6) (NS) (0.3-3.5) 
Am vs Mg Sulfate 0-3 I I 21121 28.6% (9.8) 33.3% (10) -4.7 -0.33 - - - 0.8 -0.33 (NS) 
-(-32.7-23.2) (NS) (-1.5-1.08) 
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Table 7.b Summary of subgroup analyses (continued) 
Amiodarone clinical trials (continued) 
Type of comparison Time interval No. of No. of No. of PT(SE); Pc (SE); RD(%) z Q statistic RD(%) Z 
(hrs) trials comparison patients (95% el) (95% el) (95% el) (P) (95% el) 
(b) Type of arrhythmia: 
I. Versus placebo 
AF 0-3 3 3 1011103 28.8% (4.4); 25.2% (4.3); 4.5 (-7.7-16.6) 0.72 (NS) 2.74 (0.3) - -
(20-37.4) (16.8-33.5) 
AF 3-8 3 3 1011103 51.4% (4.9); 50.5% (4.9); 0.8 (-12.8-14.4) 0.11 (NS) 0.69 (0.41) 
- -
(41.7-61) (40.9-60) 
AF 8-24 1 1 50/50 56% (7); 50% (7); 6 (-13.5-25.5) 0.6 (NS) 
- - -
(42.2-69.8) (36-63.9) 
ii. Versus others# 
Versus Digoxin 
AF 0-24 3 3 85/84 83% (3.6); 63% (5); 11.3 (-1.5-24) 1.7 (NS) 1.2 (NS) - -
(75.9-90) (53-73) 
AFL 0-24 1 1 6/5 83.3% (15.2); 60% (21.9) 23.3 (-28.9-75.6) 0.8 (NS) 
- - -
(53.5-113.5) (17.1-102.9) 
Versus Quinidine 
AF 0-1 1 1 16121 50% (12.5); 71.4% (9.9); -21.4 (-52.6-9.8) -1.3 (NS) - - -(25.5-74.5) (52-90.8) 
Versus Procainamide 
AF 0-24 1 1 7/9 71% (17); 55.6% (16.6); 15.9 (-30.7-62) 0.7 (NS) 
- - -(37.9-104.9) (23-88) 
AFL 0-24 \ \ 113 50% (50); 0 -50 (-148-48) -\ (NS) 
- - -(-48-148) 
PSVT 0-24 \ 1 212 95% (15.4); 95% (15.4); 0(-42.7-42.7) o (NS) -
- -(64.8-125) (64.8-125) 
Versus Propafenone I 
AF 0-3 2 2 39/43 25% (12.5); 81.3% (9.8); -2.9 (-9.9-4.2) -0.8 (NS) 11.9** -26 -0.93 
(0.5-49.5) (62-100) (0.001) (-80.9-28.9) 
AF 3-8 2 2 39/43 13.7% (5); 64.5% (6.8); -43.6 (-62_-25.5) -4.7·· 0.97 (NS) 
- -(3.1-24.4) (51-78) 
AFLor AF 0-3 2 2 68/56 19% (4.8); 44.6% (6.6); -25.5 (-41.6_-9.5) -3.12·· 0.004 (NS) 
- -(9.8-28.4) (31.6-57.7) 
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Table 7.b Summary of subgroup analyses (continued) 
Amiodarone clinical trials (continued) 
Type of comparison Time No. of No. of No. of Pr(SE); Pc (SE); RD(%) z Q statistic RD('7D) Z 
interval trials compari- patients (95% Cl) (95% Cl) (95% Cl) (P) (95% Cl) 
(hrs) son 
(c) Cause of arrhythmia 
i. Versus placebo 
Cardiac surgery group 
- - - - - - - - - - -
Noncardiac surgery 0-3 1 1 19/21 15.S% (O.OS) 2S.6% (9.S) -12.S (-38-12.6) -I (NS) -
- -(medical) group 
Noncardiac surgery 3-8 1 1 19/21 89.5% (7) 47.6% (0.1) 41.9 (16.4-67.3) 3.24** 
- - -
(medical) group 
ii. Versus others# 
Versus Propafenone 
Cardiac surgery group 0-3 2 2 68/56 27.7% (5); 48% (6.6); -18.3 (-34.8_-1.8) -2.2* 1.7 (0.2) 
- -(17.7-37.8) (35.2-61) 
Cardiac surgery group 3-8 2 2 68/56 81% (4.7); 67.9% (6.2); 13 (-2.3-28.5) 1.7 (NS) 0.044 (NS) 
- -(71.8-90.4 ) (55.6-80.1) 
Noncardiac surgery 0-3 2 2 42151 3.4% (2.5); 12.9% (2.4); -2.9 (-9.9-4) -0.8 (NS) 10.3** (0.001) -21.7 (-68-24.7) -0.92 (NS) 
(medical) group (-1.6-8.4) (8-17.6) 
Noncardiac surgery 3-8 2 2 42151 16.5% (5.5); 74.5% (5.5); -41 (-58.5_-23.6) -4.6** 0.33 (0.4) 
- -(medical) group (5.8-27.2) (63.7-85) 
Noncardiac surgery 8-24 2 2 42151 75.8% (3.7); 88.6% (2.8); -II (-20_-2) -2.4* 0.35 (0.6) 
- -(medical) group (68.6-83) (83-94) 
Versus Aecainide 
Noncardiac surgery 0-3 I I 19122 15.8% (8.4); 68.2% (9.9); -52.4 (-77.8_-26.9) -4** 
- - -(medical) group (-0.6-32.2) (48.7-87.6) 
Noncardiac surgery 3-S I I 19122 36.8% (11); 90.9% (6); -54 (-78.9_-29.3) -4.3** 
- - -(medical) group (15-58.5) (78.9-102.9) 
Noncardiac surgery 8-24 1 I 19/22 89.5% (7); 95.5% (4); -6 (-22.3-10.3) ..{).7 (NS) 
- - -
, 
(medical) group (75.7-103.4) (86.S-104.2) 
Versus Digoxin 
Cardiac surgery group 0-3 I I 15/15 26.7% (11.4); 20% (10.3); 6.7 (-23.5-36.S) 0.4 (NS) 
- - -(4.3-49) (-0.2·40) 
Cardiac surgery group 3-8 I I 15/15 60% (12.6); 60% (12.6); 0(-35-35) o (NS) 
- - -(35-S5) (35-85) 
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Table 7.b Summary of subgroup analyses (continued) 
Amiodarone clinical trials (continued) 
Type of comparison Time No. of No. of No. of PdSE); Pc (SE); RD(%) z Q statistic RD(%) Z 
inteTllal trials compari- patients (95% CI) (95% CI) (95% CI) (P) (95% CI) 
(hrs) son 
(d) Route of administration 
I. Versus Placebo 
IV route only 0-3 2 2 82182 33.8% (5.2); 24.4% (4.7); 9.6 1.4 (NS) 0.4 (0.6) - -
(23.6-43.98) (15-33.7) (-4-23.3) 
IV route only 3-S 2 2 82182 54.9% (5.5); 51% (5.5); 3.7 0.47 (NS) 0(1) - -
(44.2-65.7) (40.5-62) (-11.6-18.9) 
IV route only 8-24 I I 50/50 56% (7); 50% (7); 6 0.6 (NS) - - -
(42-69.8) (36-63.9) (-13.5-25.5) 
Orally 0-3 I I 19/21 15.8% (0.08) 28.6% (9.8) -12.8 -I (NS) - - -
(-38-12.6) 
Orally 3-8 1 1 19/21 89.5% (7) 47.6% (0.1) 41.9 3.24** - - -(16.4-67.3) 
ii. Versus others# 
Versus Flecainide 
IV route only 0-3 1 I 32134 40.6% (8.7); 58.8% (8.4); -18.2 -1.5 (NS) - - -
(23.6-57.6) (42-75.4) (-41.9-5.5) 
IV route only 3-S I I 32134 59.4% (S.7); 67.6% (S); -S.3 -0.7 (NS) - - -(42-76) (51.9-83.4 ) (-31-14.9) 
Orally 0-3 I I 19122 53.8% (0.09) 16.7% (0.08) -52.4 -4** 
- - -(-77.S -26.9) 
Orally 3-8 I I 19122 60.3% (5) 48.3% (5.3) -54 -4.3** - - -(-78.9 -29.3) 
Orally S-24 I I 19122 80.7% (3.8) 62.8% (4.9) 11.8 I.S (NS) - - -(-0.8-24.3) 
RD, risk difference; 95% CI; 95% confidence interval; PT and Pc, pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic, test of heterogeneity, * statistically 
significant P < 0.05; ** highly statistically significant P < 0.01; NS, nonsignificant 
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Table 7.b Summary of subgroup analyses (continued) 
Amiodarone clinical trials (continued) 
Type of comparison Time No. of No. of No. of PT(SE); Pc (SE); RD(%) z Q statistic RD(%) Z 
interval trials comparison patients (95% Cl) (95% CI) (95% Cl) (P) (95% CI) 
(hrs) 
(e) Duration of arrhythmia: 
I. Versus placebo 
> 48 hrs 0-3 I I 19/21 15.8% (0.08) 28.6% (9.8) -12.8 (-38-12.6) -I (NS) - - -
> 48 hrs 3-8 I I 19121 89.5% (7) 47.6% (0.1) 41.9 (\6.4-67.3) 3.24** - - -
< 48 hrs 0-3 1 1 51/53 40% (0.09) 25% (7.7) 15.6 (-7.1-38.3) 1.35 - - -
(NS) 
< 48 hrs 3-8 I I 51153 59.4% (8.7) 56.3% (8.8) 3.13 (-21.1-27.3) 0.25 - - -
(NS) 
ii. Versus otbers# 
Versus Digoxin 
> 48 hrs 0-3 I I 15/15 26.7% (11.4); 20% (10.3); 6.7 (-23.5-36.8) 0.4 (NS) - - -
(4.3-49) (-0.2-40) 
> 48 hrs 3-8 I I 15/15 60% (12.6); 60% (12.6); 0(-35-35) o (NS) - - -(35-85) (35-85) 
> 48 hrs 8-24 I 1 15115 86.7% (8.8); 80% (10.3); 6.7 (-19.9-33) 0.5 (NS) - - -
(69.5-103.9) (59.8-100) 
< 48 hrs 0-3 I 1 26124 53.8% 16.7% 37 (12.8-61.5) 3** -
- -
< 48 hrs 3-8 I 1 26/24 73.1% 41.7% 31.4 (5.3-57.5) 2.4* 
- - -
< 48 hrs 8-24 I 1 26/24 92% 70.8% 11.8 (-0.8-24) 1.8 (NS) 
- - -
Versus Propafenone 
> 48 hrs 0-24 I 1 98/98 80.6% (3.99); 90.8% (2.9); -10.2 (-19.9_-0.5) -2.1* - - -(72.8-88) (85-96.5) 
< 48 hrs 0-3 2 2 42151 3.4% (2.5); 12.9% (2.4); -2.9 (-9.9-4) -0.8 (NS) 10.3** (0.001) -21.7 (-68-24.7) -0.92 (NS) 
( -1.6-8.4) (8-17.6) 
< 48 hrs 3-8 2 2 42151 16.5% (5.5); 74.5% (5.5); -41 (-58.5_-23.6) -4.6** 0.33 (0.4) 
- -(5.8-27.2) (63.7-85) 
-~-
RD. risk difference; 95% CI; 95% confidence interval; PT and Pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of heterogeneity. * statistically significant 
P < 0.05; ** highly statistically significant P < 0.0 I; NS. nonsignificant 
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Table 7.c Summary of subgroup analyses 
Sotalol clinical trials 
Type of comparison Time No. of No. of No. of Pr(SE); Pc(SE); RD(%) z Q statistic RD(%) Z 
interval trials comparison patients (95% CI) (95% CI) (95% CI) (P) (95% CI) 
(hrs) 
(a) Type of arrhythmia: 
i. Versus placebo 
AF 0-3 2 2 34118 32.3% (8); 11.1 % (10.5); 26.4 (5.9-46.9) 2.5** 0.35 (0.6) -
-(16.6-48.1 ) (-9.4-3\.6) 
AFL 0-3 2 2 13/9 30.5% (12.7); 15.96% 12.97 (-22.2-48.1) 0.7 (NS) 0.001 (0.98) 
-
-(5.5-55.4) 02.2); 
(-7.8-39.8) 
PSVT 0-3 3 3 76/46 81.8% (4); 10.23% (4.4); 63.1 (50-76.1) 9.5** 0.04* (0.03) 58.5 (32.9-84) 4.5** 
(73.8-89.7) (\.6-18.9) 
ii. Versus others# I 
AF 0-3 3 3 62151 34.2% (4.6); 42% (7); 13.7 (-0.9-28.2) 1.8 (NS) 27.99** 17.3 (-29.6-64.2) 0.73 (NS) 
(25-43.2) (28.3-56) 
AF 3-8 3 3 62151 61.1% (4.7); 76.4% (5.8); -16.4 (-31.2_-1.5) -2.15* 14** -8.1 (-52-35.9) -0.36 (NS) 
(52.4-71) (65-87.83) 
AF 8-24 3 3 62151 74.3% (5); 85.7% (6.6); -18.7 (-29.2_-8.2) -3.5** 4.2 (0.123) 
- -(64.5-84.2) (72.8-98.7) 
AFL 0-3 I I III 0.5% (0.5); 0.5% (0.5); 0(-1.39-1.39) o (NS) 
- - -(-48-1.5) (-48-1.5) 
PSVT 0-3 2 2 12112 50% (14.4); 28.6% (12.2); 18.8 (-18.7-56.2) 0.98 (NS) 0.75 (0.4) 
- -(21.7-78.3) (4.7-52.5) 
RD. risk difference; 95% CI; 95% confidence interval; PT and pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of heterogeneity. * statistically 
significant P < 0.05; ** highly statistically significant P < 0.0 I; NS, nonsignificant 
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Table 7.c Summary of subgroup analyses (continued) 
Sotalol clinical trials 
Type of comparison Time No. of No. of 
interval trials comparison 
(hrs) 
(b) Cause of arrhythmia 
i. Versus placebo 
Noncardiac surgery (medical) 0-3 3 3 
group 
Cardiac surgery group - - -
ii. Versus otbers# 
Cardiac surgery group 0-3 2 2 
Cardiac surgery group 3-8 2 2 
Cardiac surgery group 8-24 2 2 
Noncardiac surgery (medical) 0-3 3 3 
group 
Noncardiac surgery (medical) 3-8 3 3 
group 
Noncardiac surgery (medical) 8-24 3 3 
group 
-----
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No. of PT(SE); Pc (SE); 
patients (95% Cl) (95% Cl) 
123n3 62.2% (4.1); 13.99% (4.9); 
(54.3-70.2) (4.4-23.6) 
- - -
31124 74.2% (7.9); 50% (11.2); 
(58.8-89.6) (28.1-71.9) 
31124 87.7% (5.9); 76.6% (8.4); 
(76.2-99.2) (60.1-93.1) 
31124 87.7% (5.9); 94.4% (4.7); 
(76.2-99.2) (85.2-103.6) 
45/40 17.2% (5.3); 33.2% (7.3); 
(6.8-27.6) (18.9-47.43) 
45/40 29.7% (6.6); 57.3% (7); 
(16.7-42.7) (43.6-71) 
45/40 48.9% (7.5); 72.7% (5.8); 
(34.3-63.5 ) (61.3-84.1 ) 
RD(%) z Q statistic RD(%) Z I 
(95% Cl) (P) (95% Cl) 
47.1 8.6** 7.1* (0.03) 47.4 (27.1-67.6) 4.6** 
(36.34-57.8) 
- - - - -
51.2 5.15** 5.7* (0.02) 49.3 (2.5-9.6) 2.1* 
(31.7-70.6) 
Il.l 1.02 1.53 (0.22) 
- -(-10.3-32.5) (NS) 
-7.3 -0.87 0.4 (0.53) 
- -(-23.7-9.1) (NS) 
-13.5 -1.45 4.5 (0.11) 
- -(-31.8-4.8) (NS) 
-29.99 -3.1** 9.6** (0.01) -8.5 (-61.7-44.7) -0.31 (NS) 
(-49 -10.9) 
-23.4 -2.5* 0.12* (0.03) -5.8 (-51.7-40.1) -0.25 (NS) 
(-42 -4.83) 
RD, risk difference; 95% CI; 95% confidence interval; PT and Pc, pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic, test of heterogeneity, * statistically 
significant P < 0.05; ** highly statistically significant P < 0.0 I; NS, nonsignificant 
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Table 7.c Summary of subgroup analyses (continued) 
Sotalol clinical trials 
Type of comparison Time No. of No. of No. of PT(SE); Pe(SE); RD(%) Z Q statistic RD(%) Z 
interval trials comparison patients (95% Cl) (95% Cl) (95'?o Cl) (P) (95% Cl) 
(hrs) 
(c) Route of administration 
i. Versus Placebo 
IV route only 0-3 3 3 123n3 62.2% (4.1); 13.99% (4.9); 47.1 (36.34-57.8) 8.6** 7.1* (0.03) 47.4 (27.1-67.6) 4.6** 
(54.3-70.2) (4.4-23.6) 
Orally 0-3 - - - - - - - - - -
Ii. Versus others# 
IV route only 0-3 I I 20/20 75% (9.6); 50% (11.2); 25 (-3.99-53.99) 1.69* 
- - -(56-93.97) (28.1-71.9) 
IV route only 3-8 I 1 20120 85% (7.98); 80% (8.9); 5 (-18.5-28.5) 0.42 -
- -(0.7-1.01) (62.5-97.5) (NS) 
IV route only 8-24 1 1 20/20 85% (7.9); 95% (4.9); -10 (-28.3-8.3) -1.07 
- - -(69.4-100.6) (85.4-104.6) (NS) 
Orally 0-3 3 4 50/38 24.7% (4.9); 33.2% (7.3); 14.6 (-0.4-29.6) 1.9 32.3** 20.9 (-34.6-76.3) 0.7 (NS) (15-34.3) (18.93-47.4) (0.06) 
Orally 3-8 3 4 50/38 52.3% (5.3); 56.8% (6.7); -21.5 (-39.4_-3.6) -2.4* 15.9** 3.6 (-46-53.2) 0.14 (NS) 
(41.9-62.6) (43.6-70) 
Orally 8-24 3 4 50/38 68% (5.7); 74.4% (5.5); -16 (-32.7-0.5) -1.9 7.9* -0.67 (-35.9-34.6) 
-0.04 (56.9-79) (63.6-85) (0.06) (NS) 
RD, risk difference; 95% CI; 95% confidence interval; PT and Pc, pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic, test of heterogeneity, * statistically 
significant P < 0.05; ** highly statistically significant P < 0.01; NS, nonsignificant 
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Table 7.c Summary of subgroup analyses (continued) 
Sotalol clinical trials 
Type of comparison Time No. of No. of No. of Pr(SE); Pc(SE); RD(%) z Q statistic RD(%) Z 
interval trials comparison patients (95% el) (95% el) (95% el) (P) (95% el) 
(hrs) 
(d) Duration of arrhythmia: 
i. Versus placebo 
< 24 hrs 0-3 3 3 123n3 62.2% (4.1); 13.99% (4.9); 47.1 (36.34-57.8) 8.6** 7.1 * (0.03) 47.4 (27.1-67.6) 4.6*· 
(54.3-70.2) (4.4-23.6) 
> 24 hrs 0-3 - - - - - - - - - -
ii. Versus others# 
< 24 hrs 0-3 3 3 50/38 24.7% (4.9); 33.2% (7.3); 14.6 (-0.4-29.6) 1.9 32.3*· 20.9 (-34.6-76.3) 0.7 (NS) 
(15-34.3) (18.93-47.4 ) (0.06) 
< 24 hrs 3-8 3 3 50/38 52.3% (5.3); 56.8% (6.7); -21.5 (-39.4_-3.6) -2.4* 15.9** 3.6 (-46-53.2) 0.14 (NS) 
(41.9-62.6) (43.6-70) 
< 24 hrs 8-24 3 3 50/38 68% (5.7); 74.4% (5.5); -16 (-32.7-0.5) -1.9 7.9* -0.67 (-35.9-34.6) -0.04 
(56.9-79) (63.6-85) (0.06) (NS) 
> 24 hrs 0-3 1 I 20120 75% (9.6); 50% (11.2); 0.25 (-3.99-53.99) 1.69* - - -(56-93.97) (28.1-71.9) 
> 24 hrs 3-8 1 1 20120 85% (7.98); 80% (8.9); 5 (-18.5-28.5) 0.42 - - -(0.7-1.01) (62.5-97.5) (NS) 
> 24 hrs 8-24 I I 20/20 85% (7.9); 95% (4.9); -10 (-28.3-8.3) -1.07 - - -(69.4-100.6) (85.4-104.6) (NS) 
--
RD. risk difference; 95% CI; 95% confidence interval; Pr and pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of heterogeneity. • statistically 
significant P < 0.05; •• highly statistically significant P < 0.01; NS. nonsignificant 
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Table 7.c Summary of subgroup analyses (continued) 
Sotalol clinical trials 
Type of Time No. of No. of No. of PT(SE); Pc (SE); RD(%) z Q statistic RD(%) Z 
comparison interval trials comparison patients (95% Cl) (95% Cl) (95% Cl) (P) (95% Cl) 
(hrs) 
Overall analysis 
Versus placebo 0-3 3 3 I 23n3 62.2% (4.\); 13.99% (4.9); 47.1 (36.34-57.8) 8.6** 7.1 * (0.03) 47.4 (27.1-67.6) 4.6** 
(54.3-70.2) (4.4-23.6) 
Sot vs Other drugs 0-3 4 5 70/58 34.9% (4.4); 38.2% (6); 16.8 (3.5-30) 2.5* 32** 21.8 (-19.5-63) 1.04 (NS) 
(all) (26.4-43.6) (26.2-50) 
Sot vs Other drugs 3-8 4 5 70/58 34.98% (4.4); 65.2% (5.4); -11.8 (-26-2.5) -1.62 (NS) 18.9** 2.5 (-32.6-37.5) 0.14 (NS) 
(all) (26.4-43.6) (54.7-75.7) 
Sot vs Other drugs 8-24 4 5 70/58 73.7% (4.6); 82.4% (4); -10.8 (-22.9-\.3) -1.75 (NS) 8.8 (0.07) -7.3 (-26.9-12.4) -0.7 (NS) 
(al/) (64.6-82.7) (74.6-90) 
-- ---
RD. risk difference; 95% CI; 95% confidence interval; PT and pc. pooled percentages of patients remaining in sinus rhythm in treatment and control groups; Q statistic. test of heterogeneity. * statistically 
significant P < 0.05; ** highly statistically significant P < 0.01; NS. nonsignificant 
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Table (1) Approximation of total mortality events, and variance of survival curve estimate by actuarial or life-table method in 
amiodarone trials which reported the number of patients remaining at risk during the follow-up 
Trial (1): Ceremuzynski et al. 1992 
Time Interval Amlodarone group 
(weeks) 
dlt nl£ 
0 
4 9 305 
8 1 296 
12 0 295 
16 1 295 
20 1 294 
24 3 293 
28 1 290 
32 2 289 
36 1 287 
40 1 286 
44 0 285 
48 0 285 
52 0 285 
Total events 19 
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
PI§ Si' SEIV 
1 1 
0.9700 0.9700 0.00992 
0.9970 0.9672 0.01034 
1 0.9672 0.01034 
0.9966 0.9639 0.01082 
0.9959 0.9600 0.01135 
0.9904 0.9508 0.01251 
0.9965 0.9475 0.01289 
0.9931 0.94098 0.01362 
0.9968 0.9380 0.01393 
0.9962 0.9344 0.01429 
1 0.9344 0.01429 
1 0.9344 0.01429 
1 0.9344 -
'I. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
¥. Standard error of the Kaplan-Meier estimate 
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Placebo group 
dlt nl£ Pi§ Si'l SEiV 
I 1 , 
11 308 0.9643 0.9643 0.01058 
4 297 0.9865 0.9866 0.01226 
2 293 0.9932 0.9932 0.01301 
3 291 0.9897 0.9897 0.01404 
4 288 0.9861 0.9861 0.01527 
2 284 0.99293 0.99293 0.01584 
1 282 0.9965 0.9965 0.01611 
3 281 0.9893 0.9893 0.01689 
2 278 0.9928 0.9928 0.01739 
1 276 0.9964 0.9964 0.01762 
0 275 1 1 0.01762 
0 275 1 1 0.01762 
0 275 1 1 0.01762 
33 
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Table (1) Approximation of total mortality events, and variance of survival curve estimate by actuarial or life-table method in 
amiodarone trials which reported the number of patients remaining at risk during the follow-up (continued) 
Trial (2): Navarro-Lopez et al. 1993 
Time Amiodarone group 
interval 
(months) 
dlt nj£ PI§ 
0 1 
6 1 1I5 0.99 
12 0 107 1 
18 2 106 0.979 
24 I 105 0.992 
30 0 100 1 
36 0 81 1 
Total events 4 
- ----
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
Placebo group 
SI'I SEI¥ dlt 
1 
0.99 0.0093 I 
0.99 0.0093 1 
0.97 0.0163 4 
0.963 0.0182 2 
0.963 0.0182 1 
0.963 0.0182 0 
9 
'I. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
¥. Standard error of the Kaplan-Meier estimate 
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Metoprolol 
group 
nl£ PI§ SI'I SEI¥ dlt nl£ PI§ Si'l SEI¥ 
1 I 1 I 
123 0.99 0.99 0.009 6 130 0.956 0.956 0.0179 
113 0.992 0.983 0.012 I 116 0.989 0.945 0.0201 : 
112 0.967 0.950 0.020 0 113 1 0.945 0.0201 
107 0.976 0.928 0.024 2 112 0.984 0.930 0.0228 
102 0.995 0.923 0.025 5 107 0.954 0.888 0.0287 
75 1 0.923 0.025 3 78 0.954 0.847 0.03441 
17 
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Table (1) Approximation of total mortality events, and variance of survival curve estimate by actuarial or life-table method in 
amiodarone trials which reported the number of patients remaining at risk during the follow-up (continued) 
Trial (3): BASIS 1993 
Time interval Amiodarone group 
(Months) 
dlt nl£ 
0 
12 3 98 
24 6 89 
36 5 84 
48 5 80 
60 5 76 
72 2 66 
84 I 51 
96 3 37 
102 0 37 
Total events 31 
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
PI§ Si'l SEI¥ 
1 1 
0.9667 0.9667 0.01812 
0.9310 0.9 0.03097 
0.9389 0.845 0.0374 
0.9335 0.789 0.04211 
0.9298 0.733 0.04546 
0.9681 0.71 0.04679 
0.9859 0.7 0.04759 
0.9143 0.64 0.05414 
I 0.64 0.05414 
'I. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
¥. Standard error of the Kaplan-Meier estimate 
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Placebo group 
dlt nl£ PI§ Si'l SEI¥ 
1 1 
Ii 114 0.9 0.9 0.0281 
5 94 0.944 0.85 0.034 
II 87 0.871 0.74 0.042 
2 82 0.973 0.72 0.043 
2 78 0.972 0.7 0.044 
10 72 0.857 0.6 0.048 
4 48 0.917 0.55 0.0499 
3 44 0.945 0.52 0.0508 
5 26 0.827 0.43 0.0570 
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Table (1) Approximation of total mortality events, and variance of survival curve estimate by actuarial or life-table method in 
amiodarone trials which reported the number of patients remaining at risk during the follow-up (continued) 
Trial (4): Garguichevich et al. 1995 
Time ioterval Amiodarooe group 
(Days) 
dlt nl£ 
0 
30 I 57 
60 1 56 
90 0 55 
120 0 55 
150 0 55 
180 0 55 
210 0 55 
240 2 55 
270 0 55 
300 I 55 
330 I 50 
360 0 50 
Total events 6 
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
PI§ Sit SEI¥ 
I I 
0.98125 0.98125 0.01797 
0.98089 0.9625 0.02516 
1 0.9625 0.02516 
I 0.9625 0.02516 
1 0.9625 0.02516 
1 0.9625 0.02516 
1 0.9625 0.02516 
0961039 0.9250 0.03486 
1 0.9250 0.03486 
0.97297 0.9000 0.03948 
0.98556 0.8870 0.04178 
I 0.8870 0.04178 
'I. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
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Placebo group 
dlt 01£ PI§ Sit SEi¥ 
I I 
2 49 0.95 0.95 0.031135 
I 46 0.9868 0.9375 0.034624 
0 45 1 0.9375 0.034624 
2 45 0.9600 0.9 0.043067 
I 44 0.9722 0.875 0.047437 
0 43 1 0.875 0.047438 
3 43 0.9286 0.8125 0.055869 
2 40 0.9539 0.775 0.059719 
0 38 I 0.775 0.059719 
I 38 0.9762 0.7566 0.061367 
0 37 I 0.7566 0.061367 
2 37 0.9418 0.7125 0.064718 
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Table (2) Approximation of total mortality events, and variance of survival curve estimate by actuarial or life-table method in 
amiodarone trials which did not report the number of patients remaining at risk during the follow-up (continued) 
Trial (1): Nicklas et al. 1991 
Time Interval Amlodarone group 
(Days) 
dlt nl£ 
0 
50 4 49 
100 2 47 
150 2 43 
180 I 41 
200 0 40 
250 0 40 
300 2 40 
350 1 38 
360 1 37 
400 1 35 
450 0 34 
500 0 34 
Total events 14 
Total reported 14 
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
PI§ SI'I SEIY 
I I 
0.925 0.925 0.03763 
0.9459 0.875 0.04684 
0.9571 0.838 0.05237 
0.9851 0.825 0.05397 
I 0.825 0.05397 
1 0.825 0.05397 
0.9394 0.775 0.059402 
0.9677 0.750 0.061628 
0.9667 0.725 0.063579 
0.9655 0.700 0.065275 
1 0.700 0.065275 
1 0.700 0.065275 
'I. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
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Placebo group 
dlt nl£ PI§ SI'I SEIY 
I I 
4 52 0.925 0.925 0.03653 
1 48 0.9865 0.913 0.03919 
1 47.45 0.9863 0.9 0.04160 
0 46.8 I 0.9 0.04160 
0 46.8 I 0.9 0.04160 
1 46.8 0.9861 0.888 0.04382 
0 46.15 1 0.888 0.04382 
2 46.15 0.9578 0.85 0.04952 
2.6 44.2 0.9412 0.8 0.05547 
2.625 42 0.9375 0.75 0.05998 
1.9 39 0.9507 0.713 0.06267 
0.68 37 0.9818 0.7 0.06349 
15.6 
9 
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Table (2) Approximation of total mortality events, and variance of survival curve estimate by actuarial or life-table method in 
amiodarone trials which did not report the number of patients remaining at risk during the follow-up (continued) 
Trial (2): The CASCADE Investigators 1993 
Time interval Amiodarone group 
(years) 
dlt nl£ 
0 
I 10.3 113 
2 10.2 102.83 
3 6.8 92.66 
4 11.3 85.88 
5 3.4 74.58 
6 11.3 71.19 
7 0 59.89 
8 0 59.89 
Total events 53 
Total reported 38 
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
PI§ Sj'l SEjY 
1 1 
0.909 0.91 0.027086 
0.9010989 0.82 0.036241 
0.9268293 0.76 0.040253 
0.8684211 0.66 0.044615 
0.9545455 0.63 0.045465 
0.8412698 0.53 0.046983 
1 0.53 0.046983 
1 0.53 0.046983 
'I. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
314 
Class lA group 
dlt nl£ PI§ SI'I SEIY 
1 1 
26.45 115 0.77 0.77 0.039243 
9.2 88.55 0.8961 0.69 0.043128 
15 79.35 0.8116 0.56 0.046289 
4.6 64.4 0.9286 0.52 0.046588 
7 59.8 0.8846 0.46 0.046476 
7 52.9 0.8696 0.4 0.045683 
0 46 1 0.4 0.045683 
0 46 I 0.4 0.045683 
69 
55 ! 
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Table (2) Approximation of total mortality events, and variance of survival curve estimate by actuarial or life-table method in 
amiodarone trials which did not report the number of patients remaining at risk during the follow-up (continued) 
Trial (3): Doval et al. (GESICA) 1994 
Time interval Amlodarone group 
(Days) 
dlt nl£ 
0 
90 21.3 260 
180 19 238.7 
270 17.7 219.8 
360 10.6 202 
450 14.2 191.45 
540 16.548 177.3 
630 5.897 160.73 
720 0 154 
Total events 105 
Total reported 87 
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
PI§ Si1 SEi¥ 
1 1 
0.918182 0.918182 0.0169982 
0.920842 0.8455 0.022414 
0.919338 0.7773 0.025802 
0.947331 0.73636 0.027325 
0.92593 0.68182 0.028886 
0.90666 0.61818 0.030129 
0.96333 0.5955 0.030437 
1 0.9955 0.030437 
'I. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
315 
Control group 
dit nil PI§ Si1 SEiV 
1 1 
25.6 256 0.9 0.9 0.01875 
31.4 230.4 0.86367 0.7773 0.02600 
13.97 199 0.92979 0.7227 0.027978 
13.96 185 0.924525 0.6682 0.029429 
17.5 171.6 0.897959 0.6 0.030607 
15.4 153.6 0.9 0.54 0.031141 
17 138.3 0.875426 0.4727 0.031197 
0 121 1 0.4727 0.031197 
135 
106 
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Table (2) Approximation of total mortality events, and variance of survival curve estimate by actuarial or life-table method in 
amiodarone trials which did not report the number of patients remaining at risk during the follow-up (continued) 
Trial (4): Singh etal. (STATCHF) 1995 
Time interval Amiodarone group 
(Months) 
dlt nl£ 
0 
12 64.4 336 
24 36.8 260 
36 32 175 
48 12 101 
51 1 33 
Total 146 
Total reported 131 
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
PI§ Sj'l SEjY 
I I 
0.8084 0.8084 0.02147 
0.8586 0.694 0.02539 
0.8164 0.5666 0.02903 
0.8825 0.5 0.03397 
0.97 0.485 0.03388 
'I. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
¥, Standard error of the Kaplan-Meier estimate 
316 
Placebo group 
dlt nl£ PI§ SI'I SEjY 
I I 
61.96 338 0.8167 0.8167 0.021045 
35 263 0.8669 0.7080 0.025009 
35.55 178 0.8003 0.5667 0.029166 
21 95 0.7793 0.4416 0.033134 
5 39 0.8719 0.3850 0.037322 
158 
143 
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Table (3) Estimation of total mortality events, and number of patients remaining at risk at beginning of the interval by curve 
fitting 
Trial (1): Nicklas er al. 1991 
Time Interval Amlodarone group 
(Days) 
d.t n.£ 
0 
50 5 49 
100 2 44 
150 2 42 
180 0 40 
200 0 40 
250 0 40 
300 2 40 
350 I 36 
360 1 26 
400 1 25 
450 0 24 
500 0 24 
Total events 14 
Total reported 14 
RMSE* 0.01486 
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
p.t S., SE.Y 
1 1 
0.89796 0.89796 0.04324 
0.9546 0.85714 0.04999 
0.9524 0.81633 0.05532 
I 0.81633 0.05532 
1 0.81633 0.05532 
1 0.81633 0.05532 
0.9500 0.77551 0.05961 
0.9722 0.75397 0.06172 
0.9615 0.72497 0.06581 
0.96 0.69597 0.06927 
1 0.69597 0.06927 
1 0.69597 0.06927 
,. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
t. Residual mean square error 
317 
Placebo group 
dlt nit Pit Si' SEiY 
I I 
6 52 0.88462 0.8846 0.04431 
0 46 I 0.8846 0.04431 
0 46 I 0.8846 0.04431 
0 46 1 0.8846 0.04431 
0 46 I 0.8846 0.04431 
0 46 I 0.8846 0.04431 
I 46 0.9783 0.8654 0.04733 
2 46 0.9565 0.8278 0.05222 
0 4 1 0.8278 0.05222 
0 2 1 0.8278 0.05222 
0 2 1 0.8278 0.05222 
0 2 1 0.8278 0.05222 
9 
9 
0.246416 
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Table (3) Estimation of total mortality events, and number of patients remaining at risk at beginning of the interval by curve 
fitting 
Trial (2): The CASCADE Investigators 1993 
Time Interval Amlodarone group 
(years) 
dlt nl£ 
0 
I 13 113 
2 7 100 
3 5 83 
4 7 49 
5 2 42 
6 4 40 
7 0 10 
8 0 10 
Total events 38 
Total reported 38 
RMSE+ 0.012009 
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
PI§ SI'I SEI¥ 
I I 
0.88496 0.88596 0.03 
0.93000 0.82300 0.0359 
0.93976 0.77343 0.0400 
0.85714 0.66294 0.0517 
0.95238 0.63137 0.0538 
0.90000 0.56823 0.05695 
I 0.56823 0.05695 
I 0.56823 0.05695 
'I. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
¥. Standard error of the Kaplan-Meier estimate 
t. Residual mean square error 
318 
Class IA group 
dlt nl£ PI§ SI'I SEI¥ 
I I 
40 115 0.65211 0.65217 0.0444 
14 75 0.81333 0.53043 0.0465 
23 61 0.62295 0.33043 0.0439 
7 38 0.81579 0.26957 0.0414 
II 31 0.64516 0.17391 0.0354 
II 20 0.45000 0.07826 0.0251 
0 9 I 0.07826 0.0251 
0 9 I 0.07826 0.0251 
106 
106 
0.59207 
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Table (3) Estimation of total mortality events, and number of patients remaining at risk at beginning of the interval by curve 
fitting 
Trial (3): Doval et al. (GESICA) 1994 
Time interval Amiodarone group 
(Days) 
dlt nl£ 
0 
90 23 260 
180 16 237 
270 14 187 
360 9 146 
450 10 137 
540 11 127 
630 4 116 
Total events 87 
Total reported 87 
RMSEt 0.005704 
t. No. of deaths at the end of the interval 
t. No. of pts at risk at the beginning of the interval 
I. Probability of surviving interval 
Pj§ Si'l SEj¥ 
I I 
0.91154 0.91154 0.01761 
0.93249 0.85 0.02215 
0.92513 0.786364 0.02622 
0.93836 0.737889 0.02916 
0.92701 0.684029 0.03162 
0.91339 0.624782 0.03355 
0.96552 0.603238 0.03408 
,. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
t. Residual mean square error 
319 
Control group 
dlt Dj£ PI§ Sj'l SEj¥ 
I I 
23 256 0.91016 0.91016 0.01787 
25 181 0.86188 0.78444 0.02797 
11 156 0.92949 0.72913 0.03057 
II 145 0.92414 0.67382 0.03248 
14 134 0.89552 0.60342 0.03410 
II 120 0.90833 0.54811 0.03482 
II 100 0.89000 0.48782 0.03542 
106 
106 
• 
0.003526 : 
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Table (3) Estimation of total mortality events, and number of patients remaining at risk at beginning of the interval by curve 
fitting 
Trial (4): Singh et al. (STATCHF) 1995 
Time Interval Amiodarone group 
(Months) 
dlt BI£ 
0 
6 28 336 
12 23 245 
18 11 215 
24 21 192 
30 23 171 
36 11 148 
42 6 137 
48 8 131 
Total 131 
Total reported 131 
RMSEt 0.011837 
t. No. of deaths at the end of the interval 
£. No. of pb at risk at the beginning of the interval 
t. Probability of surviving interval 
PI§ SI'I SEj¥ 
I I 
0.91667 0.91667 0.015078 
0.90612 0.83061 0.021873 
0.94884 0.78812 0.024218 
0.89063 0.70192 0.027935 
0.865497 0.60751 0.030331 
0.925676 0.56235 0.030331 
0.956204 0.53773 0.031214 
0.938931 0.50489 0.031392 
,. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
t. Residual mean square error 
320 
Placebo group 
dlt Bj£ PI§ Sj'l SEj¥ 
1 I 
29 338 0.9142 0.9142 0.0152 
24 309 0.9223 0.8432 0.0198 
17 241 0.9295 0.7837 0.0231 
17 221 0.9231 0.7234 0.0255 
- - - - -
23 204 0.8873 0.6419 0.0277 
17 181 0.9061 0.5816 0.0287 
16 138 0.8841 0.5142 0.0299 
143 
143 
0.004157 
Appendix 6.2 
Table (4) Approximation of sudden death events, and variance of survival curve estimate by actuarial or liCe-table method in 
amiodarone trials which reported the number of patients remaining at risk during the follow-up (continued) 
Trial (1): Garguichevich et al. 1995 
Time interval Amiodarone group 
(Days) 
dlt nl£ 
0 
30 2 57 
60 0 55 
90 0 55 
120 0 55 
150 0 55 
180 0 55 
210 0 55 
240 2 55 
270 0 53 
300 0 53 
330 0 53 
360 0 53 
Total evenlS 4 
t. No. of deaths at the end of the interval 
£. No. of pIS at risk at the beginning of the interval 
I. Probability of surviving interval 
PI§ Si'l SEI¥ 
I I 
0.967 0.967 0.02366 
0.99969 0.9667 0.02377 
I 0.9667 0.02377 
I 0.9667 0.02377 
I 0.9667 0.02377 
I 0.9667 0.0238 
1 0.9667 0.0238 
0.9597 0.92778 0.0343 
0.99997 0.92775 0.0343 
I 0.92775 0.0343 
I 0.92775 0.0343 
I 0.92775 0.0343 
t. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
321 
Placebo group 
dit nil Pi§ Si'l SEI¥ 
I I 
I 49 0.98 0.98 0.02 
0 48 0.98 0.98 0.02 
2 48 0.94 0.94 0.0339 
I 46 0.92 0.92 0.0388 
0 45 0.92 0.92 0.0388 
1 45 0.90 0.9 0.0429 
1 44 0.88 0.88 0.0465 
1 43 0.85 0.85 0.0511 
I 40 0.83 0.83 0.0538 
0 40 0.83 0.83 0.0538 
1 40 0.81 0.81 0.0562 
I 39 0.789 0.789 0.0585 
10 
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Table (4) Approximation of sudden death events, and variance of survival curve estimate by actuarial or life-table method in 
amiodarone trials which reported the number of patients remaining at risk during the follow-up (continued) 
Trial (2): Singh et al. (ST A TCHF) 1995 
Time interval Amiodarone group 
(Months) 
dlt nj£ 
0 
12 27 336 
24 13 260 
36 15 175 
48 8 101 
54 I 33 
Total 64 
t. No. of deaths at the end of the interval 
£. No. of pIS at risk at the beginning of the interval 
§. Probability of surviving interval 
Pj§ Sj'l SEjY 
1 1 
0.92 0.9200 0.0148 
0.95109 0.8750 0.0187 
0.91429 0.8000 0.02520 
0.91675 0.7334 0.031959 
0.95446 0.7000 0.040438 
1. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
322 
Placebo group 
dlt nj£ PI§ Si'l SEiY 
1 1 ! 
31 338 0.909 0.909 0.01565 
23 263 0.9131 0.83 0.02129 
\0 178 0.9398 0.78 0.02489 
10 95 0.8975 0.70 0.03299 
I 39 0.9714 0.68 0.03709 
75 
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Table (5) Approximation of sudden death events, and variance of survival curve estimate by actuarial or life-table method in 
amiodarone trials which did not reported the number of patients remaining at risk during the follow-up (continued) 
Trial (1): Doval et al. (GESICA) 1994 
Time interval Amiodarone group 
(Days) 
dit nj£ 
0 
90 8 260 
180 5 252 
270 7 247 
360 5 240 
450 9 233 
540 9 225 
Total 44 216 
Total reported 32 
t. No. of deaths at the end of the interval 
£. No. of pIS at risk at the beginning of the interval 
§. Probability of surviving interval 
Pi§ SI'I SEi¥ 
1 I 
0.97 0.97 0.010579 
0.9794 0.95 0.013519 
0.9699 0.92143 0.016688 
0.9767 0.9 0.018603 
0.9603 0.8643 0.021250 
0.9603 0.83 0.023302 
1 0.83 0.023302 
t. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
323 
Control group 
dlt ni£ Pi§ SI'I SEi¥ 
I 1 
13 256 0.95 0.95 0.0\3622 
13 243.2 0.9437 0.90 0.018750 
lO 230.3 0.9556 0.86 0.021687 
2 219.43 0.9884 0.85 0.022319 
13 217.6 0.9412 0.80 0.025002 
4 204.8 0.9821 0.7857 0.025648 
54.8 
39 
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Table (6) Estimation of sudden death events, and number of patients remaining at risk at beginning of the interval by curve 
fitting 
Trial (1): Doval et al. (GESICA) 1994 
Time interval Amiodarone group 
(Days) 
dlt nit 
0 
90 12 260 
180 3 248 
270 5 245 
360 4 195 
450 5 149 
540 3 97 
Total events 32 
Total reported 32 
RMSEt 0.00756 
t. No. of deaths at the end of the interval 
£. No. of pts at risk at the beginning of the interval 
§. Probability of surviving interval 
Pit SI'I SEI¥ 
I I 
0.95385 0.95385 0.01301237 
0.98790 0.94231 0.01446001 
0.97959 0.92308 0.01652573 
0.97949 0.90414 0.01870306 
0.96644 0.87380 0.02246443 
0.96907 0.84678 0.02664273 
'I. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
Y. Standard error of the Kaplan-Meier estimate 
f. Residual mean square error 
324 
Control group 
dit nl£ PI§ Si'l SEI¥ 
I I 
11 256 0.95703 0.957031 0.0126742 
9 173 0.94797 0.907244 0.0201358 
7 160 0.95625 0.867552 0.0242068 
2 147 0.986395 0.855748 0.0252754 
9 145 0.93793 0.802633 0.0292578 
1 136 0.99265 0.796731 0.0296319 
39 
39 
0.002445 
: 
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Table (6) Estimation of sudden death events, and number of patients remaining at risk at beginning of the interval by curve 
fitting 
Trial (2): Singh et al. (STATCHF) 1995 
Time interval Amiodarone group 
(Months) 
dlt nj£ 
0 
6 22 336 
12 8 314 
18 7 306 
24 5 200 
30 10 195 
36 3 115 
42 6 106 
48 3 100 
Total 64 
Total reported 64 
RMSEt 0.011837 
t. No. of deaths at the end of the interval 
£. No. of pIS at risk at the beginning of the interval 
§. Probability of surviving interval 
PI§ Sj'l SEi¥ 
1 1 
0.934524 0.934524 0.013495 
0.974522 0.910714 0.015557 
0.977124 0.889881 0.017078 
0.975000 0.867634 0.019333 
0.948717 0.8231399 0.022896 
0.973913 0.8016667 0.025435 
0.943396 0.7562893 0.029992 
0.970000 0.7336006 0.031825 
,. Actuarial (Kaplan-Meier) survival estimate subsequent to interval (extracted from graph) 
V. Standard error of the Kaplan-Meier estimate 
*. Residual mean square error 
325 
Placebo group 
dit nl£ Pi§ SI'I SEi¥ 
1 1 
16 338 0.9526627 0.9526627 0.01155082 
19 322 0.9409938 0.8964497 0.01657220 
10 248 0.9596774 0.8603025 0.01945069 
9 211 0.9573459 0.8236072 0.02213545 
7 184 0.9619565 0.7922743 0.02425532 
10 159 0.9371069 0.7424457 0.02737368 
4 149 0.9731544 0.7225143 0.02839499 
0 0 0 0 0 
75 
75 
0.003656 
---
I 
I 
: 
I 
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Table (7) Meta-analytic log-rank OR of total mortality in amiodarone randomised clinical trials 
Sensetivity analysis 3 months 6 months 12 months 18 months 24 months 36 months 48 months 60 months 72 months 84 months 96 months 102 months 
Isubgroups 
(1) Trials with completely 
censored data (N=4) 
Log-rank OR (Z) 1.14, 0.25 (NS) 0.63, -1.32 (NS) 0.54, -2.53·· - 0.598, -2.4·· 0.58, -2.78·· 0.63, -2.4·· 0.68, -2.03· 0.63, -2.6·· 0.61, -2.8·· 0.63, -2.7·· 0.598, -3·· 
95% CI for the OR 0.399-3.3 0.32-1.25 0.33-0.87 
-
0.39-0.9 0.39-0.85 0.43-0.92 0.47-0.99 0.44-0.89 0.43-0.86 0.45-0.89 0.43-0.83 
(1.1) Ceremuzynski 1992 and 
Garguichevich 1995 only 
Log-rank OR (z, P) 0.58, -1.5 (NS) 0.497, -2.43·· 0.52, -2.67·· - - - - - - - - -
95% a for the OR 0.29-1.19 0.28-0.87 0.32-0.84 - - - - - - - - -
(1.2) Navarro-Lopez 1993 
and Pfisterer 1993 
Log-rank OR (z, P) - - 0.38, -1.96* - 0.6, -1.7 (NS) 0.53, -2.28** - - - - - -
95% a for the OR 
- -
0.14-1.001 
-
0.3-1.14 0.3-0.9 
- - - - - -
(2) Trials with partially 
censored data (N=4) 
Log-rank OR (z, P) 0.89, -0.4 (NS) 0.83, -\'2 (NS ) 0.9, -0.8 (NS) 0.86, -\'4 (NS) 0.9, -1.6 (NS) 0.83, -1.9 (NS) 0.18, -2.6*· 
- - - - -
95% a for the OR 0.52-1.53 0.6-1.13 0.71-1.17 0.69-1.07 0.696-1.04 0.69-1.01 0.65-0.94 
- - - - -
(3) Trials with data generated 
by curve fitting (N=3) 
Log-rank OR (z, P) 1.04, 0.14 (NS) 0.84, -1.02 (NS) 0.9, -0.6 (NS) 0.89, -1.1 (NS) 0.89, -1 (NS) 0.87, -1.4 (NS) 0.87, -1.4 (NS) - - - - -
95% CI for the OR 0.61-1.78 0.61-1.17 0.7-1.19 0.71-1.1 0.72-1.103 0.7-\.07 0.72-1.06 - - - - -
(4) Trials with completely 
censored data and Trials with 
partially censored data (N=7) 
Log-rank OR (Z, P) 0.76, -1.3 (NS) 0.73, -2.2· 0.78, -2.29·· 0.77, -2.8·· 0.78, -2.8" 0.76, -3.23·· 0.74, -3.7·· 0.75, -3.6·· 0.73, -3.8·· 0.73, -3.9·· 0.73, -3.9·· 0.72, -4.1·· 
95% a for the OR 0.494-1.17 0.56-0.97 0.63-0.97 0.63-0.93 0.65-0.93 0.64-0.896 0.63-0.87 0.64-0.88 0.62-0.86 0.62-0.85 0.62-0.86 0.62-0.85 
(5) Triall with completely 
censored data and Trial. with 
data geneuted by cune 
fitting (N .. 7) 
Log-rank OR (Z, P) O.B, -0.79 (NS) 0.74, -2.0S· 0.78, -2.21· 0.77, -2.S" 0.797, -2.4· 0.78, -2.7" 
-
0.796, -2.5" 0.78, -2.8·· 0.77, -2.9" 0.78, -2.9·. 0.76, -3.1 •• 
95% a for the OR 0.55-1.29 0.56-0.98 063-0.97 0.63-0.94 0.66-0.96 0.66-0.94 
-
067-0.95 0.65-0.93 0.65-0.92 , 0.65-0.92 10.64-0.91 
• statistically significant (P<O.OS); •• highly statistically significant (P<O.OI) 
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Table (8) Meta-analytic log-rank OR of sudden death in amiodarone randomised clinical trials 
Sensetivity analysis subgroups 3 months 6 months 12 months 18 months 24 months 36 months 48 months 54 months 
(I) Trials with completely censored data (N=2) 
Log-rank OR (z, P) 0.55 (-0.65, NS) 0.34 (-1.4, NS) 0.7 (-1.4, NS) - 0.66 (-2.23*) 0.75 (-1.7, NS) 0.75 (-1.78, NS) 0.76 (-1.76, NS ) 
95% CI for the OR 0.09-3.3 0.08-1.54 0.43-1.14 - 0.46-0.95 0.54-1.05 0.55-1.03 0.6-1.03 
(2) Trials with partially censored data (N=l) 
Log-rank OR (z, P) 0.59 (-1.5, NS) 0.49, -2.2* 0.6 (-1.83, NS) 0.75 (-1.42, NS) 
- - - -
95% CI for the OR 0.25-1.4 0.26-0.92 0.38-1.03 0.497-1.12 
- - - -
(3) Trials with data generated by curve fitting 
(N=3) 
Log-rank OR (z, P) 1.08 (0.2, NS) 0.97 (-0.15, NS) 0.8 (-1.5, NS) 0.73 (-1.8, NS) 0.72 (-2.1 *) 0.79 (-1.6, NS ) 0.81 (-1.5, NS) -
95% CI for the OR 0.47-2.5 0.6-1.6 0.52-1.1 0.5-1.03 0.53-0.98 0.59-1.06 0.6-1.07 -
(4) Trials with completely censored data and 
Trials with partially censored data (N=7) 
Log-rank OR (Z, P) 0.59 (-1.32, NS) 0.46 (-2.6**) 0.67 (-2.3*) 0.73 (-2*) 0.695 (-2.53**) 0.75 (-2.1 *) 0.75 (-2.2*) 0.75 (-2.2*) 
95% CI for the OR 0.27-1.29 0.26-0.83 0.47-0.94 0.53-0.99 0.53-0.92 0.58-0.98 0.58-0.97 0.58-0.97 
(5) Trials with completely censored data and 
Trials with data generated by curve fitting 
(N=7) 
Log-rank OR (Z, P) 0.96 (-0.11, NS) 0.88 (-0.6, NS) 0.69 (-2.1 *) 0.67 (-2.4*) 0.67 (-2.6**) 0.74 (-2.1*) 0.75 (-2.1*) 0.76 (-2*) 
95% CI for the OR 0.45-2.04 0.56-1.4 0.48-0.98 0.48-0.93 0.498-0.91 0.56-0.98 0.57-0.99 0.58-0.995 
• statistically significant (P<O.05); •• highly statistically significant (P<O.OI) 
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Appendix 6.2 
Table (9) The pooled survival rates of total mortality in amiodarone clinical trials 
Time point Censored pooled with Censored pooled with curve Censored trials only Curve fittig trials only 
(months) partially censored trials fitting trials 
Amiodarone Placebo Amiodarone Placebo Amiodarone Amiodarone 
I 97.6 (69.8) 95.7 (69) - - 97.6 (69.8) -
2 95.1 (56.3) 93.8 (55.9) - - 96.5 (96.5) -
3 92.9 (48.2) 92.3 (48) 92.2 (48) 91.9 (47.9) 96.5 (69.5) 88.4 (66.5) 
4 91.7 (55.3) 91.7 (67.7) - - 96.3 (69.4) -
5 91.6 (55.3) 89.9 (54.7) - - 96 (69.3) -
6 90.98 (42.7) 88.5 (42) 91 (38.9) 88.96 (38.5) 96.7 (56.8) 85.9 (53.5) 
7 90.7 (54.99) 87.3 (53.9) 
- -
95.5 (69) 
-
S 89.4 (54.6) 85 (53.3) - - 93.3 (68.3) -
9 87.4 (53.97) 79.2 (51.4) - - 93 (68.2) -
10 86.4 (53.7) 84 (52.9) 84 (45.9) 85.6 (46.3) 91.7 (67.7) 78 (62.5) 
II 84.96 (53) 82.9 (52.6) - - 91 (67.5) -
12 85.87 (32.8) 81.2 (34.1) 85.9 (32.8) 82.1 (34.2) 94.3 (48.6) 78.9 (44) 
15 75.7 (50) 65.2 (57) - - - -
IS 73.6 (49.5) 69(48) 78 (39.5) 77 (39.3) 95 (67) 69.7 (48.2) 
24 77 (39.3) 69.2 (41.6) 77.5 (39.4) 70 (41.9) 93 (68) 69.S (48) 
36 75 (43.4) 71.4 (48.8) 75.6 (43.5) 66.2 (40.7) 89.9 65 (57) 
48 62.7 (45.7) 54.7 (52.3) 
- - -
57.3 (53.5) 
60 59.8 (44.7) 48.S (49.4) 
- - - -
72 60.7 (55) - - - - -
84 60.3 (54.9) - - - - -
96 57.99 (53.S) - - - - -
102 64 (SO) - - - - -
Test ofhomogeneily NS NS NS NS NS NS 
The standard error of the pooled rale is shown in brackets; NS. nonsignificant 
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Appendix 6.2 
Table (10) The pooled survival rates of sudden death in amiodarone clinical trials 
Time point Censored pooled with Censored pooled with curve 
(months) partially censored trials fitting trials I 
Amiodarone Placebo Amiodarone Placebo 
3 96.8 (69.8) 94.5 (68.7) 96 (69.3) 94.8 (68.9) 
6 95.8 (69.2) 90 (67.1) 94.8 (56.2) 91.9 (55.4) 
9 92.5 (68) 84.5 (65) 92.5 (68) 84.8 (65) 
12 91.6 (55) 84.6 (53) 91.4 (55.2) 84.5 (53) 
18 - 80.7 (63.5) 86.8 (65.9) 82.7 (64.3) 
24 85.2 (65.3) - - -
Test of homogeneity NS NS NS NS 
The standard error of the pooled rate is shown in brackets; NS, nonsignificant 
329 
REFERENCES 
Abedin Z, Soares J, Phillips DF, Sheldon WC. Ventricular tachyarrhythmias 
following surgery for myocardial revascularization: a follow up study. Chest 1977; 
72: 426-428. 
ACCIAHA Task Force. Guidelines for the early management of patients with acute 
myocardial infarction. JAm Coli Cardiol1990; 16: 249-292. 
Advani SV, Singh BN. Pharmacodynamic, pharmacokinetic and antiarrhythmic 
properties of d-sotalol, the dextro-isomer of sotalol. Drugs 1995; 49 (5): 664-679. 
Ahmed R, Singh BN. Antiarrhythmic drugs. Curr Opin Cardiol1993; 8: 10-21. 
Anderson J1. Reassessment of benefit-risk ratio and treatment algorithms for 
antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial. J Clin 
Pharmacol1990; 30: 981-989. 
Anderson JL. Acute treatment of atrial fibrillation and flutter. Am J Cardio11996; 78 
(8A): 17-21. 
Anderson MH. Current management of ventricular arrhythmias. Br J Hosp Med 1994; 
52: 204-209. 
Anderson TF, Bronnum-Hansen H, Sejr T, Roepstorff C. Evaluated mortality 
following transurethral resection of the prostate for benign hypertrophy! but why? Med 
Care 1990; 28: 870-879. 
Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular 
arrhythmias after coronary artery bypass surgery. A meta-analysis of randomised 
control trials. Circulation 1991; 84 (III): 111236-111244. 
Anonymous, Amiodarone vs Sotalol Study Group. Multicenter randomized trial of 
sotalol vs arniodarone for chronic malignant ventricular tachyarrhythmias. Amiodarone 
vs sotalol study group. Eur Heart J 1989; 10 (8): 685-694. 
Armitage P, Berry G (eds). Statistical Methods in Medical Research. Oxford: 
Blackwell Scientific Publications 1994. 
Bailar JC, Louis TA, Lavori PW, Polansky M. A classification tree for biomedical 
research reports. N Engl J Med 1984; 311: 482-487. 
Bailar JC, Louis T A, Lavori PW, Polansky M. Studies without controls. N Engl J 
Med 1984; 311: 156-162. 
Bauernfeind RA, Welch WJ. New hope in atrial fibrillation. Am J Cardiol 1990; 15 
(3): 708-709. 
Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat 
Soc (Series A) 1988; 151: 419-463. 
Begg CB, Berlin JA. Publication bias and dissemination of clinical research. JNCI 
1989; 81: 107-115. 
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for 
publication bias. Biometrics 1994; 50 (4): 1088-1101. 
330 
Begg CB. Publication bias. In: Cooper H, Hedges L (eds.). Handbook of Research 
Synthesis. New York: Sage Publications 1994: 399-409. 
Bell JA, Thomas JM, Isaacson JR, Snell NJC, Holt OW. A trial of prophylactic 
mexiletine in home coronary care. Br Heart J 1982; 48: 285-290. 
Bellet S (ed). Clinical Disorders of the Heart Beat. Philadelphia: Lea & Febiger 1963: 
144-145. 
Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression modd 
for meta-analysis. Stat Med 1995; 14: 395-411. 
Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods 
for combining event rates from clinical trials. Stat Med 1989; 8: 141-151. 
Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-
response data. Epidemiology 1993; 4: 218-228. 
Berns E, Hinkenberger RL, Jenkins M, Naccarelli GV. Efficacy and safety of 
flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol. 1987; 59: 1337-
1341. 
Bernstein F. The retrieval of random clinical trials in liver disease from medical 
literature: manual versus MEDLARS searches. Control Clin Trials 1988; 9 (1): 23-31. 
Biasi PO, Scrofani R, Paje A, Cappiello E, Mangini A, Santoli C. Intravenous 
amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. Ell' 
J Cardiothorac Surg 1995; 9: 587-591. 
Bigger JT. Definition of benign versus malignant ventricular arrhythmias: targets for 
treatment. Am J Cardiol 1983; 52: 47C-54C. 
Bigger JT. Identification of patients at high risk for sudden cardiac death. Am J 
Cardioll984; 54: 30-80. 
Bigger JT. The electrical activity of the heart. In: Schlant RC, Alexander R\V (eds). 
The Heart. Eighth edition, 1994; 34: 645-696. 
Boyden PA, Hoffman BF. The effects on atrial physiology and structure of surgically 
induced right atrial enlargement in dogs. Circ Res 1981; 49: 1319-1331. 
Bracken MB. Statistical methods for analysis of effects of treatment in overviews of 
randomized trials. In: Sinclair JC, Bracken MB (eds). Effective Care of the NeWborn 
Infant. Oxford: Oxford University Press 1992: 13-18. 
Breslow NE, Clayton DO. Approximate inference in generalized linear mixed models. 
J Am Stat Assoc 1993; 88: 9-25. 
Burckhardt 0, Hoffmann A, Kiowski W, Pfisterer M Burkart F. Effect of 
antiarrhythmic therapy on mortality after myocardial infarction. J Olrdiomsc 
Pharmacol 1991; 17: S77-S81. 
Butler J, Harriss Dr, Sinclair M, Westaby S. Amiodarone prophylaxis for tachycardias 
after coronary artery surgery: a randomised, double blind, placebo controlled trial. Br 
Heart J 1993; 70 (1): 56-60. 
331 
Byar OP. Why data bases should not replace randomized clinical trials. Biometrics 
1980; 36: 337-342. 
Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation: risk of stroke and role of 
antithrombotic therapy. Circulation 1991; 84: 469-481. 
Camm AJ, Bashir Y. Clinical trials of flecainide acetate in the management of 
supraventricular arrhythmias. Cardiologia 1990; 35 (3): 193-197. 
Camm AJ, Julian 0, Janse G, Munoz A, Schwartz P, Simon P, Frangin G, on behalf 
of the EMIAT Investigators. The European Myocardial Infarct Amiodarone Trial 
(EMIAT). Am J Cardiol1993; 72: 95F-98F. 
Campbell TJ, Cavaghan TP, Morgan JJ. Intravenous sotalol for the treatment of atrial 
fibrillation and flutter after cardiopulmonary bypass: comparison with disopyramid~ 
and digoxin in a randomised trial. Br Heart J 1985; 54: 86-90. 
Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M. Fontana G. 
Magnani B. Effectiveness of loading oral flecainide for converting recent-onset atrial 
fibrillation to sinus rhythm in patients without organic heart disease or with only 
systemic hypertension. Am J Cardiol 1992; 70: 69-72. 
Capucci A, Boriani G, Botto GI, Lenzi T, Rubino I, Falcone C. Trisolino G. Casa SD, 
Binetti N, Cavazza M, Sanguinetti M, Magnani B. Conversion of recent-onset atrial 
fibrillation by a single oral leading dose of propafenone or flecainide. Am J Cartiio/ 
1994; 74(5): 503-505. 
Capuccio FP, Siani A, Strazzullo P. Oral calcium supplementation and blood pressure: 
an overview of randomized controlled trials. J Hypertens 1989; 7: 941-946. 
Celeland JGF, Dargie HJ. Ventricular arrhythmias during exercise in patients with 
heart failure: the effect of amiodarone. Eur Heart J 1987; 8 (5D): 65-69. 
Ceremuzynski L, Kleczar E, Krzeminska-Pakula M. Kuch J. Nartowicz E. Smitlak-
Korombel J, Oyduszynski A, Maciejewicz J, Zaleska T, Lazarczyk-Kedzia E. Motyka 
J, Paczkowska B, Sczaniecka 0, Ysuf S. Low-dose arniodarone decreases mortality 
after myocardial infarction: multicenter, double-blind, placebo controlled study. 
Circulation 1991; 84 (II): 347. 
Chalmers I. Informed consent, clinical research and the practice of medicine. Trlllu 
Am Clin Climatol Assoc 1982; 94: 204-212. 
Chalmers I. Evaluating the effects of care during pregnancy and childbirth. In: 
Chalmers I, Enkin M, Keirse MJNC (eds). Effective Care in Pregnancy and 
Childbirth. Oxford: Oxford University Press 1989: 1-37. 
Chalmers I. Evaluating the effects of care during pregnancy and childbirth. In: Sinclair 
JC, Bracken ME (eds). Effective Care of the Newborn Infant. Oxford: Oxford 
University Press 1992. 
Chalmers I, Hetherington J, Elbourne D, Keirse MJN C. Enkin M. Materials and 
metho~s us~d in synthesizing evidence. to evalua!e the effects of care during pregnancy 
and chIldbIrth. In: Chalmers I, Enkm M, Kelfse MJNC (eds). Effective Care in 
Pregnancy and Childbirth. Oxford: Oxford University Press 1989: 38-65. 
332 
Chalmers I, Dickersin K, Chalmers TC. Getting to grips with Archie Cochranes 
agenda. Br Med J 1992; 305: 385-388. 
Chalmers TC, Smith H, Blackburn B, Silverman B, Schroeder B.. Reitman D. 
Ambroz A. A method for assessing the quality of a randomized control trial. Control 
Clin Trials 1981; 2: 31-49. 
Chalmers TC, Berrier J, Sacks HS, Levin H, Reitman D, Nagalingan R. Meta-
analysis of clinical trials as a scientific discipline. II: Replicate variability and 
comparison of studies that agree and disagree. Stat Med 1987; 6: 733-744. 
Chalmers TC, Levin H, Sacks HS, Reitman D, Berrier J, Nagalingam R. Meta-
analysis of clinical trials as a scientific discipline. 1: Control of bias and comparison 
with large co-operative trials. Stat Med 1987; 6: 315-325. 
Chamberlain DA, Jewitt DE, Julian DG. Oral mexiletine in high risk patients after 
myocardial infarction. Lancet 1980; II: 1324-1327. 
Chann SS. The epidemiology of unpublished randomised control trials. Clin Res 
1982; 30: 234A. 
Chapman MJ, Moran JL, O'Fathartaigh MS, Peisach AR, Cunningham DN. 
Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous 
procainamide and arniodarone. Intensive Care Med 1993; 19 (1): 48-52. 
Charlson ME, Horwitz R. Applying results of randornised trials to clinical practice: 
impact of losses before randomisation. Br Med J 1984; 289: 1281-1284. 
Christensensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: A 
meta-analysis adjusting for confounding variables. Gut 1995; 37: 113-118. 
Clark A, Cotter L. Cardioversion in atrial fibrillation. Br J Hosp Med 1993; 49 (4): 
256-261. 
Clarke MJ, Stewart LA. Obtaining data from randomised controlled trials: how much 
do we need to perform reliable and informative meta-analyses? Br Med J 1994; 309: 
1007-1010. 
Cochran WG. Problems arising in the analysis of a series of similar experiments. J R 
Stat Soc 1937; 4: 102-118. 
Cochran WG. The combination of estimates from different experiments. Biometrics 
1954: 101-129. 
Cohen J. Statistical Power Analysis for the Behavioural Sciences. New York: 
Academic Press 1969. 
Colditz G, Miller J, Mosteller F. The effect of study design on gain in evaluation of 
new treatments in medicine and surgery. Drug Infonnation J 1988; 22: 343-352. 
Colditz GA, Berkey CS,. Mosteller F, Bre~~r TF, ~il~on ME, Burdick E, Fineberg 
HV. The efficacy of bacIllus calmette - guenn vaccmatIOn of newborns and infants in 
the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 
1995; 96: 29-35. 
333 
Coldman AJ, Elwood JM. Examining survival data. Can Med Assoc J 1979; 121: 
1065-1071. 
Committee on Safety of MedicineslMedicines Control Agency. ClIrr Prohl 
Phannacovigilance 1996; 22. 
Connolly SJ, Mulji AS, Hoffert DL, Davis C, Shragge BW. Randomised placebo-
controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac 
surgery. JAm Coil Cardiol1987; 10: 1145-1148. 
Cooper H. Statistically combining independent studies: A meta-analysis of sex 
differences in conformity research. J Pers Soc Psychol 1979; 37: 131-146. 
Cooper H. Literature searching strategies of integrative research reviews: a first 
survey. Knowledge 1987; 8: 372-383. 
Cooper H, Arkin RM. On quantitative reviewing. J Pers 1981; 49: 225-230. 
Cooper HM (ed). Integrating Research: a Guide for Literature Reviews. Second 
edition. Sage Publications 1989. 
Cooper HM. Scientific guidelines for conducting integrative research reviews. Rev 
Educ Res 1984; 52 (2): 291-302. 
Cooper HM (ed). The Integrative Research Review. Beverly Hills, California: Sage 
Publications 1984. 
Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy & safety of 
quinidine therapy for maintenance of sinus rhythm after cardio-version: a meta-analysis 
ofrandomised control trials. Circulation 1990; 82 (4): 1106-1115. 
Cosin AJ, Bayes LA, Navarro-Lopez F, STSD Investigators. Two year follow up of 
Spanish trial on sudden death. New Trends in Arrhythmias 1992; 8: 119-124. 
Crijns HJGM, Wij KLM, Gilst WH, Kingma JH, Van Gelder IC. Lie KI. Acute 
conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. 
Comparison of two regimens. Eur Heart J 1988; 9: 634-638. 
Dalzell GW, Anderson J, Adgey AA. Factors determining success and energy 
requirements for cardioversion of atrial fibrillation. Q J M ed 1990; 76: 903-913. 
Dear KBG. Integrative generalized least-squares for meta-analysis of survival data at 
multiple times. Biometrics 1994; 50: 989-1002. 
Delamothe T. Using outcomes research in clinical practice. Br Met! J 1994; 308: 
1583-1584. 
Dersimonian R, Charette J, McPeek B, Mosteller F. Reporting on methods in clinical 
trials. N Engl J Med 1982; 306: 1332-1337. 
DerSimonian R, Laird N. Meta-analysis of clinical trials. Colltrol C/in Trials 1986; 7: 
177-188. 
334 
Detskey A, Naylor CD, O'Rourke K. Incorporating variations in the quality of 
individual randomised trials into meta-analysis. J Clin Epidemiol1992; 45: 255-265. 
Deming WE (ed). Statistical Adjustment of Data. New York: Dover 1964. 
Dhala AA, Case CL, Gillette PC. Evolving treatment strategies for managing atrial 
ectopic tachycardia in children. Am J Cardiol1994; 74 (3): 283-286. 
Diamond GA, Forrester JS. Clinical trials and statistical verdicts: probable grounds for 
appeal. Ann Intern Med 1983; 98: 385-394. 
Dickersin K, Chan S, Chalmers TC. Publication bias in clinical trials. Control Clin 
Trials 1987; 8: 343-353. 
DiFrancesco D. A new interpretation of the pacemaker current in calf purkinje fibres. J 
Physiol1981; 314: 359-376. 
Dittrich HC, Erickson JS, Schneiderman T. Echocardiographic and clinical predictors 
for outcome of electrical cardioversion of atrial fibrillation. Am J Cardiol 1989; 63: 
193-197. 
Dusman RE, Stanton MS, Miles WM, Klein LS, Zipes DP, Fineberg NS. Clinical 
features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82: 51-59. 
Early Breast Cancer Trialists Collaborative Group (EBCTCG). Treatment of Early 
Breast Cancer, Vol 1: Worldwide Evidence, 1985-1990: a systematic overview of all 
available randomised trials of adjuvant endocrine and cytotoxic therapy. Oxford: 
Oxford University Press 1990. 
Eddy DM, Hasselblad V. Shachter R. The statistical synthesis of evidence: meta-
analysis by the confidence profile method. Report issued by the Centre for Health 
Policy Research and Education. Duke University, and by the Department of 
Engineering-Economic system, Stanford University, 1989. 
Edvardsson N. Comparison of class I and class III action in atrial fibrillation. ElIr 
Heart J 1993; 14: 62-66. 
Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiologic 
articles. Drug Intell Clin Pharm 1988; 22: 813-824. 
Ellenberg SSe Meta-analysis: the quantitative approach to research review. Semin 
Onco11988; 15: 472-481. 
Ellwood PM. A technology of patient experience. N Engl J Med 1988; 318: 15-t9-
1556. 
Emerson JD, Burdick E. Hoaglin DC. An empirical study of the possible relation of 
treatment difference to quality scores in a RCT. Control Clin Trials 1990; 11: 339-
352. 
Falk RH. Flecainide induced ventricular tachycardia and fibrillation in patients treated 
for atrial fibrillation. Ann Intern Med 1989; 111 (2): 107-111. 
335 
Faniel R, Schoenfeld PH. Efficacy of iv amiodarone in converting rapid atrial 
fibrillation and flutter to sinus rhythm in intensive care patients. Eur Heart J 1983; 4: 
180-185. 
Feinstein AR. An additional basic science for clinical medicine: II. The limitations of 
randomized trials. Ann Intern Med 1983; 99: 544-550. 
Feinstein AR. Twenty scientific principles for trohoc research. In: Feinstein AR (ed). 
Clinical Epidemiology. The Architecture of Clinical Research. Philadelphia: WB 
Saunders 1985: 543-547. 
Feld GK, Chen PS, Nicod P, Fleck P, Meyer D. Possible atrial Proarrhythmic effects 
of class IC artiarrhythmic drugs. Am J Cardiol1990; 66: 378-383. 
Fine HA, Dear KBG, Loeffler JS, Black PMcL, Canellos GP. Meta-analysis of 
radiation therapy with and without adjuvant chemotherapy for malignant gliomas in 
adults. Cancer 1993; 71: 2585-2592. 
Fisch C. Electrocardiogram and mechanisms of arrhythmias. In: Podrid PJ, Kowey 
PR (eds). Cardiac Arrhythmia - Mechanisms, Diagnosis, and Management 1995; IV 
(14): 211-218. 
Fisher RA (ed). The Deign of Experiments. Edinburgh: Oliver and Boyd 1935. 
Fisher RA (ed). Statistical Methods for Research Workers. 4th edition. London: 
Oliver and Boyd 1932. 
Fleiss JL (ed). Statistical Methods for Rates and Proportions. 2nd edition. New 
York: John Wiley and Sons 1981. 
Fleiss JL (ed). Statistics Methods for Rates and Proportions. New York: Wiley 1973. 
Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2: 121-
145. 
Follath F, Candinas R, Frielingsdrof J. Treatment of atrial fibrillation with class III 
antiarrhythmic drugs. Herz 1993; 18 (1): 20-26. 
Fournier C, Brunet M, Bath M, Kindermans M, Boujon B, Tournadre F. Comparison 
of the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias 
following myocardial infarction. Eur Heart J 1989; 10 (12): 1090-1100 
Fowkes FGR, Fulton PM. Critical appraisal of published research: introductory 
guidelines. Br Med J 1991; 302: 1136-1140. 
Frishman WH, Cavusoglu E. B-adrenergic blockers and their role in the therapy of 
arrhythmias. In: Podrid PJ, Kowey PR (eds). Cardiac Arrhythmia - Mechanisms. 
Diagnosis, and Management 1995; V (25.4): 421-434. 
Frishman WHo B-adrenoreceptor antagonists. New drugs and new indications. N 
Engl J Med 1981; 305: 500-506. 
Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. 
Am J Cardiol1983; 52: 32C-36C. 
336 
Gansevoort RT, Sluiter WJ, Hemmelder MH, Zeeuw 0, Jong PE. Antiproteinuric 
effect of blood-pressure-Iowering agents: a meta-analysis of comparative trials. 
Nephrol Dial Transplant 1995; 10 (11): 1963-1974. 
Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather 
than hypothesis testing. Br Med J 1986; 292: 746-750. 
Garguichevich J, Ramos J, Cambarte E, Gentile A, Hauad S, Scapin 0, Sirena J, 
Tibaldi M, Toplikar J, The Argentine Pilot Study of Sudden Death. Argentine pilot 
study of sudden death and amiodarone: EP AMSA preliminary report. ElIr Heart J 
1992; 13: 291. 
Gentili C, Giordano F, Alois A, Massa E, Bianconi L. Efficacy of intravenous 
propafenone in acute atrial fibrillation complicating open-heart surgery. Am Heart J 
1992; 123: 1225. 
Glass GV. Primary, secondary, and meta-analysis of research. Edltc Res 1976; 5: 3-
8. 
Glass GV, McGaw B, Smith ML (eds). Meta-analysis in Social Research. Sage 
Publications CA 1981. 
Goldman S, Probst P, Salzer A, Cohn K. Inefficacy of "therapeutic" levels of digoxin 
on controlling the ventricular rate in atrial fibrillation. Am J Cardiol 1975; 35: 651-
655. 
Goldschmidt PG. Information synthesis: a practical guide. Health Serv Res 1986: 21: 
215-237. 
Gottman JJ, Glass GV. Analysis of interrupted time series experiments. In: 
Kratchowil TR (ed). Single Subject Research. New York: Academic Press 1978: 197-
235. 
Gotzsche P. Reference bias in reports of drug trials. Br Med J 1987; 295: 654-659. 
Gotzsche PC, Lange B. Comparison of search strategies for recalling double-blind 
trials from MEDLINE. Dan Med Bull 1991; 38: 476-478. 
Goy n, Kaufman U, Kappenberger L, Sigwort U. Restoration of Sinus rhythm with 
flecainide in patients with atrial fibrillation. Am J Cardiol1988; 62: 380-400. 
Grant A. Reporting controlled trials. Br J Obstet Gynaecol 1989; 96: 397-400. 
Grant AD. On the mechanism of action of antiarrhythmic agents. Am Heart J 1992; 
123: 1130-1136. 
Greco R, O'Alterio 0, Schiattarella M, Musto B, Wolff S, Boccia AS, Mininni N. 
Intravenous amiodarone in acute anterior myocardial infarction: a controlled study. 
Cardiovasc Drugs Ther 1989; 2 (6): 791-794. 
Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphan 
and prednisolone in the treatment of multiple myeloma: an overview of published trials. 
J Clin Oncoll992; 10: 334-340. 
337 
Greenland S. Quantitative methods in the review of epidemiologic literature. 
Epidemiol Rev 1987; 9: 1-30. 
Greenland S, Salvan A. Bias in the one-step method for pooling study results. Stal 
Med 1990; 9: 247-252. 
Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-
response data, with applications to meta-analysis. Am J Epidemiol 1992; 135: 1301-
1309. 
Groves PH, Hall RJC. Atrial tachyarrhythmias after cardiac surgery. ElIr lIearl J 
1991; 12: 458-463. 
Halinen MO, Huttunen M, Paakkinen S, Tarssanenl F. Comparison of sotalol with 
digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol 
Digoxin Quinidine Trial). Am J Cardioll995; 76 (7): 495-498. 
Halpern SW, Ellrodt G, Singh BN, Mandel WJ. Efficacy of intravenous procainamid~ 
infusion in converting atrial fibrillation to sinus rhythm: relation to left atrial size. Br 
Heart J 1980; 44: 589-595. 
Hamer A WF, Johns JA, Arkles LB. Beneficial effects of amiodarone in severe cardiac 
failure: a double-blind, placebo-controlled study. J Am Coil Cardiol 1988; 14 (7): 
1775-1776. 
Hamilton MA. Choosing the parameter for a (2*2) table or a (2*2*2) table analysis. 
Am J Ep idem iol 1979; 109: 362-375. 
Haynes KB. Clinical review articles. Br Med J 1992; 304: 330-331. 
Hedges LV, Olkin L (eds). Statistical Methods for Meta-analysis. London: Academic 
Press Limited 1985. 
Hedges LV. Estimation of effect size from a series of independent experiments. 
Psychol Bull 1982; 92: 490-499. 
Hedges LV. 'Commentary'. Stat Med 1987; 6: 381-385. 
Hedges LV. Directions for future methodology. In: Wachter KW, Straf ML (eds.). 
The Future of Meta-analysis. New York: Russell Sage Foundation 1990: 11-26. 
Heger 11, Prystowsky EN, Miles WM, Zipes DP. Clinical use and pharmacology of 
amiodarone. Med Clin North Am 1984; 68 (5): 7-11. 
Henthorn RW, Wablo AL, Anderson JL, Gilbert EM. Alport BL, Bhandari AK. 
Flecainide Supraventricular Tachycardia Study Group. Flecainide acetate prevents 
recurrence of symptomatic paroxysmal supra-ventricular tachycardia. Circulation 1991; 
83 (1): 119-125. 
Herre JM, Sauve MJ, Malone P, Griffin Je, Helmy I. Langberg JJ. Goldberg II. 
Scheinman MM. Long-term results of amiodarone therapy in patients with recurrent 
sustained ventricular tachycardia or ventricular fibrillation. J Am Coli Cardiol 1989; 
13: 442-449. 
338 
Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of 
sinus rhythm after electroconversion of chronic atrial fibrillation: a controlled clinical 
study. Br Heart J 1971; 33: 518-521. 
Himel HN, Liberati A, Gelber R, Chalmers TC. Adjuvant chemotherapy for breast 
cancer: a pooled estimate based on published randomised control trials. JAm Med 
Assoc 1986; 256: 1148-1159. 
Hine LK, Laird NM, Hewitt P, Chalmers TC. Meta-analysis of empirical long-term 
antiarrhythmic therapy after myocardial infarction. JAm Med Assoc 1989; 262 (21): 
3037-3040. 
Hinkle LE, Carver ST, Argyros DC. The prognostic significance of ventricular 
premature contractions in healthy people and in people with coronary heart disease. 
Acta Cardiol1974; 43: 5-32. 
Hlatky MA. Using databases to evaluate therapy. Stat Med 1991; 10: 647-652. 
Hoffman BF. The physiological basis of cardiac arrhythmias. Am J Med 1964; 37: 
670. 
Hondeghem LM. Receptor physiology and its relationship to antiarrhythmic drugs. In: 
Podrid PJ, Kowey PR (eds). Cardiac Arrhythmia - Mechanisms, Diagnosis, and 
Management 1995; V (23): 347-354. 
Hondeghem LM, Katzung BG. Time- and voltage- dependent interactions of 
antiarrhythmic drugs with cardiac sodium channels. Biophys Acta 1977; 472: 373-
398. 
Hou ZY, Chang MS, Chen CY, Tu M-S, Lin SL, Chiang HT, Woosley RL. Acute 
treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of 
intravenous amiodarone. A randomized digoxin controlled study. ElIr Heart J 1995; 
16 (4): 521-528. 
Hunter JE, Schmidt FL (eds). Methods of Meta-analysis: Correcting Error and Bias in 
Research Findings. Newbury Park, CA: Sage 1990. 
Ikeda N, Nademance K, Kannan R, Singh BN. Electrophysiological effects of 
amiodarone: experimental and clinical observations relative to serum and tissue 
concentrations. Am Heart J 1984; 108: 890-899. 
Impact Research Group. International mexiletine and placebo antiarrhythmic coronary 
trial: 1. Report on arrhythmia and other findings. J Am Coli Cardiol 1984; 4: 1148-
1163. 
International Collaborative Study Group. Reduction of infarct size with the early use of 
timolol in acute myocardial infarction. N Engl J Med 1984; 310: 9-15. 
Jenicek M. Meta-analysis in medicine: when we are and where we want to go. J Clin 
Epidemiol 1989; 42: 35-44. 
Jones DR. Meta-analysis: weighing the evidence. Stat Med 1995; 14: 137-149. 
luul-Moller S, Edvardsson N, Rehnquist-Ahlberg N. Sotalol versus quinidine for the 
maintenance of sinus rhythm after direct current conversion of atrial fibrillation. 
339 
Circulation 1990; 82 (6): 1932-1939. 
Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of atrial 
fibrillation. The Framingham Study. N Eng/ J Med 1982; 306: 1018-1022. 
Kannel WB, Abbott RD, Savage DD. Coronary heart disease and atrial fibrillation: The 
Framingham Study. Am Heart J 1983; 106: 389-396. 
Kannel WB, Wolf PA. Epidemiology of atrial fibrillation. In: Falk RH. Podrid JP. 
(eds). Atrial Fibrillation, Mechanisms and Management. New York: Raven Press 
1992: 81-92. 
Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. Am 
Stat Assoc J 1958; 53: 457-483. 
Kennedy H. Role of holter monitoring for arrhythmia (bradyarrhythmia and 
tachyarrhythmia) assessment and management. In: Podrid PJ, Kowey PR (eds). 
Cardiac Arrhythmia - Mechanisms, Diagnosis, and Management 1995; IV (15): 219-
232. 
Kerin NZ, Frumin H, Faite! K, Aragon E, Rubenfire M. Survival of patients with 
non sustained ventricular tachycardia and impaired left ventricular function treated with 
low-dose amiodarone. J Clin Pharmacol1991; 31: 1112-1117. 
Kerin NZ, Somberg J. Proarrhythmia: definition, risk factors, causes, treatment. and 
controversies. Am Heart J 1994; 128: 575-585. 
Kjekshus JK, Blix AS, Elsner R, HoI R, Amundsen E. Myocardial blood flow and 
metabolism in the diving seal. Am J Physiol1982; 242: 97-104. 
Kjekshus JK. Importance of heart rate in determining B-blocker efficacy in acute and 
long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-
49F. 
Kleinbaum DG (ed). Epidemiological Research, Principles and Quantitative Methods. 
Belmont California, New York: Lifetime Learning Publications 1982. 
Koes BW, Assendelft WJ, Vander Heijdel GJ. Spinal manipulation and mobilisation 
for back and neck pain: a blinded review. Br Med J 1991; 303: 1298-1303. 
Kopelman HA, Horowitz LN. Efficacy and toxicity of amiodarone for the treatment of 
supraventricular tachyarrhythmias. Prog Cardiovasc Dis 1989; 31: 355-366. 
L'Abbe KA, Detsky AS. Meta-analysis in clinical research. Ann [mem Met! 1987; 
107: 224-233. 
Laird NM, Mosteller F. Some statistical methods for combining experimental results. 
Int J Tech Assess Health Care 1990; 6: 5-30. 
Larbuisson R, Venneman I, Stiels B. The efficacy and safety of intravenous 
propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or 
flutter after cardiac surgery. J Cardiothorac Vase Anesth 1996; 10: 229-234. 
340 
Lazzara R. From first class to third class: recent upheaval in antiarrhythmic therapy -
Lessons from clinical trials. Am J Cardioll996; 78 (4A): 28-33. 
Levy S. Amiodarone as a first-line drug in the treatment of atrial fibrillation: The 
protagonist viewpoint. Cardiovasc drugs ther 1994; 8 (5): 769-771. 
Lewis RV. Atrial fibrillation: the therapeutic options. Drugs 1990; 40 (6): 841-853. 
Liberati A, Himel HN, Chalmers TC. A quality assessment of randomised control 
trials of primary treatment of breast cancer. J Clin Oncoll986; 4: 942-951. 
Licciardone JC, Brownson RC, Chang JC, Wilkins JR. Uterine cervical cancer risk in 
cigarette smokers: a meta-analysis study. Am J Prev Med 1990; 6: 274-281. 
Lichtenstein MJ, Mulrow CD, Elwood PC. Guidelines for reading case-control 
studies. J Chron Dis 1987; 40: 893-903. 
Lievre M, Leizorovicz A, Boissel JP. Intermediary and substitution criteria in the 
development of antiarrhythmic agents. Arch Mal Coeur 1991; 84 (II): 27-33. 
Light RI. Six evaluation issues that synthesis can resolve better than single studies. 
In: Yeaton W, Wortman P (eds). Issues in Data Synthesis: New Direction for Program 
Evaluation. San Francisco: Jossey-Bass 1984. 
Light RI, Smith PV. Accumulating evidence: procedures for resolving contradictions 
among different research studies. Harvard Educ Rev 1971; 41: 429-471. 
Light RJ, Pillemer DB (eds). Summing Up: The Science of Reviewing Research. 
Cambridge, Massachusetts: Harvard University Press 1984. 
Li Wan Po A. Evidence-based pharmacotherapy. Phann J 1996; 256: 308-312. 
Louis PCA (ed). Recherches sur les effects de la saignee. Paris: De Mignaret 1835. 
Louis PCA (ed). Essay on Clinical Instruction (translated by Martin). London: S 
Highley 1834. 
Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1987; 29: 469-489. 
Lubsen J. Clinical trials of antiarrhythmic therapy - an improper answer to a proper 
question? Cardiology 1987; 74: 32-39. 
Lubsen J. Secondary preventive trials with antiarrhythmic agents: are we asking the 
right question? Eur Heart J 1984; 5 (13): 109-111. 
Luna AB, Cosin J, Navarro-Lopez F, Spanish Trial on Sudden Death Investigators. 
Spanish trial on sudden death: 1 year follow up of 325 patients. Ellr Heart J 1990; 11: 
338. 
MacMahon S, Cutler J, Brittain E, Higgins M. Obesity and hypertension: 
epidemiological and clinical issues. Eur Heart J 1987; 8 (B): 57-70. 
Madrid AH, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of 
flecainide and procainamide in cardioversion of atrial fibrillation. ElIr Heart J 1993; 14 
(8): 1127-1131. 
341 
Mahmarian n, Smart FW, Moye LA, Young JB, Francis MJ, Kingry CL, Verani MS, 
Pratt CM. Exploring the minimal dose of amiodarone with anti-arrhythmic and 
hemodynamic activity. Am J Cardioll994; 74 (7): 681-686. 
Mantel N, Haenszel W. Statistics aspects of the analysis of data from retrospective 
studies of disease. JNCI 1959; 22: 719-748 
Massie BM, Fisher SG, Deedwania PC, Singh BN, Fletcher RD, Singh SN. The 
CHF-ST AT Investigators. Effect of amiodarone on clinical status and left ventricular 
function in patients with congestive heart failure. Circulation 1996; 93 (12): 2128-
2134. 
McAlister HF, Luke RA, Whitlock RM, Smith WM. Intravenous amiodarone bolus 
versus oral quinidine for atrial flutter and fibrillation after cardiac operations. J 17wTllc 
Cardiovasc Surg 1990; 99: 911-918. 
McCain N. Meta-analysis of nursing interventions. West J Nurs Res 1986; 8: 155-
167. 
McCormack JP, Levine M. Meaningful interpreration of risk reduction from clinical 
drug trials. Ann Pharmacother 1993; 27: 1272-1277. 
McDonald C, Hui S. The analysis of humongous databases: problems and promises. 
Stat Med 1991; 10: 511-518. 
McKenna WJ. Harris L, Perez G, Krikler DM, Oakley C, Goodwin JF. Arrhythmia in 
hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in 
treatment. Br Heart J 1981; 46: 173-178. 
Meijler FJ, Wittkampf FHM (eds). Atrial fibrillation: the blind man's elephant. In: 
Current Topics in Cardiology. New York: Elsevier 1991: 186-198. 
Messineo FC. Ventricular ectopic activity: prevelance and risk. Am J Cardiol 1989; 
64: 53J-56J. 
Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G. Belloli C. Albasio Gd, 
De Simone G. Martini N. Effectiveness of 5-aminosalcylic acid for maintaining 
remission in patients with chron's disease: a meta-analysis. Am J GaslroenteroI199 ... ; 
89: 692-698. 
Messori A. Rampazzo R and SIFO Study Group of Meta-analysis. Meta-analysis of 
clinical trials based on censored end-points: simplified theory and implementation of the 
statistical algorithms on a microcomputer. Comput Progr Meliz Bionled 1993,40: 261-
267. 
Michael JC, Stewart LA. Obtaining data from randomised controlled trials: how much 
do we need for reliable and informative meta-analyses? Br Med J 1994; 309: 1007. 
1010. 
Middle~auf HR, Stevenson Wf!. Steve~son LW. Saxon LA. Antiarrhythmic drug 
therapy In 367 advanced heart faIlure patlents: class I drugs but not amiodarone are not 
associated with increased sudden death risk (abstract). JAm Coil Cardiol 1991; 17: 
92A. 
342 
Middlekauff HR, Wiener I, Saxon LA, Stevenson WG. Low-dose amiodarone for 
atrial fibrillation: Time for a prospective study: Ann Intern Med 1992; 116 (12. 1): 
1017-1020. . 
Mike V. Clinical studies in cancer: a historical perspective. In: Mike V. Stanley KE 
(eds). Statistics in Medical Research: Methods and Issues with Applications in Cancer 
Research. New York: Wiley 1982. 
Miller IN, Colditz GA, Mosteller F. How study design affects outcomes in 
comparisons of therapy. II: Surgical. Stat Med 1989; 8: 455-466. 
Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the 
quality of randomised controlled trials: An annotated bibliography of scales and 
checklists. Control Clin Trials 1995; 16: 62-73. 
Morganroth J. Premature ventricular complexes - diagnosis and indications for 
therapy. JAm Med Assoc 1984; 252: 673-676. 
Morganroth J, Goin JE. Quinidine related mortality in the short to medium-tenn 
treatment of ventricular arrhythmias. A meta-analysis. Circulation 1991; 84: 1977-
1983. 
Morganroth J. Early and late proarrhythmia from antiarrhythmic drug therapy. 
Cardiovasc Drugs Ther 1992; 6 (1): 1-4. 
Morganroth J. Indications for antiarrhythmic suppression of ventricular arrhythmias: a 
definition of life-threatening ventricular arrhythmias. Am J Cardiol1993; 72: 3A-7 A. 
Morganroth J, Horowitz LN. Flecainide: its Proarrhythmic effect and expected 
changes on the surface electrocardiogram. Am J Cardiol1984; 53: 89B-948. 
Morris RD, Audet AM, Angelillo IF, Chalmers .TC, Mosteller. F. Chlorination. 
chlorination by-product and cancer: a meta-analYSIS. Am J Public Health 1992; 82: 
955-963. 
Morris RD. Meta-analysis in cancer epidemiology. Environ Health Perspect 1994: 
102 (58): 61-66. 
Mosteller FM, Bush RR. Selected quantitative techniques. In: Lindzey G (cd). 
Handbook of Psychology: 1, Theory and Method. Cambridge. MA: Addison-\Vesley 
1954: 289-334. 
Mullen B (ed). Advanced Basic Meta-analysis. New Jersy. Hillsdale. CA: LEA 1989. 
Mulrow CD. The medical review articles: state of the science. Ann Intern !tied 1987: 
106: 485-488. 
Mulrow CD. Rationale for systematic reviews. Br Med J 1994; 309: 597-599. 
Myerburg RJ, Kessler KM, Castellanos A. Recognition, clinical assessment and 
management of arrhythmias and conduction disturbances. In: Schlant RC Alexander 
RW (eds). The Heart. Eighth edition 1994; 36: 705-751. • 
Naccarelli oy, Dougherty AH. Amiodaron~: A review of its pharmacologic. 
antiarrhythmic and averse effects. In: Podnd PJ, Kowey PR (eds). Cardiac 
343 
Arrhythmia - Mechanisms, Diagnosis, and Management 1995; V (25.5): 434-449. 
Nadamanee K, Singh BN, Stevenson WG, Weiss IN. Amiodarone and post MI 
patients. Circulation 1993; 88: 764-774. 
Neal MJ. Antiarrhythmic drugs. In: Medical Pharmacology at a Glance. 2nd edition. 
London: Blackwell Scientific Publications 1992; 17: 40-44. 
Newman D, Gillis A, Gilbert M, Dorian P. Chronic drug therapy to prevent recurrence 
of atrial fibrillation. Can J Cardiol1996; 12: 24A-28A. 
Noble D (ed). Initiation of Heart Beat. London: Oxford University Press 1979. 
Norris RM, Sammel NL, Clarke ED. Treatment of acute myocardial infarction with 
propranolol: further studies on enzyme appearance and subsequent left ventricular 
function in treated and control patients with developing infarcts. Br Heart J 1980; 43: 
617-622. 
Novo S, Alaimo G, Abrignani MG, Immordino R, Cutietta A, Indovina A, Licata G, 
Strano A. Effects of low doses of amiodarone on cardiac arrhythmias in patients with 
chronic ischemic heart disease. Eur Heart J 1988; 9 (5N): 164-168. 
Ollitraut I, Quilliet L, Sheck F, Lelong B, Richard A, lorry G, Guize L. Single 
infusion of intravenous cibenzoline in treatment of supraventricular tachyarrhythmias 
following heart surgery. A double-blind placebo-controlled parallel study. ElIr Heart J 
1994; 15 (9): 1274-1278. 
Olshansky B. Management of atrial fibrillation after coronary artery bypass graft. Am 
J Cardiol1996; 78 (8A): 27-34. 
Ormerod OJM, McGregor CGA, Stone DL, Wisbey C, Petch MC. Arrhythmias after 
coronary bypass surgery. Br Heart J 1984; 51: 618-621. 
Orwin, RG. A fail-safe N for effect sizes in a meta-analysis. J Edllc Stat 1983; 8: 
157-159. 
Oxman AD, Guyatt GH. Guidelines for reading literature reviews. Call Med Assoc J 
1988; 138: 697-703. 
Oxman AD (1995). A systematic review of interventions to improve the performance 
of health care professions. Commissioned by NHS Executive (North Thames) 
Research and Development Directorate. 
Parmley WW. Publication bias. Am J Cardiol1994; 24 (5): 1424-1425. 
Pearson K. Report on certain enteric fever inoculation statistics. Br Med J 1904; 3: 
1243-1246. 
Peto R. Why do we need systematic overviews of randomized trials? Stat Med 1987; 
6: 233-240. 
Peto R, Collins R, Gray R (eds). Large-scale randomized evidence: large, simple trials 
and overviews of trials. Doing more good than harm: the evaluation of health care 
interventions. New York: New York Academy of Sciences 1993; 703: 314-340. 
344 
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, 
McPherson K, Peto J, Smith PG. Design and analysis of randomised clinical trials 
requiring prolonged observation of each patient. Br J Cancer 1976; 34: 585-612. 
Pignon JP, Arrigada R, Ihde DC. A meta-analysis of thoracic radiotherapy for small-
cell lung cancer. N Engl J Med 1992; 327: 1618-1624. 
Podrid PJ. Exercise testing and its role in the management of patients and arrhythmia. 
In: Podrid PJ, Kowey PR (eds). Cardiac Arrhythmia - Mechanisms, Diagnosis. and 
Management 1995; 16: 233-246. 
Podrid PJ. Aggravation of ventricular arrhythmia. A drug-induced complication. 
Drugs 1985; 29 (4): 33-44. 
Pritchett ELC, Lee KL. Designing clinical trials for paroxysmal atrial tachycardia and 
other paroxysmal arrhythmias. J Clin Epidemioll988; 41 (9): 851-858. 
Proclemer A, Facchin D, Vanuzzo D, Feruglio GA. Risk stratification and prognosis 
of patients treated with amiodarone for malignant ventricular tachyarrhythmias after 
myocardial infarction. Cardiovasc Drugs Ther 1993; 7: 683-689. 
Puech P. Practical aspects of the use of amiodarone. Drugs 1991; 41 (2): 67-73. 
Rark SF, McCarthy EA, Lee KL, Pritchett ELC. Observations on the occurrence of 
atrial fibrillation in paroxysmal supraventricular tachycardia. Am J Cardiol 1986; 57: 
571-575. 
Raudenbush SW, Bryk AS. Empirical Bayes meta-analysis. J EdllC Stat 1985; 10: 
75-98. 
Ravi-Kishore AG, Camm AJ. Guidelines for the use of propafenone in treating 
supraventricular arrhythmias. Drugs 1995; 50 (2): 250-262. 
Reid FDS, Mercer PM, Harrison M, Bates T. Cholecystectomy as a risk factor for 
colorectal cancer: A meta-analysis. Scand J Gastroenteroll996, 31 (2): 160-169. 
Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol 
for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol1993; 71: 
558-563. 
Reimold SC, Chalmers TC, Berlin JA, Antman EM. Assessment of the efficacy and 
safety of antiarrhythmic therapy for chronic atrial fibrillation: observations on the role 
of trial design and implications of drug-related mortality. Am Heart J 1992; 124: 92-'. 
Roark SF, McCarthy EA, Lee KL, Pritchett ELC. Observations on the occurrence of 
atrial fibrillation in paroxysmal supraventricular tachycardia. Am J Cardiol 1986; 57: 
571-575. 
Roden DM. Risks and benefits of antiarrhythmic therapy. Drug Tiler 199-'; 331: 785-
791. 
Rodriguez LM, Smeets J, O'Hara GE, Geelen P, Brugada P, Wellens HJJ. Incidence 
and timing .recurrences of sudden death. a~d ve~tricular tachycardia during 
antiarrhythmIc drug treatment after myocardIal mfarctlon. Am J Cardiol 1992; 69: 
345 
1403-1406. 
Roper WL, Winkenweroler W, Hackbarth GM, Krakaulk H. Effectiveness in health 
care: an initiative to evaluate and improve medical practice. N Eng/ J Med 1988; 319: 
1197-1202. 
Rosenthal R, Rubin DB. Interpersonal expectancy effects: the first 345 studies. Behav 
Brain Sci 1978; 3: 377-415. 
Rosenthal R. The "File Drawer Problem" and tolerance for null results. Psycho/ Btlll 
1979; 86: 638-641. 
Rosenthal R (ed). Meta-analytic Procedures for Social Research. Newbury Park, CA: 
Sage 1984. 
Rosenthal R (ed). Meta-analytic Procedures for Social Research. Newbury Park, CA: 
Sage 1991. 
Rothman KJ (ed). Modem Epidemiology. Boston: Little, Brown and Company 1986. 
Rubin DA, Nieminski KE, Reed GE, Hennan MV. Predictors, prevention and long-
tenn prognosis of atrial fibrillation after coronary artery bypass graft operations. J 
Thorae Cardiovasc Surg 1987; 94: 331-335. 
Rubin DB. Estimating causal effects of treatments in randomised and nonrandomised 
studies. J Educ Psycholl974; 66: 688-701. 
Rubin DB. A new perspective. In: Wachter KW, Straf ML (eds). The Future of 
Meta-analysis. New York: Russell Sage Foundation 1990. 
Runick Paul A, McElhinney L, Mitchell T, Kronzon I. The alteration between atrial 
flutter and atrial fibrillation. Chest 1992; 101 (1): 34-36. 
Ryden L, Amman K, Conrad son TB. Prophylaxis of ventricular tachyarrhythmias 
with intravenous and oral tocainide in patients with and recovering from acute 
myocardial infarction. Am Heart J 1980; 100: 1006-1012. 
Sackett DL, Cook RJ. Understanding clinical trials: What measures of efficacy should 
journal articles provide busy clinicians? Br Med J 1994; 309: 11-16. 
Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. 
N Engl J Med 1979; 301: 1410-1412. 
Sackett DL, Haynes RB, Guyatt GH, Tugwell P (eds). Clinical Epidemiology - A 
Basic Science for Clinical Medicine. 2nd edition. BostonfforontolLondon: Little. 
Brown and Company 1991. 
Sacks HS, Berrier J, Reitman D. Meta-analyses of randomised control trials. N Eng/ J 
Med 1987; 316: 450-455. 
Schaffer WA, Cob LA. Recurrent ventricular fibrillation and modes of death in 
survivors of out-of-hospital ventricular fibrillation. N Engl J Med 1975; 293: 295-
262. 
346 
Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA. 
Platia EV, Wilber DJ, Kowey PRo Dose-ranging study of intravenous amiodarone in 
patients with life threatening ventricular tachyarrhythmias. The Intravenous 
Amiodarone Multicenter Investigators Group. Circulation 1995; 92 (11): 3264-3272. 
Schmidt G, Goedelmeinen L, Baedeker W. Wirtzfeld A. Jahns G, Linne R, Schaudig 
U, Kein G. Long-term efficacy of class-I antiarrhythmic agents and amiodarone in 
patients with malignant ventricular arrhythmias. Drugs 1985; 29 (3): 37-46. 
Schneilder AP. Breast milk jaundice in the new born: a real entity. JAm Med Assoc 
1986;255: 3270-3274. 
Scott D. Cardiac arrhythmias. In: Walker R, Edwards C. Clin Phannco/ Tiler 1994; 
19: 281-293. 
Sechrest L, Figulkedo AJ. Approaches used in conducting outcomes and effectiveness 
research. Paper presented at a conference of the association for health services 
research, April 1991. 
Segal BL, Iskandrian AS, Kotler MN. Sudden cardiac death. In: Morganroth J, 
Horowitz LN (eds). Sudden Cardiac Death 1985; 1: 1-21. 
Selzer A. Atrial fibrillation revisited. N Engl J Med 1982; 306: 1044-1045. 
Selzer A, Wary HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring 
during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17-26. 
Siddoway LA. Pharmacologic principles of antiarrhythmic drugs. In: Podrid PJ, 
Kowey PR (eds.). Cardiac Arrhythmia - Mechanisms, Diagnosis, and Management 
1995; V (24): 355-368. 
Siebels J, Schneider MAE, Ruppel R, Kuck KH, the CASH Investigators Group. The 
Cardiac Arrest Study Hamburg (CASH): Preliminary Results. Circulation 1992; 86 
(4): 1-535. 
Silberman G, Droitcour JA, Scullin EW. Cross Design Synthesis: A New Strategy for 
Medical Effectiveness Research. Washington DC: US General Accounting Oftice 
1992. 
Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Met! 
1987; 6: 11-29. 
Simon p. Wittes RE. Methodological guidelines for reports of clinical trials. Cancer 
Treatments Reports 1985; 69: 1-3. 
Sinclair JC, Bracken ME (eds). Effective Care of the Newborn Infant. Oxford: 
Oxford University Press 1992. 
Singer DH, Lazzara R, Hoffman BF. Interrelationships between automaticity and 
conduction in purkinje fibres. Circ Res 1967; 21: 537-558. 
Singh BN, Vaughan Williams EM. The effect of amiodarone. a new antiarrhythmic 
drug. on cardiac muscle. Br J Phannacol1970; 39: 657-667. 
347 
Singh BN. When is drug therapy warranted to prevent sudden cardiac death? Dnlgs 
1991; 41 (2): 24-46. 
Singh BN. Expanding indications for the use of class III agents in patients at high risk 
for sudden death. J Cardiovasc Electrophysiol1995; 6 (10, II): 887-900. 
Singh BN. Controlling cardiac arrhythmias with calcium channel blockers. In: Podrid 
PI, Kowey PR (eds). Cardiac Arrhythmia - Mechanisms, Diagnosis, and Management 
1995; V (25.7): 466-478. 
Singh BN. The coming of age of the class III antiarrhythmic principle: retrospective 
and future trends. Am J Cardiol1996; 78 (4A): 17-27. 
Singh S, Fletcher RD, Fisher S, Deedwania P, Lewis D, Massie B, Singh B, Colling 
CL, The CHF-STAT Investigators. Congestive heart failure: Survival trial of 
antiarrhythmic therapy (CHF STAT). Control Clin Trials 1992; 13: 339-350. 
Singh SN, Fletcher RD, Fisher S, Lazzeri, Singh BN, Colling C, The CHF-STAT 
Investigators. Veterans Affairs congestive heart failure antiarrhythmic trial. Am J 
Cardiol1993; 72 (16): 99F-102F. 
Smith SI, Caudill SR, Steinberg KK, Thacker SB. On combining dose-response data 
from epidemiological studies by meta-analysis. Stat Med 1995; 14: 531-544. 
Smyllie HC, Doar IWH, Head CD, Leggett RJE. A trial of intravenous and oral 
mexiletine in acute myocardial infarction. Eur J Clin Phannacol1984; 26: 537-542. 
Sodermark T, Jonsson B, Olsson A, Oro L, Wallin H, Edhag 0, Sjogren OE. Effect 
of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter: 
A multicentre study from Stockholm. Br Heart J 1975; 37: 486-492. 
Sopher SM, Camm AI. Atrial fibrillation: maintenance of sinus rhythm versus rate 
control. Am J Cardiol1996; 77 (3): 24A-37A. 
Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack M, Flanders WD, Berkelman 
RL. A meta-analysis of the effect of oestrogen replacement therapy on the risk of 
breast cancer. JAm Med Assoc 1991; 265: 1985-1990. 
Stewart LA, Parmar MKB. Meta-analysis of the literature or of individual patient data: 
Is there a difference? Lancet 1993; 341: 418-422. 
Stewart RA, McKenna WI, Poloniecki JD, Michelson JK, Das SK, Morady F, Schork 
MA, Pitt B, Nicklas JM. Prospective, randomised, double-blind, placebo-controlled 
trial of low dose amiodarone in patients with severe heart failure and frequent 
ventricular ectopy. Eur Heart J 1989; 10: 229. 
Strasberg B, Kus~eic. I, Zlo~ikamie~ B, Ma.ger At S~larovsky S. Lon.g term follow up 
of post myocardial mfarctIOn patients With ventncular tachycardia or ventricular 
fibrillation treated with amiodarone. Am J CardioI1990; 66: 673-678. 
Switzer DF, Waldo AL, Henthorn RW. Hemodynamic effects of tachycardia. A. 
Supraventricular tach~cardia .. In: S~sena S, Goldscblager N (eds). Electrical Therapy 
for Cardiac Arrhythmias. Philadelphia: WB Saunders, 1990: 467-477. 
348 
Talajic M, MacDonald RG, Nattel S. Restoration of sinus rhythm in patients with atrial 
fibrillation. Can J Cardiol1996; 12: 29A-34A. 
Task Force of the Working Group on Arrhythmias of the European Society of 
Cardiology. The Sicilian Gambit. A new approach to the classification of 
antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. 
Circulation 1991; 84: 1831-1851. 
Teagarden JR. Meta-analysis: whither narrative review? Phannacotherapy 1989; 9 (5): 
274-284. 
Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in 
suspected acute myocardial infarction: overview of randomised trials. Br Med J 1991; 
303: 1499-1503. 
Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in 
acute myocardial infarction: an overview of results from randomized control trials. J 
Am Med Assoc 1993; 270: 1589-1595. 
Ter Riet G, Kleijnen J, Knipschild P. Acupuncture and chronic pain: a criteria-based 
meta-analysis. J Clin Epidemiol 1990; 43: 1191-1199. 
The Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary Repol1: 
Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia 
suppression after myocardial infarction. N Engl J Med 1989; 321 (6): 406-411. 
The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the 
antiarrhythmic agent moricizine on survival after myocardial infarction. N Eng/ J Med 
1992; 327: 227-233. 
The Coronary Drug Project Research Group. Prognostic importance of premature 
beats following myocardial infarction: experience in the coronary drug project. J Am 
Med Assoc 1973; 223: 1116-1124. 
The International Collaborative Study Group. Reduction of infarct size with the early 
use oftimolol in acute myocardial infarction. N Engl J Med 1984; 310: 9-15. 
Thomas A, Spiegelhalter D, Gilks W. BUGS: a program to perform bayesian 
inference using gibbs sampling. In: Bernardo J, David A, Smith A (eds). Bayesian 
Statistics. Oxford: Oxford University Press 1992; 4: 837-842. 
Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet 1991; 338: 127-
130. 
Thompson, SG. Why sources of heterogeneity in meta-analysis should be 
investigated. Br Med J 1994; 309: 1351-1355. 
Tippet LHC (ed). The Methods of Statistics. London: Williams and Norgage 1931. 
Tones K. Health education, behaviour change, and the public health. In: Octels R. 
Holland WW, McEwen J, Omenn GS (eds). Oxford Textbook of Public Health. 
Oxford: Oxford University Press 1997; 2(3): 783 
Tunick PA, McElhinney L, Mitchell T, Kronzon I. The alteration between atrial flutter 
and atrial fibrillation. Chest 1992; 101: 34-36. 
349 
Tweedie RL, Mengersen KL. Meta-analytic approaches to dose-response 
relationships, with application in studies of lung cancer and exposure to environmental 
tobacco smoke. Stat Med 1995; 14: 545-569. 
Vandekerckhove P, 0' Donovan PA, Lilford RJ, Harada TW. Infertility treatment: 
from cookery to science. The epidemiology of randomised controlled trials. Br J 
Obstet Gynaecol1993; 100: 1005-1036. 
Vaughan Williams EM. Classifying antiarrhythmic actions: by facts or speculation. J 
Clin Pharmacol1992; 32 (11): 964-977. 
Vaughan Williams EM. Classification of antiarrhythmic actions reassessed after a 
decade of new drugs. J Clin Pharmacol1984; 24: 129-147. 
Vaughan Williams EM. Relevance of cellular to clinical electrophysiology in 
interpreting antiarrhythmic drug action. Am J Cardiol1989; 64: 5J-91. 
Vaughan Williams EM. Classification of antiarrhythmic drugs. In: Sandoe E (cd). 
Cardiac Arrhythmias. Sodertalje, Sweden: Ad Astra 1970: 449. 
Vecht RJ, Nicolaiden EP, Ikwenke JK, Liassides CH, Cleary J, Cooper WB. 
Incidence and prevention of supraventricular tachyarrhythmia after coronary artery 
bypass surgery. Int J Cardiol1986; 13: 125-134. 
Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB. Aggravation and provocation 
of ventricular arrhythmias by anti-arrhythmic drugs. Circulation 1982; 65 (5): 886-
893. 
Vietti-Ramus G, Beglio F, Marchisio U, Burzio P, Latini R. Efficacy and safety of 
short intravenous amiodarone in supraventricular tachyarrhythmias. Int J Cardioll992; 
35: 77-85. 
Waldo AL, MacLean WAH, Cooper TB, Kouchoukos NT, Karp RB. The use of 
temporarily placed epicardial atrial wire electrodes for the diagnosis and treatment of 
cardiac arrhythmias following open heart surgery. J Thorac Cardiovasc Surg 1978; 
76: 500-505. 
Waldo AL, Maclean WAH (eds). Diagnosis and treatment of arrhythmias following 
open heart surgery - emphasis on the use of epicardial wire electrodes. New York: 
Futura, 1980. 
Waldo AL. Mechanisms of atrial fibrillation, atrial flutter, and ectopic atrial tachycardia 
- a brief review. Circulation 1987; 75: III 37-40. 
Waldo AL. Wit AL. Mechanisms of cardiac arrhythmias and conduction disturbances. 
In: Schlant RC, Alexander RW (eds). The Heart. Eighth edition 1994; 34: 645-696. 
Wellens HJJ, Brugada P, Abdollah H, Dassen WR. A comparison of 
electrophysiologic effects of intravenous and oral amiodarone in the same patient. 
Circulation 1984; 69: 120-124. 
Wells JL Jr, Maclean WAH, James TN, Waldo AL. Characterization of atrial flutter. 
Studies in man after open heart surgery using fixed atrial electrodes. Circulation 1979; 
60: 665-673. 
350 
Wheeler PJ, Puritz R, Ingram OV, Chamberlain OA. Amiodarone in the treatment of 
refractory supraventricular and ventricular arrhythmias. Post grad Med J 1979; 55: 1-9. 
WHOIISC Task Force. Am Heart J 1978; 95: 796-806. 
WHO Drug Information 1993; 7 (2): 65. 
WHO Drug Information 1997; 11 (1): 18. 
Willerson JT, Powell WI, Guiney TE, Stark n, Sanders CA, Leaf A. Improvement in 
myocardial function and coronary blood flow in myocardial function and coronary 
blood flow in ischemic myocardium after mannitol. J Clin Invest 1972; 51: 2989. 
Wilson JS, Podrid PJ. Side effects of amiodarone. Am Heart J 1991; 121: 158-171. 
Wittes RE. Problems in the medical interpretation of overviews. Stat Med 1987; 6: 
269-276. 
Woolf B. On estimating the relation between blood group and disease. Ann HlIm 
Genet 1955; 9: 251. 
Wortman PM, Yeaton WH .. Synthesis of results i~ contro~led clin.ical trials of coronary 
bypass graft s~rgery. In: L~ght. RJ (ed). EvaluatIOn StudIes ReVIew Annual. Beverly 
Hills, CalifornIa: Sage PublIcatIons 1983; 8. 
Yusuf S, Peto R, ~ewis J, Col~ins R, Sleight P .. Beta ~lockade during and after 
myocardial infarctIOn: an overVIew of the randOmIzed tnals. Prog Cardiovasc Dis 
1985; 27: 335-371. 
Yusuf S, Sim<?n R, ~llenber~ SS. Preface ~o the pr?ceed.ings on the workshop on 
methodologic Issues In overvIews of randomIsed clInIcal tnals, May 1986. Stal Met! 
1987; 6: 217-218. 
Yusuf S. On obtaining medically meaningful answers from an overview of randomized 
clinical trials. Stat Med 1987; 6: 281-286. 
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Overview of results of randomized 
clinical trials in heart disease. I.Treatment following myocardial infarction. JAm Med 
Assoc 1988; 260 (14): 2088-2093. 
Yusuf S Wittes J, Friedman L. Overview of results of randomized clinical trials in 
heart dis~ase. 1. Treatment following myocardial infarction. JAm Med Assoc 1988; 
260 (14): 2088-2093. 
Zarembski OG, Nolan PE, Sla~k ¥K, ~aruso AC. Empiric long-term amiodurone 
prophylaxsis following myocardIal InfarctIOn: a meta-analysIs. Arch Intern Med 1993; 
153 (23): 2661-2667. 
Zarembski OG, Nol~ PE, S.lack MK. Treatm~~t of resistant atrial fibrillation. A 
meta-analysis comparIng amIodarone and flecatmde. Arch Intern Med 1995; 155: 
1885-1891. 
Zaim B, Zaim S, Garan H. Invasive car~iac eIectroph~siology studies in assessment 
and management of cardiac arrhythmIas. In: Podnd PJ, Kowey PRo Cardiac 
351 
Arrhythmia - Mechanisms, Diagnosis, and Management 1995; 18: 258-279. 
Zipes DP. Specific arrhythmias: diagnosis and treatment. In: Braunwald E (ed). Heart 
Disease. A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders 1992. 
Zoble RG, Brewington J, Olukotun A Y, Gore R. Comparative effects of nadolol-
digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation. 
Am J Cardiol1987; 60: 39D-45D. 
352 
